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Introduction and overview of the Thesis 
High-risk Intervention in the Drug-eluting stent era 
The introduction and fast uptake of drug-eluting stents in 
the world market has been a major breakthrough in the 
field of interventional cardiology. While in-stent 
restenosis has long been considered the main limitation 
hampering long-term efficacy of coronary stenting, the 
development of stents able to temporarily elute drugs to 
the injured arterial wall has been shown to be an 
effective and overall safe approach to suppress intimal 
hyperplasia. The sirolimus eluting stents have virtually 
abolished restenosis in the First-In-Man (FIM)1 and in the 
RAndomized study with sirolimus-eluting Bx Velocity 
balloon-expandable stent in the treatment of patients 
with de novo native coronary artery lesions (RAVEL)2
studies. This led to the approval of this device in Europe 
in 2002. The results of the randomized, double-blind 
Sirolimus Eluting Stent in de Novo Coronary Lesions 
(SIRIUS) trial, involving 1055 patients3, were 
subsequently used to gain approval of the device by the 
Food and Drug Administration (FDA) in the United States 
in 2003.
The randomized, double blind TAXUS-IV, involving 1314 
patients4, assessed the safety and efficacy of the slow-
release paclitaxel-eluting stent in single, previously 
untreated lesions and led to FDA approval of this active 
stent in 2004. 
Other drugs, including zotarolimus, everolimus, 
tacrolimus, biolimus A9, and new delivery systems are 
currently being tested in conjunction with new or 
traditional metallic stents in randomized controlled trials5-
8. The great majority of these new active stents however 
remains in the investigational phase at present and even 
if approval for clinical use has already been obtained for 
some of them in Europe, concerns regarding their 
safety/efficacy profile and/or limited data availability are 
currently limiting their use worldwide. This thesis will 
entirely focus on the first two drug eluting stents 
introduced in the market, the Cypher sirolimus-eluting 
stent (Cordis, Johnson & Johnson) and the Taxus slow-
release paclitaxel-eluting stent (Boston Scientific), 
attempting to unravel some of the remaining issues 
regarding their use in patients undergoing high-risk 
coronary interventions.
The concept of “high-risk intervention” is sometimes 
elusive and potentially misleading since this term has 
been applied to a great variety of different conditions in 
the medical literature9-12. Throughout this thesis, 
interventions at coronary arteries are considered to be at 
high risk based on specific anatomical location or 
extension of the treated disease (Parts 1, 4 and partially 
5); due to the clinical context in which intervention is 
performed (Part 3) or if undertaken in patients with 
reduced left ventricular systolic function (Part 5).  
The interventions which are performed under these 
circumstances are at high-risk based on the concept that 
the rate of major adverse events is known to be 
relatively higher in such settings. At the some time, the 
presence of these conditions makes intervention at 
coronary arteries a treatment with well-established 
prognostic implications. Thus, particular attention to 
improve the therapeutic and safety profile of catheter-
based intervention in these patient/lesion subsets is 
warranted.
Prognostic implications of coronary 
revascularisation in the setting of stable coronary 
artery disease 
In patients with one or two coronary artery disease 
without involvement of left main coronary artery and 
good left ventricular function, percutaneous coronary 
intervention does not confer any clear benefit in terms of 
long-term hard clinical outcomes compared with 
conservative medical treatment, especially in cases 
where the proximal left anterior descending artery is not 
involved13. Indeed, a trend for increased risk of 
myocardial infarction in patients undergoing 
percutaneous coronary intervention compared to 
conservative management has been observed13. This 
evidence is in agreement with historical data comparing 
surgical revascularisation versus medical treatment. 
Yusuf et al. performed a systematic overview using 
individual patient data from the seven randomised trials 
comparing a strategy of initial coronary artery bypass 
graft surgery (CABG) with one of initial medical therapy 
to assess the effects on mortality in patients with stable 
coronary heart disease14.
The CABG group had significantly lower mortality than 
the medical treatment group at 5 years (10.2 vs. 15.8%; 
odds ratio 0.61 [95% CI 0.48-0.77], p = 0.0001), 7 years 
(15.8 vs. 21.7%; 0.68 [0.56-0.83], p < 0.001), and 10 
years (26.4 vs. 30.5%; 0.83 [0.70-0.98]; p = 0.03). The 
risk reduction was greater in patients with left main 
artery disease than in those with disease in three vessels 
or one or two vessels (odds ratios at 5 years 0.32, 0.58, 
and 0.77, respectively). The absolute benefits of surgery 
were most pronounced in patients in the highest risk 
categories. This effect was most evident when several 
prognostically important clinical (reduced left ventricular 
ejection fraction) and angiographic (left main disease, 
three vessel disease, especially with proximal left anterior 
descending artery) risk factors were integrated. In low-
risk patients, the data showed again a non-significant 
trend towards greater mortality with surgical 
revascularisation.
Thus, taking together the results generated by 
comparing surgical or percutaneous revascularisation 
versus medical management, current evidence suggests 
that coronary revascularisation in patients with stable 
coronary artery disease reduces hard clinical end-point 
only when specific high-risk features are present, 
including anatomic/angiographic variables (left main 
coronary artery disease, three vessel disease, 
involvement of proximal anterior descending artery) and 
clinical characteristics (reduced left ventricular ejection 
fraction).
Chapter  1
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Prognostic implications of percutaneous 
revascularisation in the setting of ST-segment 
elevation myocardial infarction 
Patients presenting with ongoing ST-segment elevation 
myocardial infarction are well known to derive greater 
benefit from primary percutaneous intervention with 
improved safety compared to the pharmacological 
approach.
Primary percutaneous intervention is associated with a 
37% relative reduction in the odds of 30-day mortality 
when compared with in-hospital fibrinolytic therapy, 
which is only slightly attenuated to 28% when 
accelerated t-PA trials are separately considered15.
Similarly, the incidence of re-infarction is reduced from 
7% to 3% and stroke from 2% to 1% with the use of 
systematic mechanical compared to standard 
pharmacological reperfusion16. Thus, despite the benefit 
of pre-hospital thrombolysis in patients presenting with 
short duration of symptoms (less than 2 or 3 hours) is 
actively debated, especially in cases where transportation 
time may exceeds 60 minutes, percutaneous coronary 
intervention in patients with on-going ST-segment 
elevation myocardial infarction has clear prognostic 
implications in term of both mortality and morbidity17.
Outline of the Thesis 
Thesis-Part 1 
The first part of the thesis examines the safety and 
efficacy of drug eluting stent implantation in patients with 
left main coronary artery disease. In chapter 2, 
observational proof from the prospective Rapamycin 
Eluting- and Taxus-Stent Evaluated At Rotterdam 
Cardiology Hospital Registries (RESEARCH and T-SEARCH) 
that the use of DES in this subset of patients lead to an 
improved outcome without safety concerns is provided. 
Chapter 3 focuses on comparative angiographic and 
clinical efficacy of sirolimus eluting versus paclitaxel-
eluting stents, while chapter 4 and 5 evaluate the role of 
intravascular ultrasound guidance and single versus 
bifurcation stenting in the treatment of elective 
unprotected left main coronary artery and in all-comers 
distal left main disease, respectively. Chapter 6 reports 
findings on a limited and retrospectively selected group of 
patients who underwent serial angiographic follow-up at 6 
and 12 months after drug-eluting stent implantation for 
the treatment of left main coronary artery disease. By a 
pooled analysis of 340 patients treated for elective 
unprotected left main coronary artery disease at three 
European referral centers, the temporal distribution of 
major adverse events has been analyzed in chapter 7.  
Finally, the prognostic implications of distal location of 
the disease within the trunk of the left main stem and its 
interaction with surgical risk status have been analyzed 
in chapter 8, both with and without the presence of 
surgical high risk conditions.  
Thesis-Part 2 
This section of the thesis examines plaque composition in 
relation to coronary ostia. In chapter 9, the reference 
segment is the 10 mm segment located at the ostium of 
the three major coronary arteries, i.e. left anterior 
descending, circumflex and right coronary arteries in 
relation to those segments which are more distally 
located along the vessel, while in chapter 10 the focus is 
on left main coronary artery with respect to the ostial 
segments of left anterior descending or circumflex 
arteries. By contrasting plaque composition in those 
coronary segments known to be at high- (proximal 
segments of the main three coronary arteries) with those 
at low- (left main coronary artery and distal tract of 
coronary vessels) risk for developing acute coronary 
occlusions or prone to rupture lesions, we primarily 
intended to analyze whether lipid rich plaque regions co-
localize where culprit lesions are known to be more 
frequently located. This may carry implications for locally 
applied preventive treatment of plaque rupture in the 
future.
Thesis-Part 3 
This section focuses on the treatment of patients with 
ST-segment elevation myocardial infarction in the drug-
eluting stent era. Chapter 11 describes the study design 
while chapter 12 reports the principal findings of the 
randomized comparison of tirofiban infusion followed by 
sirolimus eluting stent implantation versus the use of 
abciximab and with bare metal stenting in this subset of 
patients. Chapter 12 reports on a sub-analysis evaluating 
the value of platelet reactivity in predicting response to 
treatment and 1-year outcome in a subset of the enrolled 
patients.
Thesis-Part 4 
The safety and efficacy of sirolimus eluting stent in 
patients with multivessel disease has been evaluated in 
this thesis section based on sub-analyses of the 
Revascularization Therapies Study (ARTS) II. In Chapters 
14, 15, 17, the effect of clinical presentation (stable 
versus unstable coronary artery disease), the use and 
impact on outcomes of glycoprotein 2b/3a inhibitors and 
the impact of disease location in proximal left anterior 
descending artery have been evaluated, respectively. 
Finally, in chapter 17, the role of a recently described 
angiographic scoring system, the so called Syntax score, 
has been tested on those patients presenting with three 
vessel disease in the context of ARTS II study.  
Thesis-Part 5 
This last section of the thesis describes the use and the 
effect on haemodynamic variables of a new 
percutaneous left ventricular assist device, the Impella 
RECOVER LP 2.5 in patients with depressed left 
ventricular ejection fraction or extensive coronary artery 
disease undergoing left ventricular pressure-volume 
loops analysis.
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Drug-Eluting Stent for Treatment of LM Disease 
Short- and Long-Term Clinical Outcome After Drug-Eluting
Stent Implantation for the Percutaneous Treatment of Left
Main Coronary Artery Disease
Insights From the Rapamycin-Eluting and Taxus Stent Evaluated At
Rotterdam Cardiology Hospital Registries (RESEARCH and T-SEARCH)
Marco Valgimigli, MD; Carlos A.G. van Mieghem, MD; Andrew T.L. Ong, MBBS, FRACP;
Jiro Aoki, MD; Gaston A. Rodriguez Granillo, MD; Eugene P. McFadden, MD, FRCPI;
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Background—The impact of drug-eluting stent (DES) implantation on the incidence of major adverse cardiovascular
events in patients undergoing percutaneous intervention for left main (LM) coronary disease is largely unknown.
Methods and Results—From April 2001 to December 2003, 181 patients underwent percutaneous coronary intervention
for LM stenosis at our institution. The first cohort consisted of 86 patients (19 protected LM) treated with bare metal
stents (pre-DES group); the second cohort comprised 95 patients (15 protected LM) treated exclusively with DES. The
2 cohorts were well balanced for all baseline characteristics. At a median follow-up of 503 days (range, 331 to 873 days),
the cumulative incidence of major adverse cardiovascular events was lower in the DES cohort than in patients in the
pre-DES group (24% versus 45%, respectively; hazard ratio [HR], 0.52 [95% CI, 0.31 to 0.88]; P�0.01). Total mortality
did not differ between cohorts; however, there were significantly lower rates of both myocardial infarction (4% versus
12%, respectively; HR, 0.22 [95% CI, 0.07 to 0.65]; P�0.006) and target vessel revascularization (6% versus 23%,
respectively; HR, 0.26 [95% CI, 0.10 to 0.65]; P�0.004) in the DES group. On multivariate analysis, use of DES,
Parsonnet classification, troponin elevation at entry, distal LM location, and reference vessel diameter were independent
predictors of major adverse cardiovascular events.
Conclusions—When percutaneous coronary intervention is undertaken at LM lesions, routine DES implantation, which
reduces the cumulative incidence of myocardial infarction and the need for target vessel revascularization compared
with bare metal stents, should currently be the preferred strategy. (Circulation. 2005;111:1383-1389.)
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Despite the recognition that coronary revascularization,in selected patients with multivessel disease, can
presently be accomplished by either a surgical or a
percutaneous approach with no significant difference in
long-term mortality,1,2 coronary artery bypass grafting
(CABG) is still considered the treatment of choice in
patients with left main (LM) disease.3 Several trials have
reported on the safety and feasibility of stent implantation
to treat LM stenosis.4,5 However, particularly in this subset
of patients, restenosis remains a major, and potentially
fatal, complication, precluding more widespread use of
percutaneous coronary intervention (PCI).4,6 In the first
observational report of patients treated with a sirolimus-
eluting stent (SES) for LM disease, a low rate of binary
restenosis and a favorable clinical outcome were reported.7
However, the benefit of drug-eluting stents (DES) on the
short- and long-term incidence of major adverse cardio-
vascular events in this setting, compared with bare metal
stents (BMS), remains largely unknown.
The purpose of the present study was to investigate, in this
subset of patients undergoing revascularization in a tertiary
referral center, the differential impact of DES as opposed to
conventional BMS on the occurrence of short- and long-term
major cardiovascular events.
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Methods
Study Design and Patient Population
Since April 16, 2002, SES (Cypher, Johnson & Johnson, Cordis unit)
have been used as a default strategy for every PCI at our institution
as part of the Rapamycin-Eluting Stent Evaluated At Rotterdam
Cardiology Hospital (RESEARCH) registry. From the first quarter of
2003, paclitaxel-eluting stents (PES) (Taxus, Boston Scientific
Corporation) became commercially available, replacing SES as the
strategy of choice in every PCI because of cost-effectiveness
considerations, as part of the Taxus Stent Evaluated At Rotterdam
Cardiology Hospital (T-SEARCH) registry. As a policy, all elective
patients presenting with significant (�50% by visual estimation) LM
disease, referred to our institution for coronary revascularization, are
evaluated by both interventional cardiologists and cardiac surgeons,
and the decision to opt for PCI or surgery is reached by consensus on
the basis of a comprehensive evaluation of the following items:
suitable anatomy and lesion characteristics for stenting and size and
quality of vessels distal to the disease and of arterial and/or venous
conduits for grafting. Finally, patient and/or referring physician
preferences for a percutaneous approach, with both aware of the
procedural risks and contraindications to surgery on the basis of the
presence of comorbidity as evaluated by a cardiac surgeon, are also
considered.
From April 16, 2002, to December 31, 2003, a total of 95
consecutive patients were treated exclusively with �1 DES in the
LM as part of an elective or nonelective revascularization procedure
and constitute the DES group of the present report. Fifty-two patients
in the first cohort (of whom procedural details and medium-term
follow-up were previously reported for 317), received SES exclu-
sively (available, at that time, in diameters from 2.25 to 3.00 mm),
whereas in the following group of 43 patients, PES (available in
diameters from 2.25 to 3.5 mm) were implanted. A control group for
comparison was composed of 86 consecutive patients who received
conventional BMS (available in diameters from 2.5 to 5.00 mm) for
LM treatment in the period immediately before the introduction of
SES. The following BMS were used: BX Sonic or BX Velocity in
35% (Cordis, Johnson & Johnson Company), R-Stent in 29% (Orbus
Medical Technologies), Multi-Link Penta in 28% (Guidant Corp),
Multi-Link Tetra in 8% (Guidant Corp), and other stents in 4%.
Therefore, the total study population comprised all 181 consecutive
patients who underwent percutaneous LM treatment from April 2001
to December 2003 with either BMS or DES in the 2 study phases,
respectively. To stratify the study population into high– and low–
surgical risk groups, the Parsonnet surgical risk score was calculated
for each patient.8 A score �15 was used to identify patients at high
risk, as previously suggested.6,9 Protected LM segment was defined
as the presence of at least 1 patent arterial or venous conduit to at
least 1 left coronary segment. Nonelective treatment was defined as
a procedure performed on referral before the beginning of the next
working day.10
This protocol was approved by the hospital ethics committee and
is in accordance with the Declaration of Helsinki. Written informed
consent was obtained from every patient.
Procedures and Postintervention Medications
All interventions were performed according to current standard
guidelines, and the final interventional strategy, including the use of
glycoprotein IIb/IIIa inhibitors, was left entirely to the discretion of
the operator, except for the stent utilization. Angiographic success
was defined as residual stenosis �30% by visual analysis in the
presence of Thrombolysis in Myocardial Infarction (TIMI) 3 flow
grade. All patients were advised to maintain the use of aspirin
lifelong. One-month clopidogrel treatment (75 mg/d) was recom-
mended for patients treated in the pre-DES phase. For patients
treated with either SES or PES, clopidogrel was prescribed for 6
months.
End Point Definitions and Clinical Follow-Up
The primary outcome was the occurrence of major adverse cardiac
events, defined as (1) death, (2) nonfatal myocardial infarction (MI),
or (3) target vessel revascularization. Patients with �1 event have
been assigned the highest ranked event, according to the previous
list. All deaths were considered to be of cardiac origin unless a
noncardiac origin was established clinically or at autopsy. MI was
diagnosed by a rise in the creatine kinase level to more than twice the
upper normal limit with an increased creatine kinase-MB fraction.
Target vessel revascularization was defined as a repeated interven-
tion (surgical or percutaneous) to treat a luminal stenosis within the
stent or in the 5-mm distal or proximal segments adjacent to the
stent, including the ostium of the left anterior descending artery
(LAD) and/or circumflex artery. Information about in-hospital out-
comes was obtained from an electronic clinical database for patients
maintained at our institution and by review of hospital records for
those discharged to referring hospitals (patients were referred from a
total of 14 local hospitals). Postdischarge survival status was
obtained from the Municipal Civil Registries. Information on occur-
rence of MI or repeated interventions at follow-up was collected by
consulting our institutional electronic database and by contacting
referring physicians and institutions and all living patients.
Statistical Analysis
Continuous variables are shown as mean�SD and were compared by
Student unpaired t test. Categorical variables are presented as counts
and percentages and were compared with the Fisher exact test.
Survival curves were generated by the Kaplan-Meier method, and
survival among groups was compared with the log-rank test. Cox
proportional hazards models were used to assess risk reduction of
adverse events. Patients lost to follow-up were considered at risk
until the date of last contact, at which point they were censored.
Univariate analysis was performed with the consideration of all
variables reported in Tables 1 and 2. Multivariate analyses, with
consideration of all variables with a value of P�0.10, were per-
formed to identify independent predictors of adverse events. Proba-
bility was significant at a level of �0.05. All statistical tests were
2-tailed. Statistical analysis was performed with the use of Statistica
6.1 (Statsoft Inc).
Results
Baseline and Procedural Characteristics
Baseline and procedural characteristics are shown in Table 1
and Table 2. The 2 groups were well matched for all baseline
characteristics, including comorbidities. Overall, the average
left ventricular ejection fraction was slightly �40%, and
approximately half of the patients in both groups were
admitted with acute coronary syndromes. Acute MI was the
indication to the procedure in 19%; 10% of the patients
presented with severe hemodynamic compromise at entry.
The distal LM was involved in two thirds of cases in both
groups, whereas patients treated with DES had significantly
more 3-vessel disease, more bifurcation stenting, a higher
number of stents, and greater total stent length per patients.
The nominal stent diameter, as a result of limited size
availability, was on average smaller in the DES group, which
explains the more common practice of postdilatation in this
group of patients. Procedural success was 99% in patients
receiving DES: in 1 patient who presented with acute MI and
shock, a final TIMI 1 flow grade was obtained, and the patient
died 3 hours after the procedure. The procedural success was
98% in patients treated in the pre-DES phase: in 2 patients
with acute MI and TIMI 0 flow grade in the left coronary
artery, the LM and proximal LAD were stented, and subse-
quently CABG was performed because of residual critical
stenosis in the left circumflex artery.
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Thirty-Day Outcomes
There were no significant differences between the DES and
the pre-DES groups in the incidence of major adverse
cardiovascular events during the first 30 days (Table 3). In the
DES group, all deaths except 3 occurred in patients pres-
enting with ST-segment elevation acute MI and cardiogenic
shock at entry. In all these patients except 4 with severe
peripheral artery disease, an intra-aortic balloon was placed
during PCI. In the elective population, a total of 2 deaths
occurred; both patients presented with unstable angina with
mild troponin elevation and were refused by surgeons be-
cause of old age (84 years), low left ventricular ejection
fraction (�30%), and diabetic chronic renal insufficiency in 1
patient and diffuse 3-vessel disease associated with small-
caliber vessels in the second. In this second patient the right
coronary artery was occluded. The reason for death was
pulmonary infection, which developed 19 days after the
procedure in the first patient, and cardiogenic shock, which
developed during the intervention, resistant to hemodynamic
support (left ventricular assist device) in the other patient. In
the pre-DES group, all 6 deaths occurred in patients with
ST-segment elevation acute MI, of whom 4 were in cardio-
genic shock at entry. No documented thrombotic stent occlu-
sion occurred in the first 30 days or thereafter.
Long-Term Outcome
After a median follow-up of 503 days (range, 331 to 873
days), the cumulative incidence of major adverse cardiovas-
cular events (death, MI, or target vessel revascularization)
was significantly lower in the DES patients than in the
pre-DES patients (24% versus 45%, respectively; hazard ratio
TABLE 1. Baseline Characteristics of the Study Population
Variables
Pre-DES Group
(n�86)
DES Group
(n�95) P
Age, y * 66�10 64�12 0.18
Men, %* 62 66 0.53
Body mass index, kg/m2* 26�4 27�4 0.31
Diabetes, %* 22 30 0.23
Non–insulin-dependent, % 17 20 0.71
Insulin-dependent, % 5 10 0.17
Hypertension, %* 57 53 0.65
Hypercholesterolemia, % 55 56 0.88
Current smoking, % 19 18 0.8
Creatinine, �mol/L* 102�80 95�31 0.36
LVEF, %* 42�13 41�14 0.85
Medical history, %
Protected LM 22 16 0.17
PCI 35 28 0.42
MI 41 38 0.58
Transient ischemic attack/stroke 8 11 0.81
Heart failure* 16 20 0.36
Severe COPD*† 5 8 0.38
Peripheral arterial disease* 24 22 0.86
Carotid artery disease* 6 6 0.98
Clinical presentation, %
Stable angina 50 48 0.8
Unstable angina 33 33 1
Acute MI* 17 20 0.70
Cardiogenic shock at entry* 9 12 0.66
Parsonnet score 16�11 19�12 0.17
LVEF indicates left ventricular ejection fraction; COPD, chronic obstructive
pulmonary disease.
*Parameters included in the Parsonnet classification.
†Resulting in functional disability or hospitalization, requiring chronic
bronchodilator therapy, or forced expiratory volume in 1 second �75% of
predicted.8
TABLE 2. Angiographic and Procedural Characteristics of the
Study Population
Variables
Pre-DES
Group
(n�86)
DES Group
(n�95) P
Lesion location, %
Ostium 18 27 0.20
Body 40 37 0.31
Distal 66 65 0.9
Pure LM disease, % 2 3 1
LM plus 1-vessel disease, % 29 17 0.4
LM plus 2-vessel disease, % 42 21 �0.001
LM plus 3-vessel disease, % 27 59 0.003
Right coronary artery �70%
stenosis, %
27 53 0.02
Right coronary artery occlusion, % 13 19 0.43
No. of implanted stents 1.2�0.5 1.4�0.6 0.01
Nominal stent diameter, mm 3.6�0.5 3.1�0.32 �0.001
Total stent length per patient, mm 20�9 24�13 0.02
Predilatation, % 67 71 0.62
Cutting balloon, % 5 6 0.94
Rotational atherectomy, % 1 3 0.8
Directional atherectomy, % 6 0 0.007
Postdilatation, % 58 80 0.01
Larger balloon inflated, mm 4�0.6 3.9�0.4 0.07
Maximal pressure, atm 17�2 17�3 0.85
Bifurcation stenting, % 10 26 0.02
Culotte* 11 36 0.4
T technique* 88 44 0.35
Crush* 0 12 0.56
Kissing technique* 0 8 0.91
Intravascular ultrasonography, % 23 27 0.36
Glycoprotein IIb/IIIa inhibitors, % 26 28 0.83
Intra-aortic balloon pump, % 16 15 0.88
Left ventricular assist device, % 0 2 0.52
Minimal lumen diameter, mm,
preintervention
1.05�0.59 1.09�0.44 0.58
Minimal lumen diameter, mm,
postintervention
2.97�0.6 2.83�0.49 0.09
Reference vessel diameter, mm,
postintervention
3.37�0.6 3.25�0.5 0.2
*Relative to patients with bifurcation stenting.
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[HR], 0.52 [95% CI, 0.31 to 0.88]; P�0.01) (Figure, A).
Mortality was similar in the DES (14%) and pre-DES cohort
(16%; HR, 0.79 [95% CI, 0.38 to 1.66]; P�0.54) (Figure, B),
whereas there was a significant reduction in both the rate of
MI (4% versus 12%, respectively; HR, 0.22 [95% CI, 0.07 to
0.65]; P�0.006) and composite death/MI (Figure, C) as well
as in the need for target vessel revascularization (6% versus
23%, respectively; HR, 0.26 [95% CI, 0.10 to 0.65];
P�0.004) (Figure, D) in the DES group. Seventy-four per-
cent of the deaths were cardiac, whereas 3 of 13 in the DES
group and 4 of 14 in the pre-DES phase were attributed to
extracardiac reasons. In Table 4, the baseline and procedural
characteristics of those patients in the DES group who
underwent target vessel revascularization during follow-up
are reported. In all cases, the lesion was located in the distal
LM, in 50% of cases diabetes was present, and all except 1
were women. In 3 cases, in-stent restenosis occurred; in 2
patients intimal hyperplasia developed at the distal edge of
the stent, whereas in 1 patient severe ostial side branch
restenosis (circumflex artery) necessitated reintervention. In
all cases, restenosis was focal (�10 mm in length) and was
successfully treated with repeated PCI. In the pre-DES group,
13 cases of pure in-stent restenosis, of which 3 were focal,
were treated with PCI (9 patients) or CABG (4 patients). In 2
patients, diffuse intimal hyperplasia associated with progres-
sion of atherosclerotic disease in other vessels was treated
with CABG, and in 5 patients (3 with ST-segment elevation
acute MI as the indication for LM intervention), staged
reintervention with CABG (in 4 patients) and PCI (in 1
patient) was performed because revascularization remained
incomplete at the time of the index procedure.
One-year adverse events in patients treated with BMS before the introduction of DES (pre-DES group) and in patients treated exclusively with
DES implantation (DES group). Cumulative risk of major adverse cardiovascular events (MACE) (A), death (B), death or MI (C), and target ves-
sel revascularization (TVR) (D) is shown.
TABLE 3. Thirty-Day Outcomes
Variables
Pre-DES Group
(n�86)
DES Group
(n�95) P*
Death, n (%) 6 (7) 10 (11) 0.60
Nonfatal MI, n (%) 8 (9) 4 (4) 0.24
Death or nonfatal MI, n (%) 14 (16) 14 (15) 0.84
Target vessel revascularization, n (%) 2 (2) 0 (0) 0.22
Repeated PCI 1 (1) 0 (0)
CABG 1 (1) 0 (0)
Any event, n (%) 16 (19) 14 (15) 0.56
Stent thrombosis, n (%)† 0 (0) 0 (0) 1
*By Fisher exact test.
†Angiographically documented.
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Predictors of Adverse Events
The Parsonnet score, ranging from 2.5 to 55.5 (mean value,
18�2; interquartile range, 16.5) was 16�11 and 19�12 in
the pre-DES and DES groups, respectively (P�0.17) (Table
1), with a trend toward a higher rate of patients considered at
high surgical risk (58% versus 46%, respectively; P�0.13) in
the DES compared with the pre-DES cohort.
On univariate analysis, Parsonnet classification, use of
intra-aortic balloon pump, presence of shock at entry,
lesion located in the distal LM, nonelective PCI, troponin
elevation at entry, TIMI flow grade before and after PCI,
reference vessel diameter, left ventricular ejection fraction,
and the use of DES were identified as significant predic-
tors of adverse events. On multivariate analysis, Parsonnet
classification, troponin elevation at entry, lesions located
at distal site, reference vessel diameter, and the use of DES
were independent predictors of major adverse cardiovas-
cular events (Table 5).
Discussion
Despite the feasibility and the high procedural success rate of
percutaneous LM intervention, the long-term incidence of
adverse events in the pre-DES “era” was often reported to be
unacceptably high in this subset of patients.4,6 This reflected
the inclusion of high-risk patients, such as those not consid-
ered “good surgical candidates,” as well as the dramatic
impact of treated vessel failure in this specific anatomic
context. In consecutive patients receiving elective BMS for
unprotected LM treatment, the 3-year cumulative incidence
of death was recently reported to be �16%.6 In that series,
28% of the population was at high surgical risk. More than
50% of our study population was at high surgical risk
according to the Parsonnet classification, thus explaining the
relatively high rate of adverse events we observed. In this
setting, when patients treated with DES were compared with
those treated with BMS, a marked benefit with respect to the
rate of major adverse cardiac events, as evidenced by a 47%
relative risk reduction, emerged in the former. This was
mainly due to the difference in the incidence of MI (67%
relative risk reduction) and target vessel revascularization
(65% relative risk reduction), with no effect on mortality. The
higher prevalence of 3-vessel disease and bifurcation stenting
in the DES group makes the observed benefit even more
convincing. The difference in the incidence of events between
TABLE 4. Characteristics of Patients in the DES Group Who Underwent Target
Vessel Revascularization During Follow-Up
Patient No.
1 2 3 4 5 6
Age, y 66 77 36 70 52 56
Gender F F F M F F
Diabetes Yes No No Yes No Yes
Lesion location Distal Distal Distal Distal Distal Distal
Severe calcification Yes No No No No No
Stent type SES SES PES PES PES PES
Stent No. 2 2 1 2 1 2
Total stent length, mm 16 36 20 48 16 36
Bifurcation stenting No Yes No Yes No Yes
Technique � � � Crush � � � Culotte � � � Culotte
Postdilatation Yes Yes Yes Yes Yes Yes
Final kissing No No No Yes No No
Gap between stents No No No No No No
Stent underexpansion Yes No No No No No
Restenosis location In-stent In-stent* RS In-stent DER DER*
Revascularization type PCI PCI PCI PCI PCI PCI
QCA after PCI
Reference vessel diameter, mm 3.74 3.27 3.53 2.65 2.44 2.76
Minimal lumen diameter, mm 2.12 1.06 3.34 2.49 1.94 2.32
Lesion length, mm 13.4 19.7 13.5 21.3 8.9 18.9
QCA at follow-up
Reference vessel diameter, mm 3.87 3.43 3.21 2.32 1.82 2.36
Minimal lumen diameter, mm 1.23 0.57 0.98 0.99 0.6 0.71
Restenosis length, mm 5.8 9.06 3.6 5.48 7.72 9.5
QCA indicates quantitative coronary angiography; In-stent, restenosis located within the stent
margins; RS, restenosis located in the side branch (the ostium of the circumflex artery); and DER,
distal edge restenosis located within the 5-mm segment distal to the stent.
*More than 1 focal site.
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the 2 groups emerged slowly after the procedure, with no
clear advantage at 30 days, possibly reflecting the specific
mechanism of action of DES on intimal hyperplasia.
The overall advantage of DES remained significant after
adjustment for the Parsonnet score, the anatomic site of
obstruction, and troponin status at entry. Therefore, our data
suggest that when percutaneous treatment of LM coronary
artery disease is undertaken, DES should be used as the
default strategy.
The LM bifurcation was frequently involved (�60%) in
our series, and even when the obstruction was more proxi-
mally located and did not directly involve the LAD or left
circumflex artery ostia, its treatment often required the
management of LM bifurcation. To date, the results of SES
implantation to treat bifurcated lesions have been relatively
disappointing, with high rates of restenosis in the side
branch.11 Our present findings are in keeping with these
previous observations, confirming that in the DES era distal
LM location is an independent predictor of adverse events at
follow-up. Furthermore, because the strategy and technical
aspects of bifurcation management were left entirely to the
preference of treating physicians, no clear conclusions can be
drawn in this regard.
Inconsistent findings have been reported thus far with
regard to the effect of DES on long-term cumulative
incidence of MI. In the first randomized clinical trials
comparing SES or PES with BMS, no difference in the
incidence of MI was observed.12,13 Second-generation
randomized trials assessing the benefit of DES in patients
selected to be at intermediate risk for in-stent restenosis or
all-inclusive registries reported trends toward MI reduction
in the DES group, but none of them reached statistical
significance.14,15 Recently, a clear reduction in the cumu-
lative incidence of MI in the DES group was reported in
the SES-SMART trial, in which a selected group of
high-risk patients has been evaluated.16 Similarly, in our
patient population, a reduced incidence of MI was ob-
served in the DES group. Of note, 2 and 1 cases of MI in
the pre-DES phase were related to target vessel revascu-
larization and not related to target vessel revascularization,
respectively. Whether this difference between studies is
the reflection of a type II error in studies enrolling patients
at low or intermediate risk remains unclear, but when the
retrospective nature of our investigation is considered, data
from prospective studies are needed to confirm our
findings.
Limitations of the Study
The present study is a single-center experience from a tertiary
referral center and lacks the clear advantages of a multicenter
randomized study. In keeping with the aim of our investiga-
tion, an “all-comers” population has been enrolled, clearly
resulting in a heterogeneous group of patients. Further stud-
ies, with larger sample sizes, are required to investigate the
differential impact of DES versus BMS in prespecified
subgroups, stratified according to clinical presentation (stable
versus unstable) or protected versus unprotected type of
treatment.
Despite the fact that the study was conducted over a relatively
short period, we cannot exclude the possibility that improve-
ments in technique or differences in drug prescription could have
partially accounted for the difference observed in terms of major
adverse cardiovascular events between groups. However, con-
ducting randomized trials that seek to assess the efficacy of DES
versus BMS in this specific subset of patients seems unlikely,
and our understanding of the benefit of drug-coated stents to
treat this group of patients will probably also rely in the near
future on well-conducted registries that are able to record and
monitor our daily clinical practice.
Conclusions
The use of DES as a default strategy to treat LM disease was
associated with a significant reduction in adverse events. The
effectiveness of DES persisted even after adjustment for
clinical and procedural variables, including the Parsonnet
TABLE 5. Univariate and Multivariate Cox Proportional
Hazards Analysis
Variables P
Hazard Ratio
(95% CI) �2
Univariate analysis
Distal LM disease 0.003 2.7 (4.8–1.53) 13.3
DES use 0.019 0.54 (0.9–0.32) 5.48
Nonelective PCI 0.0047 2.1 (3.5–1.3) 8
Intra-aortic balloon pump
use
0.0002 2.9 (4.9–1.7) 14
LVEF, % 0.00001 0.95 (0.97–0.93) 20
Parsonnet score �0.00001 1.07 (1.09–1.05) 44
Reference vessel diameter 0.00001 0.36 (0.58–0.32) 19
Shock at entry �0.00001 4.48 (7.9–2.5) 21
TIMI flow before PCI 0.03 0.75 (0.96–0.58) 4.3
TIMI flow after PCI 0.03 0.58 (0.85–0.39) 4.7
Troponin T �0.02 �g/L
at entry
0.0002 3.15 (5.26–1.9) 18
Multivariate analysis 1
Distal LM disease 0.0007 2.94 (5.5–1.57) 76
DES use 0.00009 0.33 (0.57–0.19)
LVEF, % 0.09 0.98 (1.001–0.95)
Parsonnet score 0.0009 1.04 (1.07–1.01)
Reference vessel diameter 0.005 0.51 (0.79–0.33)
Troponin T �0.02 �g/L at
entry
0.02 2.3 (4.4–1.2)
Multivariate analysis 2
Distal LM disease 0.00017 3.3 (6.1–1.7) 68
DES use 0.00018 0.35 (0.6–0.20)
LVEF, % 0.00013 0.95 (0.98–0.94)
Reference vessel diameter 0.0011 0.48 (0.74–0.30)
Shock at entry 0.006 3.49 (8.6–1.4)
Troponin T �0.02 �g/L at
entry
0.016 2.27 (4.2–1.17)
Multivariate analysis model 1 was performed with all major adverse
cardiovascular event predictors on univariate analysis; in multivariate analysis
model 2, the Parsonnet score was removed because of colinearity between the
variables included in the model and those used in the calculation of the score,
such as left ventricular ejection fraction (LVEF), use of intra-aortic balloon
pump, and presence of shock.
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surgical risk score. Our findings apply to a selected group of
patients referred for percutaneous LM treatment and suggest
that in this setting routine DES implantation, by reducing the
cumulative incidence of major adverse cardiovascular events,
should be currently regarded as the strategy of choice. Until
new evidence is provided by randomized clinical trials
directly comparing the surgical and percutaneous approaches,
CABG should remain the preferred revascularization treat-
ment in good surgical candidates presenting with LM coro-
nary artery disease.
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OBJECTIVES The purpose of this study was to investigate the long-term clinical and angiographic proﬁle
of sirolimus-eluting stent (SES) versus paclitaxel-eluting stent (PES) in patients undergoing
percutaneous intervention for left main (LM) coronary disease.
BACKGROUND The long-term clinical and angiographic impact of SES as opposed to PES implantation in
this subset of patients is unknown.
METHODS From April 2002 to March 2004, 110 patients underwent percutaneous intervention for LM
stenosis at our institution; 55 patients were treated with SES and 55 with PES. The two
groups were well balanced for all baseline characteristics.
RESULTS At a median follow-up of 660 days (range 428 to 885), the cumulative incidence of major
adverse cardiovascular events was similar (25% in the SES group vs. 29%, in the PES group;
hazard ratio 0.88 [95% conﬁdence interval 0.43 to 1.82]; p � 0.74), reﬂecting similarities in
both the composite death/myocardial infarction (16% in the SES group and 18% in the PES
group) and target vessel revascularization (9% in the SES group and 11% in the PES group).
Angiographic in-stent late loss (mm), evaluated in 73% of the SES group and in 77% of the
PES group, was 0.32 � 74 in the main and 0.36 � 0.59 in the side branch in the SES group
vs. 0.46 � 0.57 (p � 0.36) and 0.52 � 0.42 (p � 0.41) in the PES group, respectively.
CONCLUSIONS In consecutive patients undergoing percutaneous LM intervention, PES may perform closely
to SES both in terms of angiographic and long-term clinical outcome. (J Am Coll Cardiol
2006;47:507–14) © 2006 by the American College of Cardiology Foundation
Routine drug-eluting stent (DES) implantation, by reducing
the need for target vessel revascularization (TVR) and angio-
graphic restenosis, has been recently proposed as the preferred
strategy in poor surgical candidates undergoing percutane-
ous left main coronary artery (LM) intervention (1–3).
The longest average follow-up available for this treatment
is currently one year, and whether sirolimus-eluting stent
(SES) or paclitaxel-eluting stent (PES) is performing better
in these patients is unknown (1–3).
Similarly, even for more conventional lesions, the differ-
ential safety and efﬁcacy proﬁle of these two DES options is
largely debated (4–8). When taken together, current evi-
dence possibly suggests that in more complex lesion/patient
subsets, SES performs better and more safely than PES
(4–7,9).
The percutaneous management of LM lesions is a chal-
lenging intervention, where bifurcated vessels, extensive
wall calciﬁcation, and poor hemodynamic tolerance often
coexist during treatment.
The purpose of the present study was to investigate, in a
high-risk subset of patients undergoing revascularization in
a tertiary referral center, the differential long-term impact of
SES compared with PES in terms of clinical and angio-
graphic outcome. Intravascular ultrasound analysis has also
been carried out at follow-up to quantity neointimal hyper-
plasia volume.
METHODS
Study design and patient population. Since April 16,
2002, SES (Cypher; Johnson & Johnson-Cordis, Warren,
New Jersey) has been used as a default strategy for every PCI
at our institution as part of the Rapamycin-Eluting Stent
Evaluated at Rotterdam Cardiology Hospital (RESEARCH)
registry. From the ﬁrst quarter of 2003, PES (Taxus; Boston
Scientiﬁc Corp., Natick, Massachusetts) became commercially
available, replacing SES as the strategy of choice in every PCI,
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as part of the Taxus-Stent Evaluated at Rotterdam Cardiology
Hospital (T-SEARCH) registry. As a policy, all elective
patients presenting with signiﬁcant (�50% by visual estima-
tion) LM disease, referred to our institution for coronary
revascularization, are evaluated both by interventional cardiol-
ogists and by cardiac surgeons, and the decision to opt for PCI
or surgery is reached by consensus as previously described (1).
From April 16, 2002, to March 6, 2004, a total of 110
consecutive patients were treated exclusively with one or
more DES in the LM as part of an elective or nonelective
revascularization procedure and constitute the patient pop-
ulation of the present report. Fifty-ﬁve patients ﬁrst received
exclusively SES, available at that time in diameters from
2.25 to 3.00 mm, and then 55 patients received PES,
available in diameters from 2.25 to 3.5 mm. To ensure
comparability between the two study groups, the Parsonnet
surgical risk score, based on both clinical presentation proﬁle
and comorbidities, and the William Beaumont Hospital
simpliﬁed scoring system were calculated for each patient
(10,11). Nonelective treatment was deﬁned as a procedure
carried out on referral before the beginning of the next
working day (12).
The protocol was approved by the hospital ethics com-
mittee and is in accordance with the Declaration of Hel-
sinki. Written informed consent was obtained from every
patient.
Procedures and postintervention medications. All inter-
ventions were performed according to current standard
guidelines, and, except for the stent utilization, the ﬁnal
interventional strategy was left entirely to the discretion of
the operator. Angiographic success was deﬁned as residual
stenosis �30% by visual analysis in the presence of Throm-
bolysis In Myocardial Infarction (TIMI) ﬂow grade 3. All
patients were advised to maintain aspirin lifelong, and
clopidogrel was prescribed for 6 months in both groups.
End point deﬁnitions and clinical follow-up. The occur-
rence of major adverse cardiac events, deﬁned as death,
nonfatal myocardial infarction, or target vessel revascular-
ization, was recorded. Patients with more than one event
were assigned the highest ranked event, according to the
previous list. End point deﬁnitions were previously reported
(1). In order to make the clinical follow-up of the two
sequential cohorts of patients comparable, clinical outcome
of the SES cohort was censored at two years.
Quantitative angiographic and intravenous ultrasound
analysis. Quantitative analyses of all angiographic data
were performed with the use of edge-detection techniques
(CAAS II; Pie Medical, Maastricht, the Netherlands). A
value of 0 mm was assigned for the minimal luminal
diameter (MLD) in cases of total occlusion at baseline or
follow-up. Binary restenosis (BR) was deﬁned as stenosis of
�50% of the luminal diameter in the target lesion. Acute
gain was deﬁned as the MLD after the index procedure
minus the MLD at baseline angiography. Late loss (LL)
was deﬁned as the MLD immediately after the index
procedure minus the MLD at angiographic follow-up.
Quantitative angiographic measurements of the target le-
sion were obtained in the in-lesion zone (including the
stented segment as well as the margins 5 mm proximal and
distal to the stent). Intravascular ultrasound (IVUS) analysis
was performed after administration of 200 �g of intracoro-
nary nitroglycerin, with an automated pullback at 0.5 mm/s.
All IVUS procedures were recorded on VHS videotape, and
Table 1. Baseline Characteristics of the Study Population
Variables
SES Group
(n � 55)
PES Group
(n � 55)
p
Value
Age (yrs)* 64 � 12 63 � 12 0.54
Males (%)* 64 58 0.84
Body mass index (kg/m2)* 23 � 4 25 � 5 0.31
Diabetes (%)* 34 24 0.29
Hypertension (%)* 54 53 �0.99
Hypercholesterolemia (%) 58 56 �0.99
Current smokers (%) 16 20 0.8
Creatinine (�mol/l)* 96 � 32 100 � 80 0.68
LV ejection fraction (%)* 44 � 16 44 � 12 0.95
Medical history (%)
Protected left main 18 15 0.80
PCI 31 33 �0.99
Myocardial infarction 38 47 0.44
TIA/stroke 9 11 0.74
Heart failure* 16 16 �0.99
COPD severe*† 4 5 �0.99
Peripheral arterial disease* 22 16 0.63
Carotid artery disease* 9 5 0.71
Clinical presentation (%)
Stable angina 49 45 0.86
Silent ischemia 0 4 0.12
Unstable angina 33 33 �0.99
Acute myocardial infarction* 15 18 0.72
Cardiogenic shock at entry* 9 9 �0.99
Parsonnet score 20 � 13 17 � 11 0.27
William Beaumont Hospital
score‡
7.7 � 4.28 7.36 � 4.7 0.73
*Parameter included in the Parsonnet classiﬁcation. †Resulting in functional disabil-
ity, hospitalization, requiring chronic bronchodilatator therapy, or FEV1 �75% of
predicted. ‡Based on age �65 years, creatinine elevation, multivessel disease, and
occurrence of myocardial infarction within the previous 14 days.
COPD � chronic obstructive pulmonary disease; LV � left ventricular; PCI �
percutaneous coronary intervention; PES � paclitaxel-eluting stent; SES �
sirolimus-eluting stent; TIA � transient ischemic attack.
Abbreviations and Acronyms
BMS � bare-metal stent
BR � binary restenosis
CX � left circumﬂex coronary artery
DES � drug-eluting stent
IVUS � intravascular ultrasound
LAD � left anterior descending coronary artery
LL � late loss
LM � left main coronary artery
MACE � major adverse cardiac events
MI � myocardial infarction
MLD � minimal luminal diameter
PES � paclitaxel-eluting stent
RCA � right coronary artery
SES � sirolimus-eluting stent
TVR � target vessel revascularization
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images were digitized for analysis. A computer-based con-
tour detection was performed with Qurad QCU analysis
software (Curad, Wijk Bij Duurstede, the Netherlands) as
previously described (13). Intimal hyperplasia volume was
calculated as stent volume minus luminal volume. Percent-
age intimal hyperplasia was deﬁned as intimal hyperplasia
volume divided by stent volume.
Statistical analysis. The sample size was calculated on the
assumption that average late loss in the SES and PES group
would be around 0.15 mm and 0.35 mm, respectively, based
on previous ﬁndings. To detect this effect size with a sigma
value of 0.3, 85% power, and a type I error (alpha) of 0.05,
32 patients per group were required. Continuous variables
are shown as mean � standard deviation (SD) and were
compared using Student unpaired t test. Categorical vari-
ables are presented as counts and percentages and compared
with the Fisher exact test. Survival curves were generated by
the Kaplan-Meier method, and survival among groups was
compared using the log rank test. Cox proportional hazards
models were used to assess risk reduction of adverse events.
Multivariable analysis, considering all variables reported in
Tables 1 and 2 with a p value of less than 0.10, was
performed to adjust for possible confounders and identify
whether the stent received was an independent predictor of
adverse events. Probability was signiﬁcant at a level of
�0.05. All statistical tests were two-tailed. Statistical anal-
ysis was performed with Statistica 6.1 software (Statsoft,
Tulsa, Oklahoma).
RESULTS
Baseline and procedural characteristics. Baseline and pro-
cedural characteristics are shown in Tables 1 and 2. The two
groups were well matched for all baseline characteristics. In
both cohorts, half of the patients presented with a left
ventricular ejection fraction of 45% or less or with acute
coronary syndrome as indication to treatment, and 9% of
the patients presented with severe hemodynamic compro-
mise at entry. The distal LM was overall involved in
two-thirds of cases. In the SES group, nominal stent
diameter was smaller—reﬂecting the unavailability of stent
bigger than 3.0 mm during the study period—and cumula-
tive stent length tended to be shorter than in the PES
group. Bifurcation stenting was equally employed in both
groups with a clear preference for T-stenting and for culotte
technique in the SES and PES groups, respectively.
Thirty-one patients (56%) in the SES and 25 (45%) in
the PES group received intervention in one or more non-LM
lesion(s) during index procedure (p � 0.18). Complete
Table 2. Angiographic and Procedural Characteristics of the Study Population
Variables
SES Group
(n � 55)
PES Group
(n � 55) p Value
Lesion location (%)*
Ostium 27 22 0.51
Body 29 24 0.54
Distal 64 76 0.28
Pure left main disease (%) 5 5 �0.99
LM plus 1-vessel disease (%) 18 18 �0.99
LM plus 2-vessel disease (%) 20 24 0.82
LM plus 3-vessel disease (%) 57 53 0.87
Right coronary artery �70% stenosis (%) 69 64 0.88
Right coronary artery occlusion (%) 24 20 0.82
Number of implanted stents 1.43 � 0.53 1.50 � 0.6 0.49
Nominal stent diameter (mm) 3.00 � 0.25 3.29 � 0.28 �0.001
Total stent length per patient (mm) 23 � 11 27 � 13 0.07
Predilation (%) 71 60 0.15
Cutting balloon (%) 7 7 �0.99
Rotational atherectomy (%) 2 4 �0.99
Directional atherectomy (%) 0 0 �0.99
Postdilatation (%) 82 72 0.15
Bigger balloon inﬂated (mm) 3.75 � 0.48 3.70 � 0.5 0.48
Maximal pressure (atm) 18 � 5 19 � 3 0.55
Bifurcation stenting (%) 29 33 0.84
Culotte 0 20 0.009
T-technique 20 5 0.05
Crush 7 4 0.67
Kissing technique 2 4 �0.99
Intravascular ultrasonography (%) 33 27 0.53
IIb/IIIa inhibitors (%) 33 27 0.68
Intra-aortic balloon pump (%) 20 18 �0.99
Left ventricle assist device (%) 5 0 0.24
Temporary pacing during procedure (%) 7 9 �0.99
*Location of disease was not mutually exclusive among LM segments.
LM � left main coronary artery; other abbreviations as in Table 1.
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revascularization was achieved in 27 (49%) patients in the
SES and 36 (65%) in the PES group (p � 0.17).
Overall procedural success was 98%. In one patient
receiving SES, presenting with acute MI and shock, a ﬁnal
TIMI ﬂow grade 1 was obtained. An abrupt irreversible
occlusion of the circumﬂex occurred in one PES patient
after deployment of a stent in the left main and proximal left
anterior descending coronary artery (LAD).
Thirty-day outcomes. There were no signiﬁcant differ-
ences between the SES and PES groups in the incidence of
major adverse cardiac events (MACE) (death, target vessel
revascularization, or myocardial infarction [MI]) during the
ﬁrst 30 days (Table 3). Eight deaths occurred in 10 patients
presenting with ST-segment elevation acute myocardial
infarction and cardiogenic shock at entry. One elective
patient, undergoing LM treatment under left ventricular
assist device due to end-stage heart disease, died 2 days after
for cardiogenic shock, while the second elective patients
died for non-cardiovascular reasons after 19 days. No
documented thrombotic stent occlusion occurred in the ﬁrst
30 days or thereafter.
Long-term clinical outcome. After a median follow-up of
660 days (range 428 to 885 days), the cumulative incidence
Figure 1. Adverse events in patients treated with sirolimus-eluting stent
(SES group) and in patients treated exclusively with paclitaxel-eluting stent
implantation (PES group). (A) Cumulative risk of major adverse events
(MACE); (B) death or myocardial infarction (MI); and (C) target vessel
revascularization (TVR). CI � conﬁdence interval.
Table 3. 30-Day and Long-Term Outcomes
Variables
SES
Group
PES
Group
p
Value*
30-day outcome
Whole population (n � 55) (n � 55)
Death, n (%) 7 (13) 3 (5) 0.32
Nonfatal MI, n (%) 2 (4) 2 (4) �0.99
Death or nonfatal MI, n (%) 9 (16) 5 (9) 0.40
TVR, n (%) 1 (2) 0 (0) �0.99
Any event, n (%) 10 (18) 5 (9) 0.27
Stent thrombosis, n (%)† 0 (0) 0 (0)
Elective population (n � 43) (n � 43)
Death, n (%) 2 (5) 0 (0) 0.49
Nonfatal MI, n (%) 2 (5) 2 (5) �0.99
Death or nonfatal MI, n (%) 4 (9) 2 (5) 0.68
TVR, n (%) 1 (2) 0 (0) �0.99
Any event, n (%) 5 (12) 2 (5) 0.44
Stent thrombosis, n (%)† 0 (0) 0 (0) �0.99
Long-term outcome
Whole population (n � 55) (n � 55)
Death, n (%) 6 (11) 7 (13) 0.70
Nonfatal MI, n (%) 2 (4) 4 (7) 0.25
Death or nonfatal MI, n (%) 9 (16) 10 (18) 0.90
TVR, n (%) 5 (9) 6 (11) 0.67
Any event, n (%) 14 (25) 16 (29) 0.74
Stent thrombosis, n (%)† 0 (0) 0 (0) �0.99
Elective population (n � 43) (n � 43)
Death, n (%) 2 (5) 2 (5) 0.98
Nonfatal MI, n (%) 2 (5) 4 (9) 0.22
Death or nonfatal MI, n (%) 4 (9) 6 (14) 0.51
TVR, n (%) 5 (12) 5 (12) 0.82
Any event, n (%) 9 (21) 11 (25) 0.55
Stent thrombosis, n (%)† 0 (0) 0 (0) �0.99
*By Fischer exact test for 30-day outcome and by log rank test for long-term outcome.
†Angiographically documented.
MI � myocardial infarction; TVR � target vessel revascularization; other
abbreviations as in Table 1.
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of MACE did not signiﬁcantly differ in the SES compared
to the PES patients (25% vs. 29%, respectively; hazard ratio
[HR] 0.88 [95% conﬁdence interval (CI): 0.43 to 1.82]; p�
0.74) (Fig. 1A). The composite death/MI was 16% in the
SES and 18% in the PES group (HR 0.95 [95% CI: 0.38 to
2.33]; p � 0.90) (Fig. 1B), and cumulative incidence of
TVR was 9% in the SES and 11% in the PES group (HR
0.77 [95% CI: 0.23 to 2.56]; p � 0.66) (Fig. 1C).
In the elective patient population (43 patients in each
group), the cumulative incidence of MACE was similar in
the SES (21%) and PES groups (25%; HR 0.77 [95% CI
0.32 to 1.8]; p� 0.55). The composite of death/MI was 9%
in the SES and 14% in the PES group (HR 0.66 [95% CI
0.19 to 2.3]; p � 0.52), and the need for TVR was 12% in
both groups (HR 0.87 [95% CI 0.24 to 3]; p � 0.8).
The cumulative incidence of MACE was similar in
patients receiving single-vessel stenting (24% in the SES
and 27% in the PES group) and those treated with bifur-
cation stenting (31%, HR 1.38 [95% CI 0.47 to 4]; p �
0.55; and 33%, HR 1.22 [95% CI 0.45 to 3.3]; p � 0.69;
respectively.
After adjustment for nominal stent diameter and total
stent length at multivariable Cox regression analysis, SES
implantation as opposed to PES failed to emerge as an
independent predictor of MACE (HR 0.79 [95% CI 0.5 to
1.5]; p � 0.66). The same remained true after forcing the
Parsonnet score into the model.
Angiographic outcome. Thirty-ﬁve patients in the SES
(73% of eligible patients) and 38 patients in the PES group
(77% of those eligible) underwent angiographic follow-up.
Data regarding the quantitative coronary angiography for
main and side branches are presented in Tables 4 and 5,
respectively.
MAIN BRANCH. In the SES and PES groups, the main
treated branch circumﬂex was LM-LAD in 22 (63%) and
21 (55%) patients, respectively followed by LM-circumﬂex
in 6 (17%) and 8 (21%), LM alone in 5 (14%) and 6 (16%),
and LM-intermediate branch in 2 (6%) and 3 (8%), respec-
tively. In unprotected patients in the SES and PES groups,
LM-LAD was the main treated branch in 77% and in 63%,
respectively, followed by LM alone in 15% and 17%,
LM-circumﬂex in 8% and 14%, and LM-intermediate
branch in 0% and 6%, respectively.
Baseline and follow-up angiographic variables did not
differ in the two study groups. No difference was noted in
terms of BR in the two groups as the result of a similar
in-stent and in-lesion LL (Table 4).
SIDE BRANCH. All baseline angiographic variables were well
matched between SES and PES groups in the side branches
receiving stent. At follow-up, both LL and BR were similar
in the two study groups. For those side branches that did not
undergo stenting as part of LM treatment, despite a bigger
reference vessel diameter in the SES than in the PES group,
the pattern of LL was around zero in both groups (Table 5).
COMBINED ANALYSIS. When both main and side branches
were evaluated on a patient basis, in-lesion BR occurred in
7 (20%) and 12 (32%) patients in the SES and PES groups,
respectively (p � 0.44). All cases of nonocclusive restenosis
were focal (length �10 mm).
IVUS analysis. Overall, 46 patients (18 in the SES and 28
in the PES group) underwent IVUS investigation at follow-
up. Their baseline and procedural characteristics did not
differ from those receiving angiographic examination with-
out IVUS (data not shown). In 11 patients in the SES and 16
in the PES group, LM-LAD was evaluated; the study vessel
was LM-CX in 4 SES and 7 PES and LM alone in 3 SES and
5 PES patients. In two patients per group, stent malapposition
was noted. As shown in Table 6 the degree of neointimal
hyperplasia did not differ between the two study groups.
DISCUSSION
Since their introduction to the market, DES use has steadily
increased. Depending on the health care system, they are
Table 4. Quantitative Coronary Angiography Analysis of the
Main Branch
Variables
SES
Group
(n � 35)
PES
Group
(n � 38)
p
Value
Before procedure
RVD (mm) 3.20 � 0.57 3.2 � 0.73 0.82
MLD (mm) 1.26 � 0.74 1.38 � 0.49 0.62
Diameter stenosis (%) 60 � 24 59 � 16 0.85
Lesion length (mm) 9.5 � 3.34 10 � 4.44 0.56
After procedure
In-stent
RVD (mm) 3.10 � 0.5 3.2 � 0.6 0.43
MLD (mm) 2.76 � 0.5 2.81 � 0.5 0.32
Acute luminal gain (mm)* 1.50 � 0.78 1.43 � 0.75 0.66
Diameter stenosis (%) 10.7 � 10 10.8 � 9 0.97
In-lesion
RVD (mm) 2.86 � 0.6 2.77 � 0.66 0.54
MLD (mm) 2.47 � 0.54 2.46 � 0.58 0.61
Acute luminal gain (mm)* 1.21 � 0.84 1.10 � 0.83 0.54
Diameter stenosis (%) 13 � 10 11 � 9 0.45
Follow-up
In-stent
RVD (mm) 3.19 � 0.6 3.01 � 0.6 0.31
MLD (mm) 2.44 � 0.85 2.35 � 0.6 0.60
Diameter stenosis (%) 21.3 � 25 22.8 � 19 0.76
Late loss (mm)† 0.32 � 74 0.46 � 0.57 0.36
Binary restenosis, n (%)‡ 3 (9) 5 (13) 0.71
Reocclusion, n (%)§ 2 (6) 0 (0) 0.24
In-lesion
RVD (mm) 3.00 � 0.66 2.89 � 0.66 0.41
MLD (mm) 2.24 � 0.83 2.2 � 0.63 0.77
Diameter stenosis (%) 22 � 24 22 � 19 0.97
Late loss (mm)† 0.22 � 0.73 0.25 � 0.46 0.86
Binary restenosis, n (%)‡ 3 (9) 4 (11) �0.99
Reocclusion, n (%) 2 (6) 0 (0) 1
*Difference between MLD after procedure and MLD before procedure. †Difference
between MLD at follow-up and MLD after procedure. ‡All non-occlusive restenosis
were focal (length �10mm). §All two restenotic reocclusions occurred in protected
LM lesions.
MLD � minimal lumen diameter; PES � paclitaxel-eluting stent; RVD �
reference vessel diameter; SES � sirolimus-eluting stent.
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now partially or almost completely replacing bare-metal
stents (BMS) during coronary intervention.
Recently, some concerns for the consequences of using
these devices liberally have been raised, which emphasizes
the need to scrutinize those patient/lesion subsets that were
excluded from landmark randomized trials, particularly beyond
conventional eight to nine months’ follow-up (14–17). Yet
in both controlled and observational studies, a potential
differential efﬁcacy and safety proﬁle between SES and PES
has been observed, especially in patient populations consid-
ered to be at higher risk for adverse events. Thus, current
available evidence reinforces the idea that it would be improper
to attribute a class effect to DES and that a high-risk patient
population should be better evaluated to further compare
the safety/efﬁcacy proﬁle of these two stents.
The percutaneous management of LM lesions is a chal-
lenging intervention, where bifurcated vessels, extensive
wall calciﬁcation, and poor hemodynamic tolerance often
coexist during treatment as natural extensions of the ana-
tomic characteristics of the lesions (18,19). Moreover,
percutaneous LM intervention, being usually reserved to
poor surgical candidates, is often undertaken in patients
with low ejection fraction or renal dysfunction, which are
known predictors of adverse events even in patients receiv-
ing DES (16).
The main results of our analysis show that, as predicted
by the risk status of the patients, the overall event rate was
higher than that previously reported for non-LM lesions.
However, the safety/efﬁcacy proﬁle of the two DES evalu-
ated was apparently maintained at long-term follow-up,
with PES performing closely to SES in terms of both
clinical and angiographic outcome.
This statement is based on the following ﬁndings:
1. The great majority of events occurred in both groups
within one year, considering either the whole (86% in
the SES and 81% in the PES) or the elective population
(78% in the SES and 73% in the PES group). No early
or late angiographically conﬁrmed stent thrombosis has
been observed, with only one sudden death occurring in
an 86-year-old woman affected by a hematological
malignancy seven months after the index procedure.
2. The short- and long-term clinical event rate in the two
study groups was not different, and at multivariable
analysis the stent implanted failed to emerge as an
independent predictor of adverse events.
3. Angiographic and IVUS investigation demonstrated
that late loss and neointimal hyperplasia volume were
similar in the two groups of patients. The angiographic
Table 5. Quantitative Coronary Angiography Analysis in the Side Branches
Stented Branches Nonstented Branches
Variables SES Group PES Group p Value SES Group PES Group p Value
Before procedure n � 12 n � 15 n � 21 n � 23
RVD (mm) 2.63 � 0.67 2.70 � 0.61 0.69 2.44 � 0.72 2.00 � 0.55 0.02
MLD (mm) 1.16 � 0.52 1.27 � 0.77 0.69 1.68 � 72 1.47 � 0.67 0.31
Diameter stenosis (%) 56 � 21 54 � 24 0.61 27 � 28 26 � 25 0.96
Lesion length (mm) 10 � 4 11 � 8 0.76 5.7 � 3 4.9 � 2.1 0.30
After procedure
RVD (mm) 2.73 � 0.79 2.85.0 � 0.57 0.65 2.26 � 0.7 2.00 � 0.6 0.12
MLD in-stent (mm) 1.95 � 0.43 2.32 � 0.45 0.041 — —
MLD in-lesion (mm) 1.9 � 0.38 2 � 0.55 0.46 1.7 � 0.58 1.48 � 0.69 0.27
ALG in-stent (mm) 0.79 � 0.57 1 � 0.6 0.62 — —
ALG in-lesion (mm) 0.72 � 0.55 0.75 � 0.76 0.89 0.01 � 0.66 0.009 � 0.5 0.97
Diameter stenosis (%) 25 � 18 18 � 11 0.17 23 � 25 20 � 23 0.66
Follow-up
RVD (mm) 2.70 � 0.54 2.56 � 0.60 0.40 2.30 � 0.69 2.00 � 0.55 0.20
MLD in-stent (mm) 1.6 � 0.45 1.8 � 0.49 0.35 — —
MLD in-lesion (mm) 1.54 � 0.58 1.62 � 0.65 0.73 1.83 � 0.63 1.40 � 0.77 0.059
Diameter stenosis (%) 39 � 23 29 � 25 0.24 21 � 14 33 � 32 0.13
LL in-stent (mm) 0.36 � 0.59 0.52 � 0.42 0.41 — —
LL in-lesion (mm) 0.33 � 0.42 0.39 � 0.62 0.78 0.13 � 0.44 0.07 � 0.62 0.23
BR in-stent, n (%)* 3 (25) 3 (20) �0.99 — —
BR in-lesion, n (%)* 3 (25) 2 (13) 0.63 1 (5) 6 (26) 0.10
Reocclusion, n (%) 2 (6) 0 (0) 0.24 0 (0) 2 (9) 0.49
*All non-occlusive restenosis were focal (length �10 mm).
ALG � acute luminal gain; BR � binary restenosis; LL � late loss; other abbreviations as in Table 4.
Table 6. Quantitative Intravascular Ultrasound (IVUS) Results
IVUS Variables
SES Group
n � 18
PES Group
n � 28
p
Value
IVUS volumes (mm3)
Luminal 237 � 183 250 � 167 0.80
Vessel 473 � 371 528 � 351 0.63
Stent 256 � 194 267 � 174 0.81
Intimal hyperplasia 19.3 � 26 28 � 60 0.44
Intimal hyperplasia/10 mm* 6.3 � 9 9.6 � 13 0.74
Percentage intimal hyperplasia (%) 7.5 � 8 10 � 14 0.68
*Calculated as intimal hyperplasia volume divided by the length of the region of
interest expressed in mm (24 � 19 in the SES and 29 � 19 in the PES group; p �
0.49), multiplied by 10.
PES � paclitaxel-eluting stent; SES � sirolimus-eluting stent.
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outcome of the nonstented side branches was also
remarkably similar between the two groups.
Among these observations, the last one was unexpected and
deserves special attention.
In all major randomized controlled trials evaluating the
beneﬁt of SES versus BMS, the average in-stent LL for
SES was reported to be constantly equal to or below 0.20,
whereas the same ﬁgure for PES, based on PES versus BMS
studies, was around two times higher. The Prospective,
Randomized, Multi-Center, Comparison of the Cypher
Sirolimus-Eluting and the Taxus Paclitaxel-Eluting Stent
Systems (REALITY) study showed a difference between
these two DES in terms of angiographic end points that was
even bigger, with a mean in-stent LL of 0.9 in SES and 0.31
in the PES group (5). Conversely, in the current investiga-
tion we failed to show any difference between the two stents
in terms of in-stent or in-segment LL or BR, either in the
main branch or in the stented side branches. Interestingly,
this was conﬁrmed by the IVUS analysis. Although the
difference was more striking for SES, the LL in both groups
were actually much higher than the ﬁgures expected. The
explanation for this discrepancy can only be speculative for
the moment and it may suggest that angiographic response
to DES is lesion/patient-speciﬁc. Data so far available in the
literature are inconclusive in this regard. Park et al. (2)
recently reported an average late loss of 0.05 mm in 102
patients receiving SES for the treatment of unprotected left
main disease, whereas the same ﬁgure in 85 LM patients at
higher risk status, treated with either PES or SES, was
cumulatively reported to be 0.58 mm (3). Unfortunately, in
that study no distinction between SES and PES was made
(3).
The lack of availability of SES sizes bigger than 3.0 mm
during the study period, which imposed an aggressive
overdilation strategy to match LM reference diameter,
might have theoretically played a role. However, this tech-
nical issue was at least partially encountered in the series
reported by Park et al. (2) as well.
Alternatively, this difference between studies could pos-
sibly reﬂect a selection bias, with patients at higher clinical
risk based on previous cardiovascular history and comor-
bidities being more prone to develop a more aggressive
intimal proliferation after DES. To investigate this possi-
bility in an exploratory fashion (this analysis was not
prespeciﬁed for the current study), we pooled the LL for
both main branch and all stented side branches as the
outcome variable in a linear regression model. At univariate
analysis including all variables reported in Tables 1 and 2 we
found protected status to be the strongest predictor for high
LL (�� 0.47 [95% CI 0.24 to 0.7]; p� 0.001; adjusted R2�
0.39). Accordingly, we observed that in patients receiving
unprotected LM intervention (n� 59) LL was cumulatively
lower (0.31 � 0.41 vs. 0.63 � 72; p � 0.037) than in
patients receiving protected treatment (n � 14), and, of
note, all occlusive binary restenosis occurred in the protected
group of patients.
Interestingly, none of the variables reported in Tables 1
and 2 differed signiﬁcantly between patients receiving pro-
tected versus unprotected LM intervention, with the overall
Parsonnet score being 16 � 7.5 in protected versus 18 � 10
in unprotected patients (p � 0.4).
The observed difference in LL between protected versus
unprotected LM intervention might possibly outline a role
for shear stress as potential modulator of vessel response to
DES, as recently suggested by our group (20). This analysis
was exploratory in nature and clearly beyond the scope of
the current investigation. However, it underscores the need
to consider DES performance in the context of the patient
population in which the device was actually tested.
Taken together, our observations suggest that DES may
perform more effectively in good than in poor surgical
candidates, which reinforces the interest in assessing the
value of this treatment as compared with conventional
surgical approach in a properly designed randomized trial.
Study limitations. The present study is a single-center
experience from a tertiary referral center and lacks the clear
advantages of a multicenter randomized study. In particular,
despite the fact that the study was conducted over a
relatively short period, we cannot exclude the possibility that
improvements in technique or differences in drug prescrip-
tion could have partially confounded our main results.
Accordingly, the results of our study are encouraging, but
they cannot be conclusive. Studies with bigger sample sizes
and more prolonged clinical follow-ups are clearly required
to rule out the occurrence of less common device-related
side effects.
Clinical implications of the combined RESEARCH and
T-SEARCH analysis. In the overall results of the unse-
lected RESEARCH versus T-SEARCH comparison, a
shift toward more complex lesions has been noted from SES
to PES cohort (8). This difference was not conﬁrmed in our
current analysis, which focused on LM lesions cumulatively
treated over a longer period of time: more patients in the
SES group received concomitant intervention in non-LM
lesions and fewer reached complete revascularization than in
the PES cohort. However, the stent length was greater in
the PES group. When this ﬁnding is combined with the
observed shift from T-stenting in the SES period to culotte
in the PES period as bifurcation technique, it may suggest
that operators have become progressively more familiar with
DES over time and that full lesion coverage with DES had
been more frequently performed in the PES than in the
SES group. The impact of these confounders on our ﬁnal
result remains incompletely understood.
When taken together, the combined RESEARCH and
T-SEARCH analysis may reinforce the concept that in an
uncontrolled setting such as our clinical practice, the coro-
nary device in itself should probably be regarded among the
principal but clearly not as the only component of the long-
term procedural success in the DES era. Rather, the two
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drug-eluting stents available on the market should always be
put in the context of the characteristics of the treated
patients and the operator’s experience to better forecast their
effect on short- and long-term outcome.
Conclusions. After a median follow-up of two years, no
late serious adverse events, possibly suggesting a time-
dependent change in the therapeutic proﬁle of the investi-
gated devices, were observed.
In a consecutive group of patients undergoing percutane-
ous LM intervention, PES may perform closely to SES in
terms of both clinical and angiographic outcome.
A multinational multicenter randomized study is currently
ongoing to estimate the clinical value of PES-supported LM
intervention with respect to conventional surgical treatment.
Reprint requests and correspondence: Prof. Patrick W. Serruys,
Thoraxcenter, Bd-406, Dr Molewaterplein 40, 3015-GD Rotter-
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Value of IVUS in Guiding LM Stenting 
Comparison of Early Outcome of Percutaneous
Coronary Intervention for Unprotected Left
Main Coronary Artery Disease in the Drug-Eluting
Stent Era With Versus Without Intravascular
Ultrasonic Guidance
Pierfrancesco Agostoni, MD, Marco Valgimigli, MD, Carlos A.G. Van Mieghem, MD,
Gaston A. Rodriguez-Granillo, MD, Jiro Aoki, MD, Andrew T.L. Ong, MBBS,
Keiichi Tsuchida, MD, Eugène P. McFadden, MD, Jurgen M. Ligthart, BSc,
Pieter C. Smits, MD, PhD, Peter de Jaegere, MD, PhD, George Sianos, MD, PhD,
Willem J. Van der Giessen, MD, PhD, Pim De Feyter, MD, PhD, and
Patrick W. Serruys, MD, PhD
The aim of this study was to assess the short- and
mid-term clinical impact of intravascular ultrasound
guidance in 58 patients referred for elective percuta-
neous treatment of unprotected left main coronary
artery disease with drug-eluting stents. The use of
intravascular ultrasound, used in 41% of the proce-
dures, was not associated with additional clinical
beneﬁt with respect to angiographic-assisted stent
deployment. �2005 by Excerpta Medica Inc.
(Am J Cardiol 2005;95:644–647)
Intravascular ultrasound (IVUS) guidance is consid-ered mandatory by some groups for percutaneous
treatment of left main (LM) coronary artery disease,1
in particular, when drug-eluting stents (DESs) are
used.2,3 No deﬁnitive evidence for such a practice in
LM treatment exists. Previous studies, assessing the
value of bare metal stenting, failed to show any addi-
tional beneﬁt of IVUS guidance in LM percutaneous
treatment.4 We investigated the differential impact of
IVUS guidance on the short- and mid-term clinical
events in patients referred for LM percutaneous revas-
cularization with DESs.
• • •
In our institution, all elective patients presenting
with symptomatic coronary artery disease and signif-
icant (�50% by visual estimation) LM disease are
routinely treated with coronary artery bypass graft
surgery. However, the decision to perform percutane-
ous coronary intervention (PCI) may be considered
based on a comprehensive evaluation of several vari-
ables, including contraindications to surgery due to
the presence of co-morbidity, patient preference for a
percutaneous approach, and LM anatomy suitable for
stenting.
For percutaneous procedures, both sirolimus-elut-
ing stents (Cypher, Johnson & Johnson-Cordis unit,
Cordis Europa, NV, Roden, The Netherlands) and
paclitaxel-eluting stents (Taxus, Boston Scientiﬁc
Corp., Natick, Massachusetts) have been used as part
of the Rapamycin-Eluting Stent Evaluated At Rotter-
dam Cardiology Hospital and the Taxus-Stent Evalu-
ated At Rotterdam Cardiology Hospital registries, re-
spectively. These protocols were approved by the
hospital ethics committee and are in accordance with
the Declaration of Helsinki. Written informed consent
was obtained from every patient.
Angiographic success was deﬁned as residual ste-
nosis �30% by visual estimate in the presence of
Thrombolysis In Myocardial Infarction grade ﬂow 3.
All patients were advised to continue aspirin therapy
lifelong. Clopidogrel (300 mg loading dose before the
procedure and 75 mg/day) was prescribed for 6
months.
Using a validated on-line quantitative coronary
angiographic system (CAAS II, Pie Medical, The
Netherlands), reference vessel diameter, minimal lu-
minal diameter, and percent diameter stenosis were
measured at baseline and after the procedure in single-
matched views showing the smallest lumen diameter.
IVUS use was left to the operator’s discretion.
Images were obtained after intracoronary injection of
nitrates using commercially available IVUS (30-MHz
Ultracross or 40-MHz Atlantis, both from Boston Sci-
entiﬁc Corp., or 20-MHz Eagle Eye from Volcano
Inc., Rancho Cordova, California) and motorized pull-
back (0.5 or 1 mm/s). All analyses were performed
on-line by experienced operators. The external elastic
membrane area and lumen cross-sectional area were
measured using computerized planimetry according to
validated protocols.5 IVUS criteria for stent optimiza-
tion were complete stent-to-vessel wall apposition,
adequate stent expansion (deﬁned as stent cross-sec-
tional area �80% of the average reference cross-
sectional area by visual estimation), and full lesion
coverage.5 The number of procedures with IVUS
guidance performed by each operator was also evalu-
ated.
The primary outcome was the occurrence of major
adverse events, deﬁned as death (either cardiac or
From the Erasmus Medical Center, Thoraxcenter, Rotterdam, The
Netherlands. Dr. Serruys’ address is: Thoraxcenter, Bd-406, Dr Molewa-
terplein 40, 3015-GD Rotterdam, The Netherlands. E-mail: p.w.j.c.
serruys@erasmusmc.nl. Manuscript received September 17, 2004;
revised manuscript received and accepted October 28, 2004.
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noncardiac), nonfatal myocardial infarction, or target
vessel revascularization. All deaths were considered
to be of cardiac origin unless a noncardiac origin was
established clinically or at autopsy. Myocardial infarc-
tion was diagnosed by an increase in the creatine
kinase level to more than twice the upper normal limit
with an increased creatine kinase-MB fraction. Target
vessel revascularization was deﬁned as a repeat inter-
vention (either surgical or percutaneous) to treat a
lesion within the stent or within 5 mm distal or prox-
imal to the stent, including the ostium of the left anterior
descending artery or circumﬂex artery, or both.
Continuous variables are expressed as mean � SD
and were compared using Student’s unpaired t test.
Categorical variables are presented as counts and per-
centages and compared with the chi-square or Fisher’s
exact tests. Survival curves were generated by the
Kaplan-Meier method and survival between groups
was compared using the log-rank test. Cox proportion-
al- hazards models were used to assess risk reduction
of adverse events. Univariate and stepwise multivari-
ate analysis (considering variables with a p value
�0.1 at univariate analysis) were performed with the
variables reported in Tables 1 and 2, and the quanti-
tative angiographic and IVUS results in Table 3 to
identify independent predictors of adverse events. A p
value �0.05 was considered statistically signiﬁcant.
All statistical tests were 2-tailed.
From April 16, 2002, to December 31, 2003, a total
of 95 patients were treated with �1 DES for LM
disease. We excluded 21 patients with acute myocar-
dial infarction or cardiogenic shock
undergoing emergency PCI (per-
formed on referral before the begin-
ning of the next working day6) and
16 patients with protected LM (with
�1 patent bypass graft on the left
coronary artery). Thus, our group
consisted of 58 patients electively
treated for unprotected LM disease.
IVUS was performed in 24 patients
(41%). In particular, it was per-
formed before and after the proce-
dure in 14 cases, only before the
procedure in 4, and only after the
procedure in 6. Clinical and proce-
dural characteristics are listed in Ta-
bles 1 and 2, whereas quantitative
coronary angiographic results and
IVUS analysis are presented in Table
3. IVUS guidance permitted optimi-
zation of stent deployment in 29% of
cases. In particular, 4 cases (17%) of
incomplete stent apposition and 1
case (4%) of stent underexpansion
on IVUS prompted additional post-
dilatation, and in 2 cases (8%), in-
complete lesion coverage required a
second stent deployment. Six opera-
tors performed all the procedures
(range of procedures per operator 5
to 13) and 3 performed IVUS exten-
sively (67% to 80%), whereas the other operators
performed IVUS in 11% to 27% of cases (p for trend
�0.01). Procedural success was achieved in all pro-
cedures.
The overall rate of major events was 15% at a
median follow-up of 433 days (range 178 to 780). At
30 days, the rates of mortality and major adverse
events were 3% and 7%, respectively. There were 2
periprocedural non–Q-wave myocardial infarctions,
with a creatine kinase-MB peak of 61 and 69 U/L,
respectively; both patients underwent multivessel cor-
onary stenting. One death occurred the day after the
TABLE 1 Baseline Characteristics of Study Group
Variable
IVUS Imaging
p Value
Yes
(n � 24)
No
(n � 34)
Age (yrs) 62 � 12 64 � 13 0.47
Men 15 (62%) 25 (73%) 0.37
Cardiac risk factors
Diabetes 9 (37%) 10 (29%) 0.52
Hypertension 14 (58%) 20 (59%) 0.97
Hypercholesterolemia* 15 (62%) 23 (68%) 0.68
Current smoker 4 (17%) 7 (21%) 0.75
Previous PCI 12 (50%) 7 (21%) 0.02
Previous myocardial infarction 9 (37%) 17 (50%) 0.35
Unstable angina pectoris† 8 (33%) 11 (32%) 0.82
Ejection fraction (%) 52 � 10 44 � 14 0.02
Serum creatinine (�mol/L) 89 � 19 90 � 28 0.85
*Deﬁned as total cholesterol �220 mg/dl or known statin therapy.
†Deﬁned as cardiac chest pain at rest, without an increase in creatine kinase
levels or new electrocardiographic Q waves.
Data are presented as mean � SD or number (percent).
TABLE 2 Angiographic and Procedural Characteristics of Study Group
Variable
IVUS Imaging
p Value
Yes
(n � 24)
No
(n � 34)
Lesion location
Ostial 7 (29%) 3 (9%) 0.08
Midshaft 7 (29%) 9 (26%) 0.9
Distal 10 (42%) 22 (65%) 0.08
3-vessel coronary disease 11 (46%) 25 (73%) 0.03
Right coronary occluded 3 (12%) 9 (26%) –
No. of implanted stents 1.5 � 0.5 1.4 � 0.5 0.27
Total stent length (mm) 27 � 14 23 � 12 0.23
Nominal stent diameter (mm) 3.2 � 0.4 3.2 � 0.3 0.52
Predilatation 12 (50%) 21 (62%) 0.37
Postdilatation 22 (92%) 26 (76%) 0.17
Bigger balloon inﬂated (mm) 4 � 0.5 3.7 � 0.4 0.01
Maximal pressure (atm) 17.8 � 3.6 17.8 � 2.1 0.86
Intra-aortic balloon pump or left ventricular
assist device
1 (4%) 5 (15%) 0.38
Glycoprotein IIb/IIIa inhibitors 11 (46%) 8 (23%) 0.08
Bifurcation stenting* 7/10 (70%) 11/22 (50%) 0.45
T-technique 3 6 –
Culotte-technique 2 3 –
Crush-technique 2 1 –
V-technique 0 1 –
Final kissing balloon* 4/10 (40%) 10/22 (45%) 1.00
Interventions in other vessels 13 (54%) 20 (59%) 0.72
*Considered only patients with distal LM disease.
Data are presented as mean � SD or number (percent).
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procedure in a patient with severe left ventricular
dysfunction due to a previous myocardial infarction
and diffuse 3-vessel disease who developed cardio-
genic shock during the intervention; the patient’s con-
dition initially stabilized with a left ventricular assist
device, but the patient ﬁnally succumbed. Another
death occurred 19 days after the procedure in an
elderly patient with a low ejection fraction and dia-
betic chronic renal insufﬁciency. The cause of death
was severe sepsis due to a pulmonary infection. A
third death occurred 9 months after the index proce-
dure due to a low-cardiac output syndrome after cor-
onary artery bypass surgery performed because of
progression of atherosclerotic dis-
ease in other vessels. Finally, there
were 4 target vessel revasculariza-
tions: 2 patients underwent repeat
PCI, whereas the others underwent
surgical revascularization. Overall,
the mortality rate was 5%, the myo-
cardial infarction rate was 3%, and
the target vessel revascularization
rate was 7%.
The incidence of major adverse
events was 2 of 24 (8%) in the IVUS
group and 7 of 34 (20%) in the non-
IVUS group (p � 0.18). At univari-
ate analysis, the only signiﬁcant pre-
dictors of events were distal LM
involvement and reference vessel di-
ameter. At multivariate analysis, dis-
tal LM disease remained a signiﬁcant
predictor of adverse events, with a
hazard ratio of 7.7 (95% conﬁdence
interval 1 to 62.6, p � 0.05). To test
the effect of IVUS guidance in dif-
ferent anatomic LM subsets, we
stratiﬁed patients into 2 groups: non-
distal versus distal LM involvement.
In the former, IVUS was performed
in 14 of 26 patients (54%) and the
rate of events was low: only 1 non-
cardiac death (4%) occurred after a
non–IVUS-guided procedure. In the
latter, IVUS was performed less of-
ten (p � 0.08) (i.e., in 10 of 32
patients [31%]), but the rate of
events was not signiﬁcantly differ-
ent between IVUS and non-IVUS
procedures (p � 0.69), with 2
events in 10 patients (20%) versus
6 in 22 patients (27%), respectively
(Figure 1).
• • •
Although IVUS guidance has
been strongly recommended in per-
cutaneous LM treatment, our re-
sults do not support the hypothesis
that routine use of IVUS is manda-
tory to optimize clinical outcome.
The rate of events did not differ
signiﬁcantly between IVUS and an-
giographic-guided procedures, where the use of
IVUS was left to the discretion of the operator.
Furthermore, the anatomic location of the athero-
sclerotic disease in the LM artery was the only
independent predictor of events at follow-up, fur-
ther strengthening this observation. When ostial or
mid-LM disease is treated with DESs, the rate of
cardiac events is particularly low. Thus, routine
IVUS does not confer any beneﬁt in this subpopu-
lation with an excellent outcome. In patients with
distal LM involvement, the rate of events was sig-
niﬁcantly higher, but also in this instance, no sig-
niﬁcant clinical beneﬁt occurred in the IVUS sub-
FIGURE 1. Kaplan-Meier major adverse events: free survival curves of IVUS versus
non–IVUS-guided procedures, stratiﬁed according to the anatomic location of athero-
sclerotic disease in the LM artery.
TABLE 3 Quantitative Coronary Angiography and Quantitative Coronary
Ultrasound Results of Study Group
Variable
IVUS Imaging
p Value
Yes
(n � 24)
No
(n � 34)
Quantitative coronary angiography
Reference vessel diameter (mm) 3.37 � 0.40 3.21 � 0.56 0.24
Lesion length (mm) 7.47 � 3.05 7.33 � 3.11 0.89
Before intervention
Minimal luminal diameter (mm) 1.19 � 0.40 1.13 � 0.39 0.53
Diameter stenosis (%) 62.0 � 11.3 62.4 � 13.8 0.91
After intervention
Minimal luminal diameter (mm) 2.93 � 0.45 2.83 � 0.50 0.45
Diameter stenosis (%) 14.5 � 10.1 12.1 � 11.1 0.24
Quantitative coronary ultrasound before
intervention
Lumen cross-sectional area (mm2) 4.4 � 0.77 – –
External elastic membrane area (mm2)* 20.2 � 2.56 – –
Minimal luminal diameter (mm) 2.03 � 0.20 – –
After intervention
Lumen cross-sectional area (mm2) 12.0 � 1.86 – –
Minimal luminal diameter (mm) 3.68 � 0.28 – –
*External elastic membrane area could not be analyzed in 3 patients (12% of patients in the IVUS
group) because of extensive calciﬁcation.
Data are presented as mean � SD.
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group. However, because IVUS was used in a
smaller number of patients with respect to the group
with nondistal LM involvement, it is possible that
routine IVUS guidance is useful when the distal LM
artery is diseased, and such a strategy warrants
further evaluation.
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Comparison of Left Ventricular Diastolic Function
After On-Pump Versus Off-Pump Coronary Artery
Bypass Grafting
Kenneth K. Ng, MBBS, Zoran B. Popovic, MD, Richard W. Troughton, MBChB,
Jose Navia, MD, James D. Thomas, MD, and Mario J. Garcia, MD
We evaluated diastolic function in patients who under-
went elective revascularization by standard on-pump
coronary artery bypass graft (CABG) surgery versus
off-pump CABG. Diastolic function improved in both
groups, but indexes of early diastolic ﬁlling and myo-
cardial relaxation improved more in patients who un-
derwent on-pump than off-pump CABG. �2005 by
Excerpta Medica Inc.
(Am J Cardiol 2005;95:647–650)
Over the last decade, several indexes of diastolicfunction have been validated for assessing left
ventricular (LV) relaxation, LV stiffness, and left
atrial contractility. Both the color M-mode Doppler-
derived propagation velocity and diastolic intraven-
tricular pressure gradients are closely related to the
time constant of isovolumic relaxation � and with LV
suction.1,2 We have also demonstrated that transmitral
pulsed Doppler early ﬁlling deceleration time may be
quantitatively used to estimate LV stiffness3 and that
a combination of the mitral inﬂow pulsed-Doppler
atrial-wave acceleration and pulmonary venous atrial
reversal velocity provides an estimate of left atrial
contractility.4 Accordingly, we sought to determine
the effect of surgical revascularization on LV diastolic
function as measured by these Doppler indexes and to
compare the changes in patients undergoing standard
on-pump coronary artery bypass surgery (CABG-
CPB) versus off-pump CABG (CABG-OP).
• • •
This was a prospective case-control study of pa-
tients who underwent elective CABG for chronic sta-
ble angina with a normal preoperative ejection frac-
tion of �50%. Patients who had valvular disorders
requiring valve replacement and those who were not
in sinus rhythm, which would make it difﬁcult to
assess diastolic function, were excluded. Fourteen pa-
tients who underwent CABG-OP and 16 patients who
underwent CABG-CPB were recruited and all of them
gave informed consent. Medications such a � block-
ers, calcium antagonists, and long-acting nitrates were
not discontinued before operation. The decision to
assign the patient to either CABG-CPB or CABG-OP
was a clinical decision made by an independent group
of cardiothoracic surgeons. The study protocol was
From the Departments of Cardiology and Cardiothoracic Surgery,
Cleveland Clinic Foundation, Cleveland, Ohio. Dr. Garcia’s address
is: Department of Cardiology, Desk F-15, The Cleveland Clinic Foun-
dation, 9500 Euclid Avenue, Cleveland, Ohio 44195. E-mail:
garciam@ccf.org. Manuscript received May 25, 2004; revised
manuscript received and accepted October 22, 2004.
TABLE 1 Demographic and Clinical Characteristics of
Patients Who Underwent Off-pump (CABG-OP) and
On-pump (CABG-CPB) Coronary Artery Bypass Surgery
CABG-OP CABG-CPG
Variable (n � 14) (n � 16) p Value
Age (yrs) 64 � 13 66 � 9 0.47
Men 9 (64%) 14 (88%) 0.50
Hypertension 9 (64%) 10 (63%) 1.0
Diabetes mellitus 5 (36%) 4 (25%) 1.0
Smoker 3 (21%) 4 (25%) 1.0
Peripheral vascular disease 3 (21%) 1 (6%) 0.39
Angiotensin-converting
enzyme inhibitor
6 (43%) 4 (25%) 0.25
�-blockers 13 (93%) 15 (94%) 1.0
Calcium channel antagonists 4 (29%) 4 (25%) 0.16
Antiplatelet agents 14 (100%) 16 (100%) NA
Statin therapy 9 (64%) 13 (81%) 0.42
Preoperative LV ejection
fraction (%)
57 � 6 55 � 4 0.33
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Single-vessel versus Bifurcation Stenting for the Treatment of Distal 
Left Main Coronary Artery Disease in the Drug Eluting Stenting Era 
Clinical and Angiographic Insights into the RESEARCH and T-SEARCH Registries 
Marco Valgimigli, MD, Patrizia Malagutti, MD, Gaston A. Rodriguez Granillo, MD, Keiichi Tsuchida, MD, PhD, Héctor M. 
Garcia-Garcia, MD, Carlos A.G. van Mieghem, MD, Willem J.Van der Giessen, MD, PhD, Pim De Feyter, MD, PhD, Peter de 
Jaegere, MD, PhD, Patrick W Serruys, MD, PhD 
Background: Routine drug eluting stent (DES) implantation has recently improved outcome in patients undergoing 
percutaneous treatment of left main (LM) coronary artery. However, even in the DES era, distal LM treatment remains 
an independent predictor of poor outcome. Whether single-vessel (SVS) or bifurcation stenting (BS) should be performed 
to optimize treatment of such a lesion is unclear. 
Methods: From April 2002 to June 2004, 94 patients affected by distal LM disease (DLMD) underwent percutaneous 
intervention at our institution either with SVS (n=48) or BS (n=46). The two groups were well balanced for all baseline 
characteristics but extension of disease in the LM carina.
Results: After a median follow-up of 587 days (range: 328-1179), the cumulative incidence of MACE was similar 
between the two groups (31% in the BS vs. 28% in SVS group; HR 0.96 [95% CI: 0.46-1.49]; p=0.92), with no 
difference for the composite death/myocardial infarction or target vessel revascularization (TVR). After adjustment for 
confounders, technique of stenting was not a predictor of either MACE or TVR. Angiographic analysis �performed in 81% 
of eligible patients in SVS and 87% in the BS group� confirmed the equivalency between single-vessel versus bifurcation 
stenting.
Conclusions: In consecutive patients undergoing catheter-based distal LM intervention, single-vessel or bifurcation 
stenting may perform equally under both clinical and angiographic perspective in current DES era. 
Am Heart J 2006, in press 
INTRODUCTION
Routine drug eluting stent (DES) implantation, by 
reducing the need for target vessel revascularization 
(TVR) and angiographic restenosis, has been recently 
shown to favourably affect outcome with respect to bare 
metal stents (BMS) in patients undergoing percutaneous 
left main (LM) intervention(1-3). However, the rate of 
major cardiovascular events in the DES era remains high 
in the first series of patients reported(1, 3).  
This appears to be especially true for patients 
undergoing treatment of distal LM disease.  
Some early observational studies in the BMS era 
identified distal location of the disease with respect to LM 
anatomy as a major determinant of restenosis in patients 
receiving percutaneous treatment of the LM(4). Similarly, 
others and we have reported that even in the DES era 
the great majority of lesions, which undergo TVR at 
follow-up, are located in the distal tract of the LM(1, 3). 
Taken together, current evidence may suggest that 
special attention must be paid to optimize treatment of 
distal LM disease. 
Two recent randomized trials, in which mainly non-LM 
bifurcated lesions were treated with the use of DES, 
reported no advantage of scaffolding the whole 
bifurcation carina compared to the simpler single-vessel 
stenting approach(5, 6). 
Whether this holds true also for the treatment of distal 
LM, where bigger reference size of the vessels involved 
in the bifurcation might theoretically better accommodate 
the stent-related intima hyperplasia, remains largely 
unknown. 
Thus, the purpose of the present study was to 
investigate the clinical and angiographic outcome of 
single-vessel versus bifurcation stenting to treat distal LM 
lesions in patients undergoing DES-supported 
revascularisation in a tertiary referral center. 
METHODS
Study Design and Patient Population 
Since April 16 2002, SES (Cypher™, Johnson � Johnson-Cordis 
unit) have been used as a default strategy for every PCI at our 
institution as part of the Rapamycin-Eluting Stent Evaluated At 
Rotterdam Cardiology Hospital (RESEARCH) registry. From the 
first quarter of 2003, PES (Taxus™, Boston Scientific 
Corporation) became commercially available, replacing SES as 
the stent of choice in every PCI, as part of the Taxus-Stent 
Evaluated At Rotterdam Cardiology Hospital (T-SEARCH) 
registry. As a policy, all elective patients presenting with 
significant (>50% by visual estimation) LM disease, referred to 
our institution for coronary revascularisation, are evaluated both 
by interventional cardiologists and cardiac surgeons and the 
decision to opt for PCI or surgery is reached by consensus, as 
previously described(1).  
From 16th April 2002 to June 28 2004, a total of 130 consecutive 
patients were treated exclusively with one or more DES in the 
LM as part of an elective or non-elective revascularisation 
procedure. Ninety-four patients, presenting with distal LM 
disease, defined as significant lumen obstruction (>50%) at 
visual estimation occupying the third distal of the LM shaft with 
the entire lesion or part of it either directly involving the ostium 
of the left anterior descending and/or circumflex artery�
including the intermediate branch if presenting with a reference 
diameter �2.5 mm� or in close contact with at least one of the 
ostia, constitute the patients population of the present report. 
Thirty-seven patients in the first cohort received exclusively SES 
–available, at that time, in diameters from 2.25 to 3.00 mm- 
while, in the following group of 63 patients, PES –available in 
diameters from 2.25 to 3.5 mm- were implanted.  
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The Parsonnet surgical risk score, based on both clinical 
presentation profile and comorbidities, was calculated for each 
patient as previously described(7). Similarly, in order to assess 
clinical outcome in the two study groups based on a previously 
validated PCI risk-score, the William Beaument Hospital 
simplified scoring system was also calculated for each 
patient(8).  
Protected LM segment was defined by the presence of at least 
one patent arterial or venous conduit to at least one left 
coronary segment. Non-elective treatment was defined as a 
procedure carried out on referral before the beginning of the 
next working day(9). 
This protocol was approved by the hospital ethics committee 
and is in accordance with the declaration of Helsinki. Written 
informed consent was obtained from every patient. 
Procedures and Post-Intervention Medications 
All interventions were performed according to current standard 
guidelines and the final interventional strategy, including single- 
versus bifurcation stenting and the use of glycoprotein IIb/IIIa 
inhibitors, was entirely left to the discretion of the operator, 
except for the stent utilization. Angiographic success was 
defined as residual stenosis < 30% by visual analysis in the 
presence of TIMI 3 grade flow. All patients were advised to 
maintain aspirin lifelong, while clopidogrel was prescribed for 6 
months in both groups. 
Endpoint Definitions and Clinical Follow-up 
The occurrence of major adverse cardiac events, defined as 1) 
death, 2) non-fatal myocardial infarction, or 3) target vessel 
revascularization was recorded. Patients with more than one 
event have been assigned the highest ranked event, according 
to the previous list. All deaths were considered to be of cardiac 
origin unless a non-cardiac origin was established clinically or at 
autopsy. Myocardial infarction was diagnosed by a rise in the 
creatine kinase level to more than twice the upper normal limit 
with an increased creatine kinase-MB fraction. Target vessel 
revascularization was defined as a repeat intervention (surgical 
or percutaneous) to treat a luminal stenosis within the stent or 
in the 5-mm distal or proximal segments adjacent to the stent, 
including the ostium of the left anterior descending artery (LAD) 
and/or circumflex artery (LCx). Information about in-hospital 
outcomes was obtained from an electronic clinical database for 
patients maintained at our institution and by review of hospital 
records for those discharged to referring hospitals (patients 
were referred from a total of 14 local hospitals). Post-discharge 
survival status was obtained from the Municipal Civil Registries. 
Occurrence of MI or repeat interventions at follow-up were 
collected by consultation of our institutional electronic database, 
by contacting referring physicians and institutions and all living 
patients. 
Statistical Analysis 
Continuous variables are shown as mean�SD or median and 
interquartile range (IQR) and were compared using Student’s 
unpaired t-test. Categorical variables are presented as counts 
and percentages and compared with the Fisher’s exact test. 
Survival curves were generated by the Kaplan-Meier method 
and survival among groups was compared using the log-rank 
test. Cox proportional hazards models were used to assess risk 
reduction of adverse events. Multivariable analysis, considering 
all variables reported in table 1 with a p value of less than 0.10, 
was performed to adjust for confounders and identify whether 
the treatment strategy was an independent predictor of adverse 
events. Probability was significant at a level of <0.05. All 
statistical tests were 2-tailed. Statistical analysis was performed 
on Statistica 6.1 (Statsoft Inc. Tulsa, Oklahoma).  
Table 1. Baseline Characteristics of the Study 
Population 
SINGLE-
VESSEL
STENTING
BIFURCATION 
STENTING
P
VALUE
VARIABLES (N=48) (N=46)  
Age
(ys)* 64�12 63�11 0.95
Males
(%)* 67 60 0.74 
Body Mass Index  
(kg/m2) * 24�4 24�4 0.98
Diabetes  
(%)* 25 28 0.82 
Hypertension  
(%)* 58 69 0.62 
Hypercholesterolemia  
(%) 61 70 0.80 
Current Smokers  
(%) 17 22 0.64 
Creatinine  
(�mol/L)* 102�52 100�45 0.82
LV Ejection Fraction  
(%)* 44�12 45�14 0.51
Medical History     
Protected LM  
(%) 19 15 0.79 
PCI 
(%) 37 24 0.37 
Myocardial Infarction 
(%) 40 39 >0.99 
Clinical Presentation     
Stable Angina 
(%) 48 54 0.86 
Unstable Angina 
(%) 27 28 >0.99 
AMI*
(%) 23 15 0.45 
Cardiogenic Shock at Entry* 
(%) 10 9 >0.99 
Parsonnet Score 
(%) 18�14 18�11 0.77
Parsonnet score > 15 
(%) 24 (50) 23 (50) >0.99 
Bifurcation lesion 
classification     
Isolate distal LM  
Stenosis (%) 22 2 0.02 
Distal LM plus ostial LAD or 
LCx (%) 35 28 0.67 
Distal LM plus both LAD/ 
LCx ostia (%) 31 61 0.06 
Isolate LAD or LCx ostium 
stenosis (%) 12 9 0.72 
LM plus 1-vessel Disease 
(%) 17 15 0.79 
LM plus 2-vessel Disease 
(%) 21 33 0.37 
LM plus 3-vessel Disease 
(%) 60 48 0.60 
Number of implanted  
stents 1.2�0.46 2.2�0.48 <0.0001
Nominal stent diameter 
(mm) 3.17�0.27 3.21�0.30 0.56
Total stent length per 
patient (mm) 20�7 38�11 <0.0001
Gp IIb/IIIa inhibitors  
(%) 33% 35% >0.99 
SES/PES  
(%) 40/60 35/65 0.67 
Final kissing ballon  
(%) 23 61 0.02 
LV: left ventricular; AMI: acute myocardial infarction; PES: paclitaxel-
eluting stent; SES: sirolimus-eluting stent; LAD: left anterior descending 
artery; LM: left main; LCx: circumflex artery; *: parameters included in 
the Parsonnet score. 
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RESULTS
Baseline and Procedural CharacteristicsAmong the 94 
patients with de novo left main lesions included in this 
analysis, 48 (51%) received single-vessel stenting (LM 
plus LAD or LM plus LCx) while 46 (49%) received 
bifurcation stenting: the culotte technique was performed 
in 17 (37%), T-stenting in 15 (33%), crush-stenting in 8 
(17%) and V-stenting in 6 (13%). Baseline and 
procedural characteristics of the patient population, 
stratified into the treatment-received, are shown in 
TABLE 1. The two groups were well matched for all 
clinical characteristics, including the Parsonnet surgical 
risk score.
The anatomical location and extension of the LM disease 
was the main driver of the choice to use a single- or 
double-vessel stenting, with single-vessel stenting (SVS) 
performed as the strategy of choice in case of isolate 
distal LM stenosis, while bifurcation stenting (BS) was 
the most frequent approach in cases of distal LM disease 
involving both LAD and LCx ostia.
Clinical Outcome 
Short- and long-term outcome is reported in Table 2.
Table 2. 30-Day and long-term Outcomes 
VARIABLES SINGLE-VESSELSTENTING
BIFURCATION 
STENTING
P
VALUE*
 (N=48) (N=46)
30-day Outcome   
Death,  
no (%) 4 (8) 3 (7) >0.99 
Non-fatal MI,  
no (%) 3 (6) ‡ 1 (2) 0.62 
Death or non fatal MI, 
no (%) 7 (15) 4 (9) 0.53 
TVR,  
no (%) 0 (0) 0 (0) >0.99 
Any Event,  
no (%) 7 (15) 4 (9) 0.53 
Stent thrombosis, 
 no (%)† 0 (0) 0 (0) >0.99 
Long-term outcome  
Death, 
no (%) 5 (10) 5 (11) 0.98 
Non-fatal MI, 
no (%) 5 (4) 2 (7) 0.44 
Death or non fatal MI, 
no (%) 10 (21) 7 (15) 0.39 
TVR,  
no (%) 5 (10) 6 (13) 0.38 
Any Event,  
no (%) 15 (31) 13 (28) 0.92 
Stent thrombosis,  
no (%)† 0 (0) 0 (0) >0.99 
*: By Fischer’s exact test for 30-days outcome and by log-Rank Test for 
long-term outcome 
†: Angiographically documented
‡: in 2 cases CK-MB increased more than 2 but less than 3 times the 
upper limit of normal; setting the threshold for the definition of 
periprocedural myocardial infarction at 3 times the upper limit of normal, 
in accordance with current ACC/AHA guidelines, would result in one event 
per group at 30 days.  
After a median follow-up of 587 days (range: 328-1179), 
the cumulative incidence of MACE was very similar in 
both groups (31% in the SB vs. 28% in SVS group; HR 
0.96 [95% CI: 0.46-1.49]; p=0.92) (FIGURE 1A): the 
composite death/MI was 21% in the SVS and 15% in the 
BS group (HR 0.64 [95% CI: 0.23-1.78]; p=0.39), while 
cumulative incidence of TVR was 10% and 13% in 
patients receiving SVS and BS, respectively (HR 1.03 
[95% CI: 0.3-3.2]; p=0.38) (FIGURE 1B). Stratifying the 
patient population into surgical risk-status according to 
Parsonnet score, the treatment received failed to be a 
predictor of MACE both in the low- (HR 1.3 [95% CI: 
0.38-4.59]; p=0.66), or in the high-risk (HR 0.86 [95% 
CI: 1.34-2.17]; p=0.74) group. The median (IQR) value 
of the William Beaument Hospital simplified scoring 
system was 7(4-11); the rate of MACE was 17% vs. 13% 
(p>0.99) in patients with a total score below 7 and 46% 
vs. 43% (p>0.99) in patients scoring above the median 
value, in the SVS and BS group, respectively. 
Similarly, the MACE rate did not differ in the single-vessel 
versus bifurcation stenting group when the cohorts of 
patients receiving SES (31% in both groups, p=0.93) or 
PES (31% and 27% in the SVS and BS, respectively; 
p=0.89) were separately analyzed. 
The stenting technique employed in the treatment of the 
left main coronary artery failed to impact on outcome  
Fig. 1 Adverse events in patients affected by distal left 
main disease, treated either with single-vessel stenting 
(SVS group) technique or with bifurcation stenting (BS 
group). 
A
0 200 400 600
Days
50
40
30
20
10
0
P
ro
ba
bi
it
y 
of
 M
A
C
E 
(%
)
Single-Vessel Stenting
Bifurcation Stenting
28%
31%
Hazard Ratio 0.96
[95% CI: 0.46-1.99];  p=0.92) 
Cumulative risk of major adverse events 
B
0 200 400 600
Days
50
40
30
20
10
0
P
ro
ba
bi
lit
y 
of
 T
V
R
 (%
)
Single-Vessel Stenting
Bifurcation Stenting
Hazard Ratio 1.03
[95% CI: 0.3-3.2];  p=0.38) 
13%
10%
Target vessel revascularization 
Chapter  5
50
even in the subgroup of patients undergoing elective 
intervention (HR 1.01 [95% CI: 0.40-2.5]; p=0.78) with 
an observed MACE rate at long-term follow-up of 33% 
and 31% in the SVS and BS group, respectively. 
After adjustment for total stent length, bifurcation lesion 
classification, use of IVUS and performance of final 
kissing, BS failed to emerge as an independent predictor 
of MACE or TVR. 
The same held true when bifurcation lesion classification, 
as factor potentially able to bias the comparison, was 
removed from multivariable analysis.
Quantitative Coronary Analysis 
Thirty-five patients (81% of eligible patients) in the SVS 
and 36 (87% of eligible patients) in the BS group 
underwent coronary angiography at follow-up.  
Main branch vessel size, minimal lumen diameter, lesion 
length and degree of stenosis were similar at baseline in 
the SVS and BS groups (TABLE 3). At both in-stent and 
in-lesion analyses, ALG was similar between the two 
groups immediately after the procedure as was the case 
for LL at follow-up. Thus, no difference in the net luminal 
gain was observed in the main branch between patients 
receiving or not receiving a stent in the SB.
In the side branch analysis, RVD tended to be bigger, 
with longer lesion length and greater degree of stenosis 
in BS group with respect to patients undergoing SVS 
(TABLE 3). ALG in the side braches receiving stenting was 
bigger than in those not receiving stent, thus offsetting 
the higher LL observed in the stent group, with an 
overall NLG of 0.04�0.75 in the BS and 0.47� 0.68 in the 
SVS group (p=0.023).  
When patients undergoing balloon angioplasty in the side 
branch were compared to those receiving stent (BS 
group) (TABLE 4 and FIGURE 2), in-lesion analysis showed 
that the two groups were well matched for all baseline 
quantitative measures. Immediately after the procedure, 
ALG tended to be bigger while DS smaller in patients 
receiving stent. However, at follow-up LL was 
significantly higher in the SB group, which completely 
compensated the bigger gain obtained immediately after 
the procedure compared to the balloon group, with a 
final net luminal gain almost identical between patients 
treated with stent or balloon angioplasty.Finally, on a 
patient-basis, the cumulative in-lesion BR for both main 
and side branches occurred in 26% and 25% of the 
cases in the single vessel and bifurcation stenting group, 
respectively (p>0.99). 
DISCUSSION
The treatment of stenosis at a bifurcation remains one of 
the most challenging lesion subsets in coronary 
angioplasty. Bifurcation lesions carry a risk of SB 
occlusion due to plaque redistribution, the so-called 
“plaque shift” across the carina of the bifurcation. Yet, 
with the advent of metallic stent, the acute risk of side 
branch closure has remarkably decreased. However, the 
long-term outcome of side branches may be often 
disappointing when both branches have to be 
stented(10, 11). Thus, provisional stenting of the side 
branch has been regarded as the strategy of choice in 
the BMS era to handle bifurcation lesions(12). 
These two-treatment strategies, manly main branch 
stenting plus provisional stenting of the side branch 
versus default double-vessel stenting, were recently 
compared in two randomized trials accomplished with 
unrestricted use of SES(5, 6). They both showed no 
advantage of bifurcation stenting over the more simple 
one-vessel stenting technique, with some safety 
concerns related to the unexpectedly high rate for stent 
thrombosis in the group allocated to double-vessel 
stenting in one of the two investigations(6). Colombo et 
al. excluded patients with LM lesions while only three 
patients with distal LM were enrolled in the second study. 
Thus, whether single-vessel or bifurcation stenting 
should be the strategy of choice in patients presenting 
with distal LM stenosis remains currently unclear. The 
bigger reference size of the vessels involved in the 
bifurcation might better accommodate the stent-related 
intima hyperplasia, thus giving a theoretical advantage to 
the full stent-coverage of the LM carina with respect to 
balloon-based treatment of the side branch. 
The main finding of our investigation is that the short- 
and long-term outcome of patients undergoing distal LM 
intervention was similar with respect to MACE rate for 
patients receiving single-vessel or bifurcation stenting. 
This remained true in both low and high surgical risk 
cohorts of patients and was not affected by the stent 
type employed. Patients receiving bifurcation stenting, 
despite being well matched for all clinical characteristics 
with respect to patients treated with single-vessel 
stenting, were more frequently affected by a true 
bifurcation lesion with a greater disease extension in the 
ostia of main left coronary arteries. After adjusting for 
this important confounder at multivariable analysis, the 
treatment technique failed to be predictive of outcome. 
This clinical observation was supported further by our 
angiographic findings. 
The angiographic outcome of the MB did not differ in the 
SVS compared to BS group. It has been recently 
proposed in benchtop models of arterial bifurcations that 
maximizing the total cross sectional area of both 
branches through aggressive stent-based scaffolding 
could have an adverse effect on MB flow pattern and in 
so doing impair long-term MB patency(13). Our data do 
not support this hypothesis. Acute luminal gain in the SB 
was almost double in the stented compared to the non-
stented cohorts of patients, while LL and NLG in MB 
resulted to be very similar at follow-up between the two 
groups. Excluding the cases where, thanks to favorable 
anatomy, the no touch policy in the SB was carried out, 
angiographic quantitative data in the SB undergoing 
stenting were well matched at baseline compared to 
those treated with balloon angioplasty. This stratification 
process allowed us to perform a univariate direct 
comparison between these two groups: stenting a SB led 
to a greater ALG with respect to the balloon angioplasty 
after the procedure. However, even if probably reduced 
compared to historical reports with BMS(10, 11), the 
price of stenting remains in the DES era a moderate 
positive LL, while there was a mild additional gain (which 
means a negative LL) in the SB undergoing balloon-
based treatment. Thus, NLG in SB treated with either 
technique was nearly identical at follow-up despite clear 
differences in the process that led to this final result. 
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Table 3 Quantitative Coronary Analyses
SVS GROUP
STENTED VESSEL 
BS GROUP
STENTED VESSEL
SVS GROUP
NON STENTED 
VESSEL
BS GROUP
STENTED VESSEL
VARIABLES MAIN BRANCH P-VALUE SIDE BRANCHES P-VALUE
BEFORE PCI (N=35)   (N=36)  
(N=35) (N=36)  
RVD (mm) 3.05�0.59 2.98�0.59 0.65 2.3�0.7 2.6�0.7 0.08
MLD (mm) 1.13�0.66 1.22�0.59 0.55 1.5�0.7 1.2�0.6 0.10
Diameter stenosis (%) 63�20 58�21 0.35 32�28 54�20 0.0008
Lesion length (mm) 9.98�3.75 9.69�.3.83 0.76 5.75� 9.5�5.5 0.0038
AFTER PCI IN-STENT      ... 
RVD (mm) 3.10�0.66 2.93�0.0.48 0.24 ... 2.67�0.68 ...
MLD (mm) 2.69�0.51 2.58�0.40 0.33 ... 2.22�0.42 ...
Acute Luminal Gain (mm)* 1.57�0.72 1.36�0.69 0.22 ... 0.96�0.54 ...
Diameter stenosis (%) 12�10 11�9 0.75 ... 18�11 ...
AFTER PCI IN-LESION      
RVD (mm) 3.10�0.66  3.00�0.48 0. 53 2.27�0.7 2.56�0.65 0.1
MLD (mm) 2.69�0.51 2.58�0.40 0.33 1.58�0.7 2.0�0.44 0.0055
Acute Luminal Gain (mm)* 1.57�0.72 1.36�0.72 0.22 0.09�0.7 0.8�0.6 <0.0001
Diameter stenosis (%) 12�10 11�9 0.75 24�26 20�14 0.07
FOLLOW-UP IN-STENT       
RVD (mm) 3.10�0.80 2.9�0.47 0.25 ... 2.73�0.59 ...
MLD (mm) 2.24�0.83 2.17�0.59 0.70 ... 1.8�0.61 ...
Diameter stenosis (%) 25�25 24�20 0.87 ... 33�21 ...
Late Loss (mm) * 0.45�71 0.42�0.67 0.79 ... 0.41�0.54 ...
Net lumen gain (mm) 1.10�0.79 0.95�0.77 0.41 ... 0.54�0.69 ...
Binary Restenosis, no. 
(%)* 4 (11) 5 (13) >0.99 
... 5 (14) ...
FOLLOW-UP IN-LESION      
RVD (mm) 2.73�0.79 2.72�0.56 0.97 2.32�0.66 2.52�0.65 0.24
MLD (mm) 2.01�0.78 2.01�0.57 0.97 1.53�0.69 1.68�0.65 0.41
Diameter stenosis (%) 24�25 25�20 0.86 33�25 33�22 0.48
Late Loss (mm) * 0.26�0.72 0.25�0.50 0.95 0.04�0.42 0.32�0.55 0.023
Net lumen gain (mm) * 0.89�0.83 0.82�0.90 0.72 0.04�0.75 0.47�0.68 0.024
Binary Restenosis, no. 
(%)† 4(11) 4(11) >0.99 
7 (20) 5 (14) 0.76 
SVS: single-vessel stenting; BS: bifurcation stenting; ALG: acute luminal gain, BR: binary restenosis In-Les.: in-lesion, LL; late loss, MLD: Minimal 
lumen diameter; RVD: Reference vessel diameter *: See text for definitions. †: All restenosis were focal (length <10 mm) 
Limitations of the Study 
The present study is a single-center experience from 
a tertiary referral center and lacks the clear 
advantages of a multicenter randomized trial. Due to 
the retrospective nature of our investigation, we 
cannot provide intention-to-treat data. Operators 
were left free to employ single vessel or bifurcation 
stenting technique according to their 
practice/preference. Accordingly, our analysis may be  
subject to considerable risk of being biased, with 
patients showing greater plaque burden at the level  
of the bifurcation or presenting with complications or 
unsatisfactory results during the procedure being at 
much higher probability to receive bifurcation over 
single vessel stenting. A prospective randomized 
comparison based on intention to treat data would be 
ideally required to validate our findings. In 
consideration of our limited sample size, the chance 
our results are affected by a type II error is not 
negligible. Assuming a background event rate as 
presently observed in the BS group, our sample size 
would allow us to reach 80% of statistical power only 
hypothesising a relative risk reduction or a relative 
risk increase of 70% or more than 90%, respectively. 
Thus studies with bigger sample size should aim to 
investigate whether a small difference in long-term 
clinical outcome may exist between SVS versus BS. It 
may be argued that 4 different techniques were 
employed in patients receiving bifurcation stenting  
and that the overall results of the study in the 
bifurcation stenting group may have been 
confounded by the different performance of each 
different employed technique. The MACE rate in the 
bifurcation stenting group proved to be consistent, 
however, among the four bifurcation techniques 
employed in the present study (data not shown). This 
possibly reinforces the concept that, in the DES era, 
the outcome after treatment of stenosis at a 
bifurcation may not be strictly related to the 
employed bifurcation technique as it was known to be 
in the BMS era(10, 11) 
Conclusions
In consecutive patients undergoing percutaneous 
treatment for distal LM disease, short- and long-term 
clinical outcome and quantitative angiographic results 
did not differ in relation to the treatment 
accomplished: single-vessel versus bifurcation 
stenting. When our data are put into perspective with 
available evidence, the choice to adopt a single-
vessel or a bifurcation stenting in the treatment of a 
LM bifurcation lesion in the DES era should be 
probably tailored to the individual patient, based on 
the complex interplay between coronary anatomy, 
operator’s preference and foreseeable risk of 
thrombotic complication(6, 14). 
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Table 4. QCA in Side Branches 
VARIABLES
STENTED 
SIDE 
BRANCH*
(N=36) 
BALLOONED 
SIDE 
BRANCH  
(N=24) 
P
VALUE
BEFORE PROCEDURE    
RVD (mm) 2.63�0.67 2.65�0.81 0.94
MLD (mm) 1.21�0.59 1.39�0.72 0.38
Diameter stenosis (%) 54�20 43�29 0.16
Lesion length (mm) 9.8�3.8 8.5�5.3 0.18
AFTER PROCEDURE    
RVD (mm) 2.56�0.64 2.58�0.78 0.91
MLD (mm) 2.00�0.44 1.80�0.75 0.27
Acute Luminal Gain 
(mm) † 0.79�0.60 0.40�0.86 0.09
Diameter stenosis (%) 20�14 30�24 0.07
FOLLOW-UP    
RVD (mm) 2.68�0.66 2.71�0.68 0.69
MLD (mm) 1.68�0.55 1.89�0.61 0.31
Diameter stenosis (%) 33�22 29�17 0.56
Late Loss (mm)† 0.32�0.55 -0.10�0.60 0.03
Net luminal gain (mm) †  0.47�0.68 0.49�0.76 0.92
 Binary Restenosis, no. 
(%) 5 (14) 3 (13) >0.99 
* In-lesion analyses were used for this comparison. †: See text for 
definitions MLD: minimal lumen diameter; RVD: reference vessel 
diameter. 
Fig. 2 
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Persistence of Neointimal Growth 12 Months After Intervention and Occurrence
of Delayed Restenosis in Patients With Left Main Coronary Artery Disease
Treated With Drug-Eluting Stents
To the Editor: Although long-term follow-up after drug-eluting
stent (DES) implantation shows a sustained clinical beneﬁt in
several registries and randomized trials (1), little is known about
the pattern of neointimal growth beyond the ﬁrst six to nine
months. In particular, when exactly neointima growth after DES
implantation begins to subside remains largely unknown.
The mechanism of action of DES on neointimal proliferation
seems to be partially explained by a delay in vascular response,
which has supported the concern that late restenosis (i.e., occurring
beyond six months) might occur in humans (2).
This would be of clinical relevance especially for patients
receiving DES implantation for the treatment of left main coro-
nary artery (LMCA) disease, in whom restenosis is considered a
major, and potentially fatal, complication after percutaneous in-
tervention.
Up to March 6, 2004, a total of 110 consecutive patients were
treated exclusively with one or more DES in the LMCA as part of
an elective or non-elective revascularization procedure at our
institution. Seventy-three patients received 6-month angiographic
follow-up, of whom 15 underwent paired angiographic measures at
12 months, which was not preceded by target vessel reintervention,
and constitute the patient population of the present report.
Quantitative angiographic analyses were performed with the use
of edge-detection techniques (CAAS II, Pie Medical, Maastricht,
the Netherlands). Binary restenosis was deﬁned as stenosis of more
than 50% of the luminal diameter in the target lesion. Late loss was
deﬁned as the minimal lumen diameter (MLD) immediately after
the index procedure minus the MLD at angiographic follow-up.
Continuous variables are shown as median and interquartile
range and were compared using Wilcoxon test or a general liner
mixed model followed by post-hoc analysis after log transforma-
tion for normalization. Probability was signiﬁcant at a level of
�0.05.
The characteristics of the study population (Table 1) did not
differ with respect to the patients receiving no or six-month
angiographic follow-up only.
The reason for repeating a second coronary angiogram included
risk-stratiﬁcation before non-cardiac major surgery in three (Pa-
tients #1, #6, and #14), evidence of inducible ischemia at nonin-
vasive stress test in two (Patients #4 and #15), a staged procedure
for the treatment of the right coronary artery in one (Patient #13),
and the willingness to repeat a second coronary angiogram in the
remaining nine after counselling about the potential consequence
of in-stent restenosis at the time of the index procedure. No major
adverse cardiovascular event previously occurred in this cohort of
patients, and all except one were asymptomatic at the time of
repeated catheterization.
Quantitative coronary analysis on paired measurements in the
main treated branch (i.e., LMCA or LMCA and the proximal
tract of the left anterior descending artery) is shown in Table 1.
When all intervened coronary segments were cumulatively consid-
ered (n � 20), including the stented proximal tract of the
circumﬂex artery in ﬁve patients receiving bifurcation stenting, the
MLD decreased from 2.78 (2.49 to 2.95) after the procedure to
2.44 mm (2.07 to 3.09) (p � 0.37) and 2.25 (1.85 to 2.70) (p �
0.005 vs. post-procedure and p � 0.054 vs. 6-month) at 6 and 12
months, respectively. The late loss (mm) increased from 0.29 (0.07
to 0.4) at 6 months to 0.63 (0.37 to 0.76) after 12 months (p �
0.001) (Fig. 1). Cumulatively, Patient #13, presenting with mild
intimal hyperplasia at 6 months, received a target vessel revascu-
larization at 12 months due to severe focal in-stent restenosis in the
mid-shaft of the LMCA (Fig. 1C), while a focal restenosis in the
ostium of the circumﬂex artery detected at 12-month follow-up in
Patient #2 was left untreated due to normal coronary reserve at
non-invasive nuclear stress imaging.
Previous serial angiographic analyses showed that intimal hyper-
plasia peaks after 12 to 16 weeks after intervention and that restenosis
rarely occurs beyond 3 months after bare metal stent implantation (3).
These observations justify current practice to perform angiographic
follow-up six to eight months after percutaneous coronary revascular-
ization, when the intimal growth has ceased and the net lumen gain
is likely to be maintained over time. Indeed, a partial regression of the
in-stent intimal hyperplasia at longer-term follow-up in patients
receiving bare metal stents has been reported (3).
When exactly neointima growth after DES implantation begins
to subside remains largely unknown, but based on experimental
ﬁndings, a late catch up phenomenon has been hypothesized (2). Of
some concern is the fact that similar argumentations have been
previously raised after intravascular brachytherapy, based on ﬁnd-
ings on animals, which were subsequently conﬁrmed in humans
(4). In the longest available angiographic follow-up after DES
implantation, neointimal growth has been shown to mildly non-
signiﬁcantly progress beyond one year (1). Whether this would
result in delayed restenosis remained unclear.
In our small series of patients undergoing serial angiographic
monitoring, a signiﬁcant increase of late loss between 6 and 12
months was noted, and, more importantly, one patient devel-
oped late in-stent restenosis of the LMCA, which necessitated
reintervention.
Our preliminary ﬁndings raise several unanswered questions.
This study was not pre-speciﬁed, as it was urged by the one-year
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reated exclusively with one or more DES in the LMCA as part of
an elective or non-elective revascularization procedur at our
institution. Se nty-three patients received 6-month angiogr phic
follow-up, of whom 15 und rw nt paired ngiographic m asures at
12 months, which was not receded by target vessel rei tervention,
and constitute the patient population of the present report.
Quantitative angiographic analyses we e performed with the use
of edge-detection techniques (CAAS II, Pi M dical, Maastricht,
the Netherlands). B na y restenosis was deﬁn d as stenosis of mor
than 50% of the luminal diameter in the target lesion. Late loss was
deﬁned as the minimal lumen diameter (MLD) immediately after
e index proc d re minus the MLD a angiographic follow-up.
Continuous var ables ar shown as median and interquartile
range and wer compared using Wilcoxon test or a general liner
mixed model followed by post-hoc analysis after log transforma-
tion for normalization. Probability was signiﬁcant at a level of
�0.05.
The characteristics of the study population (Table 1) did n t
differ with respect to the patients receiving no or six-month
angiographic follow-up only.
The reason for repeating a seco d coronary angiogram included
risk-stratiﬁcati n before on-cardiac major surgery in three (Pa-
tients #1, #6, and #14), eviden e of inducible ischemia at nonin-
vasive stress test in two (Patients #4 and #15), a staged procedure
for the treatme t of the right coronary artery in one (P tient #13),
and the willingness to repeat a second coronary angiogram in th
remaining nine after counselling about the potential consequence
of in-stent resteno is at th time of the index procedure. No major
adverse card ovascular event previously occurred in this cohort of
patients, and all except one were asymptomatic at the time of
repeated catheterization.
Quantitative coronary a alysis on paired easurements in the
main treated branch (i.e., LMCA or LMCA and the proximal
tract of the left anterior descending artery) is shown in Table 1.
When all intervened coronary segments were cumulativ ly c nsid-
ered (n � 20), including the stented proximal tract of the
circumﬂex artery in ﬁve patients rec iving bifurcation st nting, the
MLD decreased from 2.78 (2.49 to 2.95) after the procedure to
2.44 m (2.07 to 3.09) (p � 0.37) and 2.25 (1.85 to 2.70) (p �
0.005 vs. post-procedure and p � 0.054 vs. 6-month) at 6 and 12
months, respectively. The late loss (mm) increased from 0.29 (0.07
to .4) at 6 months to 0.63 (0.37 to 0.76) after 12 months (p �
0.001) (Fig. 1). Cumulatively, Patient #13, presenting with mild
intimal hyperplasia at 6 months, received a target vessel revascu-
larization at 12 months due to severe focal in-stent restenosis in the
mid-shaft of the LMCA (Fig. 1C), while focal restenosis in the
ostium of the circumﬂex artery detected at 12-month follow-up in
Patient #2 was left untreated due to normal coronary reserve at
non-invasive nuclear stress imaging.
Previous serial angiographic analyses showed that intimal hyper-
plasia pe ks after 12 to 16 weeks after intervention and that restenosis
rarely occ rs beyond 3 mont s after bare metal stent implant tion (3).
These observations justify current practice to perform angiographic
follow-up six to eight onths after percutaneous coronary revascular-
ization, when the intimal growth has ceas d and the net lumen gain
is likely to be maintained over time. Indeed, a partial regression of the
in-ste t intimal hyperplasia at longer-term follow-up in patients
receiving bare metal st nts has be n reported (3).
When exactly neointima growth after DES implantation begins
to subside r mains largely unknown, but based on experimental
ﬁndings, a late catch up phenomenon has been hypothesized (2). Of
s me concern is the fact that similar argumentations have been
previously r ised after intravascular br chythera y, based on ﬁnd-
ings on animals, which were subsequently co ﬁrmed in humans
(4). In the longest available angiogr p ic follow-up after DES
implantation, neointimal growth has been shown to mildly no -
signiﬁcantly progress beyond one year (1). Whether this would
result in delayed restenosis remained unclear.
In our small series of patients undergoing serial angiographic
monitoring, a signiﬁcant incre se of late loss between 6 and 12
mo ths was not d, and, more importantly, one p tient devel-
oped late in-stent restenosis of the LMCA, which necessitated
reinterventio .
Our preliminary ﬁndings raise several unanswered questions.
This study was not pre-speciﬁed, as it was urged by the one-year
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Delayed Neointimal Growth after LM Stenting 
ﬁndings on Patient #13. Importantly, the increase in late loss from
6 to 12 months turned out to be a consistent observation also in
other LMCA-intervened patients, triggering the present report. It
remains unclear based on our data whether intima hyperplasia
peaks at 12 months or even later after DES LMCA stenting.
Whether our results are applicable also to non-left main lesions is
currently unknown.
Recently, Wessely et al. (5) reported on two patients treated
with sirolimus-eluting stent in the left anterior descending artery
and right coronary artery who presented at 13 and 19 months,
respectively, with recurrence of symptoms and angiographically
conﬁrmed in-stent restenosis. Of note, both patients had under-
gone previous coronary angiogram at seven months, which showed
no evidence of intima growth at that stage.
The ﬁnding that intima growth may persist well beyond the
conventional six to eight months after intervention may cast a
shadow of doubt on current attempts to employ power transfor-
mation of late loss at six to eight months to predict long-term stent
performance.
The clinical implications of the delayed occurrence of in-stent
restenosis after DES in patients undergoing intervention for
LMCA disease remain unclear.
A prolonged clinical and angiographic surveillance in this subset
of patients seems to be warranted.
Figure 1. Change of minimal lumen diameter (MLD) (A) and lumen diameter stenosis (B) as a consequence of treatment in 20 intervened coronary segments,
including the LMCA (and the proximal tract of the left anterior descending artery if stented) in 15 patients and the proximal segment of the circumﬂex artery in
5 patients who received bifurcation stenting. (A) At 12 months, the MLD (mm) reduced signiﬁcantly compared to post-intervention (p � 0.001) and tended to
be smaller than that noted at 6 months (p � 0.054). The late loss passed from 0.29 (0.07 to 0.4) at 6 months to 0.63 (0.37 to 0.76) after 12 months (p � 0.001).
�p� 0.001 vs. late loss recorded at six months. (B)The vessel diameter stenosis (%) passed from 54 (50 to 60) before to 7 (2 to 10) after the procedure (p� 0.001),
to 14 (9 to 18) at 6 months (p� 0.3 vs. post-procedure) and to 28 (17 to 35) at 12 months (p � 0.066 vs. 6 months). PCI� percutaneous coronary intervention.
Continued on next page.
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Figure 1 Continued. (C) Sequential coronary angiographies showing the left main coronary artery (magniﬁed at the right) and the proximal and mid-tract
of circumﬂex and anterior descending arteries of Patient #13. Panel I: A stenosed distal left main coronary artery with its magniﬁcation in the right quadrant
and a suboccluded circumﬂex artery are visible before treatment. Panel II: Angiographic result immediately after treatment. At six months (panel III), a
moderate focal restenosis in the proximal tract of the left main coronary artery was present (arrowhead) that did not cause signiﬁcant obstruction of the
lumen at intravascular ultrasound (IVUS) investigation (lower panel) and did not result to be ﬂow-limiting, with a fractional ﬂow reserve of 0.85. At 12
months (panel IV), control angiogram revealed a tight in-stent restenosis (arrowhead), magniﬁed in the insert, through which the IVUS probe could not
be negotiated and required reintervention. Lower panel is showing four IVUS cross-sections (Atlantis 40 Mhz, Boston Scientiﬁc, Natick, Massachusetts)
from the left main coronary artery at six months: (a) proximal edge of the stent in the left main coronary artery, with a malapposed strut visible at 7 o’clock;
(b) in-stent concentric growth of intimal hyperplasia at the minimal lumen area; (c) minor degree of in-stent eccentric hyperplasia located in the mid-tract
of the left main coronary artery at 9 o’clock; (d) left main coronary artery carina, showing no sign of intimal hyperplasia, with the stented circumﬂex artery
originating at 11 o’clock.
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Temporal Distribution of Cardiac Events after LM Stenting 
Revisiting the Incidence and Temporal Distribution of Cardiac and 
Sudden Death in Patients Undergoing Elective Intervention for 
Unprotected Left Main Coronary Artery Stenosis in the Drug Eluting 
Stent Era. 
A pooled analysis on 340 patients treated at three European referral centers 
Marco Valgimigli, MD, Alaide Chieffo, MD, Thierry Lefèvre MD, Antonio Colombo, MD, Marie-Claude Morice MD, Patrck W. 
Serruys, MD, PhD on behalf of the Executive Committee of the Syntax Study
Background: Whether restenosis remains a major, and potentially fatal, complication after percutaneous intervention 
for left main coronary artery (LMCA) stenosis and whether routine surveillance angiography should be a necessary part 
of the follow-up of these patients in current drug eluting stent (DES) era is largely debatable. 
Methods and Results: Patients who underwent elective treatment of unprotected LMCA with DES in three referral 
centres in Europe were pooled as follows: i) 147 patients treated in Massy, between 12 August 02 and 31 December 04; 
ii) 107 patients, treated in Milan, San Raffaele hospital and Columbus clinic, between 16th April 02 and 31st July 04 iii) 86 
patients treated at the Thoraxcenter, Rotterdam, between 16th April 2002 and 28th June 04 leading to a total 340 elective 
consecutive patients. The rate of in-hospital mortality was 0.6% (2/340). The out of hospital event rate in terms of 
cardiac death or myocardial infarction was 1.2% between discharge and 3 month, 0.6% between three and 6 months 
and 0.6% between 6 months and 1 year. Two (0.6%) sudden and unexpected deaths were cumulatively observed, at 8 
days and 2 months after intervention, respectively. The rate of confirmed or possible stent thrombosis was 0.9%. At 1 
year, the out of hospital cumulative incidence of cardiac death or MI was 2.4%. In the cohort of patients who refused to 
undergo angiographic surveillance, no death and no MI occurred.
Conclusions: Cardiac and sudden death and the incidence of stent thrombosis after LMCA intervention with DES were 
reasonably low and compared favourably with what reported in non-LMCA lesions. At the time intimal hyperplasia is 
expected to peak (i.e. beyond 6 months), no increase of adverse events, in terms of death or myocardial infarction was 
observed.
Submitted
INTRODUCTION
Following the widespread adoption of drug eluting stents 
in current practice and their growing use in off-label 
indications, there is clear need to re-evaluate some of 
the dogmas on the treatment of the left main coronary 
artery (LMCA) stenosis, when undertaken percutaneously. 
In particular, whether restenosis remains a major, and 
potentially fatal, complication after LMCA treatment and 
whether routine surveillance angiography is needed to 
decrease the risk of cardiac and sudden death related to 
intimal hyperplasia is largely debatable and controversial. 
In the ULTIMA registry, two hundred seventy-nine 
consecutive patients who had elective or emergent LMCA 
treatment with PCI at 1 of 25 sites between 1993 and 
1998 were studied1, 2. Forty-six percent of these patients 
were deemed inoperable or at high surgical risk. Thirty-
eight patients (13.7%) died in hospital. The 1-year 
incidence was 24.2% for all-cause mortality and 20.2% 
for cardiac mortality. An excess of deaths was observed 
predominantly in patients initially deemed inoperable. 
However, 2% per month death rate among hospital 
survivors was noted over the first 6 months. Of concern, 
most of the myocardial infarction (MI) cumulatively 
observed at one year, occurred in the first three months 
after treatment. Based on these findings, the 
interpretation that restenosis may lead to major fatal or 
non fatal complications in this cohort of patients was put 
forward and the need to perform routine surveillance 
angiography at 2 and 4 months after treatment was 
subsequently formulated. This recommendation was in 
agreement with previous studies showing that intimal 
hyperplasia after bare metal stenting peaks 12-16 weeks 
after intervention.  
However, the uptake of this recommendation varied 
considerably between centres and, even when this 
recommendation has been followed, a single 
angiographic follow-up at 6 months, not two at 2 and 4 
months, has been mainly carried out3-6.
The discrepancy between what has been recommended 
and clinical practice has several potential explanations. 
Firstly, the evidence on which the need to perform 
routine angiographic surveillance relies is rather weak. 
Whether the clustering of events in the few months after 
LMCA treatment is directly related to the development of 
restenosis remains speculative since no protocol-
mandated angiographic follow-up was prespecified in the 
ULTIMA registry. Moreover, almost 50% of the included 
population was deemed to be inoperable or at high- 
surgical risk, which may in itself explain the high 
incidence of adverse events observed in the study 
population (mortality rate at 1 year was 79%, 24% and 
3% in high, intermediate and low risk patients, 
respectively). No demonstration that the performance of 
routine early angiographic follow-up translates into a 
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clinical benefit in this patient population exists. Finally, 
there is concern for the iatrogenic hazard related to 
multiple angiographic follow-ups in this cohort of patients.  
Drug eluting stent (DES) implantation, by reducing the 
need for target vessel revascularization (TVR) and 
angiographic restenosis, has been recently shown to 
favourably affect outcome compared to bare metal stents 
(BMS) in patients undergoing percutaneous left main 
(LM) intervention. Current evidence suggests that both 
the magnitude and the peak of intimal growth may 
markedly differ in patients treated with DES as compared 
to BMS, which may offer the unique opportunity to re-
evaluate the temporal incidence of major adverse events 
in this cohort of DES-treated patients. 
Against this background, the principal aim of the present 
survey was to accrue data regarding the rate and 
temporal distribution of cardiac and sudden death or out 
of hospital MI in patients undergoing unprotected and 
elective LMCA intervention in the DES era. These 
observations might help re-examining the notion that in-
stent restenosis may lead to fatalities or myocardial 
necrosis in patients undergoing percutaneous LMCA 
intervention. The second exploratory objective was to 
collect information in terms of clinical outcome on 
patients who refuse to undergo angiographic follow-up 
after LMCA treatment. This information may be critical in 
assessing the need for routine angiographic surveillance 
in this cohort of patients.
Patients’ selection 
Patients who underwent elective treatment of 
unprotected LMCA with DES in three referral centres in 
Europe were pooled as follows: 
� One hundred forty seven patients, treated in 
Massy (France), between 12 August 02 and 31 December 
04, [12 (8%) treated with sirolimus-eluting stent (SES) 
and 135 (92%) receiving paclitaxel-eluting stent (PES)]. 
This cohort of patients had a mean (SD) clinical follow-up 
of 6.8 ± 2.12 months. All patients were initially 
scheduled to undergo 6-month angiographic surveillance, 
which was actually performed in 65% of eligible patients. 
No data regarding this cohort of patients has been 
previously reported. 
� One hundred seven patients, treated in Milan 
(Italy), San Raffaele hospital and Columbus clinic, 
between 16th April 02 and 31st July 04 [55 (51%) treated 
with sirolimus-eluting stent (SES) and 52 (49%) receiving 
paclitaxel-eluting stent (PES)]. All eligible patients 
underwent 1-year clinical follow-up. All patients were 
scheduled to undergo angiographic surveillance at 6 
months, which was performed in 85% of those eligible. 
Six month outcome of the first 85 patients here included 
has been previously reported5.
� Eighty-six patients treated at the Thoraxcenter, 
Rotterdam (the Netherlands) between 16th April 2002 
and 28th June 04 [36 (41%) treated with sirolimus-
eluting stent (SES) and 50 (59%) receiving paclitaxel-
eluting stent (PES)]. All eligible patients underwent 1-
year clinical follow-up. For research purpose, all patients 
were initially scheduled to undergo angiographic follow-
up, which was finally carried out in 76% of those eligible. 
A subset of this cohort of patients has also previously 
reported3.
Thus, from 16th April 2002 to December 31 2004, a total 
of 340 consecutive patients were treated, in three 
referral European centres, exclusively with one or more 
DES in the LMCA as part of an elective revascularisation 
procedure and constitute the patients population of the 
present report.
Procedures and post-intervention medications 
All interventions were performed according to current 
standard guidelines and the final interventional strategy, 
including the use of glycoprotein IIb/IIIa inhibitors and 
stenting techniques, was entirely left to the discretion of 
the operator, except for the stent utilization. All patients 
were advised to maintain aspirin lifelong, while 
clopidogrel was prescribed for at least 6 months in 
patients treated in Rotterdam or Milan or 2 months only 
for those undergoing treatment in Massy. 
Endpoint definitions 
The primary outcome of interest was the occurrence of 
total and cardiac mortality.
All deaths were considered to be of cardiac origin unless 
a non-cardiac origin was established clinically or at 
autopsy. Myocardial infarction (MI) was diagnosed by a 
rise in the creatine kinase level to more than twice the 
upper normal limit with an increased creatine kinase-MB 
fraction. The cumulative rate of post-discharge MI will be 
presented for all included patients, while occurrence of 
in-hospital myocardial infarction is available for only 
those patients enrolled at the Thoraxcenter. 
RESULTS
Mortality rate 
In-hospital 
The rate of in-hospital mortality was 0.6% (2/340). 
Overall, two fatal episodes occurred. Patient #1, affected 
by unstable angina following a recent MI (Braunwald 
class III C) presented with distal LMCA stenosis. The 
proximal and mid LAD and circumflex arteries were also 
diffusely diseased. This patient was refused by surgeons 
due to severe left ventricular dysfunction (left ventricular 
ejection fraction=25%) and underwent an elective 
intervention under left ventricular assist device (Tandem 
Heart). The procedure was successful but during the 
positioning of the last stent in the circumflex artery a 
dissection of ascending aorta occurred. The patient died 
immediately after surgery: The Patient #2 was a 90 
years old female admitted for unstable angina. Coronary 
angiogram revealed severe triple vessel disease. The 
patient was considered too old for surgery. She had an 
uncomplicated and successful intervention but died 2 
days after the procedure for hemorrhagic shock due to a 
severe groin haematoma, despite blood transfusion. 
Sudden death 
Cumulatively, two sudden and unexpected deaths 
occurred (0.6%): i) patient #3 died suddenly 8 days 
after the procedure; ii) Patient #4 died 2 months after 
intervention after anti-platelet therapy discontinuation 
because of concomitant acute pancreatitis.  
Cumulatively total and cardiac mortality 
There were a total of 13 fatal events (13/340, 3.8%), of 
which 8 (2.3%) were considered to be of cardiac origin 
as detailed in table 1. However, since patient #2 died as 
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Table 1 Baseline and procedural characteristics of patients who died for cardiac or procedure-related reasons 
Patient No. 1 2 3 4 5 6 7 8 9 
Age, ys 54 90 77 82 71 53 54 80 75 
Gender M F M M M F M M M 
Enrolling Site Rot. Mas. Mas. Mil. Mas. Mil. Mil. Rot. Mas. 
Diabetes Yes No Yes Yes Yes No Yes Yes Yes 
Renal insufficiency No No No No Yes No No NO No 
Clinical Presentation UA IIIC UA IIIB SA UA SA UA UA UA IIIC UA 
Euroscore 12 8 4 13 6 3 9 8 13 
Comorbidities COPD No No COPD, PVD, CVA Dialysis Hypothyroidi PVD, Obesity PVD, Obesity COPD 
Refused for Surgery Yes Yes No Yes No No No Yes No 
Lesion location Distal Distal Distal Distal Ostial Distal Distal Distal Distal 
Severe calcification Yes Yes No No Yes No No Yes No 
Stent type SES PES PES SES PES PES SES PES PES 
Stent No. 2 1 2 2 1 2 3 1 1 
Total Stent Length, mm 25 76 71 41 55 44 84 24 43 
Bifurcation Stenting Yes Yes Yes Yes No Yes Yes No Yes 
Technique T-stent Provisional T 1 stent T-stent Crush NA Culotte Crush 
… Provisional
T 1 stent 
Post-dilatation No Yes Yes Yes Yes Yes Yes Yes Yes 
Final Kissing No Yes Yes Yes NA Yes Yes No Yes 
Cardiac Death    Yes  Yes yes   
   Reasons AAD GH SD1 SD2 PO1 CABG1 PO2 CABG2 PCI 
   Days after PCI 0 2 8 56 60 136 164 243 312 
UA: Unstable Angina; SA: stable angina; PCI; percutaneous coronary intervention; SES; sirolimus eluting stent; PES; paclitaxel eluting stent; Mas.; Massy; 
Mil. Milan; Rot.;Rotterdam; COPD: chronic obstructive pulmonary; PVD: peripheral vascular disease; CVA; previous cerebrovascular accident. Reasons for 
death: AAD; dissection of the ascending aorta during index procedure, the patient died immediately after surgery; GH; groin haematoma with subsequent 
haemorrhagic shock despite blood transfusion; SD1: sudden death; SD2: sudden death following antiplatelet therapy discontinuation due to acute 
pancreatitis; PO1; Pulmonary oedema during dialysis; CABG1: due to recurrent angina, the patient was admitted in a peripheral hospital and submitted to 
CABG (angiogram not available), the patient died in the intensive care unit immediately after surgery, PO2: pulmonary oedema in patient known to have 
severe mitral and aortic regurgitation while he was in the waiting list for surgery. CABG2: the patient underwent intervention for the right coronary artery 
resulted in acute pericardial effusion due to vessel perforation (Figure X). The patient died 2 days after surgery; PCI: the patient presented with restenosis 
in the ostium of the LAD, during reintervention a thrombotic embolus occurred in the left main, the procedure ended successfully but the patient died 2 
days later for cardiogenic shock 
consequences of the index intervention (hemorrhagic 
shock due to groin hameatoma), there were 9 (2.6%) 
cardiac or index procedure- related deaths. In the 
remaining 4 patients, death occurred due to pulmonary 
infection (n=1), massive bleeding during dialysis (n=2) 
and ischemic stroke (n=1). 
Rate of stent thrombosis 
One single episode of angiographically confirmed stent 
thrombosis (ACT) occurred (0.3%) 3 months after 
intervention in a patient who was still under double anti-
platelet treatment. Hypothesizing that the two observed 
episodes of sudden deaths were attributable to ACT, the 
rate of confirmed or possible stent thrombosis was 0.9%. 
Rate of myocardial infarction 
In-Hospital (n=84): There was no episode of Q-wave 
MI, while 4 (4/86; 4.6%) episodes of CK-MB elevation 
above twice upper limit of normal (ULN) occurred. By 
elevating the threshold of CKMB rise to 3 times ULN, as 
currently recommended by ACC/AHA guidelines, the rate 
of MI was 1.1% (1/86). No episode of CK-MB elevation 
above 5 times ULN occurred.  
Follow-up (n=340): There was one single episode of 
myocardial infarction which occurred at 3 month due to 
ACT, as previously described. Thus, the cumulatively rate 
of out of hospital MI at 1 year was 0.3%. 
Cardiac death or myocardial infarction 
The out of hospital event rate in terms of cardiac death 
or myocardial infarction was 1.2% between discharge 
and 3 month, 0.6% between three and 6 months and 
0.6% between 6 months and 1 year. At 1 year, the out 
of hospital cumulative incidence of cardiac death or MI 
was 2.4%. 
To explore the safety of avoiding systematic 
angiographic follow-up in this cohort, patients treated in 
Massy and Rotterdam were pooled, with a final 
population of 233 patients. Patients treated in Milan were 
not considered for this analysis due to the high rate of 
angiographic follow-up carried out in this cohort. 
Between discharge and 6 months, the rate of death was 
3.4%, with no MI occurring after discharge. After 6 
months, 160 (69%) patients underwent angiographic 
control. In this group, the rate of death from 6 to 12 
months was 1.3%, with two cardiac deaths, both 
occurring due to complications during target vessel 
revascularization (in one case during PCI, in the second 
case the patient died one day post-CABG). In the cohort 
of patients who refused to undergo angiographic 
surveillance, no death and no MI occurred.  
Discussion
With a total population of 340 patients, this report 
represents the biggest series of patients undergoing 
unprotected and elective LMCA intervention ever 
reported. In addition, by limiting our observations to only 
those patients undergoing DES-supported intervention, 
the current survey may represent a benchmark study for 
future randomized trials.
The main findings of this survey may be summarized as 
follows:
1) The overall mortality rate after LMCA intervention 
with unrestricted use of DES appears to be in the range 
of 4% at one year, which drops to 2.3% when the 
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Figure 1 
Index procedure in patient#1, while assisted by left ventricular assist device, is shown before treatment (I and II), during stent implantation in the LMCA 
(III and IV) and at the end of the procedure (V and VI ) where dissection of the ascending aorta is visible.
cardiac mortality alone is considered. The observations 
that non-cardiac mortality may significantrly contribute to 
total mortality is not an unexpected finding. Patients 
included in the current survey, in line with what is 
recommended by current guidelines, have major 
contraindications to surgery often due to the presence of 
relevant comorbities; they may play a role in explaining 
long-term survival in this patient population almost as 
much as LMCA disease does. This notion needs to be 
considered in planning future investigations comparing 
percutaneous versus surgical LMCA treatment, where 
patients with serious concomitant disease, in order to be 
eligible to both treatments, have necessarily to be 
excluded so that the overall and non-cardiac mortality 
might be correspondingly lower in such a setting. 
2) The rate of sudden death in our series of patients 
was below 1%. Importantly, our data do not support the 
idea that SD may be causally connected to in-stent 
restenosis. One case of SD occurred 8 days after 
treatment, while the second case occurred 3 months 
after intervention immediately after the discontinuation 
of antiplatelet therapy. The temporal relationship with 
intervention in the first case and awareness that anti-
platelet treatment discontinuation is the biggest predictor 
of early and late stent thrombosis in the DES era 7, argue 
in favor of stent thrombosis as the most likely 
mechanism of SD in our cohort of patients. 
3) The rate of stent thrombosis appeared to be in the 
range of 1% in the worst possible scenario, where 
confirmed or suspected thrombotic events were pooled. 
This finding favorably compares to the rate of stent 
thrombosis in the BMS era and does not seem to differ 
from what was previously reported in consecutive series 
of patients undergoing liberal DES-supported 
intervention7, 8.
4) A clear clustering of fatal and non-fatal hard adverse 
events in the first three months after treatment was 
noted, with a 50% decrease in death or MI form 3 to 6 
months, which appeared to stabilize thereafter, at least 
until 12 months. This drop of major adverse events after 
three months is in full agreement with what previously 
reported in the BMS era2. As previously discussed, this 
was interpreted as the hazard of developing in-stent 
restenosis after LMCA treatment. This speculation was 
supported by the notion that intimal hyperplasia after 
BMS is known to peak 14-16 weeks after intervention. 
The finding that after DES implantation the same 
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Figure 2. 
Index procedures of patients #2 (A), #3 (B) and #9 (C) before (I) and after (II) treatment is shown. 
Figure 3.
Patient #8 before (I) and immediately after (II) treatment. Due to persistence of symptoms, the patient had a second angiogram at follow-up showing a 
significant disease in the right coronary artery (III), during treatment a coronary rupture with pericardial effusion occurred (IV). The patient was sent to 
emergent surgery but died soon afterwards
clustering of adverse events persists in the first months 
after treatment, offers the unique possibility to challenge 
previous beliefs about the malignant role of intima 
hyperplasia in this cohort of patients. In the longest 
available angiographic follow-up after drug eluting stent 
implantation, neointimal growth has been shown to 
mildly non-significantly progress even beyond one year9.
Recently, Wessely et al. reported on two patients treated 
with sirolimus-eluting stent in the left anterior 
descending artery and right coronary artery who 
presented at 13 and 19 months, respectively, with 
recurrence of symptoms and angiographically confirmed 
in-stent restenosis. Of note, both patients had undergone 
previous coronary angiogram at 7 –month which showed
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Figure 4. 
Angiogram of patient #4 before treatment (I), showing diffuse coronary calcification (II), during intervention at the left main coronary artery (III) and 
immediately at the end of the procedure (IV).
no evidence of intima growth at that stage10. Finally, in 
15 patients who underwent treatment with DES for LMCA 
disease at the thoraxcenter, serial angiographic follow-up 
at 6 and 12 months after the index procedure was 
recently carried out. Of note, the late loss which was 
observed at 6 months [median (IQR): 0.29 (0.07-0.4] 
doubled at 1 year [0.63 (0.37-0.76), p<0.001], with two 
patients presenting with mild intima hyperplasia at 6 
months who developed late in stent restenosis at 1 year 
(JACC, in press).
Thus, current evidence confirms the notion that intimal 
hyperplasia after DES implantation may be much more 
delayed with respect to what was observed in the BMS 
era. Of note, even after LMCA intervention with DES, the 
same clustering of adverse events in the first few months 
afterwards, as it has previously reported in BMS treated 
patients, seems to occur according to the present survey. 
Thus, when taken together, available data may argue in 
favor of mechanisms different from intimal hyperplasia as 
putative explanation for the different rate of death or MI 
over time in this patient population.
5) In those patients who refused to undergo 
angiographic follow-up (n=65), no increase of adverse 
events was noted in the current survey. Notably, no fatal 
or non fatal major adverse event occurred in this group 
of patients. We cannot rule out the possibility that these 
findings may be subject to a considerable selection bias. 
Ideally, a randomized prospective study allocating 
consecutive LMCA treated patients to protocol-mandated 
angiographic surveillance versus conservative 
management would be in demand to evaluate the safety 
of avoiding systematic angiographic examination in this 
cohort of patients. However, the present study does not 
support the previous recommendation that routine 
angiographic surveillance seems to be mandatory in 
LMCA patients undergoing percutaneous treatment. The 
fact that early angiographic control may underestimate 
the real incidence of in-stent restenosis, coupled with the 
potential hazard to undergo multiple angiographic 
examinations over time should not be neglected if 
current recommendation to obtain multiple early 
angiograms in this patient population is followed.
In conclusion, based on the largest series of patients 
undergoing unprotected and elective LMCA intervention 
ever reported, current study shows that in this cohort of 
patients i) the rate of SD, cardiac death and stent 
thrombosis favorably compares to what reported in 
patients receiving treatment for non-LMCA lesions, ii) in 
this patient population at high surgical risk, the 
contribution of non-cardiac death to overall mortality 
may be substantial, iii) a clustering of adverse events in 
the first months after treatment, as was in the BMS era, 
could be confirmed in patients receiving DES 
implantation. This finding, coupled with the rising notion 
that the peak of intima hyperplasia may be much delayed 
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Figure 5. 
Patient #6 at the time of the index procedure (Panel A) showing left coronary artery before (I) and after (II) treatment and right coronary artery (III). At 
first angiographic follow-up (Panel B) no restenosis of the left main coronary artery was detected (I). However, a significant in-stent restenosis of the 
proximal left anterior descending artery required reintervention (II) with excellent final angiographic result (III). At the second angiographic follow-up 
(Panel C), there was not detectable restenosis in the left coronary artery (I) while a progression of disease in the mid tract of the right coronary artery (II) 
required reintervention (III).
after DES with respect to BMS and that no safety 
concern emerged in the current analysis in those patients 
refusing to undergo angiographic control, may suggest 
that postponing angiographic follow-up beyond the 
conventional 6 months does not affect the outcome of 
these patients, while this would allow to monitor the 
vessel status when the intimal growth has more probably 
ceased and the net lumen gain is likely to be maintained 
over time. 
There remains considerable uncertainty, however, 
around the need to perform or not a mandatory 
angiographic control in patients undergoing LMCA 
intervention. Thus, no clear recommendation can be 
made in this setting. We cannot exclude the possibility 
that in selected patient subsets “malignant” early intimal 
hyperplasia takes place which may contribute to explain 
the clustering of adverse events in the first few months 
after treatment.  
In conclusion, our survey shows that in patients 
undergoing elective intervention with DES for 
unprotected LMCA stenosis, the short and mid-term 
outcome is favourable. The great majority of major 
observed cardiac events occurred in the first few months 
after treatment, while at the time when intima 
hyperplasia is expected to peak (beyond 6 months) there 
was no detectable increase of death or myocardial 
infarction. Prospective randomized controlled 
investigations are in demand in order to evaluate the 
safety to avoid systematic angiographic surveillance in 
this group of patients.
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Figure 6. 
Patient #7 during the index procedure (Panel A) before (I), during (II) and after treatment (III) and at the time of angiographic follow-up, showing a focal 
restenosis in the ostium of left anterior descending artery (II) which required reintervention with good final angiographic result (III).
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Intervention in the Drug-Eluting Stent Era
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Evelyn Regar, MD, PHD, Willem J. Van der Giessen, MD, PHD, Peter de Jaegere, MD, PHD,
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Rotterdam, the Netherlands
OBJECTIVES This study sought to investigate whether the anatomical location of the disease carries
prognostic implications in patients undergoing drug-eluting stent (DES) implantation for the
left main coronary artery (LMCA) stenosis.
BACKGROUND Liberal use of DES, compared with a bare metal stent (BMS), has resulted in an improved
outcome in patients undergoing LMCA intervention. However, the overall event rate in this
subset of patients remains high, and alternative tools to risk-stratify this population beyond
conventional surgical risk status would be desirable.
METHODS From April 2002 to June 2004, 130 patients received DES as part of the percutaneous
intervention for LMCA stenoses in our institution. Distal LMCA disease (DLMD) was
present in 94 patients. They were at higher surgical risk and presented with a greater coronary
disease extent compared with patients without DLMD.
RESULTS After a median of 587 days (range 368 to 1,179 days), the cumulative incidence of major
adverse cardiac events (MACE) was signiﬁcantly higher in patients with DLMD at 30%
versus 11% in those without DLMD (hazard ratio [HR] 3.42, 95% conﬁdence interval [CI]
1.34 to 9.7; p � 0.007), mainly driven by the different rate of target vessel revascularization
(13% and 3%; HR 6, 95% CI 1.2 to 29; p� 0.02). After adjustment for confounders, DLMD
(HR 2.79,95% CI 1.17 to 8.9; p � 0.032) and surgical risk status (HR 2.18,95% CI 1.06 to
4.5; p � 0.038) remained independent and complementary predictors of MACE.
CONCLUSIONS Distal LMCA disease carries independent prognostic implications, and it may help in
selecting the most appropriate patient subset for LMCA intervention beyond the conven-
tional surgical risk status in the DES era. (J Am Coll Cardiol 2006;47:1530–7) © 2006 by
the American College of Cardiology Foundation
Routine implantation of drug-eluting stents (DES), by
reducing the need for target vessel revascularization (TVR)
and angiographic restenosis, recently has been shown to
favorably affect outcome compared with bare-metal stents
(BMS) in patients undergoing percutaneous left main cor-
onary artery (LMCA) intervention (1–3). However, the rate
of major cardiovascular events in the DES era remains high
in the ﬁrst series of patients reported (1,3). Catheter-based
LMCA treatment is today mainly reserved for poor surgical
candidates, which may at least partially explain the high rate
of adverse events observed in this patient population. This
hypothesis is based on the ability of surgical risk scores to
predict both short-term and long-term outcomes in this
subset of patients (1,4).
The identiﬁcation of novel independent predictors of
outcome beyond surgical risk status would further expand
our capability to risk-stratify this patient population.
In particular, a clinical or angiographic parameter able to
differentiate outcomes between percutaneous LMCA treat-
ment and surgical revascularization would be highly desir-
able. This might help in selecting the appropriate subset of
patients with LMCA disease in whom catheter-based
treatment would be indicated, independent of surgical risk
status (5).
Observational studies in the BMS era identiﬁed the distal
location of the disease within the LMCA anatomy as a
possible determinant of restenosis in patients undergoing
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percutaneous treatment of the LMCA (6). However, other
investigators have not conﬁrmed this observation (7,8), and
whether this holds true in the DES era remains largely
unknown.
The treatment of distal left main disease (DLMD) is
offset by the need to handle the bifurcation between LMCA
and the main proximal left coronary branches. The treat-
ment of such a lesion, even with the use of DES, may
remain challenging (9).
Therefore, the purpose of the present study was to
investigate the clinical and angiographic outcomes of
DLMD treatment in patients undergoing percutaneous
revascularization in the DES era.
METHODS
Study design and patient population. Since April 16,
2002, sirolimus-eluting stent (SES) implantation (Cypher,
Johnson & Johnson-Cordis unit, Warren, New Jersey) have
been used as a default strategy for every percutaneous coronary
intervention at our institution as part of the Rapamycin-
Eluting Stent Evaluated At Rotterdam Cardiology Hospital
(RESEARCH) registry. From the ﬁrst quarter of 2003,
paclitaxel-eluting stents (Taxus, Boston Scientiﬁc, Natick,
Massachusetts) became commercially available, replacing
SES as the stent of choice in every percutaneous coronary
intervention, as part of the Taxus-Stent Evaluated At
Rotterdam Cardiology Hospital (T-SEARCH) registry. As
a policy, all elective patients presenting with signiﬁcant
(�50% by visual estimation) LMCA disease referred to our
institution for coronary revascularization are evaluated both
by interventional cardiologists and by cardiac surgeons, and
the decision to opt for percutaneous coronary intervention or
surgery is reached by consensus, as previously described (1).
From April 16, 2002, to June 28, 2004, a total of 130
consecutive patients were treated exclusively with one or
more DES in the LMCA as part of an elective or nonelec-
tive revascularization procedure and constitute the patient
population of the present report. Fifty-ﬁve patients in the
ﬁrst cohort received exclusively SES, which were avail-
able at that time in diameters from 2.25 to 3.00 mm,
whereas in the next group of 75 patients, paclitaxel-
eluting stents—available in diameters from 2.25 to 3.5
mm—were implanted.
To stratify the study population into high surgical risk
and low surgical risk groups, the Parsonnet surgical risk
score was calculated for each patient (10). A score of �15
was used to identify patients at high risk as previously
suggested (4,11). Protected LMCA segment was deﬁned by
the presence of at least one patent arterial or venous conduit
to at least one left coronary segment. Nonelective treatment
was deﬁned as a procedure carried out on referral before the
beginning of the next working day (12).
This protocol was approved by the hospital ethics com-
mittee and is in accordance with the Declaration of Hel-
sinki. Written informed consent was obtained from every
patient.
Procedures and post-intervention medications. All inter-
ventions were performed according to current standard
guidelines. The ﬁnal interventional strategy, including the
use of glycoprotein IIb/IIIa inhibitors, was entirely left to
the discretion of the operator, except for the stent use. Total
stent length was calculated as the sum of the length of each
single stent placed to treat LMCA, provided at least one
stent strut was in direct contact with the left main stem at
visual estimation. Angiographic success was deﬁned as
residual stenosis �30% by visual analysis and the presence
of Thrombolysis In Myocardial Infarction (TIMI) ﬂow
grade 3. All patients were advised to maintain aspirin
Table 1. Baseline Characteristics of the Study Population
Variables
Distal
LMCA
Disease
(n � 94)
Nondistal
LMCA
Disease
(n � 36)
p
Value
Age (yrs)* 65 � 12 61 � 12 0.09
Male (%)* 63 72 0.64
Body mass index* 24 � 4 24 � 3 0.50
Diabetes (%)* 27 22 0.83
Hypertension (%)* 63 47 0.41
Hypercholesterolemia (%) 65 61 0.87
Current smokers (%) 19 25 0.64
Creatinine (�mol/l)* 101 � 72 89 � 25 0.32
LV ejection fraction (%)* 44 � 16 46 � 14 0.42
Medical history (%)
Protected left main 14 14 �0.99
PCI 31 22 0.53
Myocardial infarction 39 47 0.60
TIA/stroke 10 8 �0.99
Heart failure* 15 17 �0.99
COPD severe*† 7 5 �0.99
Peripheral arterial disease* 22 16 0.63
Carotid artery disease* 9 5 0.71
Clinical presentation (%)
Stable angina 53 47 0.86
Unstable angina 32 36 0.90
Acute myocardial infarction* 15 17 0.95
Cardiogenic shock at entry* 7 8 �0.99
Parsonnet score 18 � 13 14 � 10 0.048
*Parameters included in the Parsonnet classiﬁcation. †Resulting in functional disabil-
ity, hospitalization, requiring chronic bronchodilator therapy or FEV1 �75% of
predicted (10).
COPD � chronic obstructive pulmonary disease; LMCA � left main coronary
artery disease; LV � left ventricular; PCI � percutaneous coronary intervention;
TIA � transient ischemic attack.
Abbreviations and Acronyms
BMS � bare-metal stent
DES � drug-eluting stent
DLMD � distal left main disease
LMCA � left main coronary artery
MACE � major adverse cardiac events
MI � myocardial infarction
MLD � minimal luminal diameter
SES � sirolimus-eluting stent
TIMI � Thrombolysis In Myocardial Infarction
TVR � target vessel revascularization
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lifelong, and clopidogrel was prescribed for 6 months in
both groups.
End point deﬁnitions and clinical follow-up. Distal
LMCA disease was deﬁned as signiﬁcant lumen obstruction
(�50%) at visual estimation occupying the third distal area
of the LMCA shaft with the entire lesion or part of it either
directly involving the ostium of the left anterior descending
and/or circumﬂex artery or in close contact with at least one
of them. The primary outcome was the occurrence of major
adverse cardiac events, deﬁned as: 1) death, 2) nonfatal
myocardial infarction, or 3) target vessel revascularization.
Patients with more than one event have been assigned the
highest rank event, according to the previous list. All deaths
were considered to be of cardiac origin unless a noncardiac
origin was established clinically or at autopsy. Myocardial
infarction was diagnosed by an increase in the creatine
kinase level to more than twice the upper normal limit and
with an increased creatine kinase-MB fraction. Target
vessel revascularization was deﬁned as a repeat intervention
(surgical or percutaneous) to treat a luminal stenosis in the
stent or within the adjacent 5-mm segments adjacent to the
stent, including the ostium of the left anterior descending
artery and/or circumﬂex artery. Information about in-
hospital outcomes was obtained from an electronic clinical
database for patients maintained at our institution and by
review of hospital records for those discharged to referring
hospitals (patients were referred from a total of 14 local
hospitals). Post-discharge survival status was obtained from
the Municipal Civil Registries. Data on occurrence of
myocardial infarction (MI) or repeat interventions at
follow-up were collected by consultation of our institutional
electronic database, by contacting referring institutions, and
from all living patients.
Quantitative angiographic analysis. Quantitative analyses
of all angiographic data were performed with the use of
edge-detection techniques (CAAS II, Pie Medical, Maas-
tricht, the Netherlands). A value of 0 mm was assigned for
the minimum luminal diameter (MLD) in cases of total
occlusion at baseline or follow-up. Binary restenosis was
deﬁned as stenosis of more than 50% of the luminal
diameter in the target lesion. Acute luminal gain was
deﬁned as the MLD after the index procedure minus the
MLD at baseline angiography. Late loss was deﬁned as
the MLD immediately after the index procedure minus
the MLD at angiographic follow-up. Net luminal gain
was deﬁned as the difference between MLD at follow-up
and MLD before the procedure. Quantitative angiographic
measurements of the target lesion were obtained in-stent
and in-lesion (including the stented segment as well as the
margins 5 mm proximal and distal to the stent).
Statistical analysis. Because the T-SEARCH is an ongo-
ing registry at out institution, the selection of the cohort of
Table 2. Procedural and Angiographic Characteristics of the Study Population
Variables
Distal LMCA
Disease
(n � 94)
Nondistal LMCA
Disease
(n � 36) p Value
Pure LMCA disease (%) 0 19 0.0002
LMCA plus 1-vessel disease (%) 12 25 0.12
LMCA plus 2-vessel disease (%) 20 22 0.82
LMCA plus 3-vessel disease (%) 54 33 0.22
Bifurcation lesion classiﬁcation (%)
Isolate distal LMCA stenosis 11 – –
Distal LMCA plus ostial LAD or CFX 40 – –
Distal LMCA plus both LAD/CFX ostia 49 – –
Right coronary artery �70% stenosis (%) 69 64 0.21
Right coronary artery occlusion (%) 17 22 0.63
Number of implanted stents 1.65 � 0.65 1.22 � 0.42 0.0003
Main branch/bifurcation stenting (%) 51/49 89/11 0.005
Culotte/T-stent/Crush/V-stent (%)* 37/33/17/13 50/25/25/0 0.29
Nominal stent diameter (mm) 3.19 � 0.28 3.26 � 0.37 0.22
Total stent length per patient (mm) 29 � 13 18 � 13 �0.0001
SES/PES (%) 37/63 42/58 0.63
Pre-dilation (%) 73 70 �0.99
Cutting balloon (%) 3 14 0.05
Rotational atherectomy (%) 0 5 0.08
Post-dilation (%) 79 75 0.88
Bigger balloon inﬂated (mm) 3.66 � 0.46 3.87 � 0.47 0.025
Maximal pressure (atm) 18 � 3 17.8 � 3 0.67
Intravascular ultrasonography (%) 20 47 0.045
Glycoprotein IIb/IIIa inhibitors (%) 34 36 0.85
Intra-aortic balloon pump (%) 20 18 �0.99
Left ventricle assist device (%) 2 6 0.32
Temporary pacing during procedure (%) 7 9 �0.99
*Referred to the total number of patients treated with bifurcation stenting.
CFX � circumﬂex artery; LAD � left anterior descending artery; PES � paclitaxel-eluting stent; SES � sirolimus-eluting
stent; other abbreviations as in Table 1.
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patients for the present report was based on the following
criteria: a minimum follow-up time of 1 year, and an
expected major adverse cardiac events (MACE) rate of 10%
in the group of patients without DLMD with a 3� event
rate increase in the DLMD, based on previous ﬁndings (1),
with alpha and beta errors of 5% and 20%, respectively.
Continuous variables are shown as mean � SD and were
compared using the Student unpaired t test. Categorical
variables are presented as counts and percentages and are
compared with the Fisher Exact test. Survival curves were
generated by the Kaplan-Meier method, and survival among
groups was compared using the log-rank test. Cox propor-
tional hazards models were used to assess risk reduction of
adverse events. Multivariable analysis, considering all vari-
ables reported in Tables 1 and 2 with a p value of �0.10,
was performed to adjust for possible confounders and to
identify whether DLMD was an independent predictor of
adverse events. Probability was signiﬁcant at a level of
�0.05. All statistical tests were two-tailed. Statistical anal-
ysis was performed on Statistica 6.1 (Statsoft Inc., Tulsa,
Oklahoma).
RESULTS
Baseline and procedural characteristics. Baseline and
procedural characteristics of the patient population, strati-
ﬁed into LMCA disease location, are shown in Tables 1 and
2. Patients with DLMD tended to be older and presented
with an overall higher Parsonnet surgical risk score com-
pared with those without DLMD. Similarly, coronary artery
disease extent, number of stents, and total stent length were
greater and the use of intravascular ultrasound was less than
in DLMD patients. In one patient per group, both present-
ing with acute myocardial infarction, procedural success was
not obtained because of TIMI ﬂow grade �3 after stenting.
Clinical outcome based on left main disease location. At
30 days, there was no difference in clinical outcome between
patients with and without DLMD, considering either the
whole population, those receiving an elective intervention,
or those at low surgical risk according to the Parsonnet score
(Table 3). Overall, no documented thrombotic stent occlu-
sion occurred in the ﬁrst 30 days or thereafter.
After a median follow-up of 587 days (range 368 to 1,179
days; 577 days [range 368 to 1,156 days] in the DLMD
group vs. 598 days [range 398 to 1,179 days] in the group
without DLMD, p � 0.56), the cumulative incidence of
MACE (death, MI, or TVR) was signiﬁcantly higher in
patients with DLMD (30% vs. 11% in those without
DLMD; hazard ratio [HR] 3.42, 95% conﬁdence interval
[CI] 1.34 to 9.7; p � 0.007) (Fig. 1A). The composite
death/MI was 17% in the DLMD group and 8% in patients
without DLMD (HR 2.11, 95% CI 0.45 to 10; p � 0.34),
whereas the cumulative incidence of TVR was 13% versus
3% in patients with and without DLMD (HR 6, 95% CI
1.2 to 29; p � 0.02) (Fig. 1B).
In the elective patient population (106 patients overall, 73
in the DLMD group), the cumulative incidence of MACE
remained greater in the DLMD subgroup (26%) compared
with those without DLMD (9%; HR 3.59, 95% CI 1.23 to
12.1; p � 0.01) (Fig. 1C). The composite of death/MI was
11% in patients with and 6% in those without DLMD (HR
2.48, 95% CI 0.7 to 8.5; p� 0.35), whereas the need for TVR
was 15% and 3% in the two groups, respectively (HR 6.1, 95%
CI 1.6 to 21; p � 0.02) (Fig. 1C). Even after excluding
patients receiving protected intervention, the MACE rate
remained higher in patients with compared with those without
DLMD (HR 3.1, 95% CI 1.08 to 9.1; p � 0.01).
Complex bifurcation stenting was more common in the
DLMD subgroup. However, the technique of stent deploy-
ment in itself failed to affect outcome, with a MACE rate of
31% in DLMD patients undergoing stenting of the main
branch versus 28% in those treated with bifurcation stenting
(HR 0.96, 95% CI 0.46 to 1.49; p � 0.92).
Patients at high surgical risk according to the Parsonnet
score had a higher MACE rate compared with those at low
risk, conﬁrming previous ﬁndings (Fig. 2A).
To explore the additive prognostic value of combining the
anatomical location of LMCA disease and surgical risk
status, Kaplan-Meier curves were constructed according to
the four combinations generated by having distal or non-
distal LMCA disease and being at high or low surgical risk.
As shown in Figure 2, the cumulative event rate in the
group of patients affected by nondistal LMCA disease with
low surgical risk was 10-fold lower (4%) than that observed
in surgical high-risk patients with DLMD (40%, p � 0.002).
Table 3. 30-Day Outcomes
Variables
Distal
LMCA
Disease
Nondistal
LMCA
Disease
p
Value*
Whole population (n � 94) (n � 36)
Death, n (%) 7 (7) 3 (8) �0.99
Nonfatal MI, n (%) 4 (4) 0 (0) 0.57
Death or nonfatal MI, n (%) 11 (12) 3 (8) 0.76
TVR, n (%) 0 (0) 1 (3)‡ 0.28
Any event, n (%) 11 (12) 4 (11) �0.99
Stent thrombosis, n (%)† 0 (0) 0 (0) �0.99
Elective population (n � 71) (n � 33)
Death, n (%) 1 (1) 2 (6) 0.25
Nonfatal MI, n (%) 4 (6) 0 (0) 0.32
Death or nonfatal MI, n (%) 4 (6) 2 (6) 0.11
TVR, n (%) 0 (0) 1 (3)‡ 0.31
Any event, n (%) 4 (6) 3 (9) 0.68
Stent thrombosis, n (%)† 0 (0) 0 (0) �0.99
Low-surgical-risk population (n � 47) (n � 22)
Death, n (%) 0 (0) 0 (0) �0.99
Nonfatal MI, n (%) 1 (2) 0 (0) �0.99
Death or nonfatal MI, n (%) 1 (2) 0 (0) �0.99
TVR, n (%) 0 (0) 1 (4)‡ 0.32
Any event, n (%) 1 (2) 1 (4) 0.54
Stent thrombosis, n (%)† 0 (0) 0 (0) �0.99
*By Fisher exact test. †Angiographically documented. ‡In a patient with calciﬁed
ostium of the left main coronary artery (LMCA), a residual�50% stenosis despite use
of cutting balloon and rotablator justiﬁed elective surgical revascularization.
MI � myocardial infarction; TVR � target vessel revascularization.
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Surgical high-risk status seemed to stratify patients at greater
probability of early events independent of the anatomical
location of LMCA disease, whereas DLMD identiﬁed pa-
tients at higher risk for late events irrespective of surgical risk.
Multivariable analysis. After adjustment for Parsonnet
risk score (which includes age), the extent of coronary
disease, number of deployed stents, post-procedural mini-
mal lumen diameter, bigger balloon inﬂated, and use of
intravascular ultrasound at multivariable Cox regression
analysis, DLMD remained an independent predictor of
MACE (HR 2.79, 95% CI 1.17 to 8.9; p � 0.032)
independent of surgical risk status (assessed as high risk
versus low risk; HR 2.18, 95% CI 1.06 to 4.5; p � 0.038).
The estimates of these two covariates remained unchanged
if: 1) treatment technique (main branch vs. bifurcation
stenting) or 2) treatment technique but not number of
deployed stents—to check for possible colinearity between
these two variables—were introduced in the model.
No statistical interaction emerged between the anatomi-
cal location of LMCA disease and the surgical risk with
respect to MACE (p � 0.3).
Quantitative angiographic analysis. Seventy-one patients
in the DLMD group (84% of eligible patients) and 28
patients without DLMD (85% of eligible patients) under-
went eight-month angiographic follow-up (p � 0.99).
Quantitative coronary angiography analysis is reported in
Table 4. As shown, despite a similar LMCA reference
vessel diameter, patients with DLMD location tended to
have a longer lesion length and a slightly smaller MLD.
In-stent and in-segment acute luminal gain seemed to be
similar in the two groups, whereas late loss was almost
double in the DLMD group. Thus, in-stent and in-segment
Figure 1. Adverse events in patients treated for distal left main coronary artery (LMCA) disease (DLMD) as compared with patients treated for nondistal
LMCA disease (NDLMD). Cumulative risk of major adverse cardiac events (MACE) (A) and target vessel revascularization (TVR) (B) in the whole
population, and cumulative risk of MACE (C) and TVR (D) in the elective population.
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net luminal gain was signiﬁcantly lower in patients with as
compared with those without DLMD.
DISCUSSION
The percutaneous treatment of LMCA disease is a chal-
lenging task, with historical event rates often reported to be
unacceptably high (4,13,14). The advent of BMS has not
been regarded as a major breakthrough in the percutaneous
treatment of such lesions (15) because the occurrence of
in-stent restenosis was believed to be associated with fatal-
ities (4,13). Recently, the liberal use of DES to treat LMCA
has been shown to favorably affect outcome compared with
the use of BMS (1–3). However, the rate of major cardio-
vascular events in the DES era remains high in some of the
ﬁrst series of patients reported (1,3).
Whether the percutaneous treatment of LMCA should
be strictly reserved for poor surgical candidates or offered
with less restriction to patients known to be at low risk for
future MACE remains highly debated (5). Ideally, risk
factors able to differentiate outcomes between those under-
going catheter-based LMCA treatment and those receiving
surgical revascularization might help in selecting the most
appropriate revascularization strategy. Anatomical charac-
teristics of the LMCA lesion have great potential in this
regard because they may theoretically inﬂuence the percu-
taneous but not the surgical revascularization technique.
Some early observational studies in the BMS era identiﬁed
distal location of the disease with respect to LMCA
anatomy as a major determinant of restenosis in patients
receiving percutaneous treatment of the LMCA (6). Simi-
larly, we and other groups have reported that the great
majority of lesions, which undergo TVR at follow-up, are
located in the distal tract of the LMCA (1,3,16).
The main ﬁnding of our investigation is that the long-
term outcome of patients undergoing percutaneous treat-
ment for DLMD is signiﬁcantly worse compared with that
of patients treated for LMCA lesions not located in the
distal tract. Interestingly, this remained true in both elective
and low-surgical-risk groups. The procedural success rate
along with the short-term (30 days) outcome was remark-
ably similar between the two groups, whereas the difference
between patients with and without DLMD emerged at
long-term follow-up, mainly driven by a higher need for
TVR in the former group. Despite the lack of statistical
signiﬁcance, the composite of death and nonfatal MI was
consistently two times higher in the DLMD group, both in
the total cohort of patients (17% vs. 8% in the non-DLMD
group, p � 0.34) and after selection for elective cases only
(11% vs. 6.% in the non-DLMD group, p � 0.35).
Whether these results on death and MI reﬂect a type II
error or a chance ﬁnding remains unclear.
Our multivariable model, based on all possible confound-
ers of clinical outcome, showed that DLMD is an indepen-
dent predictor of poor outcome in this subset of patients,
with an adjusted risk for MACE of almost three-fold higher
than that for non-DLMD at long-term follow-up.
To further rule out the possibility that treatment
technique, more than the anatomical location of the
disease, was responsible for the difference in long-term
outcomes between patients with and without DLMD,
the MACE rate in patients receiving bifurcation stenting
was compared with that in patients undergoing single-
vessel stenting in the DLMD subgroup. The MACE rate
was remarkably similar between these two groups of
patients, supporting the hypothesis that the anatomical
location of the LMCA disease more than the techniques
Figure 2. Cumulative risk of major adverse events in patients with high surgical risk (Parsonnet score�15) as compared with that of patients at low surgical
risk (Parsonnet score�15) (A), and in patients at high surgical risk affected by DLMD as compared with that of patients at high surgical risk and NDLMD,
low surgical risk and DLMD, and low surgical risk and NDLMD (B). *p � 0.002; †p � 0.048; ‡p � 0.066. Abbreviations as in Figure 1.
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used to treat it was responsible for the higher overall event rate
in the DLMD group.
In the quantitative angiographic analysis, the late loss was
higher, the acute luminal gain was lower, and the binary
restenosis rate also tended to be higher in the DLMD
group, which provides a possible mechanistic explanation
for our clinical ﬁndings.
Finally, to investigate the prognostic power of DLMD in
relation to surgical risk status, Kaplan-Meier curves were
constructed according to the four combinations generated
by having distal or nondistal LMCA disease and being at
high or low surgical risk. Surgical risk status seemed to
stratify patients at a greater probability of events indepen-
dent of the anatomical location of LMCA disease, whereas
DLMD identiﬁed patients at a higher risk for poor prog-
nosis irrespective of surgical risk. Of note is that the surgical
risk status seemed to better risk-stratify patients according
to early events, with survival curves running parallel after the
ﬁrst month of treatment. Conversely, DLMD identiﬁed
patients with a higher event rate at follow-up, with the two
survival curves diverging at around 180 days after the
procedure. Interestingly, we failed to identify a statistical
interaction between surgical risk status and the location of
LMCA disease in our patient population, which implies
that the risk associated with DLMD is additive—not
multiplicative—with respect to that of being at high surgical
risk status. This further conﬁrms that the two currently used
approaches for risk stratiﬁcation, namely surgical risk status
and anatomical location of the disease, are independent and
possibly complementary to each other.
As a potential corollary to our ﬁndings, the extremely low
event rate in patients at low surgical risk undergoing LMCA
intervention for nondistal LMCA disease should not go
unnoticed. This subset of patients with excellent long-term
outcome after catheter-based treatment should be ideally
selected to prospectively test whether percutaneous inter-
vention is a valuable alternative to surgical revascularization
in future trials.
Study limitations. A limitation of proposing distal loca-
tion of LMCA disease as a risk-stratifying tool lies in the
recognition that the distal site is the most prevalent site of
disease in LMCA patients undergoing catheter-based in-
tervention in the DES era. Whether this partially reﬂects
the fact that patients with DLMD are more likely to be at
higher surgical risk or tend to be older, as in our present
series, and consequently are more likely to undergo percu-
taneous instead of surgical revascularization, remains to be
addressed.
The results of our study are encouraging, but they cannot
be conclusive. Studies with larger sample sizes and more
prolonged clinical follow-up are clearly in demand to
conﬁrm our ﬁndings and extend our capability to risk-
stratify this challenging subset of patients.
Conclusions. The percutaneous treatment of DLMD
emerged as a major predictor of poor long-term outcome,
independent of the type of procedure (elective versus non-
elective) and the overall surgical risk status. Conversely, the
event rate after treatment for non-DLMD seemed to be
remarkably low, with an excellent short-term and long-term
prognosis, especially in the low surgical risk population. Our
current ﬁndings extend the previous knowledge about risk
stratiﬁcation for patients undergoing catheter-based treat-
ment of LMCA, and may help in identifying the most
appropriate LMCA population, in which catheter-based
intervention may be indicated beyond surgical risk status in
the DES era.
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Distance from the ostium as an independent
determinant of coronary plaque composition in vivo:
an intravascular ultrasound study based radiofrequency
data analysis in humans
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Aims Relative plaque composition, more than its morphology alone, is thought to play a pivotal role
in determining propensity to vulnerability. Thus, we investigated in vivo whether the distance from
coronary ostium to plaque location independently affects plaque composition in humans. This may
help explaining the recently reported non-uniform distribution of culprit lesions along the vessel in
acute coronary syndromes.
Methods and results In 51 consecutive patients (45 men), aged 38–76 years (mean age: 58+ 10), a non-
culprit vessel was investigated through spectral analysis of IVUS radiofrequency data (IVUS-Virtual His-
tologyTM). The study vessel was the left anterior descending artery in 23 (45%) patients; the circumﬂex
artery in nine (18%), and right coronary artery in 19 (37%). The overall length of the region of interest,
subsequently divided into 10 mm segments, was 41.5+ 13 mm long (range: 30.2–78.4). No signiﬁcant
change was observed in terms of relative plaque composition along the vessel with respect to
ﬁbrous, ﬁbrolipidic, and calciﬁed tissue, whereas the percentage of lipid core resulted to be increased
in the ﬁrst (median: 8.75%; IQR: 5.7–18) vs. the third (median: 6.1%; IQR: 3.2–12) (P ¼ 0.036) and fourth
(median: 4.5%; IQR: 2.4–7.9) (P ¼ 0.006) segment. At multivariable regression analysis, distance from
the ostium resulted to be an independent predictor of relative lipid content [b ¼20.28 (95%CI:
20.15, 20.41)], together with older age, unstable presentation, no use of statin, and presence of
diabetes mellitus.
Conclusion Plaque distance from the coronary ostium, as an independent determinant of relative lipid
content, is potentially associated to plaque vulnerability in humans.
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Coronary plaque rupture or erosion, by triggering local
thrombosis is thought to play a pivotal role in the genesis
of acute coronary syndromes (ACS) and sudden death.1,2
A series of landmark angiographic studies in the mid-1980s
demonstrated that nearly two-thirds of all myocardial
infarction originate from non-ﬂow limiting atherosclerotic
lesions and prior angiographic studies focusing on plaque
morphology alone failed to identify quiescent plaques
prone to rapidly progress or rupture.3–7
Consequently, the mechanical and biological properties of
coronary plaques, which overall reﬂect plaque composition,
along with systemic inﬂammation has mainly been targeted
for the diagnosis and treatment of plaque instability.8
Epidemiological studies in patients with ST-segment
elevation myocardial infarction (STEMI) report that sites of
occlusion are not uniformly distributed throughout each of
the major epicardial coronary arteries but tended to
cluster within the proximal third of each of the vessels.9,10
Accordingly, despite the recognition that several factors
involved in the pathogenesis of plaque vulnerability are
widespread,11–14 local trigger(s) should be also targeted to
explain the presence of high-risk coronary spots.15
Plaque composition, favouring propensity to vulnerability,
might also be non-uniformly distributed along each coronary
vessel. This might explain the higher likelihood for plaque
erosion or rupture to occur proximally in the coronary tree.
To investigate this hypothesis, the non-culprit, non-
treated vessel containing angiographically non-obstructive
(,50%) lesions was systematically investigated to assess
plaque composition through spectral analysis of IVUS radio-
frequency data [IVUS-Virtual HistologyTM (IVUS-VH)] in
consecutive patients referred to our institution for percuta-
neous coronary intervention (PCI).
Our ﬁndings support for the ﬁrst time to the best of our
knowledge in vivo the hypothesis that plaque composition
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in humans may differ in relation to plaque localization along
the coronary tree.
Methods
Study protocol and patients enrolment
This was a single-center, investigators-driven, observational pro-
spective study aimed to evaluate the distribution of plaque
composition along the coronary vessel in consecutive patients
referred to our institution for elective or urgent PCI, in whom the
non-culprit, non-treated vessel was judged suitable for a safe
IVUS 30 mm-pullback or more, based on angiographic (absence of
the following: .50% stenotic disease, extensive calciﬁcation,
severe vessel tortuosity) and clinical (haemodynamic stability)
ﬁndings. According to the protocol, not more than one vessel-per
patient could be evaluated and the region of interest (ROI), sub-
sequently divided into 10 mm segments, had to start from the
coronary ostium. Thus, an analysable interrogated vessel length of
at least 30 mm, starting from coronary ostium, was the main
selection criterion, once the patient was included in the study.
In the group of patients presenting with an ACS, the culprit lesion
has been categorized as complex or non-complex, based on angio-
graphic ﬁndings as previously described.12
This protocol was approved by the Hospital Ethics Committee and
is in accordance with the declaration of Helsinki. Written informed
consent was obtained from every patient.
IVUS-VH acquisition and analysis
Details regarding the validation of the technique, on explanted
human coronary segments, have previously been reported.16
Brieﬂy, IVUS-VH uses spectral analysis of IVUS radiofrequency data
to construct tissue maps that classify plaque into four major com-
ponents. In preliminary in vitro studies, four histological plaque
components (ﬁbrous, ﬁbro-lipid, lipid core, and calcium) were cor-
related with a speciﬁc spectrum of the radiofrequency signal.16
These different plaque components were assigned colour codes.
Calciﬁed, ﬁbrous, ﬁbrolipidic, and lipid-necrotic regions were
labelled white, green, greenish-yellow, and red, respectively.17
IVUS-VH data was acquired after intracoronary administration of
nitrates using a continuous pullback (0.5 mm/s) with a commercially
available mechanical sector scanner (UltracrossTM 2.9F 30 MHz cath-
eter, Boston Scientiﬁc, Santa Clara, CA), by a dedicated IVUS-VH
console (Volcano Therapeutics, Rancho Cordova, CA). The IVUS-VH
data were stored on a CD-ROM and sent to the imaging core lab
for ofﬂine analysis. IVUS B-mode images were reconstructed from
the RF data by customized software (IVUSLab, Volcano Thera-
peutics, Rancho Cordova, CA).17 Manual contour detection of both
the lumen and the media-adventitia interface was performed and
the RF data was normalized using a technique known as ‘Blind
Deconvolution’, an iterative algorithm that deconvolves the
catheter transfer function from the backscatter, thus accounting
for catheter-to-catheter variability.18,19
Statistical analysis
The sample size was calculated on the assumption that plaques
located in the proximal segment of the coronary artery, deﬁned as
the ﬁrst 10 mm coronary segment, would display a mean lipid
content of around 40%, with a sigma of around 35% based on previous
ﬁndings,20 with a lipid content of 10% in the distal plaques, deﬁned as
those located beyond the ﬁrst 20 mm from the coronary ostium. To
detect this effect size with 80% power and a type-I error (alpha) of
0.05, 48 patients were required. Four main models were constructed
based on the number of 10 mm segments that were included.
Model 1 comprised three 10 mm segments available in all patients
included.
Model 2 comprised four 10 mm segments available in 43 patients.
Models 3 and 4, composed of ﬁve and six 10 mm segments in 20 and
11 patients, respectively, were considered as exploratory analysis
because of limited sample size.
Values are expressed as mean+ SD and median and inter-quartile
range (IQR) as appropriate.
As all cross-sectional areas (CSA) provided by IVUS analysis, were
shown to have a non-normal distribution at Kolmogorov–Smirnov
goodness-of-ﬁt test, they were log-transformed before analysis.
Similarly, to all percentages relative to stenosis rate and plaque
composition were applied an arcsin transformation.21 Comparisons
between the two groups were performed with the Student’s t-test.
Fisher’s exact test was used for categorical variables. Comparisons
among 10 mm segments were accomplished through a general
linear mixed model with a compound symmetry correlation struc-
ture and the intercept as only random effect. Maximum likelihood
method was adopted to estimate parameters in the models. Linear
contrasts were applied to evaluate effects of distance, analysed as
dummy variable, on the studied parameters. Post hoc comparisons
were systematically performed by Turkey honest signiﬁcance
difference test.22
Because of limited statistical power in models 3 and 4, the multi-
variable analysis regarding both clinical presentation and plaque
location along the vessel, along with the interaction between the
two was restricted to models 1 and 2.
In order to establish the determinants of lipid relative content in
the plaques in our model and conﬁrm distance from the coronary
ostium as an independent predictor of relative lipid content, a uni-
variate (including age, sex, history of hypertension, hypercholester-
olaemia, cardiovascular disorders in the family, diabetes mellitus,
levels of LDL, HDL, and triglycerides, use of statin, coronary
vessel analysed, clinical presentation, and distance for the ostium
stratiﬁed into 10 mm segments) and multivariable (with all variables
showing a P-value of �0.1 at univariate analysis) linear mixed model
using percentage of lipid content in all 10 mm segments, analysed as
outcome variable, was also applied.
All statistical tests were two-tailed. Probability was signiﬁcant at
a level of ,0.05. Statistical analysis was performed using Statistica
6.1 Software (Statsoft Inc.) and R-language (R Foundation).
Results
From 16 April 2003 to 10 September 2004, 67 patients were
prospectively included in the protocol. Sixteen patients
were subsequently excluded from the ﬁnal analysis
because of short (,30 mm) IVUS pullback in 10, poor IVUS
quality in two and lack of coronary plaque at IVUS investi-
gation in four patients. Thus, 51 patients (45 men), aged
38–76 years (mean age: 58+ 10) constituted the ﬁnal
patient population. Their baseline characteristics are pro-
vided in Table 1. Overall, 33 patients were affected by
stable angina (SA), whereas the remaining 18 patients
were admitted to hospital because of a non-ST-elevation
ACS. In the SA group, the mean Cardiovascular Canadian
Score was 2+ 1, whereas the TIMI risk score, the percen-
tage of patients with troponin T above upper limit of
normal (0.02 mg/L) and the delay from symptoms onset to
PCI were 4+ 2, 56% and 4+3 days in the ACS group,
respectively. In the ACS group, the culprit lesion was
located in the proximal coronary segments in 13 (72%)
patients, including 6 (33%) in the left anterior descending
artery (LAD), four (22%) in the circumﬂex artery (CFX),
and three (17%) in the right coronary artery (RCA), while
in the remaining ﬁve (28%) patients the culprit lesion was
located in the mid or distal segment of the coronary
vessels. Overall, 11 out of 18 identiﬁed culprit lesions in
the ACS group satisﬁed the criteria for complex lesions
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based on angiographic ﬁndings. The study vessel was the LAD
artery in 23 (45%) patients, the CFX in nine (18%), and RCA in
19 (37%). The overall length of the ROI was 41.5+ 13 mm
long [(range: 30.2–78.4) (41+ 13 in SA group vs. 42+ 13
in ACS group, P ¼ 0.6)]. The results regarding quantitative
coronary IVUS analysis in the whole population, stratiﬁed
into 10 mm vessel length (paired-segment analysis), are
reported in Table 2. Lumen CSA signiﬁcantly decreased
every 10 mm in model 1, whereas this happened starting
from the third segment, as compared with ﬁrst coronary
tract, in model 2.
As compared with ostial 10 mm segment, vessel CSA
resulted to be decreased in the third and fourth segment
in models 1 and 2, respectively, whereas plaque CSA reduc-
tion reached statistical signiﬁcance only in the fourth
segment of model 2. Distance from the coronary ostium
did not affect the percentage of stenosis. The third and
fourth models, restricted to a progressively lower number
of patients but based on a longer vessel length, mainly
conﬁrmed the trends observed in the ﬁrst two models.
Change in plaque composition along
the study vessel
The results regarding quantitative coronary plaque compo-
sition analysis are reported in Table 3.
Fibrous tissue was the most prevalent component of
plaque composition in each 10 mm segment throughout the
four models considered, followed by ﬁbrolipidic tissue,
lipidic core, and calcium.
No signiﬁcant change was observed in terms of relative
plaque composition passing from the most proximal to
those progressively more distally located segments along
the vessel with respect to ﬁbrous, ﬁbrolipidic, and calciﬁed
tissue. Conversely, the percentage of lipid core resulted to
be increased in the ﬁrst [(mean: 13%; 95%CI: 10, 16),
(median: 8.75%; IQR: 5.7, 18)] with respect to the third
segment [(mean: 8.7%; 95%CI: 6.5, 11), (median: 6.2%;
IQR: 2.6, 12.1)] in model 1 (P, 0.05; primary endpoint)
and to third [(mean: 8.4%; 95%CI: 6, 11), (median: 6.1%;
IQR: 3.2–12)] (P, 0.05) and fourth [(mean: 6.8%; 95%CI:
4, 9.6), (median: 4.5%; IQR: 2.4–7.9)] (P, 0.01) segment
in model 2 (Figure 3). A similar shift in relative plaque
composition along the vessel was observed in models 3 and
4. Interestingly, ACS patients presenting with the culprit
lesion located in the proximal segment of the coronary
artery did not differ in terms of relative plaque distribution
along the vessel with respect to those with culprit lesion
sited in the mid of distal tract.
Clinical presentation and change in plaque
composition along the study vessel
No signiﬁcant change in calcium content with respect to
clinical presentation (stable vs. unstable) was observed
(data not shown). In model 1, ﬁbrous plaque content was
overall signiﬁcantly increased in stable (68%) [95%CI: 65%,
71%] vs. unstable (63%) [95%CI: 59%, 64.7%] group,
whereas a decrease in stable (17%) [95%CI: 16%, 19%] vs.
unstable (22%) [95%CI: 20%, 24%] patients was observed for
Table 1 Study population
Variables Patients
All
(n ¼ 51)
SA Group
(n ¼ 33)
ACS Group
(n ¼ 18)
Age (years) 58+ 10 56+ 12 59+ 9
Males, no. (%) 45 (88) 28 (85) 16 (94)
Weight (kg) 80+ 9 80+ 8 81+ 9
Height (cm) 174+ 7 174+ 7 175+ 8
BMI (kg/m2) 27+ 4 27+ 3 28+ 5
Diabetes, no. (%) 12 (23) 8 (24) 4 (22)
Hypertension, no. (%) 20 (39) 14 (42) 6 (33)
Current smokers, no. (%) 19 (37) 13 (39) 6 (33)
Previous smoker, no. (%) 16 (31) 9 (27) 7 (39)
Medical history, no. (%)
CABG 3 (6) 2 (6) 1 (6)
PCI 11 (22) 8 (24) 3 (17)
ACS 23 (45) 18 (54) 5 (28)
Medical treatment at entry, no. (%)a
Aspirin 51 (100) 33 (100) 18 (100)
Clopidogrel 51 (100) 51 (100) 18 (100)
Statin 38 (75) 25 (76) 13 (72)
ACE-inhibitor 40 (78) 30 (91) 10 (56)
b-Blocker 48 (94) 32 (97) 16 (89)
Plus–minus values are means+ SD. BMI, Body mass index; CABG, coronary artery bypass grafting;
ACE, angiotensin converting enzyme.
The SA group was well matched (P-value .0.3) with the ACS group with respect to all variables
reported earlier.
aFor this analysis we considered all medications administered in the previous 4 or more days. At dis-
charge all patients except one were taking statins.
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ﬁbrolipid content when all 227 segments were pooled
together (P ¼ 0.03 and P ¼ 0.006, respectively). However,
when distance from the ostium, stratiﬁed into 10 mm
segments, was also inserted into the model, only trends
towards increase in ﬁbrous and decrease in ﬁbrolipidic
content in stable vs. unstable patients were observed,
which did not reach statistical signiﬁcance. This was
conﬁrmed in model 2. In contrary, even when analysed
simultaneously, both plaque location along the vessel
(P ¼ 0.044 and P ¼ 0.002 for models 1 and 2, respectively)
and clinical presentation (stable vs. unstable) (P ¼ 0.01
and P ¼ 0.004 for models 1 and 2, respectively) resulted to
be independent predictors of lipid content (Figures 1B
and 2B) after adjustment for age, sex, diabetic status,
type of coronary artery analysed, and use of statin.
Finally, in order to evaluate whether the shift in lipid
content along the vessel was inﬂuenced by clinical presen-
tation, the interplay between these two main determinants
of lipid content was investigated, but no statistical
interaction emerged between plaque location and lipid
core content (P ¼ 0.8 and P ¼ 0.49 for models 1 and 2,
respectively).
Distance from the ostium as an independent
predictor of lipid content
In Table 4 the variables found to be associated to the rela-
tive lipid content along the vessel are shown. The lipid
core in the most distally located coronary segment
(segment 3) in model 1 was signiﬁcantly lower compared
with segment 1, taken as a reference, independently from
all other identiﬁed predictors. When all 227 segments
were included in the model, distance from the ostium, stra-
tiﬁed into 10 mm segments, resulted to be an independent
predictor of relative lipid content along vessel wall,
together with older age, unstable presentation, no use of
statin, and the presence of diabetes mellitus. In keeping
with the results obtained at the post hoc analysis, after
adjusting for clinical presentation, relative lipid content in
segment 1 did not differ from segment 2 [b 20.08 (95%CI:
20.28, 0.116)], while it did so starting from segment 3 [b
20.22 (95%CI: b 0.39, b 0.05)], with a progressively lower
b-value for segment 4 [b 20.34 (95%CI: 20.39, 20.05)]
and 5 [b 20.38 (95%CI: 20.55, 20.21)].
Discussion
Several lines of research in the last decades have clearly
pointed out how factors involved in pathogenesis and pro-
gression of atherosclerotic lesions are widespread through-
out the circulatory bed.8,11,12,14,23,24
As a corollary to this, evidence that a single pharmaco-
logical or mechanical treatment, when applied locally, is
able to affect progression of coronary atherosclerosis is
weak and not conclusive.25 On the other hand, systemic
Table 2 Quantitative vessel analysis at IVUS
Coronary segments Mean cross-sectional areas (mm2) Stenosis (%)
Lumen Vessel Plaque
Model 1; n ¼ 51
18 (0–10 mm) 9.4+ 3.6 17.1+ 8.1 7.3+ 3.7 41.4+ 10.5
28 (10–20 mm) 7.8+ 2.9† 15.7+ 7.8 7.2+ 3.4 46+ 12
38 (20–30 mm) 7.1+ 2.8‡ 14.2+ 8‡ 6.2+ 2.7 45+ 11
P-value 0.002 0.01 0.12 0.08
Model 2; n ¼ 43
18 (0–10 mm) 9.3+ 3.6 17.4+ 8.6 7.6+ 3.9 42+ 11
28 (10–20 mm) 7.7+ 2.7 15.9+ 8.2 7.3+ 3.5 46+ 12
38 (20–30 mm) 7+ 2.6* 14.5+ 8.7 6.3+ 2.8 45+ 11.2
48 (30–40 mm) 6.4+ 2.7‡ 13.5+ 9.7‡ 6+ 3.4† 45.3+ 12.4
P-value 0.0002 0.001 0.02 0.4
Model 3; n ¼ 20
18 (0–10 mm) 10.4+ 4.3 20.5+ 11.5 9+ 5.2 39.8+ 10.5
28 (10–20 mm) 8.8+ 2.8 19+ 11 8.2+ 4.7 41.7+ 12
38 (20–30 mm) 8+ 2.9 17.4+ 12 6.9+ 3 42+ 10
48 (30–40 mm) 7.3+ 3.2 16.5+ 13.3 6.8+ 4.2 42+ 12
58 (40–50 mm) 7+ 2.9 16.2+ 15 5.7+ 2.3 41+ 11.4
P-value 0.07 0.12 0.054 0.98
Model 4; n ¼ 11
18 (0–10 mm) 10.7+ 2.8 19.3+ 2.7 8.6+ 2.1 45+ 7.8
28 (10–20 mm) 9.3+ 3.7 18+ 4 8.6+ 2.4 49+ 10
38 (20–30 mm) 8.6+ 2.3 16.8+ 4.6 8.2+ 2.4 48+ 8.3
48 (30–40 mm) 8.3+ 2.2 17.1+ 5 8.8+ 2.8 51+ 5.7
58 (40–50 mm) 7.5+ 2.5 15.3+ 4.9 7.8+ 2.6 51.3+ 4.8
68 (50–60 mm) 6.7+ 2.6† 13+ 4 6.2+ 2 48.2+ 9.7
P-value 0.023 0.06 0.063 0.4
*P, 0.01; †P , 0.05; ‡P, 0.001 as compared with segment 1 at post hoc analysis.
Results are given as mean+ SD.
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therapy, such as an intensive lipid-lowering treatment, has
been convincingly shown to be able to stop atherosclerotic
disease progression and even induce coronary lesions
regression in some studies.26–30 The same paradigm is
thought to be true for factors involved in atherosclerotic
lesions vulnerability, albeit probably in a more elusive
way.25
These ﬁndings should be combined, however, with the evi-
dence provided by recent epidemiological studies, which
corroborate the hypothesis according to which sites of
occlusions are not uniformly distributed throughout the
coronary tree, rather they show a tendency to cluster in
partially predictable hot spots located within the proximal
third of each coronary vessels.9,10
Thus, the interplay among systemic and local factors able
to promote progression and vulnerability of atherosclerotic
coronary lesions should be probably both targeted in the
attempt to control the chronic and acute consequences of
coronary atherosclerosis.15
Among local factors known to affect genesis and pro-
gression of coronary atherosclerotic lesions, shear stress
(SS) has been extensively investigated.
Fluid SS, acting on genes ‘sensitive’ to local haemo-
dynamic forces, is known to elicit a large number of
humoural, metabolic, and structural responses in endo-
thelial cells (EC).31 Low SS on ECs partially explains the
local arterial susceptibility to atherosclerosis, as low SS
enhances the oxidation of lipids and their accumulation in
the intima.31,32
Moreover, ﬂuid turbulence in itself is able to directly
activate platelets, thus possibly playing a pivotal role in
thrombogenesis as well.33
It is tempting to speculate that other local factors
could play additional roles in modulating progression
and instability of atherosclerotic lesions in coronary
arteries. Among them, pathological studies have
suggested that the distribution of thin-cap atheromas,
which are lipid rich core plaques known to be at particu-
larly high-risk for rupture, are not uniformly distributed
along the coronary vessels in post-mortem examin-
ations.34 Rather, they cluster in the proximal segments
of the three main coronary arteries, which is in keeping
with the longitudinal distribution of both ruptured and
healed plaques.34
This non-uniform distribution of vulnerable plaques in
humans could partially explain the clustering of occlusive
culprit lesion in the proximal or middle tract of coronary
arteries. In this regard, we hypothesized that plaque compo-
sition was also not uniformly distributed in vivo in humans in
patients with symptomatic coronary disease. Thanks to a
recently developed technology based on spectral analysis
of IVUS radiofrequency data (IVUS-VH),16,17 we prospec-
tively evaluated whether plaque composition is indepen-
dently affected by the distance from coronary ostium in a
Table 3 Plaque composition stratiﬁed into 10 mm segments
Coronary segments Plaque composition (%)
Calcium Fibrous Fibrolipidic Lipid core
Model 1; n ¼ 51
18 (0–10 mm) 0.69 (0.26–1.98) 67.1 (60–74.4) 16.86 (11.2–24) 8.8 (5.7–18)
28 (10–20 mm) 0.67 (0.3–1.58) 68.3 (60–77) 18.1 (12.7–23.1) 9.6 (4.3–15.1)
38 (20–30 mm) 0.79 (0.37–1.82) 69 (64–78) 18.7 (13.4–25.3) 6.2 (2.6–12.1)*
P-value 0.67 0.40 0.84 0.039
Model 2; n ¼ 43
18 (0–10 mm) 0.76 (0.28–2.3) 64.7 (59.3–74) 17.7 (13.4–24.5) 8.01 (5.7–18)
28 (10–20 mm) 0.70 (0.4–1.58) 66.9 (57.9–77) 18.6 (14–24.4) 10 (4.2–16.7)
38 (20–30 mm) 0.75 (0.37–1.82) 69 (63.9–77.8) 19.8 (14.3–25.4) 6.1 (3.5–12)*
48 (30–40 mm) 0.48 (0.09–1.5) 68.7 (60.8–75) 21.1 (17–28.2) 4.5 (2.4–8)†
P-value 0.36 0.55 0.63 0.0058
Model 3; n ¼ 20
18 (0–10 mm) 0.77 (0.5–2.6) 71.4 (49.7–76.4) 17.3 (13.4–23.7) 8 (6–25)
28 (10–20 mm) 0.49 (0.18–1.15) 72.3 (57.9–79.59) 17.2 (100–22.7) 9.3 (4.1–14.6)
38 (20–30 mm) 0.87 (0.1–2.4) 69.3 (61.1–79.6) 17.4 (13.1–25.3) 6.8 (4.1–12)
48 (30–40 mm) 0.9 (0.2–2.6) 67.8 (57.1–77.6) 19.1 (17.4–30) 6.1 (3–8.3)
58 (40–50 mm) 0.65 (0–1) 75.3 (60.6–81.4) 16.4 (14.5–32.6) 3.5 (0.7–5.8)*
P-value 0.14 0.8 0.71 0.039
Model 4; n ¼ 11
18 (0–10 mm) 0.3(0.2–1.6) 74.1 (61–79) 20.8 (16–28) 5.97 (2.25–12)
28 (10–20 mm) 0.8 (0.4–1) 74 (64–79) 20.5 (18–22) 5.7 (3–13)
38 (20–30 mm) 0.54 (0.13–1.6) 75.1 (70–80) 18.5 (16.8–22) 5 (2.8–6.5)
48 (30–40 mm) 0.63 (0.1–1.8) 75.7 (66–77) 21 (20–27) 3.4 (92.4–5.7)
58 (40–50 mm) 0.38 (0.1–1.3) 73.1 (67–81) 21.2 (15–27) 3.2 (2.7–5.3)
68 (50–60 mm) 0.37 (0–0.8) 77.3 (66–79) 24 (19–28) 2.7 (1–4.3)*
P-value 0.65 0.78 0.98 0.036
* P, 0.05; †P , 0.01 as compared with segment 1 at post hoc analysis.
Results are given as median (IQR).
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consecutive series of patients. Our ﬁndings support the
concept that coronary plaques located in the proximal
tract (�20 mm) of coronary vessels are relatively richer in
lipid content with respect to those more distally located,
independently from clinical presentation. In this regard,
the magnitude of lipid content appeared to be relatively
higher in patients presenting with clinical instability but
no interaction emerged in our model between clinical pres-
entation and lipid content, suggesting that the relative
change in plaque composition along the vessel is a well-
preserved phenotype in both groups of patients. Moreover,
distance from the coronary ostium resulted to be an inde-
pendent predictor of relative lipid content along the
vessel wall in our regression model, together with age,
unstable presentation, presence of diabetes mellitus, and
no use of statin.
Our current ﬁndings should be regarded as an attempt to
extend the pathophysiological knowledge on plaque vulner-
ability, mainly because of the well-known linkage between
plaque composition and risk of plaque rupture or
erosion.34–36 Thus, this might contribute to explain the
higher likelihood for plaque erosion or rupture to occur
proximally in the coronary tree. Moreover, the ﬁnding
that coronary plaques show a relatively higher lipid
content if proximally located along the longitudinal axis
of the vessel with respect to those more distally located
might elicit new methodological issues in future inves-
tigations. In particular, hypothesizing that plaque
progression/regression studies accomplished through
aggressive lipid-lowering regimen would mainly affect the
lipid content in the plaque, it seems reasonable to
believe that the relative effect of the tested medication
observed at IVUS investigation in terms of overall plaque
CSA, could differ in relation to the localization of ROI
with respect to the coronary ostium. This could bear
special hazard particularly in those studies having limited
ROI length.37
An interesting ﬁnding of our study was that the percen-
tage of stenosis did not differ in relation to the distance
from the ostium, whereas plaque area was progressively
smaller moving form proximal to distal segments. This
might be explained by the interplay between the physio-
logical proximal–distal tapering of the coronary vessel
and the higher propensity of the proximal segments to
undergo positive remodelling with respect to those
located more distally. This seems to be in keeping with
our recent ﬁndings that positive remodelling is indeed
more pronounced in lipid-rich coronary segments.38
Limitations of the study
As exploratory-pilot investigation, our current ﬁndings
should be regarded as provisional. In particular, to assess
relatively minor changes in plaque composition along longi-
tudinal vessel axis, such as that observed for ﬁbrous tissue,
or for highly dispersed data such as for relative calcium
content, a bigger, properly powered, sample size is clearly
needed. Similarly, the observed insigniﬁcant trends for
ﬁbrous tissue to be increased and ﬁbrolipidic content to be
decreased in stable vs. unstable patients may reﬂect a
type-II error. Our results mainly apply to the ﬁrst 40 mm of
the three main coronary arteries, whereas the longitudinal
pattern of shift in coronary plaque composition in coronary
segments more distally located or in left main coronary
artery should be evaluated in studies speciﬁcally designed
for such an aim. In particular, in keeping with our primary
endpoint, the only comparison for which this study was
properly powered for is the one between the ﬁrst and the
Figure 1 Relative change in plaque composition with respect to segment 1. Starting from segment 3, relative lipid content showed a progressive decrease with
respect to ostial segment (segment 1) taken as a reference. Relative changes in segments 2 and 3 were calculated using model 1, whereas for the relative change
in segments 4, 5, and 6, models 2, 3, and 4 were employed, respectively. All relative changes are expressed as mean value and standard deviation.
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third segment in model 1. All other analyses, including the
tests for four models and all post hoc comparisons should
be regarded as exploratory. Despite careful examination of
all angiograms, we cannot completely rule out the
possibility that patients with a higher number of IVUS inter-
rogated 10 mm segments had a more favourable coronary
anatomy as compared with those in whom a long pull-back
could not been obtained.
Relevant to this point, it is the fact that: (i) plaque com-
position in the ﬁrst three coronary segments did not differ in
patients with 30 mm pull back length as compared with
those in whom a longer IVUS pull back was obtained; and
(ii) the change in plaque composition along the study
vessel was remarkably consistent in all the four models
analysed.
We failed to ﬁnd sex-related differences in the proximal–
distal pattern of plaque composition. However, the great
majority (88%) of patients enrolled were males, which
Table 4 Predictors of plaque lipid content at uni- and multi-
variate analysis in model 1
Variables Beta-values (95% CI) P-values
Univariate analysis
Age (years) 20.12 20.25, 0.008 0.069
Sex (M vs. F) 0.029 20.101, 0.16 0.66
Smoking status 0.022 20.108, 0.15 0.7
Previous history of
Hypertension 0.048 20.08, 0.16 0.48
CVD in the family 20.038 20.16, 0.082 0.56
Hypercholesterolaemia 0.08 20.032, 0.197 0.21
Diabetes mellitus 0.14 0.023, 0.257 0.041
ACS 0.044 20.086, 0.174 0.50
Coronary
revascularization
20.15 20.2, 20.028 0.02
Coronary vessela 0.038 21.93, 2.008 0.5
ACS at presentation 0.25 0.11, 0.39 0.0032
LDL (mg/dL) 0.09 20.04, 0.22 0.42
HDL (mg/dL) 20.12 20.25, 0.01 0.067
Triglycerides (mg/dL) 0.04 20.09, 0.17 0.78
Use of statin 20.25 20.37, 20.12 0.0001
Distance from ostiumb 20.32 20.45, 20.30 ,0.0001
Multivariable analysisc
Distance from ostiumb 20.28 20.15, 241 ,0.0001
Age (years) 20.26 20.12, 240 0.0004
ACS at presentation 0.16 0.03, 0.29 0.005
Use of statin 20.18 20.36, 0.004 0.057
Diabetes mellitus 0.21 0.07, 0.34 0.003
Coronary
revascularization
20.07 20.02, 0.12 0.46
HDL (mg/dL) 20.02 20.05, 0.21 0.84
CVD, cardiovascular disease; LDL, low-density lipoprotein; HDL, high-
density lipoprotein.
aAnalysed as left anterior descending vs. circumﬂex vs. right coronary
artery
bAnalysed as segment 1 taken as a reference vs. segment 3.
cAdjusted R2 ¼ 0.36 for the model.
Figure 2 Per-segment distribution of relative lipid content in the study
population. Per-segment distribution of relative lipid contents both in the
whole population and stable vs. unstable patients in model 1 (A) and 2 (B).
Bars indicate median values in the whole population. As shown in Table 3,
relative lipid content signiﬁcantly decreased in the whole population in
segment 3 in model 1 and in segments 3 and 4 in model 2 with respect to
segment 1 at post hoc analysis.
Figure 3 IVUS-VH CSA along a coronary vessel. IVUS-VH cross-sectional areas
in a representative patient showing the change in plaque composition
(calcium: white; ﬁbrous: green; ﬁbrolipidic: greenish-yellow; and lipid
core: red) along the longitudinal axis of the vessel. LM, left main coronary
artery; CFX, circumﬂex artery; LAD, left anterior descending artery. The dis-
tance between the cross-sectional area and the ostium of the vessel is
reported in millimetres (mm).
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calls for future studies with more balanced sex-distribution
to properly address this gender issue.
Finally, it should not undergo unnoticed that the
proportion of lipid core content predicted by our multi-
variable regression model, despite highly signiﬁcant, was
far from being optimal. This means that future investi-
gations should probably aim to increase the capability to
predict relative lipid content in coronary plaques taking
a broader set of possible independent predictors into
account.
Conclusion
Our study provides proof of concept for a non-uniform
longitudinal distribution of plaque composition mainly in
terms of lipid core content along the main coronary arteries
in vivo in humans. The clinical and pathophysiological
meaning of this observation and whether it could help
explaining the non-uniform distribution of vulnerable
plaques along the coronary vessel remains unclear. Future
studies are needed to extend and possibly conﬁrm our
current ﬁndings.
Conﬂict of interest: none declared.
References
1. Burke AP, Farb A, Pestaner J, Malcom GT, Zieske A, Kutys R, Smialek J,
Virmani R. Traditional risk factors and the incidence of sudden coronary
death with and without coronary thrombosis in blacks. Circulation
2002;105:419–424.
2. Shah PK. Mechanisms of plaque vulnerability and rupture. J Am Coll
Cardiol 2003;41:15S–22S.
3. Ambrose JA, Tannenbaum MA, Alexopoulos D, Hjemdahl-Monsen CE,
Leavy J, Weiss M, Borrico S, Gorlin R, Fuster V. Angiographic progression
of coronary artery disease and the development of myocardial infarction.
J Am Coll Cardiol 1988;12:56–62.
4. Giroud D, Li JM, Urban P, Meier B, Rutishauer W. Relation of the site of
acute myocardial infarction to the most severe coronary arterial stenosis
at prior angiography. Am J Cardiol 1992;69:729–732.
5. Hackett D, Davies G, Maseri A. Pre-existing coronary stenoses in patients
with ﬁrst myocardial infarction are not necessarily severe. Eur Heart J
1988;9:1317–1323.
6. Lichtlen PR, Nikutta P, Jost S, Deckers J, Wiese B, Rafﬂenbeul W.
Anatomical progression of coronary artery disease in humans as seen by
prospective, repeated, quantitated coronary angiography. Relation to
clinical events and risk factors. The INTACT Study Group. Circulation
1992;86:828–838.
7. Little WC, Constantinescu M, Applegate RJ, Kutcher MA, Burrows MT,
Kahl FR, Santamore WP. Can coronary angiography predict the site of a
subsequent myocardial infarction in patients with mild-to-moderate
coronary artery disease? Circulation 1988;78:1157–1166.
8. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J,
Badimon JJ, Stefanadis C, Moreno P, Pasterkamp G, Fayad Z, Stone PH,
Waxman S, Raggi P, Madjid M, Zarrabi A, Burke A, Yuan C, Fitzgerald PJ,
Siscovick DS, de Korte CL, Aikawa M, Airaksinen KE, Assmann G,
Becker CR, Chesebro JH, Farb A, Galis ZS, Jackson C, Jang IK, Koenig W,
Lodder RA, March K, Demirovic J, Navab M, Priori SG, Rekhter MD,
Bahr R, Grundy SM, Mehran R, Colombo A, Boerwinkle E, Ballantyne C,
Insull W Jr, Schwartz RS, Vogel R, Serruys PW, Hansson GK, Faxon DP,
Kaul S, Drexler H, Greenland P, Muller JE, Virmani R, Ridker PM,
Zipes DP, Shah PK, Willerson JT. From vulnerable plaque to vulnerable
patient: a call for new deﬁnitions and risk assessment strategies: Part
II. Circulation 2003;108:1772–1778.
9. Gibson CM, Kirtane AJ, Murphy SA, Karha J, Cannon CP, Giugliano RP,
Roe MT, Harrington RA, Ohman EM, Antman EM. Distance from the
coronary ostium to the culprit lesion in acute ST-elevation myocardial
infarction and its implications regarding the potential prevention of
proximal plaque rupture. J Thromb Thrombolysis 2003;15:189–196.
10. Wang JC, Normand SL, Mauri L, Kuntz RE. Coronary artery spatial
distribution of acute myocardial infarction occlusions. Circulation 2004;
110:278–284.
11. Buffon A, Biasucci LM, Liuzzo G, D’Onofrio G, Crea F, Maseri A.
Widespread coronary inﬂammation in unstable angina. N Engl J Med
2002;347:5–12.
12. Valgimigli M, Agnoletti L, Curello S, Comini L, Francolini G, Mastrorilli F,
Merli E, Pirani R, Guardigli G, Grigolato PG, Ferrari R. Serum from
patients with acute coronary syndromes displays a proapoptotic effect
on human endothelial cells: a possible link to pan-coronary syndromes.
Circulation 2003;107:264–270.
13. Madjid M, Zarrabi A, Litovsky S, Willerson JT, Casscells W. Finding vulner-
able atherosclerotic plaques: is it worth the effort? Arterioscler Thromb
Vasc Biol 2004;24:1775–1782.
14. Maseri A, Fuster V. Is there a vulnerable plaque? Circulation 2003;
107:2068–2071.
15. VanderLaan PA, Reardon CA, Getz GS. Site speciﬁcity of atherosclerosis:
site-selective responses to atherosclerotic modulators. Arterioscler
Thromb Vasc Biol 2004;24:12–22.
16. Nair A, Kuban BD, Tuzcu EM, Schoenhagen P, Nissen SE, Vince DG.
Coronary plaque classiﬁcation with intravascular ultrasound radio-
frequency data analysis. Circulation 2002;106:2200–2206.
17. Rodriguez-Granillo GA, Aoki J, Ong ATL, Valgimigli M, van Mieghem CAG,
Regar E, McFadden E, de Feyter P, Serruys PW. Methodological consider-
ations and approach to cross-technique comparisons using in vivo coro-
nary plaque characterization based on intravascular radiofrequency
data analysis: insights from the integrated Biomarker and Imaging
Study (IBIS). Int J Cardiovasc Interv 2005;7:52–58.
18. Ka˚resen K. Deconvolution of sparse spike trains by iterated window maxi-
mization. IEEE Trans Signal Process 1997;45:1173–1183.
19. Ka˚resen KF BE. Blind deconvolution of ultrasonic traces accounting for
pulse variance. IEEE Trans Ultrason Ferroelectr Freq Contr 1999;
46:564–573.
20. Mann JM, Davies MJ. Vulnerable plaque. Relation of characteristics to
degree of stenosis in human coronary arteries. Circulation 1996;
94:928–931.
21. Draper NR, Smith H. Applied Regression Analysis. New York, NY: Wiley;
1981.
22. Diggle PJ, Heagerty PJ, Liang KY, Zeger SL. Analysis of Longitudinal Data.
New York, NY: Oxford University Press; 2002.
23. Monroe VS, Kerensky RA, Rivera E, Smith KM, Pepine CJ. Pharmacologic
plaque passivation for the reduction of recurrent cardiac events in
acute coronary syndromes. J Am Coll Cardiol 2003;41:23S–30S.
24. Casscells W, Naghavi M, Willerson JT. Vulnerable atherosclerotic plaque:
a multifocal disease. Circulation 2003;107:2072–2075.
25. Ambrose JA, D’Agate DJ. Classiﬁcation of systemic therapies for potential
stabilization of the vulnerable plaque to prevent acute myocardial infarc-
tion. Am J Cardiol 2005;95:379–382.
26. Balk EM, Karas RH, Jordan HS, Kupelnick B, Chew P, Lau J. Effects of
statins on vascular structure and function: a systematic review. Am J
Med 2004;117:775–790.
27. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton
GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T, Blankenship
JC, Kerensky R. Effect of recombinant ApoA-I Milano on coronary athero-
sclerosis in patients with acute coronary syndromes: a randomized
controlled trial. JAMA 2003;290:2292–2300.
28. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA,
Crowe T, Howard G, Cooper CJ, Brodie B, Grines CL, DeMaria AN.
Effect of intensive compared with moderate lipid-lowering therapy on
progression of coronary atherosclerosis: a randomized controlled trial.
JAMA 2004;291:1071–1080.
29. Matsuzaki M, Hiramori K, Imaizumi T, Kitabatake A, Hishida H, Nomura M,
Fujii T, Sakuma I, Fukami K, Honda T, Ogawa H, Yamagishi M. Intravascular
ultrasound evaluation of coronary plaque regression by low density
lipoprotein-apheresis in familial hypercholesterolemia: the Low Density
Lipoprotein-Apheresis Coronary Morphology and Reserve Trial
(LACMART). J Am Coll Cardiol 2002;40:220–227.
30. Lima JA, Desai MY, Steen H, Warren WP, Gautam S, Lai S. Statin-induced
cholesterol lowering and plaque regression after 6 months of magnetic
resonance imaging-monitored therapy. Circulation 2004;110: 2336–2341.
31. Malek AM, Alper SL, Izumo S. Hemodynamic shear stress and its role in
atherosclerosis. JAMA 1999;282:2035–2042.
32. Kinlay S, Libby P, Ganz P. Endothelial function and coronary artery
disease. Curr Opin Lipidol 2001;12:383–389.
33. Einav S, Bluestein D. Dynamics of blood ﬂow and platelet transport in
pathological vessels. Ann NY Acad Sci 2004;1015:351–366.
Page 8 of 9 M. Valgimigli et al.
91
Longitudinal Change in Coronary Plaque Composition 
34. Kolodgie FD, Burke AP, Farb A, Gold HK, Yuan J, Narula J, Finn AV,
Virmani R. The thin-cap ﬁbroatheroma: a type of vulnerable plaque:
the major precursor lesion to acute coronary syndromes. Curr Opin
Cardiol 2001;16:285–292.
35. Fayad ZA, Fuster V. Clinical imaging of the high-risk or vulnerable
atherosclerotic plaque. Circ Res 2001;89:305–316.
36. Kolodgie FD, Virmani R, Burke AP, Farb A, Weber DK, Kutys R, Finn AV,
Gold HK. Pathologic assessment of the vulnerable human coronary
plaque. Heart 2004;90:1385–1391.
37. Okazaki S, Yokoyama T, Miyauchi K, Shimada K, Kurata T, Sato H, Daida H.
Early statin treatment in patients with acute coronary syndrome: demon-
stration of the beneﬁcial effect on atherosclerotic lesions by serial
volumetric intravascular ultrasound analysis during half a year after
coronary event: the ESTABLISH Study. Circulation 2004;110: 1061–1068.
38. Rodriguez-Granillo GA, Serruys PW, Garcia-Garcia HM, Aoki J, Valgimigli M,
van Mieghem CA, Mc Fadden E, de Jaegere PP, de Feyter P. Coronary
artery remodelling is related to plaque composition. Heart 2005;
doi:10.1136/hrt.2004.057810.
Longitudinal change in coronary plaque composition Page 9 of 9

Chapter 10 Plaque Composition in the Left Main Stem Mimics the Distal 
but not the Proximal Tract of the Left Coronary Artery. 
Influence of Clinical Presentation, Length of the Left Main 
Trunk, Lipid Profile and Systemic Inflammatory Status 
Marco Valgimigli  
Gastón A. Rodriguez-Granillo  
Héctor M. Garcia-Garcia  
Sophia Vaina  
Keiichi Tsuchida
Evelyn Regar
Peter De Jaegere  
Pim De Feyter 
Patrick W Serruys 
J Am Coll Cardiol, in press

95
Coronary Plaque Composition in the Left Main Coronary Artery 
Plaque Composition in the Left Main Stem Mimics the Distal but not 
the Proximal Tract of the Left Coronary Artery 
Influence of Clinical Presentation, Length of the Left Main Trunk, 
Lipid Profile and Systemic levels of C-Reactive Protein 
Marco Valgimigli, MD, Gastón A. Rodriguez-Granillo, MD, Héctor M. Garcia-Garcia, MD, Sophia Vaina, MD, Peter De 
Jaegere, MD, PhD, Pim De Feyter, MD, PhD, Patrick W Serruys, MD, PhD 
Objective: To investigate whether plaques located in the left main stem (LMS) differ in terms of necrotic core content 
from those sited in the proximal tract of the left coronary artery.
Background: Plaque composition, favoring propensity to vulnerability, might be non-uniformly distributed along the 
vessel. This might explain the higher likelihood for plaque erosion or rupture to occur in the proximal but not in the distal 
tracts of the coronary artery or in LMS.
Methods: 72 patients were prospectively included: 48 (32 men; mean age: 57�11), [25 with stable angina (SA); 23 
affected by acute coronary syndromes (ACS)] underwent a satisfactory non-culprit vessel investigation through spectral 
analysis of IVUS radiofrequency data (IVUS-Virtual HistologyTM). The region of interest was subsequently divided into 
LMS and LMS carina, followed by six consecutive non-overlapping 6 mm-segments in left anterior descending (LAD) 
artery in 34 or in circumflex artery (CFX) in 14 patients.  
Results: Necrotic core content (%) i) was minimal in LMS [median (IQR): 4.6 (2-7)]; peaked in the first 6-mm coronary 
segment [11.8 (8-16); p<0.01], while it then progressively decreased distally; ii) was overall higher in ACS [11.4 (5.5-
19.8) than SA patients [7.3 (3.2-12.9)]; (p<0.001); iii) was largely independent from plaque size and iv) did not 
correlate to systemic levels of CRP or lipid profile.  
Conclusions: Plaques located in the LMS carry minimal necrotic content. Thus, they mimic the distal but not the 
proximal tract of the left coronary artery where plaque rupture or vessel occlusion occurs more frequently. 
J Am Coll Cardiol 2006, in press 
INTRODUCTION 
The distribution of ruptured or prone to rupture plaques 
is known to be non-uniform throughout the coronary 
tree(1-5). Pathological studies have suggested the so 
called “thin-cap atheromas” �necrotic rich core plaques 
at high risk for rupture� are infrequent in the left main 
stem (LMS) and in the distal tracts of the coronary 
vessels, while they group together with ruptured and 
healed plaques in the proximal segments of the three 
main coronary arteries(1). 
Similarly i) angiographic studies in patients with 
ST-segment elevation myocardial infarction (STEMI) have 
recently shown that sites of occlusion are clustered 
within the proximal third of each of the vessels(2,3) and 
ii) intravascular ultrasound (IVUS) analyses have 
observed that plaque rupture rarely occurs in the LMS or 
the distal part of the coronary arteries, whereas it is far 
more common in the proximal part of the coronary 
vessels(4), especially in the left anterior descending 
artery (5). 
The reasons why vulnerable or ruptured plaques 
tend to spare the LMS and distal segments of the left 
coronary vessels remain poorly understood. Plaque 
composition, favoring propensity to vulnerability(6-8), 
might also be non-uniformly distributed along the 
coronary arteries.
We sought to investigate whether the plaques 
located in the LMS, which are known to be at low 
probability of rupture, differ in terms of composition from 
those sited in the proximal tract of left anterior 
descending or circumflex artery, where rupture or 
occlusion occurs more frequently. This may contribute 
establishing in vivo the role of plaque composition as key 
determinant of vulnerability in humans. In this context, 
the role of clinical presentation, length of LMS, lipid 
profile and systemic level of C-reactive protein were also 
investigated.
METHODS
Study Protocol and Patients Enrolment 
This was a single-centre, investigators-driven, 
observational study aimed to evaluate the distribution of plaque 
composition along the left coronary artery in consecutive 
patients referred to our institution for elective or urgent PCI, in 
whom the non-culprit, non-treated vessel was judged suitable 
for a safe IVUS 35 mm-pullback or more, based on angiographic 
(absence of the following: >50% stenotic disease, extensive 
calcification, severe vessel tortuosity) and clinical 
(haemodynamic stability) findings.  
According to the protocol, not more than one vessel-
per patient could be evaluated and the region of interest (ROI) 
was subsequently divided into the following coronary segments: 
LMS and LMS carina, based on anatomical landmarks, followed 
by six consecutive non-overlapping 6 mm-segments, with the 
first one to be started at the coronary ostium of either left 
anterior descending or circumflex artery. The length chosen for 
those coronary segments located distally to the LMS carina was 
based on the median length of LMS in the study population.  
To ensure that the ostial-proximal part of the LMS was 
included in the IVUS pullback and to rule out the occurrence of 
deep intubation by the guiding catheter, the last part of the 
pullback was filmed and each angiogram carefully inspected 
before patient inclusion. An analyzable interrogated vessel 
length of at least 35 mm beyond LMS carina, starting from 
coronary ostium, was the main selection criterion, once the 
patient was included in the study. This protocol was approved 
by the hospital ethics committee and is in accordance with the 
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declaration of Helsinki. Written informed consent was obtained 
from every patient. 
IVUS-VH Acquisition and Analysis 
Details regarding the validation of the technique, on 
explanted human coronary segments, have previously been 
reported (9). Briefly, IVUS radiofrequency data (IVUS-Virtual 
HistologyTM) uses spectral analysis of IVUS radiofrequency data 
to construct tissue maps that classify plaque into four major 
components. In preliminary in vitro studies, four histological 
plaque components (fibrous, fibro-lipid, necrotic core and 
calcium) were correlated with a specific spectrum of the 
radiofrequency signal (9). These different plaque components 
were assigned color codes. Calcified, fibrous, fibrolipidic and 
necrotic core regions were labeled white, green, greenish-yellow 
and red respectively(10).  
IVUS-VH data was acquired after intracoronary 
administration of nitrates using a continuous pullback (0.5 mm 
per second) with commercially available mechanical sector 
scanners (UltracrossTM 30 MHz catheter, Boston Scientific, Santa 
Clara, CA-USA- or Eagle EyeTM 20 MHz catheter, Volcano 
Corporation, Rancho Cordova, USA), by a dedicated IVUS-VH 
console (Volcano Therapeutics, Rancho Cordova, CA). The IVUS 
VH data were stored on a CD-ROM/DVD and sent to the imaging 
core lab for offline analysis (Cardialysis). IVUS B-mode images 
were reconstructed from the RF data by customized software 
and contour detection was performed using cross-sectional 
views with a semi-automatic contour detection software to 
provide geometrical and compositional output (IvusLab 3.0 for 
30 MHz acquisitions and IvusLab 4.4 for 20 MHz acquisitions 
respectively; Volcano Corporation, Rancho Cordova, USA)(10).  
The contours of the external elastic membrane (EEM) 
and the lumen-intima interface enclosed an area that was 
defined as the coronary plaque plus media area. Plaque burden 
was calculated as [(EEMarea - Lumenarea / EEMarea) X 100]. Plaque 
eccentricity was defined as minimum plaque thickness divided 
by maximum plaque thickness. Geometrical and compositional 
data were obtained for each cross-sectional area (CSA) and an 
average was calculated for each coronary and for the total 
coronary tree. RF data was normalized using a technique known 
as “Blind Deconvolution”, an iterative algorithm that 
deconvolves the catheter transfer function from the backscatter, 
thus accounting for catheter-to-catheter variability (11,12).  
Biochemical measures 
Antecubital venous blood was collected from all 
patients at entry, left in ice for 45 min, centrifuged at 1700�g at 
4°C for 15 min and serum obtained finally stored at –80°C. 
High-sensitive (hs) C-reactive protein (CRP) was measured in 
serum using a commercially available kit (N High Sensitivity 
CRP, Dade Behring, Marburg, Germany). Plasma concentrations 
of total cholesterol, high-density lipoprotein cholesterol (HDL), 
and triglycerides were measured in the local laboratory. The 
Friedewald formula was used to derive low-density lipoprotein 
cholesterol (LDL) levels.  
Statistical Analysis 
The sample size was calculated on the assumption 
that plaques located in the most proximal 6-mm segment of the 
LAD or CFX, would display a mean necrotic core content of 
approximately 10% and a standard deviation of 10%, based on 
previous findings(13), with a relative necrotic core content of 
around 5% in plaques located in the LMS. To detect this effect 
size with 80% power and a type I error (alpha) of 0.05, at least 
46 patients were required (model 1). Model 2 was also created 
to explore whether in patients with LMS length beyond median 
value (long LMS cohort) plaque composition differs in the 
proximal compared to the distal tract of the LMS. No formal 
sample size was calculated for model 2 as it was meant to be a 
hypothesis generating analysis.  
Values are expressed as mean�SD and median and 
interquartile range (IQR) whenever appropriate. Since all cross 
sectional areas, provided by IVUS analysis, were shown to have 
a non-normal distribution at Kolmogorov-Smirnov goodness-of-
fit test, they were log-transformed before analysis. Similarly, to 
all percentages relative to stenosis rate and plaque composition 
an arcsin transformation was applied (14). Assumptions for 
normality were checked after transformation based on a p-value 
>0.20 at Kolmogorov-Smirnov test and on visual assessment of 
Q-Q plots of residuals.  
Comparisons between the two groups were performed 
with the Student’s t-test. Fisher’s exact test was used for 
categorical variables. Comparisons among coronary segments 
were accomplished through a general linear mixed model and 
post hoc comparisons by Tukey honest significance difference 
test(15). Spearman’s correlation coefficients were used to detect 
any association between variables. Probability was significant at 
a level of <0.05. Statistical analysis was performed using 
Statistica 6.1 Software (Statsoft Inc.) and R-language (R 
Foundation). 
RESULTS
From 11 December 2003 to 27 July 2005, 
seventy-two patients were prospectively included in the 
protocol. Twenty-four patients were subsequently 
excluded from the final analysis due to short (< 36 mm) 
IVUS pullback in 16, uncertainty regarding the true 
interface lumen-vessel wall based on IVUS grey-scale in 
4 and occurrence of angiographically confirmed deep 
intubation of the guiding catheter during the pullback in 
4 patients. Thus, 48 patients (32 men), aged 30 to 75 
years (mean age: 57�11) constituted the final patient 
population. Their baseline characteristics are provided in 
below.
Table 1. Study Population
Patients 
Variables All(N=48) 
SA
Group
(N=25) 
ACS
Group
(N=23) 
P-
Value*
Age (ys) 57�11 58�11 57�12 0.81
Males, no. (%) 32 (67) 16 (64) 16 (65) >0.99 
Weight (kg) 82�12 81�12 84�12 0.36
Height (cm) 174�9 173�8 176�10 0.28
BMI (kg/m2) 27�3 27�4 27�2 0.81
Diabetes, no. (%) 11 (23) 5 (20) 6 (26) 0.75 
Hypertension, no. 
(%) 37 (77) 20 (80) 17 (74) >0.99 
Current
Smokers,no. (%) 19 (40) 8 (32) 11 (48) 0.32 
Previous Smoker, 
no. (%) 16 (33) 9 (36) 7 (30) 0.50 
C-reactive protein 
(mg/l) 29�48 12.7�15 38�58 0.19
Low density 
lipoprotein  
(mmol/l) 
3.09�1.22 3.26�1.3 2.9�1.3 0.44
High density 
lipoprotein  
(mmol/l) 
1.22�0.5 1.30�0.6 1.14�0.4 0.39
Cholesterol/HDL 
ratio 4.26�1.49 4.26�1.5 4.25�1.2 0.99
Medical History,  
no.  (%)     
CABG 2(4) 2 (6) 0 (0) 0.29 
PCI 11 (23) 8 (32) 3 (13) 0.32 
ACS 18 (37) 10 (40) 8 (35) >0.99 
Medical 
Treatment,  
no. (%) 
    
Aspirin 48 (100) 25 (100) 23 (100) >0.99 
Clopidogrel 48 (100) 25 (100) 23 (100) >0.99 
Statin 42 (88) 23(92) 19 (83) 0.84 
ACE-inhibitor 40 (83) 25 (100) 15 (65) 0.39 
�-Blocker 42 (88) 23 (92) 19 (83) 0.84 
Plus-minus values are means�SD. BMI: Body mass index, SA: Stable 
angina, ACS: acute coronary syndrome. CABG: coronary artery bypass 
grafting, PCI: percutaneous coronary intervention, ACE: angiotensin 
converting enzyme
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Table 2: Quantitative Vessel Analysis at IVUS stratified into coronary segments 
Cross Sectional Areas (mm2)
Lumen Vessel Plaque
Plaque Eccentricity Index Plaque Burden(%) 
MODEL 1 N=48      
CORONARY SEGMENTS      
LMS 15.2 (12-17) 24.5 (19-26) 8 (6-9) 0.11 (0.05-0.18) 34.3 (29-38) 
LMS Carina 12.2 (11-15) 20.4 (16-24) 6.7 (6-8) 0.03 (0.01-0.06)† 33.8 (31-39) 
1� (0-6 mm) 9.9 (7-11) † 16.2 (14-18) † 6.4 (5-7) 0.09 (0.07-0.14) 38.6 (36-46) 
2� (6-12 mm) 9.1 (7-10) † 16 (14-18) † 6.8 (5-8) 0.11 (0.06-0.16) 40 (39-45) 
3� (12-18 mm) 8.6 (7-10) † 15 (13-17) † 6.9 (5-8) 0.10 (0.08-0.15) 41 (40-46) 
4� (18-24 mm) 8.2 (7-10) † 14 (13-16) † 6.3 (5-7) 0.13 (0.06-0.17) 41 (37-51) 
5� (24-30 mm) 7.5 (6-9) † 13.2 (12-15) † 5.6 (5-6) 0.16 (0.10-0.20) 40 (38-54) 
6� (30-36 mm) 7.2 (6-8) † 12.3 (11-14) † 4.9 (4-6)† 0.12 (0.08-0.21) 42 (36-47) 
     
P-VALUE <0.0001 <0.0001 0.0006 0.0001 0.16
      
MODEL 2 N=24      
CORONARY SEGMENTS      
PROX. LMS 16.1 (13-19) 23.4 (21-27) 7.5 (5-9) 0.11 (0.07-0.15) 32 (29-39) 
DIST. LMS 14.6 (12-17) 25.8 (20-27)† 8.9 (7-10) 0.11 (0.07-0.25) 38 (33-43) 
LMS CARINA 13.1 (11-15)† 21.2 (18-25) 7.7 (7-8) 0.05 (0.02-0.08) 37 (31-43) 
1� (0-6 mm) 9.9 (8-11)† 16.3 (15-19)† 7.1 (6-8) 0.13 (0.09-0.14) 43 (37-48) 
2� (6-12 mm) 9.1 (7-11)† 16.6 (14-19)† 7.7 (6-9) 0.15 (0.08-0.17) 47 (45-50)* 
3� (12-18 mm) 8.6 (7-10)† 15.7 (14-18)† 7.4 (6-8) 0.11 (0.09-0.21) 50 (45-53)* 
4� (18-24 mm) 8.2 (7-10)† 14.5 (13-16)† 7.0 (5-8) 0.14 (0.09-0.17) 48 (38-51)* 
5� (24-30 mm) 8.2 (6-10)† 14.0 (12-17)† 5.7 (5-7) 0.19 (13-24) 45 (34-54) 
6� (30-36 mm) 7.0 (6-8)† 12.0 (11-14)† 5.1 (4-7)* 0.19 (0.11-0.30) 45 (39-51) 
     
P-VALUE <0.001 <0.0001 0.002 0.019 0.0093
     
P-values refer to results for the whole model at general linear analysis. *: p<0.05; †: p<0.01 at adjusted-post-hoc comparison as compared to left main 
stem (LMS) in model 1 and to Prox. LMS in model 2. Results are given as median (IQR); Prox.: proximal; Dist.: distal 
The study vessel was the LMS and left anterior 
descending (LAD) artery in 34 (71%) patients and LMS 
and circumflex artery (CFX) in 14 (29%). The overall LMS 
length was 7.49�4 mm [median (IQR): 6 (4.8-9.3); 
range: 3.4-20]; (7.3�4 in SA group vs. 7.8�5 in ACS 
group, p=0.64). Lumen and vessel cross sectional area 
(CSA) decreased significantly starting from the first 6-
mm segment of the coronary artery as compared to LMS 
(table 2). Plaque CSA in the LMS was significantly 
increased only compared to the most distal 6-mm 
segment. The degree of plaque eccentricity was relatively 
constant throughout the vessel except in the LMS carina, 
where it resulted to be higher compared to both the LMS 
and the coronary segments distal to the first one. Plaque 
burden did not change along the vessel in model 1, 
despite a trend being progressively increased from 
proximal to distal.  
Model 2 (Table 2), in which LMS has been 
stratified into the proximal and distal segment after 
selection of those patients (n=24) with long LMS (length 
>6 mm), mainly confirmed the trends observed along the 
vessels in model 1.
Change in plaque composition along the study 
vessel
Fibrous tissue was the most prevalent 
component of plaque composition in each analyzed 
segment throughout the two models, followed by 
fibrolipidic tissue, necrotic core and calcium (table 3). No 
significant change was observed in terms of relative 
plaque composition throughout the study vessel with 
respect to fibrous and calcified tissue content. The 
percentage of fibrolipidic tissue decreased in the second 
and third 6-mm segment when contrasted to the LMS. 
When compared to the 6th coronary segment, however, 
no difference emerged among the vessel tracts in terms 
of fibrolipidic content at post-hoc analysis.  
The necrotic core increased significantly in the 
first, second and third 6-mm segment compared to the 
LMS. When the most distal segment of the study vessel 
was taken as reference, the necrotic core remained 
greater in both the first and second 6-mm segment at 
post-hoc analysis. As shown in figure 1, the necrotic core 
was the plaque component with the highest relative 
change along the vessel (Figure 1). Changes in terms of 
plaque composition in model 2 are shown in table 3. 
Figure 1. Change in plaque composition along the left 
coronary artery 
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vessel 
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 B. The percentage of each plaque components are reported with respect 
to left main coronary artery (LMS) taken as reference. All analyses are 
based on model 1. 
Change in plaque composition according to clinical 
presentation 
No significant change in calcium, fibrous and fibrolipidic 
content with respect to clinical presentation (stable vs. 
unstable) was observed when all 384 coronary segments 
were pooled together (Figure 2). Necrotic core (%) was 
significantly increased in patients with [median (IQR): 
11.4 (5.5-19.8)] as compared to those [median (IQR): 
7.3 (3.2-12.9)] without ACS (p<0.001) (Figure 2). After 
introducing anatomical location stratified into eight 
coronary segments in the model, the increase in necrotic 
Table 3. Plaque Composition along the left coronary 
artery stratified into coronary segments 
Plaque Composition (%) 
Calcium 
 Core 
Fibrous  
Core
Fibrolipidic 
 Core 
Necrotic 
 core  
MODEL 1; N=48    
Coronary Segments     
LMS 0.65(0.2-1.7) 
63.5
(57-68) 
24.9
(20-29) 
4.6
(2-7) 
LMS CARINA 1.1(0.3-1.6) 
63.6
(62-71) 
23.0
(15-28) 
7.2
(4-9) 
1� (0-6 mm) 2.1(0.8-3.8) 
61.6
(59-70) 
19.8
(8-24) 
11.8
(7.8-16)†
2� (6-12 mm) 2.2(1.1-3.3) 
62.4
(59-68) 
15
(10-24)* 
10.8
(7-16)* 
3� (12-18mm) 1.9(1.0-3) 
64.4
(60-70) 
17.4
(10-21)* 
9.5
(6.5-13.3)* 
4� (18-24 mm) 1.6(1-3) 
61.7
(57-70) 
17.6
(11-23) 
8.7
(6-10) 
5� (24-30 mm) 1.2(1-3) 
63.4
(58-66) 
18.7
(13-26) 
7
(4-11) 
6� (30-36 mm) 1.4(0.6-2.4) 
61.5
(57-67) 
18.4
(11-25) 
6.1
(3-9) 
P-VALUE P=0.32 P=0.88 P=0.01 P=0.0001 
MODEL 2; N=24    
Coronary Segments     
PROX. LMS 0.85(0.08-1.5) 
62.8
(55-69) 
24.6
(20-30) 
3.8
(2.3-6.8) 
DIST. LMS 1.0(0.3-2.1) 
64.1
(59-69) 
25
(22-28) 
6.5
(4.5-8.8) 
LMS CARINA 1.3(0.3-1.6) 
64
(61-71) 
28.8
(20-29) 
7.3
(4.2-8) 
1� (0-6 mm) 2.3(1-3.4) 
62.9
(60-71) 
20.9
(13.1-25) 
11.3
(8-16)†
2� (6-12 mm) 2.3(1.2-5.0) 
62.6
(55-69) 
18.8
(13-27) 
9.1
(7-13)* 
3� (12-18 mm) 2.2(0.98-4.3) 
64.2
(60-70) 
20
(16-23) 
8.7
(6.7-13.3)* 
4� (18-24 mm) 1.2(0.9-4.5) 
64.4
(57-71) 
19.5
(11-26) 
8.9
(8-10)* 
5� (24-30 mm) 1.3(0.3-4.8) 
63.4
(58-68) 
22.5
(13-27) 
4.9
(4-8) 
6� (30-36 mm) 1.2(0.6-4) 
59.9
(52-66) 
22.2
(13-29) 
3.5
(1.8-6) 
P-VALUE 0.36 0.89 0.19 <0.0001
P-values refer to results for the whole model at general linear analysis. *: 
p<0.05; †: p<0.01 at adjusted-post-hoc comparison as compared to left 
main stem (LMS) in model 1 and to Prox. LMS in model 2. Results are 
given as median (IQR). Prox.: proximal; Dist.: distal. 
core in ACS patients was mainly confined to the LMS [6.9 
(2.6-9.4) vs. 3.5 (1.4-6.2) in stable patients; p=0.02], in 
the first [14.9 (7.7-19.6) vs. 11.5 (4.9-17.3) in stable 
patients; p=0.03], second [12.2 (5.5-16.1) vs. 9.4 (5.1-
20.6) in stable patients; p=0.03] and third 6-mm 
coronary segment [11.4 (5.4-15) vs. 8 (3.6-14.4) in 
stable patients; p=0.04]. However, the statistical 
interaction between necrotic core and the anatomical 
location of the segments did not reach the significance 
(p=0.12).
LMS length as a predictor of plaque composition 
along the study vessel  
Patients were stratified into two groups based on median 
LMS length (short LMS � 6 mm and long LMS >6 mm). 
These two groups did not differ in terms of baseline and 
procedural characteristics. When each coronary segment 
was separately analyzed, no difference emerged between 
the two groups for IVUS-derived quantitative vessel 
analysis. The same held true if all 384 
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Figure 2. Plaque composition in relation to clinical 
presentation 
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 Plaque composition on a per segment based analysis in patients with 
stable angina (stable pts) or with acute coronary syndromes (ACS) 
(unstable pts). The necrotic core (%) was significantly increased in 
patients with [median (IQR): 11.4 (5.5-19.8)] as compared to those 
[median (IQR): 7.3 (3.2-12.9)] without ACS.  
*: p<0.001 vs. stable pts. 
coronary segments were cumulatively considered 
independently from their anatomical location. Calcium, 
fibrous and fibrolipid content did not differ between the 
two groups (data not shown). The pattern of necrotic 
distribution in relation to LMS length is shown in figure 3.  
Figure 3. Necrotic core distribution along the left 
coronary artery according to the length of LMS 
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The necrotic core peaked in the first and in the second 6-mm segment in 
patients with long (above median value) and short left main coronary 
artery (LMS), respectively. After the peak, the necrotic core decrease was 
more pronounced in the long than in the short LMS group. As a 
consequence, the necrotic core content resulted to be significantly 
increased in the fifth and sixth 6-mm segments in the short as compared 
to the long LMS group.  
*: p<0.05 vs. short LMS. 
Correlations
In a segment-based analysis, necrotic core was 
largely independent from plaque area (r=0.17; p=0.06; 
R2=0.09). Similarly, we failed to find an association 
between necrotic core content and C-reactive protein 
levels (r=0.09, p=0.8), level of LDL (p=0.11, p=0.23) or 
HDL (r=-0.2, p=0.4) at entry. However, there was a 
significant, although weak, direct correlation between 
necrotic core and cholesterol/HDL ratio (r=0.18, p=0.01; 
R2=0.1).
Figure 4. Correlation between arcsin transformed plaque 
cross sectional area (CSA) and log transformed necrotic 
core content 
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CSA: cross sectional area.  
DISCUSSION
There is increasing evidence that the distribution of 
ruptured or prone to ruptured plaques is not uniform 
along the coronary vessel: they cluster in the proximal 
tract of the three major coronary vessels while they tend 
to spare both the LMS and distal segments of coronary 
arteries(4,16).
These findings have been recently confirmed by mapping 
the distribution of angiographic sites of occlusive or non-
occlusive culprit lesions along the coronary arteries in 
patients with ST segment elevation acute coronary 
syndromes(2,3).
The reason why vulnerable plaques show a 
tendency to cluster in partially predictable hot spots
located within the proximal tracts of coronary vessel is 
largely unknown. Atherosclerotic plaques also cluster 
within the proximal portions of the three major 
coronaries(17-20). Thus, the risk to undergo rupture may 
be identical for each coronary plaque independently from 
its anatomical location, being rupture simply more likely 
to occur where atherosclerotic plaques are more 
frequently clustered(21). This may easily explain the 
non-uniform distribution of ruptured or prone to rupture 
plaques without calling into question the idea that plaque 
rupture is partially a site-specific phenomenon.  
Alternatively, plaques located within the proximal 
third of each coronary may harbour some specific 
hallmark of vulnerability which makes them individually
more likely to undergo rupture.  
To gain some insights into this topic of debate, we 
hypothesized that plaque necrotic core content, which is 
a well-known determinant of vulnerability(7,8,22), may 
differ along the coronary vessel, being greater at the 
spots where plaque rupture is known to be more 
frequent. 
Our main findings can be summarized as follows: 
1) The plaque necrotic content was minimal in the 
LMS, particularly in the most proximal tract, while it 
peaked in the first 6-mm segments after the ostium of 
the two major left coronaries, progressively decreasing 
towards the more distal segments. 
2) The plaque CSA was largely unrelated to 
necrotic core content throughout the left coronary vessel. 
This statement is supported by the absence of correlation 
between necrotic content in plaques and plaque CSA at 
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the segment-based analysis and by the observation that 
plaque CSA showed a progressive increase in the distal-
proximal direction along the vessel whereas plaque 
necrotic content did not.  
3) The necrotic core was higher in patients with 
clinical instability, presenting with ACS compared to 
those affected by stable atherosclerotic disease.  
4) The necrotic content was not related to 
systemic inflammatory status, as measured by a well 
recognized prognostic marker of inflammation such as C-
reactive protein nor LDL or HDL alone, while it showed a 
significant although weak correlation to cholesterol/HDL 
ratio.
5) The length of left main trunk was shown to 
affect the distribution of necrotic core along the vessel. 
In patients with long LMS, necrotic core content peaked 
immediately in the first coronary segment after LMS and 
rapidly decreased distally. Conversely, the necrotic core 
content peaked in the second 6-mm segment in patients 
with short LMS and it resulted to be increased in the two 
most distally analyzed segments compared to the long 
LMS group. 
It is tempting to speculate that the observed 
clustering of ruptured or prone to rupture plaques in the 
proximal segment of each coronary artery is not just a 
simple reflection of the non-uniform distribution of 
atherosclerosis along the coronary vessel. The necrotic 
content of those plaques located in these proximal 
segments, independent of their size, was higher, both 
compared to the LMS and to those segments which are 
more distally located. The plaques located within the 
proximal segments of the left coronary artery, being 
relatively richer in necrotic content, may undergo rupture 
more easily than those located in the LMS or in the distal 
tracts of the vessel.
Some preliminary unpublished findings by our 
group suggest that plaque necrotic core content, as 
assessed through IVUS-VH, may be the only independent 
predictor for mechanically deformable regions (high-
strain spots)(23) throughout the coronary arteries in 
humans. Thus, when our findings are put in perspective 
of current evidence, they support the idea that 
vulnerability may cluster in necro-lipid-rich regions 
throughout the vessel. 
Necrotic core content in the present study was 
higher in patients with ACS, suggesting again that plaque 
composition in itself may play a pivotal role in 
determining vulnerability. Interestingly, it was recently 
reported that when rupture of coronary plaques occurs in 
the LMS, the distal half of LMS is more likely to be 
involved (24). Our findings that the distal LMS tends to 
harbour a greater necrotic core content compared to 
proximal half, together with the well established role of 
shear stress in bifurcated lesions(25), may contribute to 
explain the non-uniform distribution of plaque rupture 
even within the LMS.  
The reasons why the plaque necrotic core 
seems to exceed in the proximal as compared to the 
distal tracts of the coronary vessel or the LMS remain 
speculative at the present time. Low-oscillatory shear 
stress is known to induce a loss of the physiological flow-
oriented alignment of the endothelial cells, an 
enhancement of the expression of adhesion molecules 
and a weakening of cell junctions, ultimately leading to 
an increase in permeability to lipids and 
macrophages(25). The segments located in the first few 
centimetres of the coronary arteries, due to flow 
turbulence generated by high velocity blood impacting 
against anatomical flow dividers(26), may be more 
exposed to low-oscillatory shear stress compared to the 
most proximal (i.e. LMS) or more distal coronary 
segments, thus possibly explaining our present 
findings(27). Concomitant quantitative measurement of 
shear stress and plaque composition along coronary 
vessels in vivo would be pivotal in corroborating this 
working hypothesis.
Limitations of the Study 
Based on previous findings and the well known 
role of necrotic core content in determining 
vulnerability(6-8,22), our investigation was primarily 
focused on the distribution of necrotic core content along 
the left coronary artery. In order to assess relatively 
minor changes in plaque composition along the 
longitudinal artery axis, such as that observed for fibrous 
tissue, a bigger properly powered sample size is clearly 
needed. In keeping with previous considerations, all 
other analyses and comparisons performed in the current 
manuscript should be regarded as exploratory and 
hypothesis-generating since we cannot rule out the 
possibility that inflation of type I error due to multiple 
comparisons may have confounded our results. 
In our study the operators were left free to wire 
the most suitable vessel for the IVUS pullback, provided 
it was supplying a major left ventricle territory. This 
resulted in the predominance of LAD as region of 
interest, while the CFX artery was mainly investigated in 
those patients presenting with small or tortuous LAD. 
The distribution of necrotic core along the vessel did not 
differ in LAD as compared to CFX. The same held true for 
other studied plaque components. However, the applied 
selection process may have biased this comparison. 
Thus, whether the distribution of plaque composition 
may differ in relation to the studied vessel remains to be 
tested. Similarly, in order to maximize patients’ safety 
and avoid potential IVUS-related complications, 
individuals with severe angiographic calcification were 
excluded. Despite this decision may have clearly 
contributed to generate some selection bias, the 
distribution of calcium along the coronary vessel 
intriguingly mirrored the one observed for the necrotic 
core. Further studies are needed to investigate the 
specific role of calcium content in determining plaque 
vulnerability.
Patients with proximal occlusions have bigger MI 
and thus they are more likely to present to hospital and 
be referred for angioplasty. Similarly, myocardial 
infarction due to LMS as culprit artery may often result in 
immediate death. Thus, it may be argued that a selection 
bias might have artificially increased the prevalence of 
patients with culprit lesions located in the proximal 
compared to distal tracts of coronaries or LMS. This is 
obviously theoretical possible. However, for the following 
reasons, we believe that this possibility is relatively 
unlikely:
A. The Necrotic core in our series clustered in the 
same coronary spots where previous studies, based on 
post-mortem examination, found a higher prevalence of 
ruptured or healed plaques.  
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B. Our results are based on the investigation of the 
non-culprit vessel. Thus, they are potentially less prone 
to suffer from clinical selection due to the location of the 
culprit lesion in the culprit vessel.  
C. Although it seems to be exacerbated in patients 
presenting with clinical instability, the non-uniform 
distribution of plaque composition along the vessel has 
been observed also in patients with stable coronary 
disease, in whom the selection bias due to the 
importance of the culprit lesion is less obvious, at least 
for the comparison LMS vs. proximal tracts of LAD or 
CFX.
Thus, based on these considerations, we think that 
our findings, especially when put in the context of 
previous evidence(1-5), may help reinforcing the notion 
that there may be some hot spots along the coronary 
vessel which are per se more prone to develop 
vulnerable plaque and as such undergo plaque rupture.  
Summary and Conclusions 
Plaque composition was found to be not uniformly 
distributed along the left coronary artery with a 
progressive increase in necrotic core starting from the 
proximal half of the LMS to the most proximal segments 
of the LAD or CFX, followed by a steady decline towards 
those segments which are more distally located along the 
vessel. The necrotic core appeared to be increased in 
patients with ACS, especially in the LMS and in the three 
proximal coronary segments of LAD or CFX, while it did 
not correlate with the CRP or lipid profile. The relatively 
site-specificity of necrotic core content towards the 
proximal segment of the left coronary artery is in keeping 
with the increasing evidence that a clear clustering of 
ruptured or prone to rupture plaques occurs in humans 
within this region (2,3,5). Our findings i) reinforce the 
notion the plaque composition may be a major 
determinant for and subsequently a potential target of 
plaque vulnerability in humans and ii) call for prospective 
evaluation of the independent role of plaque composition 
on long-term outcome in patients with established 
coronary artery disease.
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TRIAL DESIGN
High-Dose BoluS TiRoﬁbAn and Sirolimus Eluting
STEnt versus Abiciximab and Bare Metal Stent
in Acute MYocardial Infarction (STRATEGY)
Study—Protocol Design and Demography
of the First 100 Patients
Marco Valgimigli1,2, Gianfranco Percoco1,
Giordano Cicchitelli1, Fabrizio Ferrari1, Dario
Barbieri1, Lucia Ansani1, Gabriele Guardigli1,
Giovanni Parrinello3, Patrizia Malagutti1, Olga
Soukhomovskaia1, Alessandro Bettini1, Gianluca
Campo1, and Roberto Ferrari1,2
1Chair of Cardiology, University of Ferrara, Italy;
2Cardiovascular Research Centre, Salvatore Maugeri
Foundation, IRCCS Gussago (BS), Italy; 3Medical Statistics
Unit, University of Brescia, Italy
Summary. Background: Primary bare metal stenting and
abciximab infusion are currently considered the best avail-
able reperfusion strategy for acute ST-segment elevation
myocardial infarction (STEMI). Sirolimus eluting stents
(SES), compared to bare metal stent (BMS), greatly reduce
the incidence of binary restenosis and target vessel revascu-
larisation (TVR), but their use on a routine basis results in a
signiﬁcant increase inmedical costs.With current European
list prices, the use of tiroﬁban instead of abciximab would
save enough money to absorb the difference between SES
and BMS.
Aim: To assess whether in patients with STEMI the com-
bination of SES with high dose bolus (HDB) tiroﬁban re-
sults in a similar incidence of major cardiovascular events
(MACE) but in a lower binary restenosis rate after six
months compared to BMS and abciximab.
Methods and Results: 160 patients are required to sat-
isfy the primary composite end-point, including MACE and
binary restenosis. The study is ongoing: the current pa-
per focuses on the methodology and demography of the
ﬁrst 100 patients so far enrolled. Patients randomised to
HDB tiroﬁban (n = 50, mean age: 62 ± 12, 40 males)
and abciximab (n = 50, mean age: 63 ± 12, 38 males) do
not differ for medical history, presentation proﬁle, medica-
tions at discharge, angiographic proﬁle and creatine-kinase
MB-fraction at peak.
Conclusions: The results of the trial will be available by
the end of 2004: they will be crucial for the cardiologists to
know whether the gold standard for AMI treatment should
be reconsidered after the introduction of SES into the
clinical practice.
Key Words. Sirolimus eluting stents, high dose Bolus
tiroﬁban, Abciximab, primary percutaneous coronary inter-
vention
Background
Primary angioplasty is the current preferred thera-
peutic option for patients with ST-segment elevation
myocardial infarction (STEMI) [1]. The superiority
of mechanical reperfusion in patients with acute
myocardial infarction (AMI) reﬂects of the techno-
logical advances fulﬁlled by catheter-based coronary
interventions in the last ten years, mainly consist-
ing of widespread use of last generation stents and
glycoprotein IIb/IIIa inhibitors.
Routine coronary stent implantation inpatientswith
AMI decreases the need for target-vessel revascular-
ization (TVR) [2,3], while the use of abciximab is associ-
ated to a lower incidence of subacute stent thrombosis
and recurrent ischaemia during the ﬁrst month after
primary PCI [4,5]. Therefore, despite no clear data are
available on the cost-effectiveness of the combination
[6], stenting plus abciximab has been recently advo-
cated as the gold standard for STEMI treatment [7].
Drug eluting stents (DES) are one of the most
promising new ﬁelds of research in interventional
cardiology. Sirolimus eluting stents (SES), compared
to baremetal stent (BMS), greatly reduce the incidence
of binary restenosis and clinically-driven TVR [8]. In
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a consecutive series of 96 AMI patients treated with
SES, a good safety proﬁle was also reported, suggest-
ing that the long-term beneﬁt of SES implantation
could be duplicated in AMI patients, with low incidence
of short-term complications [9].
However, the cost of combining only one single SES
with abciximab infusion in an average-weight patient
will much exceed 3000 Euros and this would result in a
considerable increase of medical care costs.
The STRATEGY trial is a single-centre, single-
blind randomised trial comparing the current recom-
mended gold standard therapy for AMI, namely BMS
plus abciximab, vs. a new combination based on the
association of SES plus tiroﬁban with high-dose bolus
(HDB).
The rationale behind the use of tiroﬁban is:
(i) With current European list prices, the combina-
tion of tiroﬁban with one SES leads to a com-
parable economical impact than one BMS plus
abciximab;
(ii) HDB has recently replaced the RESTORE-
regimen, showing promising results in elective and
urgent PCI. Possibly, this revised tiroﬁban regi-
men will ﬁll the gap with abciximab in the subset
of patients undergoing urgent PCI, thus promot-
ing allocation of the current economical resources
to the emerging DES technology during primary
PCI.
Methods
Patients
All consecutive patients older than 18 years, scheduled
for primary PCI, presenting with ST-segment eleva-
tion AMI are being enrolled according to the following
inclusion criteria: (i) chest pain persisting >30 min, as-
sociated with ST-segment elevation of at least 0.1 mV
in two or more contiguous ECG leads; and (ii) admis-
sion either within 12 h from symptom onset or between
12 and 24 h if there was evidence of continuing is-
chaemia. The exclusion criteria included previous ad-
ministration of ﬁbrinolytic or any glycoprotein IIb/IIIa
inhibitors, history of bleeding diathesis or allergy to
the studies drug, major surgery within 15 days, active
bleeding, previous stroke in the last six months and
inability to obtain informed consent. According to the
protocol, cardiogenic shock—deﬁned as systolic blood
pressure<90 mmHg (without inotropic or intra-aortic
balloon support) thought to be secondary to ventricu-
lar dysfunction and associated with signs of end-organ
hypoperfusion such as: cold or diaphoretic extremities;
alteredmental status; or anuria—will not be considered
an exclusion criterion.
Our localEthicsCommittee onHumanResearch has
approved the protocol in January 2003 and all partici-
pants are asked to give their informed consent before
entering the study.
Randomisation
Patients whomeet the eligibility criteria are being ran-
domly assigned—with the use of computer-based 1:1
randomisation scheme—to HDB tiroﬁban (Aggrastat,
Merck,West Point, Pa.) or abciximab (Reopro, ReoPro,
Centocor, Malvern, Pennsylvania) on a single-blind ba-
sis. The study drug is started as soon as possible in the
intensive cardiac care unit (CCU), and subsequently
patients are transferred to the cath-lab.
All patients with a reference infarct related artery
(IRA) diameter >2.25 mm at visual estimation are eli-
gible for stenting.
Per protocol, patients randomised to tiroﬁban re-
ceive SES (Cypher; Johnson & Johnson, Cordis Corp.),
and crossover to other types of stent is allowed only
after failure of SES implantation attempt, or impossi-
bility to match available stent size with coronary refer-
ence diameter.
Patients allocated in the abciximab arm are eligible
only to BMS: the ﬁrst choice is Sonic stent (Johnson
& Johnson, Cordis Corp.), but any bare metal stent
type approved by regulatory agency can be implanted.
Coronary stenting is accomplished using a standard
technique or directly, without pre-dilatation, at the dis-
cretion of the operator.
Analyses of the data will be based on the intention-
to-treat principle.
Angiographic analysis
The angiographic images are acquired with a General
Electrics Advantage CRS V 5.6.5 single-plane system
at a cine rate of 25 frames/s. Basal TIMI ﬂow and col-
lateral circulation to the culprit vessel are evaluated on
the ﬁrst angiogram. TIMI ﬂow, corrected TIMI frame
count and myocardial blush (MB) is graded on the an-
giograms taken immediately after PTCA, as previously
described [10–12]. Latero-lateral view for the left an-
terior descending coronary artery (LAD), right ante-
rior oblique 45◦ view for the right coronary artery, and
latero-lateral or right anterior oblique 45◦ views for the
circumﬂex artery are used in most cases. Ten seconds
of cine ﬁlming are required to allow some ﬁlling of the
venous system to evaluate the washout phase of con-
trast dye. In order to facilitate the subjective grading
of MB, angiograms are also digitised and a logarithmic
non-magniﬁed mask-mode background subtraction is
applied to the image subset to eliminate non-contrast
medium densities. The analysis are being carried out
by two cardiologists who are blinded to the patient’s
identity and ECG ﬁndings. Blush is graded according
to the dye density score: grade 0 to 1 was minimal to
no MB or contrast density (relative to the dye density
in uninvolved areas); grade 2 was moderate MB; and
grade 3 was normal MB.
Quantitative coronary angiography on results ob-
tained immediately at the end of PCI and at month
6 will include IRA reference diameter and minimum
lumen diameter.
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Medications and procedures
All patients will receive aspirin (160–325 mg orally as
loading dose (LD) and then 80–125 mg orally indeﬁ-
nitely) and clopidogrel (300 mg orally as LD and then
75 mg/day for at least three months). Tiroﬁban is given
as a bolus of 25 µg/Kg/3-min, followed by an infusion
of 0.15 µg/Kg/min for 18–24 h. Heparin is adjusted as
follows: all patients, at the time of study drug bolus in-
fusion, receive 50–70 U/Kg heparin (maximum 7000 U)
with additional boluses to achieve and maintain an ac-
tivated clotting time of at least 200 secs.
IRA is the only target of the procedure. Intra-aortic
counterpulsation is performed in case of haemodynamic
instability. TIMI grade 3 coronary ﬂow in the treated
vessel with a residual stenosis<20% is considered suc-
cessful PTCA.
A 12-lead ECG is recorded before and continuously
30 min after IRA recanalisation. Two observers, un-
aware of the clinical and angiographic data, perform
the analysis. ST-segment changes are evaluated in the
single lead with the most prominent ST-segment el-
evation as well as cumulative before and after me-
chanical intervention. ST-segment elevation is mea-
sured to the nearest 0.5 mm at 60 ms after the J
point, with the aid of hand-held calipers. Creatine ki-
nase (CK)measurements are systematically performed
on hospital admission, every 3 h for the subsequent
24 h, and then every 12 h for two days. The peak CK
value and the time to peak CK are evaluated in each
patient.
The protocol anticipates to discontinue heparin after
the procedure and remove arterial sheath whenACT is
<180 secs with arteriotomy closure device or with ex-
ternal compression for haemostasis. Investigators can
modify these guidelines at their discretion to meet the
medical needs on a patient-by-patient basis. Patients
will not be discharged before four days after revascu-
larisation.
Angiographic follow-up
Complete angiographic follow-up at month 6 will be
carried out unless patients die, undergone repeated
revascularisation, have an occluded vessel at the end
of the procedure or do not undergo a revascularization
procedure after the initial coronary angiography (e.g.,
because the rate of ﬂow in the target vessel was
classiﬁed as grade 3 according to the classiﬁcation of
the Thrombolysis in Myocardial Infarction [10] trial
and the stenosis was judged to be less than 50 percent),
or refuse angiography at month 6.
Study end-points
The primary end-point is a composite of death, non-
fatal MI, stroke and binary restenosis within a me-
dian follow-up of 180 days after index procedure.
Patients with more than one event will be assigned
the highest ranked event, according to the previous
list.
Nonfatal MI is deﬁned as recurrent chest pain
with ST-segment or T-wave changes and recurrent
elevation of cardiac enzymes. Stroke is deﬁned as
an acute neurologic defect that lasts >24 h and re-
sults in death or an inability to perform normal
activities.
Angiographic binary restenosis, dichotomised in in-
stent and in-segment (5 mm above and after the stent
margins) is deﬁned as a >50% diameter stenosis by
quantitative coronary angiography.
Secondary end-points include the composite one
at day 30 and month 6 of death, recurrent MI, stroke
and clinically-driven target vessel revascularisation
(TVR), deﬁned as any coronary artery bypass graft
surgery, or a second PCI of the original target ves-
sel, performed on a non-elective basis for recurrent
myocardial ischaemia, and degree of myocardial
perfusion according to ST-segment resolution and
MB analysis after the procedure. For an analysis of
safety, the end-points of major and minor bleeding
complications are deﬁned according to the criteria
of the Thrombolysis in Myocardial Infarction Trial
[13].
Statistical analysis
The sample size was calculated on the assumption
that incidence of death, reinfarction and stroke at six
month would be around 5% in both groups and that
the rate of binary restenosis would be 25% in the
abciximab-BMS group and 8% in the tiroﬁban-SES
group. To detect this effect size with 80% power and
a type I error (alpha) of 0.05, 160 patients will be re-
quired, after augmenting to take in account of a 10% of
drop-outs.
One single interim analysis is planned after the
angiographic follow-up of the ﬁrst 50 patients, ap-
plying the Lan-DeMets approach [14]. If neces-
sary, the estimated sample size will be re-powered
accordingly.
Discrete data will be summarized as frequencies,
whereas continuous data will be expressed as mean
± SD. The chi-squared and Fisher’s exact tests will
be used for comparison of categorical variables. The
Student’s t-test and Mann-WhitneyU test will be used
to test differences among continuous variables. Multi-
variate logistic regression analysis will be performed
to identify independent correlates of the primary end
point, six-month mortality, and cumulative six-month
mortality, reinfarction and urgent TVR. All analyses
will be conducted according to the intention-to-treat
principle. For exploratory purpose survival curves
will be generated using the Kaplan-Meier method,
and the difference between curves will be assessed
by the log-rank test. A p value <0.05 was considered
signiﬁcant. Odds ratios (ORs) with 95% conﬁdence
intervals (CIs) will be calculated. Analyses will be
performed using the package software STATISTICA
version 6.1 (Statsoft Inc.).
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Table 1. Base-line characteristics of the patients
Abciximab- HDB-Tiroﬁban-
Characteristics BMS (n= 50) SES (n= 50) P
Age (yr) 63± 12 62± 12 NS
Male sex (%) 76 80 NS
Weight (kg) 74± 13 78± 13 NS
Diabetes (%) 9 14 NS
Hypertension (%) 40 58 NS
Smoker (%) 42 38 NS
Creatinine (mg/dl) 1.13± 0.3 1.23± 0.4 NS
Creatinine Clearance () 73 68 NS
Medical history (%)
CABG 4 0 NS
PCI 2 0 NS
Acute myocardial 10 14 NS
infarction
Cerebrovascular 6 4 NS
accident
Presentation proﬁle
Systolic Pressure 132± 26 128± 23 NS
(mmHg)
Heart Rate 76± 16 76± 18 NS
(beats/min)
Anterior MI 48 58 NS
Killip class >1 14 10 NS
Medications (%)
Aspirin 86 94 NS
Clopidogrel 84 90 NS
Statin 82 66 NS
ACE-inhibitor 78 88 NS
β-blocker 78 70 NS
Results
Study enrolment began on 6 March 2003, being the
ﬁrst 100 patients included in the trial in seven month
time. Baseline clinical characteristics of the study pop-
ulation are shown in Table 1. Patients randomised to
abciximab and BMS are balanced in respect to HDB
tiroﬁban andSESgroup for baseline demography,med-
ical history, presentation proﬁle andmedications at dis-
charge. Angiographic and procedural data are shown in
Table 2. Patients randomised toHDBtiroﬁban andSES
do not differ in respect to abciximab and BMS group
for location of culprit lesion, prevalence of multivessel
disease, reference diameter of infarct related artery,
door to balloon time, prevalence of stenting and num-
ber or total length of stents delivered, ﬁnal minimal lu-
men diameter, prevalence of patients submitted to hep-
arin infusion after sheath removal and creatine-kinase
MB-fraction at peak.
STRATEGY sub-study
In a subset of patients (n = 50), platelet aggregation
assay is conducted before (T0), 5 (T1), 10 (T2) and 30
(T3) min after the bolus dose with the PFA-100 device
(Dade-Behring).
The PFA-100 analyser is a new, rapid and standard-
ised assay that reﬂects the extent of platelet adhesion
Table 2. Procedural data
Abciximab- HDB-Tiroﬁban-
Characteristic BMS (n= 50) SES (n= 50) P
Infarct-related artery (%)
LAD 58 48 NS
RCA 32 28 NS
LCx 20 12 NS
Multivessel Disease (%) 34 50 NS
Reference diameter (mm) 3± 0.52 2.94± 0.6 NS
Door-to-Balloon (min) 82± 36 74± 33 NS
Delivery of at least 96 92 NS
1 stent (%)
>1 stent implanted (%) 8 8 NS
Stent length (mm) 20± 5 22± 7 NS
Final minimal lumen 2.83± 0.6 3± 0.4 NS
diameter (mm)
Heparin after sheath 18 10 NS
removal (%)
CK-MB at peak (ng/ml) 245± 237 240± 205 NS
and aggregation blockade, and that might be helpful
in monitoring antiplatelet drug therapy and in guid-
ing dose adjustment in order to achieve optimal clinical
beneﬁt [15,16].
The PFA-100 device (Dade-Behring) is used to mea-
sure platelet adhesion and aggregation at high shear
conditions, in some way mimicking an in vivo bleeding
time [17,18].
Blood is forced to ﬂow through a synthetic capillary,
with a collagen and ADP-coated membrane with a cen-
tral hole at its end. When a haemostatic platelet plug
completely obliterates the central hole, the blood ﬂow
will stop. The time necessary to stop the ﬂow is called
“closure time” and is related to platelet function.
This sub-study will give additional information on
the degree of platelet inhibition in patients treatedwith
HDB tiroﬁban as comparedwith those treated with ab-
ciximab standard regimen. Any adverse clinical events
recorded in this subset of patients will be correlated
to the degree of platelet inhibition before and after
treatment.
Discussion
In the last years, many new catheter-based devices
have been developed for percutaneous treatment of
elective and urgent coronary interventions [19–23].
However, due to exponential growing of the costs, their
use in the cath-lab if often regarded as competitive;
even if their simultaneous use has been regarded as
promising [24], they are very rarely combined in clin-
ical practice. The potential risk of this attitude is to
progressively create a dangerous divergence between
evidenced-based medicine and clinical practice.
It has been recently shown that the unrestricted uti-
lization of sirolimus-eluting stents in the “real world” is
safe and effective in reducing repeat revascularization
at 1 year compared with bare stent implantation [25].
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However, the cost-effectiveness of this policy has been
also recently questioned [26]. The main argumentation
is that the use of DES would not probably result in
a ﬁnal reduction of death and MI. Accordingly, the
routine use of DES in the clinical arena will be justiﬁed
only if a signiﬁcant cost-reduction is provided. An
alternative and attractive approach—that is the aim of
the current ongoing clinical study—is to combine DES
with a less expensive adjunctive therapy and directly
compare this new interventional strategy with the
current golden standard.
The philosophy behind the study design is that, by
simply re-allocating the current economical resources
for the treatment ofAMI, a better clinical/angiographic
outcome can be reached, thus improving the cost-
effectiveness for medical interventions in this setting.
The STRATEGY trial is based on the assumption
that the two combination therapies will be equally ef-
fective in terms of death, myocardial re-infarction and
stroke, with the 6-month angiographic follow-up show-
ing a superiority in terms of in-segment late-loss and
binary restenosis rate in the tiroﬁban plus SES study
arm.
The choice to start the administration of glycopro-
tein IIb/IIIa inhibitors in the CCU is peculiar of the
STRATEGY trial and should be further discussed.
In the ADMIRAL study, it was clearly shown that
the earlier the administration of abciximab, the big-
ger the beneﬁt in respect to placebo therapy was [5].
This has prompted the idea—currently being tested in
randomisedclinical trials—that facilitatedprimaryPCI
could be superior to PCI even if glycoprotein IIb/IIIa
inhibitors are given at the time of the procedure.
Moreover, by administering the study drug before
assessing the coronary anatomy, the patient is en-
rolled in the trial regardless the complexity of the cul-
prit lesion(s), thus avoiding the selection bias that was
claimed to be responsible for the neutral effect of ab-
ciximab vs. placebo in the CADILLAC trial [7].
In the TARGET trial, tiroﬁban at RESTORE regi-
men was shown to offer less protection in from MACE
in respect to abciximab in unstable patients [27].
The reasons for these results are currently specula-
tive and possibly due to an inadequate early platelet
inhibition of tiroﬁban at RESTORE regimen in the
trials.
Platelet reactivity is pivotal in the pathogenesis of
complications after PCI and the degree of platelet in-
hibition with the use of glycoprotein (GP) IIb/IIIa in-
hibitors during PCI is critical for the protection from
ischaemic events [28].
In the randomised comparison of platelet inhibition
with abciximab, tiroﬁban and eptiﬁbatide during PCI
in ACS (COMPARE) trial, platelet aggregation 15 and
30 min after drug infusion was signiﬁcantly less inhib-
ited with the tiroﬁban-RESTORE regimen compared
to with abciximab and eptiﬁbatide and, at 30 min, also
compared with the tiroﬁban-PRISM-PLUS regimen
[29].
Accordingly, the bolus of tiroﬁban regimen has been
revised and increased from 10 µg/kg to 25 µg/kg (HDB
tiroﬁban) [30]. From preliminary uncontrolled ﬁndings,
this new regimen appears safe [31] and in a recently
completed double-blind placebo controlled trial, the use
of HDB tiroﬁban was shown to be superior to placebo
in both stable and unstable high-risk patients.
The STRATEGY trial will be the ﬁrst head-to-head
comparison between HDB tiroﬁban and abciximab and
its resultswill probably give some new insights into the
unexpected results of the TARGET trial.
Finally, the clinical impact of reduced restenosis rate
on prognosis is out of the scope of the present phase II
study, but preliminary data would possibly allow shap-
ing the sample size for future studies in this ﬁeld.
In case the interim analysis conﬁrms the pre-
speciﬁed sample size, the results of the STRATEGY
trial will be available by the end of 2004. By that time,
three main questions will be answered:
(i) What is the rate of MACE if HDB tiroﬁban, com-
bined to SES, is used instead of abciximab and
BMS?
(ii) What is the net gain in terms of binary restenosis
and late-loss when SES is implanted during pri-
mary PCI instead of a BMS?
(iii) Is the combination between HDB tiroﬁban and
SES superior to abciximab and BMS in terms of
composite of MACE and binary restenosis?
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BARE-METAL STENTING, BY DE-creasing the rate for target-vesse l revascular izat ion(TVR),1,2 has been endorsed as
a class I indication in the treatment of
acute ST-segment elevation myocar-
dial infarction (STEMI).3 Abciximab, by
virtue of its salutary effect on tissue per-
fusion and coronary artery patency, has
also been recommended as part of a rea-
sonable treatment strategy.3,4
Sirolimus-eluting stents greatly re-
duce the need for TVR compared with
bare-metal stents and thus have the po-
tential to further improve long-termclini-
cal outcome after primary percutane-
For editorial comment see p 2154.
Author Affiliations and Participating STRATEGY In-
vestigators are listed at the end of this article.
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of Cardiology, University of Ferrara, Cardiovascular In-
stitute, Arcispedale S. Anna, Corso Giovecca 203,
44100 Ferrara, Italy (vlgmrc@unife.it).
Context Bare-metal stenting with abciximab pretreatment is currently considered a
reasonable reperfusion strategy for acute ST-segment elevation myocardial infarction
(STEMI). Sirolimus-eluting stents significantly reduce the need for target-vessel revas-
cularization (TVR) vs bare-metal stents but substantially increase procedural costs. At
current European list prices, the use of tirofiban instead of abciximab would absorb
the difference in cost between stenting with sirolimus-eluting vs bare-metal stents.
Objective To evaluate the clinical and angiographic impact of single high-dose bo-
lus tirofiban plus sirolimus-eluting stenting vs abciximab plus bare-metal stenting in
patients with STEMI.
Design, Setting, and Patients Prospective, single-blind, randomized controlled
study (Single High Dose Bolus Tirofiban and Sirolimus Eluting Stent vs Abciximab and
Bare Metal Stent in Myocardial Infarction [STRATEGY]) of 175 patients (median age,
63 [interquartile range, 55-72] years) presenting to a single referral center in Italy with
STEMI or presumed new left bundle-branch block and randomized betweenMarch 6,
2003, and April 23, 2004.
Intervention Single high-dose bolus tirofiban regimen plus sirolimus-eluting stent-
ing (n=87) vs standard-dose abciximab plus bare-metal stenting (n=88).
Main OutcomeMeasures The primary end point was a composite of death, non-
fatal myocardial infarction, stroke, or binary restenosis at 8 months. Secondary out-
comes included freedom, at day 30 and month 8, from major cardiac or cerebrovas-
cular adverse events (composite of death, reinfarction, stroke, and repeat TVR).
Results Cumulatively, 14 of 74 patients (19%; 95% confidence interval [CI], 10%-
28%) in the tirofiban plus sirolimus-eluting stent group and 37 of 74 patients (50%;
95% CI, 44%-56%) in the abciximab plus bare-metal stent group reached the pri-
mary end point (hazard ratio, 0.33; 95% CI, 0.18-0.60; P�.001 [P�.001 by Fischer
exact test]). The cumulative incidence of death, reinfarction, stroke, or TVR was sig-
nificantly lower in the tirofiban plus sirolimus-eluting stent group (18%) vs the abcix-
imab plus bare-metal stent group (32%) (hazard ratio, 0.53; 95%CI, 0.28-0.92; P=.04),
predominantly reflecting a reduction in the need for TVR. Binary restenosis was
present in 6 of 67 (9%; 95% CI, 2%-16%) and 24 of 66 (36%; 95% CI, 26%-46%)
patients in the tirofiban plus sirolimus-eluting stent and abciximab plus bare-metal stent
groups, respectively (P=.002).
Conclusion Tirofiban-supported sirolimus-eluting stenting of infarcted arteries holds
promise for improving outcomes while limiting health care expenditure in patients with
myocardial infarction undergoing primary intervention.
JAMA. 2005;293:2109-2117 www.jama.com
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ous coronary intervention (PCI).5
However, the lack of randomized trials
to assess the safety and long-term effi-
cacy of sirolimus-eluting stent implan-
tation in patients with STEMI, in con-
junctionwith the financial consequences
of replacing bare-metal stenting with
sirolimus-eluting stenting, currently limit
use of sirolimus-eluting stents in this set-
ting.6 Furthermore, in the first tertiary
referral center to adopt unrestricted use
of sirolimus-eluting stents, a concomi-
tant decrease in the use of abciximabhas
been reported.7 This may indicate a re-
luctance to use glycoprotein (Gp) IIb/
IIIa inhibitors anddrug-eluting stents si-
multaneously for economic reasons.
Current clinical guidelines specifi-
cally recommend abciximab during pri-
mary PCI,3and recent additional evi-
dence strongly supports the value ofGp
IIb/IIIa inhibitors in this setting.8 Re-
placing abciximab with tirofiban, ad-
ministered as a single high-dose bolus
(SHDB) regimen, is a promising strat-
egy that could preserve financial re-
sources. At current European market
prices (approximately 580 € [$742] for
tirofiban vs approximately 1900 €
[$2432] for abciximab), this would ab-
sorb the additional cost of sirolimus-
eluting stenting vs bare-metal stent-
ing (European list price: approximately
1800 € [$2304] for sirolimus-eluting vs
approximately 600 € [$768] for bare-
metal stenting).
Thus, in an attempt to further im-
prove outcome aftermyocardial infarc-
tion (MI)without affecting overall costs,
we compared a strategy of tirofiban-
supported infarct artery sirolimus-
eluting stent implantation with a cur-
rent preferred strategy for STEMI
treatment in terms of angiographic and
clinical outcome.4
METHODS
Protocol and Randomization
The Single High Dose Bolus Tirofiban
and Sirolimus Eluting Stent vs Abcix-
imab and Bare Metal Stent in Myocar-
dial Infarction (STRATEGY) trial was a
prospective, single-center, randomized
trial of 2 strategies: SHDB tirofiban plus
sirolimus-eluting stent implantation vs
standard abciximab regimen plus bare-
metal stent implantation, in patients un-
dergoing primary angioplasty for acute
STEMI.Thedesignof the studyhas been
described in detail.9
Individuals eligible for enrollment
were consecutive patients presenting
with STEMI who fulfilled the follow-
ing inclusion criteria: (1) chest pain for
more than 30 minutes with ST-
segment elevation of 1 mm or more in
2 or more contiguous electrocardio-
graph leads orwith presumably new left
bundle-branch block and (2) admis-
sion either within 12 hours of symp-
tom onset or between 12 and 24 hours
with evidence of continuing ischemia.
Exclusion criteria included administra-
tion of fibrinolytic agents in the previ-
ous 30 days, history of bleeding diathe-
sis or allergy to the study drugs, major
surgerywithin15days, and active bleed-
ing or previous stroke in the last 6
months. The University of Ferrara in-
stitutional review board approved the
protocol in January 2003, and all pa-
tients gave written informed consent.
Open-label randomization was per-
formed in the coronary care unit by the
treating physician immediately after eli-
Figure 1. Study Profile
87 Included in Primary Analysis
219 Patients Assessed for Eligibility
175 Randomized
88 Completed Clinical Follow-up to 240 d 87 Completed Clinical Follow-up to 240 d
88 Assigned to Receive Abciximab and
Bare-Metal Stent
87 Assigned to Receive Tirofiben and Sirolimus-
Eluting Stent
66 Had Angiographic Follow-up
64 With Bare-Metal Stent
1 With Sirolimus-Eluting Stent
1 Who Underwent Balloon
Angioplasty
22 Did Not Have Angiographic Follow-up
12 Not Eligible
4 With Bare-Metal Stent
3 Who Underwent Balloon Angioplasty
9 Refused
9 With Bare-Metal Stent
1 With Sirolimus-Eluting Stent
5 Who Did Not Undergo PCI
67 Had Angiographic Follow-up
62 With Sirolimus-Eluting Stent
4 With Bare-Metal Stent
1 Who Underwent Balloon
Angioplasty
20 Did Not Have Angiographic Follow-up
11 Not Eligible
6 With Sirolimus-Eluting Stent
2 Who Underwent Balloon Angioplasty
9 Refused
6 With Sirolimus-Eluting Stent
3 With Bare-Metal Stent
3 Who Did Not Undergo PCI
83 Underwent PCI
77 Received Bare-Metal Stent as Assigned
2 Received Sirolimus-Eluting Stent
(Protocol Violations)∗
4 Underwent Balloon Angioplasty
5 Did Not Undergo PCI
2 Extensive Vessel Calcification
2 Diffuse Disease in Culprit Vessel
2 No Significant Lesion in Culprit Vessel
1 Small Vessel Size
1 Type 1 Aortic Dissection With Occlusion
of Right Coronary Artery
84 Underwent PCI
74 Received Sirolimus-Eluting Stent as Assigned
7 Received Bare-Metal Stent
3 Unavailable Sirolimus Stent >3.0 mm
3 Failed Sirolimus Stent Delivery
1 Dual Antiplatelet Therapy Contraindicated
3 Underwent Balloon Angioplasty
3 Did Not Undergo PCI
2 Extensive Vessel Calcification
1 Diffuse Disease in Culprit Vessel
3 No Significant Lesion in Culprit Vessel
1 Small Vessel Size
88 Included in Primary Analysis
44 Excluded
34 Did Not Meet Inclusion Criteria
10 Refused to Participate
PCI indicates percutaneous coronary intervention.
*Unjustified protocol violations in patients with diabetes and left anterior descending lesions.
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gibility criteria were met. A 1:1 com-
puter-generated random sequence sup-
pliedbyanacademic statistician,without
blocking or stratification, was used.
Sealed envelopes indicated the treat-
ment group to which the patients were
assigned: SHDB tirofiban (Aggrastat;
Merck, West Point, Pa [Europe]/
Guilford Pharmaceuticals, Baltimore,
Md [United States]) or abciximab
(ReoPro; Centocor, Malvern, Pa). The
study drug was started in the coronary
careunit and subsequently patientswere
transferred to the cardiac catheteriza-
tion laboratory. Per protocol, patients al-
located to the tirofiban group received
sirolimus-eluting stenting (Cypher;
Cordis Corp, Miami Lakes, Fla). Cross-
over to bare-metal stentingwas allowed
only when sirolimus-eluting stent im-
plantation failed or when it was impos-
sible tomatch sirolimus-eluting stent di-
ameterwith coronary referencediameter
(sirolimus-eluting stentswereonly avail-
able in diameters from 2.25-3.00 mm
during the enrollment period). Patients
allocated to the abciximab group re-
ceived bare-metal stenting: the first
choice was a Sonic stent (Cordis Corp),
but any commercially available bare-
metal stent could be implanted.
Medications
Tirofiban was given as a bolus of 25
µg/kg over 3 minutes, followed by an
infusion of 0.15 µg/kg per minute for
18 to 24 hours. Abciximab was admin-
istered as a bolus of 0.25 mg/kg over 3
minutes, followed by a 12-hour infu-
sion of 0.125 µg/kg per minute. All pa-
tients received aspirin (160-325 mg
orally as a loading dose and then 80-
125 mg/d orally indefinitely) and clo-
pidogrel (300 mg orally as a loading
dose and then 75 mg/d for at least 3
months). Heparin (50 U/kg) was ad-
ministered before the procedure, with
additional boluses administered to
achieve andmaintain an activated clot-
ting time of at least 200 seconds.
Electrocardiographic
and Platelet Measures
Cumulative ST-segment elevation,
evaluated in all leads with any ST-
segment elevation of 1 mm or greater,
was measured to the nearest 0.5 mm at
60 milliseconds after the J point.
In a subset of 70 randomly selected
patients, a platelet aggregation assaywas
conducted before and 10 minutes after
the bolus dose of Gp IIb/IIIa inhibitors
using a platelet function analyzer (PFA-
100;Dade Behring Inc,Deerfield, Ill), as
previously described.10Closure time, ie,
the time necessary to form a hemo-
static platelet plug and to stopblood flow
when the sample is aspirated at high
shear rate (5000-6000 seconds−1)
through a collagen- and adenosine di-
phosphate–coated capillary (147µmdi-
ameter), inversely reflects platelet reac-
tivity in the sample evaluated.
Angiographic Analysis
Thrombolysis inMyocardial Infarction
(TIMI) grade 3 coronary flow in the
treated vessel and a residual stenosis less
than 30% were the criteria used to de-
fine a successful PCI. Quantitative an-
giographic analyses, using a validated
edge-detection system (CAAS II; Pie
Medical, Maastricht, the Netherlands),
were performed by an experienced car-
diologist who was unaware of treat-
Table 1. Baseline Characteristics and Medications of the Patients
Characteristic
SHDB Tirofiban �
Sirolimus-Eluting Stent
(n = 87)
Abciximab �
Bare-Metal Stent
(n = 88)
P
Value
Age, median (IQR), y 62 (54-72) 63 (55-72) .69
Men, No. (%) 67 (77) 61 (69) .72
Body mass index, median (IQR)* 26 (24-29) 26 (24-29) .79
Diabetes, No. (%)† 15 (17) 11 (12) .53
Hypertension, No. (%)† 48 (55) 44 (50) .79
Smoker, No. (%)† 34 (39) 36 (41) .88
Creatinine clearance,
median (IQR), mL/min
74 (55-102) 70 (55-94) .48
Medical history, No. (%)
CABG surgery 2 (2) 2 (2) �.99
PCI 4 (5) 2 (2) .68
MI 11 (13) 8 (9) .63
Cerebrovascular accident 5 (6) 4 (5) .74
Presentation profile
Systolic blood pressure,
median (IQR), mm Hg
129 (110-150) 125 (115-145) .71
Heart rate, median (IQR), beats/min 72 (64-85) 75 (62-90) .34
Anterior MI, No. (%) 43 (49) 36 (41) .50
Killip class �2, No. (%) 15 (17) 12 (14) .68
Cardiogenic shock, No. (%) 5 (6) 5 (6) �.99
Hours from symptom onset
to intervention, No. (%)
�3 43 (49) 43 (49) �.99
3-6 32 (37) 36 (41) .77
�6 12 (14) 9 (10) .64
Median (IQR) 3 (1.8-4) 3 (2.2-4.3) .18
Medications at discharge, No. (%)
Aspirin 82 (94) 80 (91) .91
Clopidogrel 68 (78) 68 (77) �.99
Ticlopidine 16 (18) 15 (17) �.99
Oral anticoagulant 2 (2) 3 (3) �.99
Statin 63 (72) 70 (80) .73
ACE inhibitor 74 (85) 69 (78) .73
�-Blocker 64 (74) 67 (76) .90
Abbreviations: ACE, angiotensin-converting enzyme; CABG, coronary artery bypass graft; IQR, interquartile range; MI,
myocardial infarction; PCI, percutaneous coronary intervention; SHDB, single high-dose bolus.
*Calculated as weight in kilograms divided by square of height in meters.
†Patients were classified as having hypertension or diabetes based on history; patients with an active smoking habit
within 7 days before hospital admission were classified as smokers.
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ment assignment.Acute luminal gainwas
defined as the minimal luminal diam-
eter (MLD) immediately after the pro-
cedureminus theMLD at baseline. Late
loss was defined as the MLD immedi-
ately after theprocedureminus theMLD
at follow-up. The target lesion was de-
fined as the stented segment plus the
5-mm segments immediately proximal
and distal to the stent(s).
Study End Points and Definitions
The primary end point was freedom, at
8 months after randomization, from
death, nonfatal MI, stroke, and binary
restenosis. The data for all primary end
point events were reviewed by an in-
dependent adjudication committee
whosemembers were unaware of treat-
ment assignment. Nonfatal MI was de-
fined as recurrent chest pain with ST-
segment or T-wave changes and
recurrent elevation of cardiac enzyme
levels. Patients were considered eli-
gible for angiographic follow-up if
protocol-mandated PCI had been at-
tempted. Binary restenosis, dichoto-
mized for in-stent and in-segment (5
mm proximal and distal to the stent
margins) was defined as a greater than
50%diameter stenosis demonstrated by
quantitative coronary angiography.
Secondary end points included free-
dom, at day 30 and month 8, from ma-
jor cardiac or cerebrovascular adverse
events defined as the composite of death,
reinfarction, stroke, and repeat TVR.Ur-
gent TVR was defined as repeat PCI or
coronary artery bypass graft surgery per-
formedwithin 24 hours of severe recur-
rent ischemic symptoms. As a safety
analysis, the end points of major or mi-
nor bleeding along with severe or mild
thrombocytopeniawere defined accord-
ing to the criteria of the TIMI trial.11
Statistical Analysis
Sample size was calculated on the as-
sumption that the incidence of death,
reinfarction, stroke, and binary reste-
nosis at 8 months would be 13% in the
tirofiban plus sirolimus-eluting stent
group and 30% in the abciximab plus
bare-metal stent group. To detect this
effect size with 80% power and a type
I error (�) of .05, taking into account
an expected 10% rate of dropouts, re-
quired 160 patients.
All analyses were conducted accord-
ing to the intention-to-treat principle.
Discrete data were summarized as
frequencies, whereas continuous data
were expressed as median and inter-
quartile range (IQR). The Fisher exact
test (categorical variables) and Mann-
Whitney test (continuous variables)
were used to analyze differences be-
tween the 2 study groups. Event-free
survival curves were generated by the
Kaplan-Meiermethod, and survival be-
tween groups was compared using the
log-rank test. Hazard ratios (HRs) with
95% confidence intervals (CIs) were
calculated using a Cox proportional
hazards model. The proportional haz-
ards assumption was confirmed by an
academic statistician (E.B.). A 2-sided
P value less than .05was considered sig-
nificant for all tests. All analyses were
performed using STATISTICA ver-
sion 6.1 (StatSoft Inc, Tulsa, Okla).
RESULTS
Patient Population
Between March 6, 2003, and April 23,
2004,175patientswithSTEMIwereran-
domized. A trial flow diagram is shown
inFIGURE1. Baselinedemographics and
angiographic features (TABLE 1 and
TABLE 2) were well matched between
the 2 randomized cohorts. A single
patient in either group had a time from
symptom onset to intervention of
Table 2. Procedural Data
Characteristic
SHDB Tirofiban �
Sirolimus-Eluting Stent
(n = 87)
Abciximab �
Bare-Metal Stent
(n = 88)
P
Value
Infarct-related artery, No. (%)
Left anterior descending 43 (49) 36 (41) .50
Right coronary 29 (33) 33 (38) .76
Circumflex 15 (17) 19 (21) .57
No. of diseased vessels, No. (%)
1 46 (53) 57 (65) .45
2 28 (32) 20 (23) .32
3 13 (15) 11 (12) .82
Door-to-balloon time, median (IQR) [range], min 70 (55-90) [15-225] 67 (53-110) [15-210] .54
Delivery of at least 1 stent, No. (%) 81 (93) 79 (90) .91
Stent in culprit lesion, median (range) 1 (0-2) 1 (0-3) .53
Total stent length, median (IQR), mm 23 (18-28) 23 (16-23) .42
Nominal stent diameter, median (IQR), mm 3 (2.7-3) 3 (2.75-3.5) .01
TIMI flow, No. (%)
Preprocedure
Grade 0 or 1 61 (70) 65 (74) .90
Grade 2 15 (17) 13 (15) .83
Grade 3 11 (13) 10 (11) �.99
Postprocedure
Grade 0 or 1 2 (2) 4 (4) .68
Grade 2 1 (1) 2 (2) �.99
Grade 3 84 (96) 82 (93) .91
Cumulative ST-segment elevation,
median (IQR), mm
Preprocedure 10 (7-16) 9 (6-14) .74
Postprocedure 3 (2-5) 3 (2-7) .91
Cumulative ST-segment resolution, No. (%)
�50 60 (69) 54 (63)* .71
�70 43 (49) 34 (39)* .49
CK-MB at peak, median (IQR), ng/mL 188 (95-350) 206 (102-392) .55
Time to CK-MB peak, median (IQR), h 12 (9-15) 12 (9-15) .64
Abbreviations: CK-MB, creatine kinase–MB; IQR, interquartile range; SHDB, single high-dose bolus; TIMI, Thrombolysis in
Myocardial Infarction.
*Two patients presenting with left bundle-branch block were not included in this analysis.
119
The STRATEGY trial 
greater than12hours.Median time from
Gp IIb/IIIa inhibitor bolus to interven-
tionwas33 (IQR, 22-42)minutes in the
tirofiban plus sirolimus-eluting stent
group vs 35 (IQR, 23-41) minutes in
the abciximab plus bare-metal stent
group (P=.73). Total median duration
of study drug infusion was 20 (IQR,
14-28) hours in the tirofiban plus siro-
limus-eluting stent group vs 12 (IQR,
11-13) hours in the abciximab plus
bare-metal stent group (P�.001).
Procedural Results
Based on initial angiographic findings, 3
patients (3%) in the tirofiban plus siro-
limus-eluting stent group and 5 pa-
tients (6%) in the abciximab plus bare-
metal stent group did not receive PCI
(Figure 1). In 5patients (2 tirofibanplus
sirolimus-eluting stent, 3 abciximabplus
bare-metal stent), no significant lesion
was present in the culprit vessel on an-
giography, and anterograde flow was
normal. In 2 patients (1 per group) the
small size of the occluded vessel pre-
cluded intervention. Finally, 1 patient in
the abciximab plus bare-metal stent
group was found to have a type I aortic
dissection with occlusion of the right
coronary artery.Where angioplastywas
attempted, procedural success did not
differ significantly between the tirofi-
ban plus sirolimus-eluting stent group
(82/84 patients [98%]) and the abcix-
imab plus bare-metal stent (79/83 pa-
tients [95%]) group (P=.91). Nominal
stent diameter was smaller in the tirofi-
ban plus sirolimus-eluting stent group,
reflecting the limited available range of
sirolimus-eluting stent diameters.
Overall, 74 patients (85%) in the ti-
rofiban plus sirolimus-eluting stent
group and 77 (88%) in the abciximab
plus bare-metal stent group received the
protocol-mandated treatment combi-
nation (Figure 1). The extent of ST-
segment resolution (Table 2) and the
TIMI flow grade postintervention
(Table 2) did not differ between treat-
ment groups, nor did quantitative an-
giographic parameters at baseline or im-
mediately after intervention (TABLE 3).
Median platelet aggregation, evalu-
ated in 70 patients as closure time, was
similar at baseline in the tirofiban plus
sirolimus-eluting stent group (77 [IQR,
68-86] seconds) and the abciximabplus
bare-metal stent (74 [IQR, 69-83] sec-
onds) group (P=.71). Ten minutes af-
ter the start of drug infusion, 30 of 35
patients (86%) receiving abciximab vs
31 of 35 (89%) treated with tirofiban
reached full platelet inhibition (clo-
sure time, �300 seconds). In the re-
maining 9 patients, closure time was
298 (IQR, 297-299) seconds in the 4
who received tirofiban and 295 (IQR,
292-296) seconds in the 5 who re-
ceived abciximab (P=.07).
30-Day Outcomes
There were no significant differences
between the tirofiban plus sirolimus-
eluting stent group and the abciximab
plus bare-metal stent group in the in-
cidence of major adverse cardiac or
cerebrovascular events during the first
30 days (TABLE 4). Five fatal events oc-
curred: 2 (1 due to left ventricular free
wall rupture, another to cardiogenic
shock) in the tirofiban plus sirolimus-
eluting stent group and 3 (as a conse-
quence of aortic dissection, cardio-
genic shock, and left ventricular free
wall rupture) in the abciximab plus
bare-metal stent group. Among pa-
tients receiving abciximab, 2 had rein-
farction due to angiographically con-
firmed stent thrombosis requiring
urgent TVR. In 1 patient with diabe-
tes, a sirolimus-eluting stent had been
implanted as a protocol violation. In the
tirofiban plus sirolimus-eluting stent
group, 1 patient with diffuse 3-vessel
disease and cardiogenic shock at entry
satisfied the criteria for reinfarction
whilemechanically ventilated 3 days af-
ter the index procedure. Coronary an-
giography performed thereafter ex-
cluded new changes in coronary
anatomy. Finally, in 1 patient per group,
urgent TVR was required due to re-
Table 3. Quantitative Coronary Analysis
Variable
SHDB Tirofiban �
Sirolimus-Eluting Stent
(n = 87)
Abciximab �
Bare-Metal Stent
(n = 88)
P
Value
Preprocedure, median (IQR)
RVD, mm 2.27 (1.95 to 2.59) 2.33 (2 to 2.7) .34
MLD, mm 0 (0 to 0.2) 0 (0 to 0.18) .67
Diameter stenosis, % 100 (90 to 100) 100 (93 to 100) .49
Lesion length, mm 13 (9.6 to 18) 13.1 (10 to 18) .91
Postprocedure, median (IQR)
RVD, mm 2.18 (1.9 to 2.6) 2.33 (2 to 2.7) .24
MLD, mm 1.92 (1.6 to 2.2) 1.98 (1.6 to 2.3) .53
Acute luminal gain, mm* 1.85 (1.36 to 2.08) 1.9 (1.45 to 2.2) .36
Diameter stenosis, % 13 (6.5 to 20.5) 16 (5 to 26) .30
Follow-up, median (IQR)
RVD, mm 2.53 (2.1 to 2.9) 2.63 (2.2 to 3) .34
MLD, mm 1.98 (1.6 to 2.4) 1.48 (0.9 to 2) �.001
Diameter stenosis, % 15 (5.5 to 24) 42 (28 to 70) �.001
Late loss, mm† −0.22 (−0.39 to 0.19) 0.6 (0.12 to 0.96) �.001
Binary restenosis, No. (%) (n = 66) (n = 67)
In-stent 5 (7.5) 19 (28) .01
Proximal edge‡ 1 (1.5) 4 (6) .36
Distal edge‡ 0 1 (1.5) �.99
Target vessel 7 (11) 24 (36) .008
Focal restenosis, No./total (%)§ 5/6 (83) 7/24 (29) .24
Reocclusion, No. (%) 0 5 (7) � �.99
Abbreviations: IQR, interquartile range; MLD, minimal lumen diameter; RVD, reference-vessel diameter; SHDB, single
high-dose bolus.
*Postprocedure MLD minus baseline MLD.
†Postprocedure MLD minus MLD at follow-up.
‡Restenosis within the 5-mm segment proximal or distal to the stent edge.
§Length �10 mm. Percentages given refer to patients presenting with binary restenosis at follow-up.
�Two patients had subacute stent thrombosis during hospitalization, while the remaining 3 patients presented with
reocclusion at follow-up due to occlusive in-stent restenosis.
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sidual infarct-related artery dissection
threatening vessel closure. No cerebro-
vascular accident occurred. The inci-
dence of any thrombocytopeniawas sig-
nificantly lower in the tirofiban plus
sirolimus-eluting stent group vs the ab-
ciximab plus bare-metal stent group
(Table 4).
Clinical and Angiographic
Outcomes
Complete follow-up information up to
240 days was available for all patients.
Eight patients in the tirofiban plus siro-
limus-eluting stent group and 8 in the
abciximab plus bare-metal stent group
refused to undergo angiographic fol-
low-up performed after amedian of 209
days (range,148-267). In1additionalpa-
tient per group, follow-up coronary an-
giography was not performed due to a
severe allergic reaction to contrast me-
dia during the index procedure and
transfusion-dependent chronic ane-
mia. None of these patients experi-
encedmajor adverse cardiac or cerebro-
vascular events; all were asymptomatic
and none had inducible myocardial is-
chemia on stress testing. Their baseline
characteristics did not differ with re-
spect to patients who underwent fol-
low-up angiography.
Cumulatively, 14 of 74 (19%; 95%
CI, 10%-28%) patients in the tirofiban
plus sirolimus-eluting stent group and
37 of 74 (50%; 95% CI, 44%-56%) in
the abciximab plus bare-metal stent
group fulfilled the criteria for the
8-month primary end point (death,MI,
stroke, or binary restenosis) (HR, 0.33;
95%CI, 0.18-0.60; P�.001 [P�.001 by
Fischer exact test]).
The cumulative incidence of major
adverse cardiac or cerebrovascular
events (death, reinfarction, stroke, or
TVR) was significantly lower in the ti-
rofiban plus sirolimus-eluting stent
group vs the abciximab plus bare-
metal stent group (18% vs 32%, respec-
tively; HR, 0.53; 95% CI, 0.28-0.92;
P=.04) (FIGURE 2). Overall, the com-
posite of death or reinfarctionwas simi-
lar in the tirofiban plus sirolimus-
eluting stent group (13%) vs the
abciximab plus bare-metal stent group
(17%) (HR, 0.71; 95% CI, 0.34-1.5;
P=.39) (Figure 2),while therewas a sig-
nificant reduction in the need for TVR
(7%vs 20%, respectively;HR, 0.30; 95%
CI, 0.12-0.77; P=.01) in the tirofiban
plus sirolimus-eluting stent group.
The results of quantitative coronary
analyses are shown in Table 3. Cumu-
lative distribution curves (paired-
lesion analysis) for the difference of
MLD before and immediately after the
intervention and at follow-up in the 2
groups are shown in FIGURE 3. In-
lesion binary restenosis—assessed in 67
and 66 patients in the tirofiban plus
sirolimus-eluting stent and abciximab
plus bare-metal stent groups (87% and
88% of those eligible, respectively)—
was present in 6 (9%; 95% CI, 2%-
16%) and 24 (36%; 95% CI, 26%-
46%) patients, respectively (P=.002).
COMMENT
In theUnited States, the Food andDrug
Administration approved the first drug-
eluting stent (the sirolimus-eluting stent)
Table 4. 30-Day and 8-Month Outcomes and Safety Profile
Variable
No. (%)
P
Value*
SHDB Tirofiban �
Sirolimus-Eluting Stent
(n = 87)
Abciximab �
Bare-Metal Stent
(n = 88)
Outcomes
30-d
Death 2 (2) 3 (3) �.99
Reinfarction 1 (1) 3 (3) .62
Urgent TVR 1 (1) 3 (3) .62
Stroke 0 0 �.99
Subacute stent thrombosis† 0 2 (3) .24
Death/reinfarction 3 (3) 6 (7) .49
Death/reinfarction/stroke/urgent TVR 3 (3) 7 (8) .33
8-mo
Death 7 (8) 8 (9) .78
Reinfarction 6 (7) 8 (9) .60
TVR 6 (7) 18 (20) .01
TLR 5 (6) 18 (20) .006
Stroke 0 0 �.99
Late stent thrombosis† 0 0 �.99
Death/reinfarction 11 (13) 15 (17) .39
Death/reinfarction/TVR 16 (18) 28 (32) .04
Death/reinfarction/stroke/TVR 16 (18) 28 (32) .04
Safety Profile
Bleeding
Major 1 (1) 2 (2) �.99
Blood loss with no site identified 0 3 (3) .24
Minor 7 (8) 8 (9) �.99
Any bleeding events 8 (9) 14 (16) .26
Red blood cell transfusion 2 (2) 4 (4) .68
Any femoral hematoma 2 (2) 4 (4) .68
Femoral hematoma requiring surgery 1 (1) 1 (1) �.99
Thrombocytopenia‡
Severe thrombocytopenia 0 2 (2) .49
Mild thrombocytopenia 1 (1) 6 (7) .11
Any thrombocytopenia 1 (1) 8 (9) .03
Platelet transfusion 0 2 (2) .49
Abbreviations: SHDB, single high-dose bolus; TLR, target-lesion revascularization; TVR, target-vessel revasculariza-
tion.
*By Fischer exact test (log-rank test for 8-month outcomes).
†Angiographically documented.
‡Severe, mild, and any thrombocytopenia were defined by TIMI classification (see “Methods” section).
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in April 2003. Since then, penetration
of drug-eluting stenting has rapidly in-
creased, replacing bare-metal stenting in
more than80%ofPCIprocedures.12 This
rapid transition has been facilitated by
the presence of specific reimburse-
ment for drug-eluting stenting. How-
ever, evidence for the efficacy and safety
of drug-eluting stents has been ob-
tained only for highly selected patient
or lesion subgroups,13-15 andconcerns re-
garding the safety and economic con-
sequences of liberal use of these de-
vices have also been raised.12,15-20
In Europe, sirolimus-eluting stents
became available 1 year previous (April
2002). Nevertheless, overall use of
drug-eluting stents remains limited,
with penetration rates as low as 6% in
some countries.6 Thismay be related to
their high cost in conjunction with the
almost universal lack of specific reim-
bursement. Thus, their short-term costs
are currently playing a major role in
clinical decision making.
To the best of our knowledge, no ran-
domized trial has specifically exam-
ined the safety and efficacy of drug-
eluting stents in the setting of primary
intervention for STEMI. Abciximab and
drug-eluting stent implantation have
potentially complementary effects on
death or MI and the need for reinter-
vention in the setting of acuteMI,5,8,21-23
providing the rationale for testing their
combination in this setting.24 How-
ever, both therapies are expensive. The
average cost of combining abciximab
treatment with a single sirolimus-
eluting stent exceeds 50%of current re-
imbursement for acuteMI in some Eu-
ropean countries.25 Thus, financial
pressure may lead to competitive use
between drug-eluting stents and abcix-
imab on the basis of their high cost.7
Our results demonstrate that a lower-
cost strategy of tirofiban-supported siro-
limus-eluting stent implantation dur-
ing primary PCIwas safe and resulted in
improved clinical (ie, decreasedneed for
TVR)andangiographic (ie, decreased re-
stenosis) outcomes with respect to a
strategy of abciximab-supported bare-
metal stent implantation.Moreover, such
a strategy was associated with an im-
Figure 2. Cumulative Risk of Events at 240 Days in the Tirofiban Plus Sirolimus-Eluting Stent
and Abciximab Plus Bare-Metal Stent Groups
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proved safety profile with respect to
thrombocytopenia.
Two specific aspects of our studypro-
tocol deserve emphasis. First, all con-
secutive patients with acute MI re-
ferred to a single referral center for
intended primary intervention were
prospectively enrolled provided they
had no contraindication to the use of
Gp IIb/IIIa inhibitors, thus substan-
tially reducing any potential bias re-
lated to clinical presentation or angio-
graphic findings. Second, Gp IIb/IIIa
inhibitors were started at admission at
amedian interval of more than 30min-
utes before coronary intervention. In a
recent trial of patients with STEMI re-
ferred for intended bare-metal stent-
ing, a similar approach to abciximab ad-
ministration showed a benefit on total
and cardiovascularmortality.8 Further-
more, a recent meta-analysis supports
the hypothesis that early administra-
tion of Gp IIb/IIIa inhibitors to pa-
tients with STEMI is associated with
consistent trends toward a reduction in
mortality and other major adverse car-
diac events.26
In a previously reported head-to-
head comparison between abciximab
and tirofiban inpatientsundergoingPCI,
abciximabwas superior to tirofibanwith
respect to theprespecified combinedend
point.27The superiorityof abciximabwas
driven by a higher rate of periproce-
duralMI in the tirofiban group, suggest-
ing inadequate early platelet inhibition
with the bolus regimen used (10 µg/
kg). Subsequent dose-ranging studies
showed that increasing the tirofiban bo-
lus dose from 10 to 25 µg/kg was nec-
essary to obtain anoptimal level of plate-
let inhibition,28 and initial clinical trials
with the high bolus appear promis-
ing.29,30 In the present study, evalua-
tion of platelet function before and soon
after administrationof theGp IIb/IIIa in-
hibitor showed that in the primary PCI
setting, SHDB tirofiban resulted in a de-
gree of early platelet inhibition similar
to that observed with abciximab. Simi-
larly, TIMI flow patterns and ST-
segment resolution—both surrogates of
long-termmortality that have been con-
sistently improved by abciximab treat-
ment even in relatively small stud-
ies21,22—didnotdiffer between treatment
groups. A large-scale noninferiority trial
comparing a SHDB tirofiban regimen
with abciximab is currently enrollingpa-
tients. The results of this trial will
complement and extend our present
findings.
Our study has several important limi-
tations. First, itwasunderpowered to as-
sess the effect of tirofiban-supported
sirolimus-eluting stent implantation on
the rate ofmajor adverse cardiac or cere-
brovascular events, implying that the
benefit of treatment observed here was
greater than expectedbut also that larger
studies are needed to confirm our pre-
liminary observations. Second, in keep-
ing with the design of our investiga-
tion, no conclusion can be drawn
regarding the relative contribution of a
specificGp IIb/IIIa inhibitor or stent type
with respect to the other. This would
have required a factorial study design.
Third, despite careful avoidance of the
“oculo-stenotic” reflex, we cannot rule
out the possibility that protocol-
mandated angiographic follow-up has
not increased the magnitude of clinical
benefit of study treatment. Finally, a for-
mal cost-effectiveness analysis, which
would have complemented our clinical
and angiographic results, was not per-
formed in this trial.
In conclusion, our study provides
proof of concept for a new treatment
strategy in STEMI that incorporates un-
restricted use of sirolimus-eluting stent-
ing but results in no (European mar-
ket) or only a modest (US market)
increase in medical expenditure.
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Value of Platelet Reactivity in Predicting Response to Treatment and 
Clinical Outcome in Patients Undergoing Primary Coronary 
Intervention
Insights into the Single High-Dose BoluS TiRofibAn and Sirolimus Eluting STEnt versus 
Abciximab and Bare Metal Stent in 
Acute MYocardial Infarction (STRATEGY) Study 
Gianluca Campo, MD, Marco Valgimigli, MD, Donato Gemmati, MSc, Gianfranco Percoco, MD, Silvia Tognazzo, MSc, 
Giordano Cicchitelli, MD, Linda Catozzi, MSc, Stavroula Gaitani, MD, Maurizio Anselmi, MD, Corrado Vassanelli, MD, 
Gianluigi Scapoli, MD, Roberto Ferrari, MD, PhD
Objectives: 
To evaluate the value of platelet reactivity (PR) in predicting the response to treatment and outcome in patients with ST-
segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention assisted by 
glycoprotein (GP) IIb/IIIa inhibition.  
Background: There is limited prognostic information on the role of spontaneous or drug-modulated PR in STEMI 
patients.
Methods: PR was measured with Platelet Function Analyzer (PFA) 100 and light transmission aggregometry (LTA) using 
adenosine diphosphate as agonist in 70 consecutive STEMI patients -at entry (PRT0), 10 min after GP IIb/IIIa bolus 
(PRT1), at discharge (PRT2)- and in 30 stable angina (SA) patients (PRSA). Complete platelet inhibition (CPI) was based 
on closure time >300 sec at PFA-100 and percent inhibition of platelet aggregation >95% at LTA. Clinical, 
electrocardiographic and angiographic responses to treatment during 1-year follow-up were collected. 
Results: According to both techniques, PRT0 was higher than i) PRT2 and PRSA; ii) in those without CPI at T1; iii) in 
patients with final Thrombolysis In Myocardial Infarction (TIMI) flow grade <3. PRT0 assessed with PFA-100 correlated 
with i) corrected TIMI frame count (r=-0.6, p<0.001), ii) ST-segment resolution (r=45, p<0.001) and iii) CK-MB (r=-
0.47, p<0.001). At 1 year, patients with high PRT0 showed an adjusted 5 to 11-fold increase in the risk of death, re-
infarction and target vessel revascularization (HR 11; [95%CI 1.5-78]; p=0.02 at PFA-100 and HR 5.2; [95%CI 1.1-23]; 
p=0.03 at LTA). 
Conclusions: PR at entry affects response to GP IIb/IIIa inhibition, mechanical treatment and long-term outcome in 
STEMI patients undergoing primary intervention.  
J Am Coll Cardiol 2006, in press 
INTRODUCTION
Platelet activation, by favoring thrombus formation and 
coronary artery occlusion, is thought to play a key 
pathogenetic role in acute myocardial infarction. 
Percutaneous coronary intervention (PCI) is currently 
considered the preferred reperfusion strategy for patient 
with ST-segment elevation MI (STEMI) (1). Recent 
evidence strongly argues in favor of the glycoprotein 
(GP) IIb/IIIa inhibition in this setting (2) and reinforces 
the concept that platelet reactivity (PR) is a potential 
target of treatment beyond pure mechanical intervention.  
In previous studies, PR has been used to evaluate the 
risk of adverse events (3) and the extent of myocardial 
necrosis (4). Moreover, the importance of achieving a 
high level of platelet inhibition early after GP IIb/IIIa 
bolus in non-STEMI patients has been reported (5). 
Whether baseline and/or drug-modulated PR influence 
response to treatment and myocardial injury in STEMI 
patients undergoing primary PCI with GP IIb/IIIa 
inhibition is unknown. This might further extend current 
paradigm linking platelet activation to outcome in STEMI 
population.
In order to explore this hypothesis, PR was measured 
before, during and after treatment as part of a pre-
specified substudy of the Single High-Dose BoluS 
TiRofibAn and Sirolimus Eluting STEnt versus Abciximab 
and Bare Metal Stent in Acute MYocardial Infarction 
(STRATEGY) trial (6-7). To address the issue whether 
high baseline PR is a hallmark of clinical acuity, a 
matched population affected by stable angina (SA) was 
also similarly investigated. 
METHODS
Study Population 
100 patients treated with PCI in the cath-lab of the University 
Hospital of Ferrara were enrolled. This study population 
comprised 70 consecutives patients (68% male; mean age 
63±12) with STEMI (STEMI group) enrolled in a previously 
reported trial (6) and 30 age- and sex-matched patients with SA 
(SA group) treated with PCI (67% male; mean age 64±6) 
(Table 1). This study was approved by the local Ethics 
Committee and all patients gave written informed consent. 
Medications, Procedures and Assays 
The design of the STRATEGY trial has been previously reported 
(7, 8). Briefly, patients with STEMI were randomly assigned to 
single high dose bolus tirofiban (SHDB, 25 µg/kg/3 min, 
followed by an infusion of 0.15 µg/Kg/min for 18-24 hours) or 
abciximab (bolus of 0.25 �g/Kg/3-min, followed by a 12-hour 
infusion 0.125 �g/Kg/min). The study drug was started in the 
intensive cardiac care unit. Per protocol, patients randomised to 
tirofiban received sirolimus eluting stent (SES), while those 
allocated to abciximab bare metal stent (BMS). All patients 
received aspirin (250 mg i.v. followed by 100 mg/die), 
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clopidogrel (300 mg followed by 75 mg/die), heparin (50-70 
U/Kg with additional bolus if necessary) and other treatments as 
suggested by current guidelines. Patients with SA were treated 
with aspirin and received, at least 6 h before procedure, 300 mg 
of clopidogrel. 
Angiographic Analysis 
The angiographic images were acquired with a General Electrics 
Advantage CRS V 5.6.5 single-plane system at a cine rate of 25 
frames/s before and immediately after the procedure. 
Angiograms were analyzed by one experienced interventional 
cardiologists (GP), blinded to platelet assays results. All 
angiograms were assessed with a respect to Thrombolysis In 
Myocardial Infarction (TIMI) flow scale in infarct-related artery 
(IRA) at baseline and after PCI (8). The corrected TIMI frame 
counts (CTFC) and the myocardial blush grade (MBG) were 
determined on final angiogram, as described previously (9-10). 
No reflow was defined as TIMI flow grade 0 or I despite 
successful ballon angioplasty or stent insertion, in spite of 
residual stenosis <50%, absence of significant dissection or 
visible thrombus or spasm in IRA. Procedural success was 
defined as the achievement of a final <30% residual stenosis 
and TIMI grade flow 3.  
Blood Sample Collection 
In the STEMI group, three blood samples were performed: at 
entry (T0) before treatment, 10 min (10±1) after the GP 
IIb/IIIa inhibitors bolus (T1), at discharge (T2, 7±3 days). In 
the SA group, blood was drawn before PCI procedure and 
clopidogrel intake (T0). 
Platelet Function Testing 
Platelet function was measured with Platelet Function Analyzer 
(PFA 100, Dade Behring, Miami, Fla), a US Food and Drug 
Administration approved device, and with light transmission 
aggregometry (LTA).  
� Platelet Function Analyzer 100 (PFA-100) 
In the PFA system (11) blood is forced to flow throughout a 
synthetic capillary (147 µm diameter), with a collagen and 
adenosine 5’-diphosphate (ADP) coated membrane with a 
central hole at its end (CADP cartridge, 50 µg of ADP and 2 µg 
of Type 1 equine collagen). When a haemostatic platelet plug 
completely obliterates the central hole, the blood flow will stop. 
The time necessary to stop the flow is called “closure time”
(CADP-CT) and inversely reflects platelet reactivity. Its 
reference range in the absence of anti-platelet therapy is 
69-130 seconds (11-12). This instrument confines detection of 
closure to a 300 secs window and, as result, “nonclosure” is 
obtained. This degree of platelet inhibition corresponds to 
>90% inhibition of platelet aggregation by means of light 
transmission aggregometry (20 �M ADP) (12-13). CADP 
cartridge was selected in the present study to monitor the effect 
of GP IIb/IIIa inhibitors on platelet function based on available 
evidence (12-13). 
� Light Transmission Aggregometry (LTA)
Blood was centrifuged (200g×10 minutes) to obtain platelet-rich 
plasma (PRP). The platelet count in PRP was adjusted to the 
range of 150.000–300.000/L by dilution with autologous plasma 
when out of range. The remaining specimen was re-centrifuged 
(1500g×15 minutes) to obtain platelet-poor plasma (PPP). 
Platelets were stimulated with 20 µmol/l of ADP. Aggregation 
was measured at 37°C with a PACKS-4 Aggregometer (Helena 
Laboratoires) and expressed as the maximal percent change in 
light transmittance from baseline at 5 min after the addition of 
the agonist, with platelet-poor plasma as a reference. Percent 
inhibition of platelet aggregation (%IPA) was determined by the 
following formula: (%PA at baseline - %PA ten minutes after 
IIb/IIIa)/%PA at baseline.  
All samples for analysis were collected into evacuated tubes 
containing 3.8% trisodium citrate and also in evacuated tubes 
containing PPACK (D-Phe-Pro-Arg-Chloromethylketone). All 
measurements were done 0.5 to 1 hour after blood sampling. 
CADP-CT measurements with citrate and PPACK were highly 
correlated (r=0.96, p<0.001). Coefficients of variation for 
duplicate analysis averaged 4%. At baseline, CADP-CT 
correlated with aggregability measured with LTA (r=-0.95, 
p<0.001). All patients who failed to achieve nonclosure at T1 
show %IPA<95%. Complete platelet inhibition (CPI) was 
defined as CADP-CT >300 sec (nonclosure) and %IPA>95%.
Study End Points 
In order to test the role of spontaneous and drug-modulated PR, 
platelet function was related with: a) angiographic evaluation 
(TIMI flow grade, incidence of no reflow, CTFC, MBG and 
procedural success rate), b) extent of myocardial necrosis, c) 
ST-segment resolution, d) clinical outcome. Extent of myocardial 
necrosis was assessed by CK-MB (ng/dl) and Troponin I (TnI, 
ng/dl) at peak. Cumulative ST-segment elevation, evaluated in 
all leads with any ST-segment elevation �1 mm, was measured 
to the nearest 0.5 mm at 60 min after the J point, with the aid 
of hand-held callipers. The clinical end points were death, 
reinfarction, target vessel revascularization (TVR) (major 
adverse cardiac events, MACE) and stent thrombosis (ST) 
angiographically confirmed. 
Statistical Analysis 
Continuous data are presented as means ± SD, with the 
significance of differences judged by t test. Since results of PFA-
100 and LTA were both not normally distributed at Kolmogorov-
Smirnov goodness-of-fit test, the Mann-Whitney test was used 
to compare PR values between groups. Kruskal-Wallis ANOVA 
was employed to compare more than 2 groups of patients and 
to generate P-value for tend-tests reported in figure 3. 
Categorical variables were summarized in terms of number and 
percentages and were compared using two-sided Fisher’s exact 
test. Spearman’s correlation coefficients were used to detect any 
association between variables. As exploratory analysis, linear 
regression analysis was used to test association between PR and 
variables reported in table 1. Survival curves were constructed 
by the Kaplan-Meier method and survival among groups was 
compared using the Log Rank test. Cox proportional hazards 
models were used to assess risk reduction of adverse events. 
Multivariate analysis, considering all variables in Table 3 with a p 
value <0.10, was performed to identify whether PR at entry was 
an independent predictor for adverse events at 1 year. 
Probability was significant at a level of <0.05. Analysis was 
performed using STATISTICA 6.1 (Statsoft Inc, Tulsa, Okla).  
RESULTS
Baseline and procedural data of the study population are 
shown in Tables 1 and 2. Patients with SA, recruited in 
the period February-March 2004, were well matched for 
age, sex and all risk factors with respect to STEMI 
patients. Between January and April 2004, 70 STEMI 
patients, randomly allocated to receive tirofiban or 
abciximab, were prospectively enrolled in the current 
analysis. Their baseline and procedural characteristics did 
not differ from those enrolled in the cohort of the 
STRATEGY trial (6). Sixty-six (94%) patients were 
treated with stent implantation, while one patient per 
group received only balloon angioplasty. In one patient 
in the SHDB tirofiban group, coronarography was not 
followed by treatment due to both prompt restoration of 
TIMI 3 flow after intracoronary nitrates injection and 
absence of coronary obstruction, whereas in one patient 
in the abciximab group, type I aortic dissection 
determining occlusion of the right coronary artery was 
followed by emergent surgery.
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Table 1. Baseline Characteristics of the Patient
Characteristics
SHDB Tirofiban group
(n=35) 
Abciximab group
(n=35) 
P
Value
STEMI group 
(N=70) 
SA group
(N=30) 
P
Value
Age (yr) 64±13 63±12  0.6 63±12 64±6 0.3
Men no. (%) 22 (63%) 26 (74%) 0.2 48 (68%) 20 (67%) 0.5 
Diabetes no.(%) 7 (20%) 6 (17%) 0.5 13 (18%) 6 (20%) 0.5 
Hypertension no. (%) 23 (66%) 21 (60%) 0.4 44 (63%) 20 (66%) 0.4 
Smoker no. (%) 10 (28%) 16 (46%) 0.1 26 (37%) 11 (36%) 0.6 
Medical history (%)       
CABG no. (%) 0 (0%) 0 (0%) >0.9 0 (0%) 2 (6%) 0.09 
PCI no. (%) 0 (0%) 1 (3%) 0.5 1 (1.5%) 0 (0%) 0.7 
Acute myocardial infarction no. (%) 2 (6%) 2 (6%) 0.7 4 (6%) 4 (13%) 0.2 
Laboratory Values at entry       
Platelet Count (u/ml) 241±45 254±100 0.5 247±97 251±91 0.8
Hematocrit (%) 40±5 41±4 0.2 41±5 42±6 0.6
White blood count (u/ml) 11.9±4 12.1±3 0.8 12±4 8±3 <0.01
Fibrinogen (mg/dl) 420±162 395±116 0.4 407±139 400±129 0.7
Creatinine Clearance (ml/min) 85±38 84±28 0.9 85±33 82±28 0.8
SHDB=single high dose bolus. CABG=coronary artery bypass graft. PCI=percutaneous coronary intervention. 
Platelet Reactivity Assays 
PR before any treatment, evaluated both in terms of 
CADP-CT (76±11) and %PA (90±5) was higher in STEMI 
than in SA patients (96±6 and 50±6, p<0.01 for both, 
Figure 1). CADP-CT or %PA at entry was not related to 
any of the variables in Table 1. At entry, there were no 
differences between tirofiban and abciximab in terms of 
CADP-CT (77±11 vs 74±12, p=0.3) or %PA (89±4 vs. 
90±4, p=0.5) (Figure 1). Overall, 4 patients were 
assuming aspirin as chronic treatment before entry. Their 
PR did not differ in terms of PFA-100 or LTA at T0 or T1
compared to aspirin naïve patients.  
At T1, 31/35 (89%) patients treated with tirofiban vs. 
30/35 (86%) receiving abciximab reached the CPI 
(p=0.5). In the remaining nine patients, CADP-CT was 
298 �297�299� sec in the four who received tirofiban and 
294 �292�296� secs in the five who received abciximab 
(p=0.06), whereas %PA was 11±2 vs. 14±4 (p=0.3), 
respectively. In these nine patients, baseline PR was 
significantly higher than in those reaching CPI at T1 
(CADP-CT: 65±12 vs. 77±10, p=0.002; %PA: 93±4 vs. 
89±4, p=0.003). Out of all variables included in Table 1, 
only PR at T0 was related to PR at T1. At discharge (7±3 
days), PR was lower than at entry in the STEMI group 
(CADP-CT: 76±11 vs. 98±8, p<0.001) which was 
confirmed by LTA findings (Figure 1). 
Platelet Reactivity and Angiographic Data 
Baseline PR, measured as CADP-CT and %PA (Figure 2), 
was higher in patients with TIMI flow 0/1 as compared to 
those with TIMI flow grade 2/3 at first angiogram 
(p<0.001 for both). Among patients in whom angioplasty 
was attempted (68 patients), procedural success was 
reached in 61 (90%): in three patients, a final TIMI 2 
flow was obtained despite repeated administration of 
intracoronary vasodilatators; in three, an irreversible no  
reflow phenomenon after stent implantation was 
observed, while a distal macro-embolization in a 
posterolateral branch occurred in the remaining patient 
after vessel wiring. In these seven patients, baseline 
CADP-CT was lower (66±7 vs. 77±11, p=0.01) and %PA 
higher (93±4 vs. 89±4, p=0.02) as compared to that of 
those with procedural success. Four (44%) out of the 
nine patients who failed to achieve the CPI at T1 had a 
not successful intervention as compared to three (5%) in 
whom maximum platelet inhibition was obtained 
(p=0.004). Patients showing no reflow had enhanced PR 
(CADP-CT: 62±7 vs. 77±11, p=0.03; %PA: 95±3 vs. 
89±4, p=0.02). None of them reached the CPI at T1. 
CADP-CT and %PA at entry resulted to be related to 
CTFC both in all patients receiving intervention (r=-0.6, 
p<0.001) and in those with final TIMI 3 (r=-0.53; 
p<0.001). Patients with MBG 2/3 tended to have lower 
PR as compared to those with MBG 0/1 (CADP-CT: 
77±11 vs. 71±11, p=0.06; %PA: 89±5 vs. 91±4, 
p=0.05).
Platelet Reactivity and ECG Resolution 
CADP-CT and %PA at baseline was directly correlated to 
the degree of ST-segment resolution immediately after 
the procedure (r=0.45 and r=-0.42, p<0.001 for both). 
PR at entry was higher in patients without cumulative ST 
resolution >50% (CADP-CT: 67±10 vs. 78±11, p=0.001; 
%PA: 93±4 vs. 89±4, p=0.003) or >70% (CADP-CT: 
72±11 vs. 80±11, p=0.007; %PA: 91±4 vs. 88±3, 
p=0.006). Four (44%) and seven (78%) among the nine 
patients who failed to achieve CPI did not reach ST-
segment the resolution >50% or >70% as compared to 
seven (12%) and 24 (41%) out of the 59 with CPI 
(p=0.03 and p=0.04, respectively). 
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Table 2. Procedural Data 
Characteristics
SHDB Tirofiban 
group
(n=35) 
Abciximab 
group
(n=35) 
P
Value
STEMI 
group
(n=70) 
SA group 
(n=30) 
P
Value
Treated artery no. (%)       
Left anterior descending (%) 10 (29%) 17 (49%) 0.07 27 (40%) 14 (47%) 0.3 
Right coronary (%) 15 (44%) 13 (38%) 0.4 28 (41%) 6 (20%) 0.04 
Circumflex (%) 9 (27%) 4 (13%) 0.1 13 (19%) 10 (33%) 0.4 
GPIIb/IIIa-to-Balloon (min) 35±7 37±10 0.7 36±10 … …
PCI successful no. (%) 30 (88%) 31 (92%) 0.5 61 (88%) 30 (100%) 0.07 
Reference diameter, pre (mm) 2.7±0.6 2.8±0.5 0.7 2.7±0.5 2.8±0.6 0.6 
Total stent length (mm) 27±17 29±15 0.6 28±16 30±15 0.2 
Nominal stent diameter (mm) 3±0.5 3±0.4 0.6 3±0.4 3±0.7 0.8 
Stent implantation no. (%) 33 (94%) 33 (94%) 0.7 66 (94%) 30 (100%) 0.2 
TIMI flow no. (%)       
Preprocedure: Grade 0 or 1 28 (80%) 30 (86%) 0.4 58 (83%) 0 (0%) <0.01 
                          Grade 2 5 (14%) 4 (11%) 0.5 9 (13%) 8 (27%) 0.08 
                          Grade 3 2 (6%) 1 (3%) 0.5 3 (4%) 22 (73%) <0.01 
Postprocedure: Grade 0 or 1 2 (6%) 1 (3%) 0.5 3 (4%) 0 (0%) 0.3 
                           Grade 2 2 (6%) 2 (6%) 0.7 4 (6%) 0 (0%) 0.2 
                           Grade 3 30 (88%) 31 (91%) 0.5 61 (90%) 30 (100%) 0.07 
No reflow no. (%) 2 (6%) 1 (3%) 0.5 3 (4%) 0 (0%) 0.3 
� ST resolution >50% no. (%) 31 (88%) 29 (83%) 0.3 60 (86%) … …
� ST resolution >70% no. (%) 20 (57%) 17 (48%) 0.3 37 (53%) … …
CK-MB at peak (ng/ml) 210±187 227±154 0.7 218±170 … …
Troponin I at peak (ng/ml) 85±77 108±95 0.3 97±87 … …
SHDB=single high dose bolus. GP IIb/IIIa: start of GP IIb/IIIa inhibitors. PCI=percutaneous coronary intervention �=cumulative 
Figure 1. Platelet reactivity assays. 
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Black squares: patients with stable angina (SA). Circles: patients with STEMI. Black circles: abciximab subgroup. White Circles: single high dose bolus 
tirofiban subgroup. T0: baseline. T1: 10 min after IIb/IIIa bolus. T2: discharge. 
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Figure 2. Relationship between TIMI flow grade before 
PCI and baseline CADP-CT.
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Lower TIMI flow at first angiogram was associated to higher PR. CADP-CT 
was 73±11 in the TIMI 0/1 group vs. 87±8 in the TIMI 2/3 group 
(p<0.001) and %PA was respectively 91±4 vs. 85±3 (p<0.001). CADP-
CT was 75±11 in the TIMI 0/1/2 group vs. 89±6 in the TIMI 3 group 
(p=0.03) and %PA was respectively 90±4 vs. 84±2 (p=0.01). 
Platelet Reactivity and Infarct Size 
CADP-CT at T0 resulted to be inversely correlated with 
CK-MB and Tn I at peak in patients with STEMI (r=-0.47, 
p<0.001 and r=-0.48, p<0.001). CK-MB and Tn I at peak 
according to CADP-CT quartiles are shown in figure 3. All 
data were confirmed by LTA (data not shown). 
Platelet Reactivity and Clinical Outcome 
Complete follow-up information up to 365 days was 
available for all patients. In the SA group, no adverse 
event was observed. In the STEMI group at 30 days, 
three deaths and two re-infarctions occurred due to 
subacute stent thrombosis (ST), which required urgent 
TVR. At 1 year, 13 patients (18%) experienced adverse 
events, including four deaths, four re-infarctions (2 due 
to ST) and seven TVR (2 urgent TVR). 
Entry: Patients with MACE at 30 days, as compared to 
those without, had higher PR at T0 (CADP-CT: 57±8 vs. 
77±10, p<0.001; %PA: 97±4 vs. 89±4, p<0.001; Figure 
4). Of note, the two patients who had ST failed to 
achieve CPI at T1.
Patients with MACE within 1 year had lower CADP-CT at 
entry (65±9 vs. 78±11; p<0.001) and higher %PA 
(94±3 vs. 89±4, p<0.001) with respect to those with 
uneventful follow-up (Figure 4). The cumulative 
incidence of MACE was significantly lower in patients with 
high (above median value, low PR) compared to those 
with low (under median value, high PR) CADP-CT at T0 
(3% vs. 34%, p=0.0006). The patients in the high 
reactivity group showed a 12-fold increase in the risk of 
composite end point (HR 12; 95%CI 2.7-125, p=0.0009) 
(Figure 5). As showed in Table 3, there were no 
statistically significant differences between groups with 
Figure 3
0
100
200
300
400
500
600
700
p for trend = 0.0002
CK
-M
B
(n
g/
m
l)
0
100
200
300
400 p for trend = 0.0005
Q4Q3Q2Q1
Tr
op
on
in
 I
(n
g/
m
l)
Peak plasma levels of CK-MB (top) and of Troponin I (bottom) are shown 
according to quartiles (Q) of CADP-CT at admission. 
exception of percentages of diabetes mellitus, higher in 
the high PR subgroup (10% vs. 3%, p=0.03). Including 
diabetes, at multivariate analysis PR remained an 
independent predictor for MACE (HR 11; 95%CI 1.5-78, 
p=0.02). Based on LTA, there was an adjusted 5-fold 
increase in the risk of MACE (HR 5.2; 95%CI 1.1-23, 
p=0.03) in the high reactivity group.  
Discharge: PR tended to be higher in patients with as 
compared to those without adverse events at follow-up 
(CADP-CT: 94±8 secs vs. 98±8, p=0.2, %PA: 18±6 vs. 
15±5, p=0.1, respectively).  
DISCUSSION
Platelet reactivity is pivotal in the pathogenesis of acute 
coronary syndromes (ACS) and it is a well-know predictor 
for adverse outcome after PCI (3). Accordingly, inhibitors 
of GP IIb/IIIa decrease incidence of adverse events both 
in the PCI setting (14) and in patients with ACS (15). 
The three major findings of our study are: 
1. patients with STEMI have higher PR than patients 
with SA 
2. baseline PR affects the response to GP IIb/IIIa 
inhibitors soon after bolus 
3. PR at baseline and, consecutively, after GP IIb/IIIa 
inhibitors bolus, influences the angiographic success of 
the procedure, as well as the degree of ST-segment 
resolution, the extent of myocardial necrosis and the 
short- and mid-term clinical outcome in patients 
undergoing primary intervention. 
Our data demonstrated that baseline PR is a hallmark of 
clinical acuity. This statement is mainly based on the 
finding that PR was higher in the STEMI than in the 
control group (patients with SA).  
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Table 3. Clinical, biochemical and procedural data of 
STEMI patients stratified in accordance with the platelet 
reactivity at entry 
Characteristics 
High 
platelet 
reactivity 
(n=35) 
Low
platelet 
reactivity 
(n=35) 
P
Value
Age (yr) 65±12 62±12  0.4 
Men no. (%) 13 (37%) 9 (26%) 0.2 
Diabetes no.(%) 10 (28%) 3 (9%) 0.03 
Hypertension no. (%) 23 (66%) 21 (60%) 0.4 
Smoker no. (%) 12 (35%) 14 (39%) 0.4 
Medical History    
CABG no. (%) 0 (0%) 0 (0%) >0.9 
PCI no. (%) 0 (0%) 1 (3%) 0.5 
AMI no. (%) 1 (3%) 3 (8%) 0.3 
Laboratory Values at 
entry 
   
Platelet Count (u/ml) 264±115 232±76 0.2 
Hematocrit (%) 40±5 41±4 0.2 
White blood count (u/ml) 12.4±4 11.6±3 0.4 
Fibrinogen (mg/dl) 392±122 422±155 0.4 
Creatinine clearance (ml/min) 82±29 85±35 0.3 
Procedural Data    
LAD no. (%) 11 (32%) 16 (47%) 0.2 
RCA no. (%) 16 (47%) 12 (35%) 0.3 
Circumflex no. (%) 7 (21%) 6 (18%) 0.5 
RD, pre (mm) 2.7±0.6 2.8±0.5 0.7 
Total stent length (mm) 28±15 28±17 0.9 
Nominal stent diameter (mm) 3±0.5 3±0.4 0.6 
High platelet reactivity=CT at entry under the median value. Low platelet 
reactivity=CT at entry above the median value. Median value of CT at 
entry is 75 seconds. CABG=coronary artery bypass graft. 
PCI=percutaneous coronary intervention AMI=acute myocardial 
infarction; LAD=left anterior descending artery; RCA=right coronary 
artery; RD=reference diameter 
It has been demonstrated that the response to 
clopidogrel is patient-specific, with an important inter-
individual variability (16-17), and that the pretreatment 
platelet activity could influence final response to 
clopidogrel (17). Recently, two case-control studies 
associated the enhanced platelet aggregation and the 
impaired responsiveness to antiplatelet drugs with the 
stent thrombosis incidence (18-19). In our prospective 
study, with a homogenous patient population in terms of 
i) ethnicity (all patients were Caucasian), ii) clinical 
presentation (STEMI) and iii) treatment (primary PCI), 
we confirmed that there is an inter-individual variability 
in PR. This influences the response to antiplatelet 
therapy, also if GP IIb/IIIa inhibitors, the strongest 
currently available anti-platelet treatment, are used. Our 
study population comprised 13 diabetics: in keeping with 
previous evidence (20) they showed increased PR: at T0 
10 out of 13 (77%) were in the high PR subgroup 
(p=0.03 vs. non diabetics), at T1, both using PFA-100 
and LTA, 3 out of 13 (23%) achieved incomplete platelet 
inhibition vs. 6 out of 57 (11%) in the non-diabetic group 
(p=0.26), while at T2: CT in diabetics was lower (91±7 
vs. 99±8 in non-diabetics, p=0.01) and %PA higher 
(19±5 vs. 14±4 in non-diabetics p=0.001). One of them 
experienced stent thrombosis at follow-up. Cumulatively, 
five diabetic patients (38%) out of 13 satisfied the 
composite endpoint (38% vs. 14% in non-diabetics, 
p=0.05). Thus, when taken together with available 
evidence, our data suggest that diabetics, greatly 
contribute to overall inter-individual variability in PR, and 
as such may be an ideal target population for tailored 
antiplatelet therapy both in the acute and chronic 
setting.
Failure to achieve TIMI flow grade 3, the no reflow 
phenomenon and higher CTFC values after reperfusion 
therapy have been found to be associated with more 
extensive myocardial necrosis and poor clinical outcome 
(21). In the current study, we demonstrated that TIMI 
flow grade <3, no reflow as well as high CTFC occur 
significantly more frequently in patients with enhanced 
baseline PR. 
As previously reported, the enhanced platelet function 
correlated with the degree of myocardial damage in our 
study (4). Moreover, a clear association between PR and 
the degree of ST-segment resolution was found. This 
finding may be critically relevant since in STEMI patients 
treated with primary PCI, ST-segment reduction was 
independently related to 6-month mortality (2). 
In the current study, we studied PR using two 
methodologies. LTA is still considered as the gold 
standard, but it has some disadvantages such as limited 
reproducibility and complex sample preparation. 
Conversely, PFA 100 is a rapid tool that can be used in 
the clinical practice to identify patients with higher PR, 
which could potentially be exploited as a mean to tailor 
the anti-platelet treatment to the individual need. This 
may be particularly relevant in the setting of primary 
intervention for STEMI, when a short door-to-balloon 
time is needed, and other biomarkers of PR may not 
available. Further studies are needed to establish the 
optimal bedside assay to evaluate the PR in this setting. 
Study Limitations 
Due to limited sample size, our prospective investigation 
should be regarded as exploratory. In particular, in order 
to obtain a reliable estimate of the prognostic capability 
of PR at entry and to evaluate whether the response to 
Gp IIb/IIIa inhibitors is an independent outcome 
predictor beyond PR at entry, a larger prospectively 
collected study population is clearly in demand. Recently, 
it has been shown in elective patients that PR measured 
at least 24 hours after stenting independently predicts 
outcome (22). In our study, PR at discharge failed to be 
significantly associated to outcome: differences in patient 
selections, timing of platelet assays and limited statistical 
power may help explaining these different findings. PFA 
100 confines detection of closure to a 300-second 
window and because in most patients nonclosure is 
exhibited shortly after GP IIb/IIIa inhibitor 
administration, this device may be suboptimal to properly 
identify those individuals at a higher risk for subsequent 
thrombotic events. Although, this was an issue in the 
present investigation, future studies with bigger sample 
size are clearly needed. 
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Figure 4. CADP-CT stratified in relationship with the clinical outcome at 30 days and at 1 year. 
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Black circles: patients that not reached the composite end point. White Circles: patients that reached the composite end point. T0: baseline. T1: 10 min 
after IIb/IIIa bolus.  
Figure 5. Probability of MACE in patients stratified 
according to PR measured with PFA-100. 
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High platelet reactivity = CADP-CT at entry under the median value. Low 
platelet reactivity = CADP-CT at entry above the median value. Median 
value of CADP-CT is 75 secs. 
Conclusions
In patients undergoing primary PCI for STEMI, PR at 
entry was related to both angiographic and 
elettrocardiographic response to treatment as well as to 
the severity of cardiac injury as measured by the release 
of markers of cardiac necrosis. After 1 year, PR at 
presentation independently predicted major cardiac 
adverse events. Whether modulating PR through tailored
or systematic anti-platelet treatment overcomes the 
prognostic implications of spontaneous platelet function 
remains elusive and may warrant further investigations. 
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Impact of Stable versus Unstable Coronary Artery Disease on One-
year Outcome in Elective Patients Undergoing Multivessel 
Revascularization with Sirolimus-eluting Stents  
A sub-analysis of Arterial Revascularization Therapies Study (ARTS) Part II 
Marco Valgimigli, MD, Keith Dawkins, MD FRCP FACC ,Carlos Macaya, MD, FACC, Bernard de Bruyne, MD, PhD, 
Emmanuel Teiger, MD, PhD, Jean Fajadet, MD, Richardt Gert, MD, Stefano De Servi, MD, Angelo Ramondo, MD, Kristel 
Wittebols, Msc, Hans-Peter Stoll, MD, Tessa A. M. Rademaker, Msc, Patrick W. Serruys, MD, PhD, FACC 
Objective: To evaluate the impact of unstable coronary artery disease (CAD) on short- and mid-term outcome in 
patients with multivessel disease treated by multiple sirolimus eluting stents (SES) as part of the Arterial Revascularization 
Therapies Study (ARTS) Part II.  
Background: The differential safety/efficacy profile of SES when implanted in patients with unstable angina (UA) in 
comparison with stable angina (SA) undergoing multivessel intervention is largely unknown. 
Methods and Results: Between February 2003 and November 2003, 607 patients at 45 participating centres were 
treated, 221 of them (36%) presented with UA. At 30-days the cumulative rate of death, myocardial infarction (MI), 
cerebrovascular accident (CVA) and repeat revascularisation [MACCE] was 2.7% in the UA and 3.4% in the SA group 
(p=0.81). Angiographic subacute stent occlusion was documented in 1 (0.5%) and 4 (1%) patients in UA and SA group, 
respectively. At one year, the cumulative incidence of MACCE was 10.4% in both groups. Two late occlusions occurred, 
both in SA group. After adjustment for baseline and procedural characteristics, the presence of UA was not identified as 
an independent predictor of MACCE (HR 0.94 [95% CI: 0.41 to 2.12]; p=0.88). These findings remained consistent after 
lowering the threshold for peri-procedural MI from 3 to 1 time(s) the upper limit of normal for total creatine kinase and/or 
its MB fraction.  
Conclusions: In ARTS II, an unstable clinical presentation did not exert a negative impact on short- and mid-term 
outcome after SES implantation for multivessel disease.  
Submitted
INTRODUCTION
Several clinical studies, focusing on specific patient and 
lesion characteristics including long lesions(1), in-stent 
restenosis(2), small vessels(3), diabetic patients(4) and 
infarct related arteries(5), as well as all-comers 
registries(6) have established the role of the sirolimus-
eluting stent (SES) in reducing the need for further re-
intervention in comparison to bare metal stents. However, 
whether the net safety/efficacy profile of SES differs in 
relation to the acuity (i.e. stable vs. unstable) of clinical 
presentation remains an open issue. 
The thrombogenic coronary milieu in patients 
with an acute coronary syndrome (ACS), coupled with 
the well-known propensity for hyper-coagulability in this 
patient subset and possible delayed re-endothelialization 
with drug-eluting stents (DES) has resulted in concerns 
of an increased risk of stent thrombosis after 
implantation of these devices in patients with ACS(7). 
Moreover, several prior studies have identified unstable 
angina as a risk factor for restenosis after bare metal 
stent (BMS) implantation(8,9). 
The Arterial Revascularization Therapies Study 
part II (ARTS II) is a multicenter, European, open-label, 
non-randomized trial evaluating the safety and efficacy 
of SES as compared to the previous results of the 
randomized ARTS I trial(10). Thirty six percent of the 
607 patients enrolled in ARTS II had unstable angina at 
presentation.
We sought to evaluate whether clinical outcome in this 
subset of patients was comparable to that observed in 
patients with stable angina in the attempt to evaluate 
whether the net efficacy/safety profile of SES is affected 
by acuity of clinical presentation. The one year outcome 
in ARTS II, stratified into stable versus unstable 
presentation, was also compared to that of patients 
undergoing percutaneous or surgical revascularization in 
ARTS I, in keeping with the original design of the study. 
METHODS
Study design 
ARTS II study design has been previously reported(11,12). 
Briefly, patients were consecutively enrolled via a central 
telephone service, after stratification by clinical site to ensure 
the inclusion of at least one third of patients undergoing three-
vessel intervention.  
Selection of patients 
Patients were eligible for coronary revascularization if they had 
either stable angina (Canadian Cardiovascular Society class I, II, 
III, or IV), unstable angina (Braunwald class IB, IC, IIB, IIC, 
IIIB, or IIIC), or if they had silent ischemia and at least two new 
lesions located in different major epicardial vessels and/or their 
side branches (not including the left main coronary artery) that 
were potentially amenable to stent implantation. Patients were 
required to have multivessel disease with the need for treatment 
of the left anterior descending (LAD) artery and at least one 
other significant lesion (>50% diameter stenosis) in another 
major epicardial coronary artery. One totally occluded major 
epicardial vessel could also be included. The stenosis had to be 
amenable to stenting using a stent with a diameter of 2.5 to 
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3.5mm and length of 13 to 33mm, without any restriction on the 
total stent length implanted.  
Patients with any previous coronary intervention, left main 
coronary disease, overt congestive heart failure or a left 
ventricular ejection fraction of less than 30 percent were 
excluded. Additional exclusion criteria included a history of a 
cerebrovascular accident and STEMI in the preceding week or 
with persistent elevation of CK. Measurement of troponin was 
not mandatory at screening. Patients with chest pain lasting 
longer than 30 minutes within the preceding 12 hours were also 
excluded if CK was equal or more than 2 times upper normal 
limit. 
Written, informed consent was obtained from each patient prior 
to enrolment.  The study was approved by the ethics committee 
of each participating site.
Procedures and Post-Intervention Medications 
All interventions were performed according to current standard 
guidelines and the final interventional strategy, including the use 
of glycoprotein IIb/IIIa inhibitors, was left entirely to the 
discretion of the operator, except for the stent utilization. All 
patients were advised to maintain aspirin lifelong. Clopidogrel 
300 mg as a loading dose, or Ticlopidine, administered at a dose 
of 500 mg, was to be started at least 24 hours before the 
procedure. Clopidogrel 75 mg per day or Ticlopidine 250 mg 
twice a day was prescribed for at least two months after 
revascularization.  
Study Objectives and Endpoints 
The primary objective of this ARTS II sub-analysis was to 
compare the safety and effectiveness of coronary stent 
implantation using sirolimus-eluting stents in patients with 
unstable angina with that of patients undergoing similar 
treatment for the presence of stable angina. For the purpose of 
the present analysis, patients with stable angina and silent 
ischemia (defined as ‘stable angina’ group) were compared to 
unstable angina, as previously reported in ARTS I(13). The 
primary outcome measure was the incidence of major adverse 
cardiac and cerebrovascular events (MACCE) at one year 
comprising all-cause death, any cerebrovascular event, non-fatal 
myocardial infarction, or any repeat revascularization (either 
percutaneous or surgical) (contemporary comparison). 
The secondary objectives of this study are to compare 1-year 
MACCE in the ARTS II patients, stratified according to clinical 
presentation (stable versus unstable) to that of patients with 
stable and unstable angina who were randomized to either 
percutaneous bare metal stent implantation or CABG in the 
ARTS I trial (historical comparison).
End point definitions 
All deaths were considered cardiac unless a non cardiac origin 
was established clinically or at autopsy. Death from all causes 
was reported. 
Cerebrovascular events were divided into three main categories: 
stroke, transient ischemic attack (TIA), and reversible ischemic 
neurologic deficit (RIND). In the first seven days after the 
intervention, a definite diagnosis of myocardial infarction was 
made if there was documentation of new abnormal Q waves 
(according to the Minnesota code) and either a ratio of serum 
creatine kinase MB (CK-MB) iso-enzyme to total cardiac enzyme 
that was greater than 0.1 or a CK-MB value that was 5 times the 
upper limit of normal (ULN)1, 11, 12 Serum creatine kinase and CK-
MB iso-enzyme concentrations were measured 6, 12, and 18 
hours after the intervention. Beginning eight days after the 
intervention (the length of the hospital stay after surgery), 
either abnormal Q waves or enzymatic changes were sufficient 
for a diagnosis of myocardial infarction. This dual method of 
defining myocardial infarction was developed for ARTS I to 
address the difficulty of diagnosing a myocardial infarction after 
cardiac surgery. A myocardial infarction was confirmed only 
after the relevant electrocardiograms had been analyzed by the 
electrocardiographic core laboratory and adjudicated by an  
Table 1. Baseline Patient Demographics 
Patient
Parameters
Measured 
UA (N=221 
patients) 
SA (N=386 
patients)
Difference 
[95% CI] P-value
Age (years) N 221 386   
mean ± SD 62.6±10.5 62.9±9.1 -0.3 [-1.9,1.3] 0.70 
(min - max) (35 - 80) (37 - 80)   
EF (%) N 204 334   
mean ± SD 60.0±11.5 60.3±11.6 -0.3 [-2.3,1.7] 0.76 
(min - max) (30 - 97) (30 - 88)   
BMI (kg/m2) N 220 381   
mean ± SD 27.1±4.2 27.8±4.0 -0.7 [-1.4,0.0] 0.036 
(min - max) (15.2 - 42.9) (18.6 -43.0)   
Number  
of Men 
74.2%
(164/221) 
78.0%
(301/386) 
-3.8%
[-10.9%,3.3%] 0.32 
Diabetes 
Mellitus 
23.1%
 (51/221) 
28.0%
(108/386) 
-4.9%
[-12.0%,2.2%] 0.21
Hypertension 
62.0%
 (137/221) 
70.2%
(271/386) 
-8.2%
[-16.1%,-0.4%] 0.039 
Dislypidemia 
65.2%
(144/221) 
78.9%
(303/384) 
-13.7%
[-21.2%,-6.3%] <0.001
History of CVA 
1.4%
(3/221) 
0.5%
(2/385) 
0.8%
[-0.8%,2.5%] 0.36 
Family history 
of MI/SD <55 yr 
35.5%
(78/220) 
36.2%
(139/384) 
-0.7%
[-8.7%,7.2%] 0.86
PVD
7.2%
(16/221) 
6.8%
(26/385) 
0.5%
[-3.8%,4.7%] 0.87 
Previous MI 
48.0%
(106/221) 
26.7%
(103/386) 
21.3%
[13.4%,29.2%] <0.001 
Previous CABG 
0.0%
(0/221) 
0.0%
(0/386) 
0.0%
[0.0%,0.0%]  
Previous PTCA 
0.9%
(2/221) 
0.3%
(1/386) 
0.6%
[-0.7%,2.0%] 0.30 
Carotid Surgery 
1.4%
(3/221) 
1.3%
(5/385) 
0.1%
[-1.8%,2.0%] 1.00 
COPD
2.7%
(6/221) 
4.2%
(16/385) 
-1.4%
[-4.4%,1.5%] 0.50 
Previous
Smoker 
34.8%
(77/221) 
44.3%
(171/386) 
-9.5%
[-17.5%,-1.5%] 0.026 
Current Smoker 
24.4%
(54/221) 
16.3%
(63/386) 
8.1%
[1.4%,14.9%] 0.018 
Unstable Angina 
100.0%
(221/221) ... ... ...
Braunwald I 
23.1%
(51/221) ... ... ...
Ib
19.9%
(44/221) ... ... ...
Ic
3.2%
(7/221) ... ... ...
Braunwald II 
49.3%
(109/221) ... ... ...
IIb
38.0%
 (84/221) ... ... ...
IIc
11.3%
(25/221) ... ... ...
Braunwald III 
27.6%
(61/221) ... ... ...
IIIb 
20.8%
(46/221) ... ... ...
IIIc
6.8%
(15/221) ... ... ...
Stable Angina ...
83.7%
(323/386) ... ...
CCS I ...
11.1%
 (43/386) ... ...
CCS II ...
42.2%
(163/386) ... ...
CCS III ...
27.7%
(107/386) ... ...
CCS IV ...
2.6%
(10/386) ... ...
Silent Ischaemia ...
16.3%
(63/386) ... ...
Single VD 
0.0%
(0/221) 
0.5%
(2/386) 
-0.5%
[-1.2%,0.2%] 0.54 
Double VD 
47.5%
(105/221) 
45.3%
(175/386) 
2.2%
[-6.1%,10.4%] 0.61 
Triple VD 
52.5%
(116/221) 
54.1%
(209/386) 
-1.7%
[-9.9%,6.6%] 0.74 
Difference = unstable angina – stable angina; CI - Confidence Interval; 
CI - Diff ± 1.96 * SE; SE - sqrt(p1*q1/n1 + p2*q2/n2) ; CVA= 
CerebroVascular Accident; MI = Myocardial Infarction; COPD= chronic 
obstructive pulmonary disease; CABG =Coronary Artery Bypass Graft; 
PVD= periferal vascular disease; BMI= body mass index; EF= ejection 
fraction; VD= vessel diseased; PTCA = Percutaneous Transluminal 
Coronary Angioplasty; Braunwald = Braunwald Classification; CCS = 
Canadian Cardiovascular Society Classification; SD: sudden death 
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independent clinical-events committee. For the purpose of this 
analysis, to explore whether the current definition of MI may 
artificially contribute to minimize the impact of clinical acuity on 
outcome, the occurrence of non-Q Wave MI in the first seven 
days after the index procedure has also been reclassified based 
on any CK or CK-MB elevation or a CK or CK-MB value that was 
three times or more the ULN, in keeping with current ACC/AHA 
and ESC recommendations(14,15). All repeat revascularization 
procedures were recorded. Events were counted from the time 
of the initial procedure. Thrombotic occlusions were defined 
according to the protocol as either by angiographic 
documentation of a complete occlusion (TIMI flow 0 or 1) or 
angiographic documentation of a flow limiting thrombus (TIMI 
flow 1 or 2).
To allow cross comparisons with other contemporary 
investigations(16), stent thrombosis was also determined as the 
occurrence of any of the following events: angiographic 
documentation of partial or total stent occlusion detected within 
30 days of the procedure (an acute clinical ischemic event in 
addition to angiographic documentation had to be present when 
the event occurred after 30 days), or sudden cardiac death or 
post-procedural MI after successful stent implantation not 
clearly attributable to another coronary lesion. All events have 
been reviewed and adjudicated by an independent clinical-
events committee. 
Statistical analysis 
Continuous variables are shown as mean � SD if not otherwise 
stated and were compared using Student’s two-sample t-test. 
Categorical variables are presented as percentages and 
compared with the �2test. Comparison among three groups was 
performed using a general linear model. Survival curves were 
generated by the Kaplan-Meier method and survival amongst 
groups was compared using the log-rank test. Proportional 
hazards and Weibull models were used to assess risk reduction 
of adverse events. For the stable versus unstable comparison 
within the ARTS II trial, multivariable analysis, considering all 
variables reported in Tables 1 and 2 with a p-value of less or 
equal than 0.10, was performed to adjust for possible 
confounders and identify whether clinical presentation was an 
independent predictor of adverse events. Moreover, a 
simultaneous interaction test of the predicting variables with 
clinical presentation was performed. For the comparison of 
ARTS II versus ARTS I, multivariate analysis considering all 
variables reported in Table 3 with a p-value of less or equal than 
0.1 were considered in order to obtain the adjusted hazard ratio. 
Co-linearity in the model was investigated using a correlation 
matrix and by inspection of the estimate parameters obtained in 
the model. Patients lost to follow-up were considered at risk 
until the date of last contact, at which point they were censored. 
Probability was significant at a level of <0.05. All statistical tests 
were 2-tailed. Statistical analysis was performed with SAS V8.02, 
(SAS institute, Cary, NC, USA). 
RESULTS
Patients
Between February 2003 and November 2003, 607 
patients at 45 participating centers were treated. Table
1 presents their baseline demographic characteristics 
based on clinical presentation. The patients were 
predominantly males with preserved left ventricular 
function; three-vessel disease was present in more than 
50% of the cases. Patients with unstable angina had a 
slightly lower body mass index and were less frequently 
affected by hypertension and hypercholesterolemia. The 
incidence of previous myocardial infarction in the 
unstable group was almost double when compared to the 
stable patient group. Current smoking was more frequent 
in unstable as compared to stable patients. The two 
groups were otherwise comparable for all other baseline 
characteristics, including co-morbidities. 
Table 2. Hospital Stay, Procedural Characteristics and 
Medications 
Parameters
Measured 
UA
(N=221 
patients 
N=794 
Lesions) 
SA  
(N=386 
patients
N=1365 
lesions) 
Difference 
[95% CI] 
P
value 
Per Patient Analysis
Hospital Stay  Ds
mean ± SD 6.1±4.6 4.8±3.9 1.3 [0.6,2.0] <0.001 
(min - max) (1 - 37) (1 - 36)   
Ds to Procedure 
since Enrolment* 
mean ± SD 0.1±0.5 0.1±1.3 0.0 [-0.2,0.2] 0.92 
(min - max) (-1 - 4) (-7 - 21)   
Days in Hospital 
since Procedure 
mean ± SD 3.7±3.1 3.2±2.4 0.5 [0.1,1.0] 0.021 
(min - max) (1 - 31) (1 - 30)   
Duration of 
Procedure (min) 
mean ± SD 86.2±46.3 84.5±41.4 1.7 [-5.5,8.9] 0.64 
(min - max) (10 - 281) (16 - 293)   
N. of lesions > 
50% DS 
mean ± SD 3.6±1.3 3.5±1.3 0.1 [-0.2,0.3] 0.62 
(min - max) (2 - 8) (1 - 8)   
N. of vessels with 
a lesion > 50%  
mean ± SD 2.5±0.5 2.5±0.5 0.0 [-0.1,0.1] 0.79 
(min - max) (2 - 3) (1 - 3)   
N. of stented 
lesions 
mean ± SD 3.2±1.2 3.2±1.1 0.0 [-0.2,0.2] 0.70 
(min - max) (0 - 7) (0 - 8)   
N. of stents 
implanted     
mean ± SD 3.6±1.5 3.7±1.5 0.0 [-0.3,0.2] 0.72 
(min - max) (0 - 9) (0-11)   
Average stent 
lenght (mm)     
mean ± SD 19.4±3.5 19.6±3.5 -0.3[-0.8,0.3] 0.38 
(min - max) (13-30) (11-31)   
Total stent lenght 
(mm)     
mean ± SD 71.3±32.1 73.2±32.1 -1.9 [-7.2, 3.4] 0.48 
(min - max) (18-209) (12-253)   
IIB/IIIA 
inhibitors (%) 
32.6
(72/221) 
32.4
(125/386) 
0.2%
[-7.5%,7.9%] 1.00 
Lipid lowering 
agent (%) 
88.2
(195/221) 
90.7
(350/386) 
-2.4 %
[-7.6%,2.7%] 0.33
�-blockers (%) 
82.4
(182/221) 
74.9
(289/386) 
7.5%
[0.9%,14.1%] 0.034 
ACE-inhibitors
(%)
57.9
128/221) 
45.6
(176/386) 
12.3%
[4.1%, 20.5%] 0.004
Per Lesion Analysis (%)
Ostial lesions 4.7 4.1 
0.7%
[-1.2%, 2.5%] 0.50 
Moderate to 
heavy  Ca++ 27.4 33.4 
-6.0%
[-10.1%, -1.9%] 0.005
Thrombus  
present 1.2 0.2 
1.0%
[0.2%, 1.8%] 0.003 
Occlusion <3 
months 0.3 0.1 
0.2%
[-0.2%, 0.6%] 0.56
Occlusion .>3 
months 2.3 2.4 
-0.1%
[-1.4%, 1.2%] 1.00 
Classification:     
Type A/B1 33.0 28.6 
4.5%
 [0.4%, 8.6%] 0.032 
Type B2/C 67.0 71.4 
-4.5%
[-8.6%, -0.4%] 0.032 
* In ARTS2 in total 6 patients have been enrolled post procedure. 
Numbers are % (counts/available field sample size) or mean ± 1 
Standard Deviation. SD = Standard Deviation. Difference = unstable 
angina - stable angina. CI - Confidence Interval. CI - Diff ± 1.96 * SE. SE 
- sqrt(p1*q1/n1 + p2*q2/n2. SA= stable angina; UA= unstable angina. 
Overall hospital stay was on average 1.3 days longer in 
unstable patients (Table 2). Coronary lesions in patients 
with unstable angina were less frequently calcified and 
more frequently of type A/B1 than of type B2/C, while 
thrombus was more commonly observed in this group. 
There was no other difference in procedural 
characteristics between the two groups, including use of 
glycoprotein IIb/IIIa inhibitors (Table 2).
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Table 3. 
Unstable angina group Stable angina group 
ARTS II 
SES  
(221 pts , 
794 les) 
ARTS II 
BMS  
( 226 pts, 
628 les)
ARTS II 
CABG  
(224 pts, 
621 les)
P
value
ARTS II 
SES  
(386 pts , 
1366 les)
ARTS II 
BMS  
(374 pts, 
978 les)
ARTS II 
CABG  
(n= 381)
P
value
Male sex (%) 74.2 80.1 75.1 0.27 78 75.1 76.6 0.65 
Age, y (mean±SD) 62.6�10.5 61�9.6 60.9�9.5 0.12 62.9�9.1 60.5�9.7 61.4�9.2 0.001
BMI (Kg/m2) (mean±SD) 27.1�4.2 26.7�3.4 27.1�3.8 0.50 27.8�4 27.5�3.8 27.5�3.6 0.49
Diabetes (%) 23.1 18.6 14.2 0.055 28 18.7 16.8 <0.001 
Hypertension (%) 62 49.1 43.1 <0.001 70.2 42 46.1 <0.001 
Hypercholesterolemia (%) 65.2 51.3 54 0.007 78.9 61.9 59.7 <0.001 
Family history (%) 35.5 35.3 42 0.26 36.2 41.5 42 0.20 
Current smoking (%) 24.4 32 47.6 0.10 16.3 25.5 21.6 0.008 
Previous MI (%) 48 45.1 47.6 0.81 26.7 43.9 38.7 <0.001 
Stable angina (%) … … … … … … … …
     CCS 1 … … … … 11.1 7.8 7.6 0.16 
     CCS 2 … … … … 42.2 41.7 41.8 0.99 
     CCS 3 … … … … 27.7 35 37.4 0.01 
     CCS 4 … … … … 2.6 5.9 5.5 0.05 
Silent ischemia (%) … … … … 16.3 9.6 7.6 <0.001 
Unstable Angina (%) … … … … … … … …
     Braunwald I 23.1 22.6 19.1 0.54 … … … …
     Braunwald Ib 19.9 15.9 16.0 0.47 … … … …
     Braunwald Ic 3.2 6.6 3.1 0.14 … … … …
     Braunwald II 49.3 50.4 49.8 0.97 … … … …
     Braunwald IIB 38 34.1 36.9 0.68 … … … …
     Braunwald IIC 11.3 16.4 12.9 0.29 … … … …
     Braunwald III 27.6 27 31.1 0.58 … … … …
     Braunwald IIIb 20.8 22.6 26.2 0.39 … … … …
     Braunwald IIIc 6.8 4.4 4.9 0.53 … … … …
Ejection fraction (%) 60�11.5 62�13.1 58.7�13.6 0.03 60.3�11.6 60.3�11.7 61.3�2.9 0.44
No. vessel diseased 2.5�0.5 2.3�0.5 2.3�0.6 <0.001 2.5�0.5 2.2�0.5 2.3�0.5 <0.001
2-vessel (%) 47.5 68.3 61.8 <0.001 45.3 68.7 68.8 <0.001 
3-vessel (%) 52.5 28.9 33.2 <0.001 54.1 26.6 28.2 <0.001 
RCA 31 30.4 28.9 0.70 28.0 31.6 29.8 0.16 
LAD 41.1 41.2 41.2 0.99 41.8 38.2 41.0 0.20 
CX 28 28.2 29.7 0.74 30.2 30.2 29.1 0.82 
No. Treated lesions 3.2�1.2 2.6�1.0 2.9�1.0 <0.001 3.2�1.1 2.4�0.9 2.8�1 <0.001
Type A/B1 lesions 33 32.2 38.6 0.033 28.6 32.4 37.9 <0.001 
Type B2/C lesions (%) 67 67.8 61.4 0.033 71.4 67.6 62.1 <0.001 
No. of stent implanted 3.6�1.5 2.8�1.2 … <0.001 3.7�1.5 2.8�1.3 ... <0.001 
Total stent lengh (mm) 71.3�32.1 47.5�19.3 … <0.001 73.2�32.1 47.6�23 ... <0.001 
L length <10mm (%) 61.8 67.9 67 0.039 60.3 64.1 68.9 <0.001 
L length 10-20 mm (%) 26.4 24.4 27.2 0.52 27.7 29.3 24.1 0.029 
L length >20 mm (%) 11.7 7.7 5.8 <0.001 11.9 6.6 7.0 <0.001 
Occlusion < 3 mos (%) 0.3 3.0 4.3 <0.001 0.1 3.2 3.9 <0.001 
Occlusion > 3 mos (%) 2.3 0.2 1.8 <0.001 2.4 0.7 0.8 <0.001 
Mod. to heavy Ca++(%) 27.4 16.6 15.4 <0.001 33.4 18.1 14.4 <0.001 
Thrombus present (%) 1.2 1.5 1.7 0.68 0.2 1 1.3 0.001 
Maximal dilatation (atm) 16.4�2.8 14.9�2.7 ... <0.001 16.3�2.9 14.5�2.8 ... <0.001 
Lipid lowering agent (%) 88.2 33.0 28.5 <0.001 90.7 42.2 33.6 <0.001 
�-blockers (%) 82.4 58.9 57.9 <0.001 74.9 60.5 53.0 <0.001 
ACE-inhibitors (%) 57.9 21.9 16.7 <0.001 45.6 28.1 14.6 <0.001 
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Table 4. Clinical outcome in ARTS II according to clinical presentation 
UNSTABLE ANGINA
(N=221 PATIENTS)
STABLE ANGINA   
(N=386 patients) 
RELATIVE RISK
[95% CI] P-VALUE
30-day Outcome (%)     
NON HIERARCHICAL 
COMPLICATIONS
MACCE* 2.7 (6/221) 3.4 (13/386) 0.81 [0.31, 2.09] 0.81 
MACCE† 5.4 (12/221) 5.2 (20/386) 1.05 [0.52, 2.10] 1.00 
MACCE‡ 19.9 (44/221) 19.9 (71/386) 1.00 [0.72, 1.39] 1.00 
Death/CVA/MI* 0.9 (2/221) 1.0 (4/386) 0.87 [0.16, 4.73] 1.00 
Death/CVA/MI† 4.1 (9/221) 4.1 (16/386) 0.98 [0.44, 2.19] 1.00
Death/CVA/MI‡ 19 (42/221) 19.2 (74/386) 0.99 [0.71, 1.39] 1.00
Death 0.0 (0/221) 0.0 (0/386) … … 
CVA 0.0 (0/221) 0.3 (1/386) … 1.00 
Myocardial infarction† 4.1 (9/221) 3.9 (15/386) 1.05 [0.47, 2.35] 1.00 
-Q-Wave MI 0.9 (2/221) 0.8 (3/386) 1.16 [0.20, 6.92] 1.00 
-Non Q-Wave MI* 0.0 (0/221) 0.0 (0/386) … …
-Non Q-Wave MI† 3.6 (8/221) 3.1 (12/386) 1.16 [0.48, 2.8] 0.81
-Non Q-Wave MI‡ 18.6 (41/221) 18.1 (70/386) 1.05 [0.72, 1.45] 0.91 
Revascularization 2.3 (5/221) 2.6 (10/386) 0.87[0.3, 2.52]  1.00 
CABG 1.4 (3/221) 1.3 (5/386) 1.05 [0.25, 4.34] 1.00 
RPTCA 0.9 (2/221) 1.3 (4/386) 0.87 [0.16, 4.73] 1.00 
Sub-acute occlusion 0.5 (1/221) 1 (4/386) 0.70 [0.14, 3.57] 1.00 
Stent thrombosis 0.9 (2/221) 1.5 (6/386) 0.58 [0.12, 2.90] 0.77 
365-day Outcome     
HIERARCHICAL
COMPLICATIONS
MACCE* 10.4 (23/221) 10.4 (40/386) 1.00 [0.62, 1.63] 1.00 
MACCE† 12.7 (28/221) 11.9 (46/386) 0.80 [0.40, 1.60] 0.59 
MACCE‡ 27.1 (60/221) 24.9 (96/386) 1.09[0.83, 1.44] 0.56 
Death 0.9 (2/221) 1.0 (4/386) 0.87 [0.16, 4.73] 1.00 
CVA without death 0.5 (1/221) 1.0 (4/386) 0.44 [0.05, 3.88] 0.66 
MI without Death or 
CVA‡ 19 (42/221) 18.9 (73/386) 1.00 [0.72, 1.29] 1.00 
   -Q-Wave MI 0.9 (2/221) 0.8 (3/386) 1.16 [0.20, 6.92] 1.00 
   -Non Q-Wave MI*        0.0 (0/221)      0.5 (2/386) …      0.54 
   -Non Q-Wave MI† 2.7 (6/221) 3.4 (13/386)      0.82 [0.16, 4.73]   0.72 
   -Non Q-Wave MI‡ 19 (42/221) 18.7 (72/386)      1.02 [0.72, 1.44]      0.91 
Revascularization 
without Death or CVA 
or MI 
8.1 (18/221) 7.0 (27/386) 1.16 [0.66, 2.07] 0.63 
CABG without Death or 
CVA or MI 2.3 (5/221) 1.8 (7/386) 1.25 [0.40, 3.88] 0.77 
RPTCA without Death or 
CVA or MI 5.9 (13/221) 5.2 (20/386) 1.14 [0.58, 2.24] 0.71 
NON HIERARCHICAL 
COMPLICATIONS
Death/CVA/MI* 2.3 (5/221) 3.4 (13/386) 0.67 [0.24, 1.86] 0.62 
Death/CVA/MI† 5.0 (11/221) 6.2 (24/386) 0.80 [0.40, 1.60] 0.59 
Death/CVA/MI‡ 20.4 (45/221) 20.7 (80/386) 0.98 [0.71, 1.36] 1.00 
CVA 0.5 (1/221) 1 (4/386) 0.44 [0.05, 3.88] 0.66 
Myocardial Infarction* 0.9% (2/221) 1.6% (6/386) 0.58 [0.12, 2.86] 0.72 
Myocardial Infarction† 4.1 (9/221) 4.7 (18/386) 0.87 [0.40, 1.91] 0.84 
Myocardial Infarction‡ 19.5 (43/221) 19.4 (75/386) 1.00 [0.72, 1.40] 1.00 
Revascularization 9.0% (20/221) 8.0% (31/386) 1.13 [0.66, 1.93] 0.65 
CABG 2.7 (6/221) 1.8 (7/386) 1.5 [0.51, 4.40] 0.56 
RPTCA 6.3 (14/221) 6.5 (25/386) 0.98 [0.52, 1.84] 1.00 
Late occlusion 0% (0/221) 0.5% (2/386) 0.44 [0.05, 3.88] 0.54 
Stent thrombosis 0.9% (2/221) 1.8% (7/386) 0.50 [0.10, 2.38] 0.59 
*: based on protocol mandated MI definition
†: based on MI definition of CK/CK-MB 3×upper limit of normal in one or more sample(s) 
‡: based on MI definition of any CK/CK-MB above upper limit of normal in one or more sample(s)
MI: Myocardial infarction; CVA: cerebrovascular accident; CABG: coronary artery bypass grafting; RPTCA: re-PTCA;  
Baseline demographic, procedural characteristics and 
medications at discharge according to clinical 
presentation in ARTS II as compared to ARTS I are 
reported in Table 3.
ARTS II 30-day Outcomes 
No deaths occurred in the first 30 days in either group. 
There were no significant differences in patients with 
unstable with respect to those with stable angina in the 
cumulative incidence of MACCE (death, infarction, 
cerebrovascular accident or repeat revascularisation) 
during the first 30 days irrespective of the applied 
definition for myocardial infarction (Table 4). The same 
was true when each component of the MACCE was 
separately analysed (Table 4). Up to discharge, three 
angiographically confirmed thrombotic occlusions 
occurred in the stable angina group (3/386, 0.8%) 
versus none in unstable angina patients (p=0.56). From 
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discharge to 30 days, one additional thrombotic occlusion 
in each group was observed resulting in a cumulative 
rate of 1% in SA versus 0.5% in UA group (RR 0.44 
[0.05, 3.88]; p=0.66). 
ARTS II 365-day outcomes 
At one year the cumulative incidence of MACCE was 
identical in the two groups (10.4%, RR 1.00 [95% CI: 
0.62-1.63]; p=1.00), reflecting a similar rate death 
(0.9% vs. 1.0%), cerebrovascular accident (0.5% vs. 
1.0%), myocardial infarction (0.9% vs. 1.3%) and repeat 
revascularisation (8.1% vs. 7.0%) in unstable and stable 
angina groups, respectively. Unadjusted Kaplan-Meier 
estimates of MACCE, death, MI/CVA and TVR are shown 
in Figures 1A, 1B and 1C, respectively. After 
reclassifying peri-procedural non-Q-wave MI according to 
current recommendations(14,15), the overall rate of MI 
at one year remained similar in patients with stable 
angina (4.7%) as compared to the group of UA patients 
(4.1%; p=0.84), as was the case for the cumulative 
incidence of MACCE based on the revised MI definition 
(11.9% in SA vs. 12.7% in UA group, p=0.80). Defining 
non Q-wave MI as any CK/CK-MB elevation beyond the 
upper limit of normal resulted again in a remarkably 
similar, although unadjusted, outcome in stable as 
compared to unstable patients in terms of cumulative MI 
(19.4% vs. 19.5%, p=1.00) or MACCE (24.9% vs. 
27.1%; p=0.56), respectively.  
Figure 1. Kaplan-Meier curves 
A
B
C
Kaplan-Meier curves reporting (A) MACCE free Survival; (B) 
Death/CVA/MI free survival and (C) freedom from repeat 
revascularization in ARTS II study stratified into unstable (bold line) and 
stable angina (thin line).
Sub-group and Multivariable Analysis  
Focusing on higher risk patients presenting with 
Braunwald class II or III (n=170), their outcome in terms 
of MACCE at 30 days (2.4% vs. 3.4%; p=0.72) or one 
year (10% vs. 10.4%; p=0.97) did not differ compared 
to SA group, respectively. Based on CK/CK-MB elevation 
equal to or more than three times the upper limit of 
normal as definition of non-Q-wave MI, the MACCE rate 
was 4.7% and 12.4% in patients with Braunwald class II 
or III as compared to 5.2% (p=0.99) and 11.9% 
(p=0.99) in SA patients at 30 and 365 days, respectively. 
Finally, considering any CK/CK-MB elevation, the MACCE 
rate was 17.1% vs. 19.9% (p=0.84) at 30 days and 
24.7% vs. 24.9% (p=0.94) at one year in UA class II or 
III compared to SA patients.
Using the Weibull modelling and after adjusting for 
covariates as reported in Tables 1 and 2, the clinical 
status failed to become an independent predictor of 
MACCE (HR 0.94 [95% CI: 0.41 to 2.12]; p=0.88, HR 
0.87 [95% CI: 0.52 to 1.48]; p=0.61 and HR 0.88 [95% 
CI: 0.62 to 1.25]; p=0.88 based on peri-procedural non 
Q-Wave MI definition of CK/CK-MB elevation �5, �3 or 
�1 x the upper limit of normal, respectively). Similarly, 
no statistical interaction was noted between clinical 
status and the tested covariates in the model, 
irrespective of the applied peri-procedural MI definition 
(Figure 2).  
ARTS part II versus ARTS part I  
The cumulative incidence of MACCE, death/MI/CVA and 
revascularization at 1 year stratified according to clinical 
presentation in the SES group as compared to BMS or 
CABG group is shown in Figure 3. After adjustment for 
all confounders among those reported in Table 3, the 
MACCE rate observed in the ARTS II study remained 
consistently lower than that observed in the BMS group 
in stable (HR: 0.45 [95%CI: 0.16, 0.58], p=0.0004) or 
unstable patients (HR: 0.43 [95%CI: 0.18, 0.99], 
p=0.034) while it did not differ compared to the CABG 
group in stable (HR: 2.38 [95%CI: 0.33, 16.7], p=0.39) 
or unstable group (HR: 0.33 [95%CI: 0.03, 3.22], 
p=0.34) analyzed separately. 
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Figure 2. 
A
Hazard Ratios and 95% Confidence Intervals of Factors in the Multivariate Model by Anginal Status
(black: stable angina, white: unstable angina)
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B
Hazard Ratios and 95% Confidence Intervals of Factors in the Multivariate Model by Anginal Status
(black: stable angina, white: unstable angina)
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There was no observed interaction between the identified outcome predictors in the model and anginal status at presentation, irrespective of the peri-
procedural applied MI definition. A: results based on non-Q-Wave MI defined as any CK or CK-MB elevation �3 x the upper limit of normal are shown, with 
an overall p value of 0.66 for testing interaction. B: results based on non-Q-Wave MI defined as any CK or CK-MB elevation beyond the upper limit of 
normal are shown, with an overall p value of 0.58 for testing interaction
DISCUSSION
Despite the growing body of evidence supporting the 
benefit of DES in different patients/lesion subsets, 
information regarding their differential safety/efficacy 
profile in patients with stable versus unstable angina is 
scanty and in part contradictory. Patients undergoing 
coronary intervention for unstable atherosclerotic 
coronary lesions are known to present with a smaller 
atherosclerotic(17) but larger thrombotic burden as 
compared to stable angina patients. This justifies the 
need to evaluate whether these devices may perform 
differently in these two patient subsets. In the 
RESEARCH registry, where 52% of the population 
presented with acute coronary syndromes (ACS), 
patients with and without ACS benefited equally from 
SES implantation, with a relative risk reduction in the 
need for target vessel revascularisation at one year in  
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Figure 3. 
A
B
C
Kaplan-Meier curves out to one year in all three arms: (A) MACCE free 
Survival; (B) Death/CVA/MI free survival, (C) Freedom from repeat 
revascularization.Black: SES in ARTS II; Red: CABG in ARTS I, Blue: BMS 
in ARTS I. Bold line: unstable angina, thin line: stable angina 
both groups when compared to BMS of 70% and 61% 
respectively(6).  
Similar information has been provided by the STRATEGY 
trial, where patients undergoing primary intervention for 
acute myocardial infarction allocated to receive SES had 
a 70% relative reduction of TVR as compared to the BMS 
group(5). In both studies, the rate of thrombotic 
occlusion was low and not different in the SES with 
respect to control groups, suggesting that the safety 
profile of SES is maintained in patients with ACS.
In a sub-analysis of the TAXUS IV trial, an even lower 
restenosis rate was reported in patients with ACS as 
compared to stable patients receiving paclitaxel-eluting 
stents (PES)(7). However, patients with ACS treated with 
PES had a trend toward a higher rate of stent thrombosis 
at 30 days (0.8% vs. 0%, p=0.06) and of concern 
cardiac death at one year also trended higher in patients 
with ACS receiving PES (2.5% vs. 0.7%; p=0.051)(7). 
Thus, whether there is a specific risk in patients with ACS 
undergoing DES implantation remains largely debatable 
based on the available data.  
In this sub-analysis of the ARTS II trial, the hypothesis 
that SES may perform differently according to clinical 
presentation (i.e. stable vs. unstable), which in itself 
reflects a difference in biology and coronary plaque 
composition, has been formally tested.  
The main conclusion of this analysis is that elective 
multivessel patients with unstable angina, undergoing 
SES-supported coronary revascularization show a similar 
short and medium-term outcome with respect to those 
treated for stable ischemic syndromes. This conclusion is 
based mainly on the similar incidence of major adverse 
events in these two groups of patients. It is further 
reinforced by the observation that each individual 
component of MACCE i.e. death, re-infarction, CVA and 
repeat revascularization was very similar at 30 days as 
well as at one year in these two groups of patients. The 
rate of MI and the cumulative rate of MACCE remained 
remarkably similar at both univariate and multivariable-
adjusted analysis between patients with SA and UA after 
reclassification of MI based on elevation of CK/CK-MB 3× 
or even 1× the upper limit of normal. Focusing on higher 
risk patients, identified according to class II or III of 
Braunwald classification, their short and long-term 
outcome was consistently similar compared to stable 
group.
Finally, the rate of thrombotic occlusion, although not 
statistically different in the two groups of patients, was 
actually numerically lower in unstable angina patients, 
confirming previous findings(5,6).  
These results, based on a contemporary cohort of 
patients, were supported by the comparison of outcomes 
in ARTS II versus ARTS I, stratified according to clinical 
presentation. When adjusted for the baseline and 
procedural imbalance, the MACCE rate was significantly 
lower in both stable and unstable patients in the ARTS II 
with respect to those treated with BMS in ARTS I, while 
no difference was noted with respect to patients 
allocated to CABG, irrespective of stable or unstable 
presentation. The main analysis of ARTSII versus ARTSI 
based on a Bayesian statistical approach was recently 
reported(12). The results suggested that the use of SES 
in patients undergoing multivessel intervention is 
equivalent to the rate of major adverse events as 
compared to CABG treatment. In the present sub-
analysis, a conventional statistical approach was 
employed to separately compare the two contemporary 
patient cohorts (i.e. UA and SA) with the same historical 
cohorts of ARTS I. Our current findings suggest the 
efficacy and safety of SES implantation irrespective of 
stable versus unstable presentation in the context of 
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elective multivessel disease patients undergoing 
percutaneous intervention.  
Study Limitations 
Against the consistent background of favourable results 
when the treatment with SES is compared to BMS 
implantation in randomized trials so far conducted, the 
ARTS II trial should be regarded as an intermediate step 
before the fulfillment of the next era of randomized trials 
of DES-supported percutaneous revascularization versus 
surgery, such as CARDIA, FREEDOM and SYNTAX and 
COMBAT. When ARTS II was designed, the decision was 
taken to use an historical control (ARTS I) in order to 
assess the improvement in clinical outcome when SES 
are implanted. This decision precluded the possibility of 
adjusting for unmeasured confounders between the two 
groups of individuals and necessitates the use of the 
previous definitions of primary endpoint and patient 
classification, such as death (cardiac and non-cardiac), 
cerebrovascular accident (e.g. TIA, RIND, Stroke), 
myocardial infarction (Q-wave and CK�5XUNL), all 
revascularization (without TLR, TVR assessment), acute 
coronary syndrome (use of original Braunwald 
classification without systematic troponin triage), or 
thrombotic stent occlusion (angiographic definition). In 
this study the antiplatelet regimen was different from 
ARTSI due to the mandatory loading dose with 
thienopyridines administrated 24 hours prior to the 
intervention. This may have contributed in part to the 
more favorable outcome of ARTS II in comparison with 
ARTS I-BMS. Moreover, whether the neutral impact of 
clinical instability on outcome here observed is 
reproducible in the context of non-systematic 
thienopyridines pretreatment remains to be tested. 
Similarly, our results reasonably apply to medium-low 
risk ACS patients and cannot be extrapolated to patients 
with on-going or recent myocardial necrosis, 
haemodynamic instability or refractory ischemia since 
they were excluded from the study. Finally, despite the 
rate of confirmed or possible stent thrombosis was 
numerically even lower in the UA both at 30-days and 
one year compared to SA group, we cannot rule out the 
possibility that a type II error may have confounded our 
findings.
Conclusions
In elective patients with multivessel disease, undergoing 
SES-supported coronary revascularization after adequate 
pretreatment with thienopyridines, the rate of short and 
medium-term major adverse events is not affected by 
acuity of clinical presentation, irrespective of the applied 
definition of peri-procedural myocardial infarction. The 
performance of SES in patients with multivessel disease 
presenting with both stable and unstable coronary 
syndromes appears a promising alternative to 
conventional surgical revascularisation. This hypothesis, 
however, remains to be formally tested in the setting of 
a prospective randomized controlled trial.
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Use of GP IIb/IIIa inhibitors in ARTS II 
Contemporary Use and Impact on Outcomes of Glycoprotein 
IIb/IIIa Inhibitors in Patients Pre-treated with Thienopyridines 
Undergoing Multivessel Intervention with Sirolimus-eluting Stent 
Implantation
INSIGHTS INTO THE ARTERIAL REVASCULARIZATION THERAPIES STUDY PART II
Marco Valgimigli, MD, Philippe Gabriel Steg, MD, J. Wouter Jukema, MD, PhD, Ran Kornowski, MD, Amedeo Betriu, 
MD,PhD, Mark A de Belder, MD, FRCP, MD, Otmar Pachinger, MD, Lars Grip, MD, PhD, Johannes A.M. te Riele, MD, 
Kristel Wittebols, Msc, Hans-Peter Stoll, MD, Dick Goedhart, PhD, Patrick W. Serruys, MD,PhD 
Background: Current indications for glycoprotein IIb/IIIa inhibitors (GPI) after upfront administration of thienopyridines 
is debated and the efficacy of these drugs in patients treated with drug eluting stents (DES) remains mostly 
speculative.We investigated the contemporary use and impact on outcomes of GPI to support multiple sirolimus-eluting 
stent (SES) implantation in The Arterial Revascularization Therapies Study Part II (ARTS II). 
Methods: In 607 elective patients with multivessel disease (MVD) consecutively treated with SES after thienopyridines 
pretreatment, 197 (32.4%) received GPI infusion at the discretion of the treating physician. The two groups were well 
matched for most clinical characteristics, including indications to revascularization, medical history and presence of 
diabetes mellitus, while patients treated with GPI had a greater CAD extension and underwent a more aggressive 
revascularization with greater number of implanted stents and total/ C-type treated lesions.  
Results The 30-day event rate was similar in the two groups while at 1 year there was a non-significant excess of major 
adverse cardiac and cerebrovascular events (MACCE) (15.2% vs. 11%, respectively; HR 1.4 [95% CI: 0.89-2.2]; 
p=0.21), mainly driven by target vessel revascularization in patients treated with GPI. After adjustment with propensity 
analysis (C-statistic for the model 0.72, Hosmer–Lemeshow test p=0.53) the hazard ratio for MACCE was 1.08 [95% CI: 
0.71-1.8]; p=0.74. 
Conclusions: In MVD patients undergoing elective SES implantation after pre-treatment with thienopyridines, the use of 
GPI, mainly solicited by the presence of complex coronary anatomy, was not associated to an improved outcome after 
adjustment for a broad range of potential confounders. 
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INTRODUCTION
Glycoprotein (GP) IIb/IIIa inhibitors prevent 
periprocedural myocardial infarction and decrease long-
term cardiac mortality(1-3) in patients undergoing 
percutaneous coronary intervention (PCI). Developed 
and marketed in the pre-stent era, the GP IIb/IIIa 
inhibitors have been shown to be at least likewise 
beneficial in patients receiving bare metal stent 
implantation(4).
Yet, despite overwhelming evidence supporting their 
beneficial effects on short- and long-term outcomes, the 
rate of utilisation of GP IIb/IIIa inhibitors varies 
considerably among and within countries with a well 
documented discrepancy between recommendations and 
their actual use in clinical practice(5, 6).  
Two main issues contribute to generate uncertainties 
regarding the use of GP IIb/IIIa inhibitors: i) current 
indications to the use of these drugs after upfront 
administration of thienopyridines is widely debated based 
on recent data(7) and ii) the impact of these drugs in the 
contemporary era with liberal use of drug-eluting stents 
(DES) remains unclear and somewhat speculative(8), 
especially based on the paradoxical results reported in a 
recent sub-analysis of the TAXUV IV trial(9).  
The Arterial Revascularization Therapies Study Part 
II (ARTS II) was the first multicenter investigation to 
evaluate the safety and efficacy of the sirolimus-eluting 
stent (SES) in patients adequately pretreated with 
thienopyridines undergoing multi-vessel intervention 
(10). In this benchmark study, we investigated the 
contemporary use of GP IIb/IIIa inhibitors in the setting 
of multiple and often overlapping SES implantation, and 
their impact on short and long-term outcomes. 
METHODS
Study Design and Patient Population 
ARTS II was a multicenter, non-randomized, open labeled, 
stratified, non-inferiority trial designed to evaluate SES 
implantation in patients with multivessel disease using the 
surgical group of ARTS I as an historical control(10, 11). 
Patients, enrolled via a central telephone service, were stratified 
by clinical site in order to ensure the inclusion of at least 1/3 of 
patients with three-vessel disease. They were eligible for 
coronary revascularization if they had either stable angina, 
unstable angina or if they had silent ischemia and at least two 
new lesions located in different major epicardial vessels and / or 
their side branches (not including the left main coronary artery) 
that were potentially amenable to stent implantation using a 
CYPHER � sirolimus-eluting stent (Cordis, a Johnon and 
Johnson company, Warren, NJ ) with a diameter of 2.5 to 
3.5mm and length of 13 to 33mm. Patients were required to 
have multivessel disease with need for treatment of the left 
anterior descending (LAD) artery and at least 1 other significant 
lesion (>50% diameter stenosis) in another major epicardial 
coronary artery. One totally occluded major epicardial vessel 
could also be included.  
Patients with previous coronary intervention, left main coronary 
disease, overt congestive heart failure, left ventricular ejection 
fraction <30%, history of a cerebrovascular accident and STEMI 
in the preceding week or with persistent elevation of CK were 
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excluded. Measurement of troponin was not mandatory at 
screening. Patients with chest pain lasting longer than 30 
minutes within the preceding 12 hours were also excluded if the 
CK level was equal to or more than 2 times the upper limit of 
normal. 
Written, informed consent was obtained from each patient prior 
to enrolment. The ethics committee of each participating site 
approved the study. 
Procedures and Post-Intervention Medications 
All interventions were performed according to current standard 
guidelines and the final interventional strategy, including the use 
of GP IIb/IIIa inhibitors, was left entirely to the discretion of the 
operator. All patients were advised to maintain aspirin lifelong.
Clopidogrel 300 mg as loading dose, or Ticlopidine, administered 
at a dose of 500 mg, was to be started at least 24 hours before 
the procedure. Clopidogrel 75 mg per day or Ticlopdine 250 mg 
twice a day were prescribed for at least 2 months after 
revascularization. 
Study Objectives and Endpoints 
The main objectives of this analysis are i) to analyze 
contemporary use of GP IIb/IIIa inhibitors in patients 
undergoing multiple SES implantation after upfront 
administration of ADP receptor blockers and ii) to analyze the 
impact on short- and long-term outcome in patients who 
received GP IIb/IIIa inhibitors infusion before or during 
intervention compared to those who did not. The primary 
outcome measures were incidence of major adverse cardiac and 
cerebrovascular events (MACCE) at 30-days and 1 year 
comprising all-cause death, any cerebrovascular event, non-fatal 
myocardial infarction (MI), or any repeat revascularization and 
the incidence of the composite of death and non-fatal MI within 
both 30 and 365 days. Use of GP IIb/IIIa inhibitors was referred 
to as i) upstream when drug bolus and infusion were started 
outside the catheterization laboratory; ii) downstream, if drug 
bolus and infusion were started in the catheterization laboratory 
before the start of interventional treatment and iii) bailout, 
when drug bolus and infusion were started after the start of the 
procedure.
End point definitions 
Death from all causes was reported. A definite diagnosis of 
myocardial infarction was made if there was documentation of 
new abnormal Q waves (according to the Minnesota code) in 
association with a ratio of serum creatine kinase MB (CK-MB) 
isoenzyme to total cardiac enzyme that was greater than 0.1 or 
a CK or CK-MB value that was 3 times the upper limit of normal 
in one or more blood sample(s)(12). Serum CK and CK-MB 
isoenzyme concentrations were measured 6, 12, and 18 hours 
after the intervention. As a safety analysis, the end-points of 
major/minor bleedings were defined according to the criteria of 
the Thrombolysis in Myocardial Infarction Trial (13). 
Statistical Analysis 
Continuous variables are shown as mean�SD and were 
compared using Student’s unpaired t-test. Categorical variables 
are presented as counts and percentages and compared with 
the �2 test. Survival curves were generated by the Kaplan-Meier 
method and survival among groups was compared using the 
log-rank test. Cox proportional hazards models were used to 
assess risk reduction of adverse events.  
A propensity analysis was performed (14) by using a 
nonparsimonious logistic regression model (15) for the 
probability to receive GP IIb/IIIa inhibitors during index 
procedure based on all variables reported in table 1 and 2 with a 
p value of less than 0.30. The score was then incorporated into 
subsequent proportional-hazards models as a covariate; it was 
also was used to divide the population according to quartiles of 
propensity score. 
The Hosmer–Lemeshow goodness-of-fit test and the area under 
the curve were used to assess the fit of the model. All statistical 
tests were 2-tailed. Probability was considered to be significant 
at a level of <0.05. Statistical analysis was performed on 
Statistica 6.1 (Statsoft Inc. Tulsa, Oklahoma) or SAS V8.02, SAS 
institute, Cary (NC). 
Table 1. Baseline Characteristics of the Study Population 
Use of GP IIb/IIIa Inhibitors
Variables Yes
(N=197) 
No
(N=410) 
P
value
Age
(ys) 62�10 63�10 0.09
Males
 n.(%) 162 (82) 303 (74) 0.45 
Body Mass Index 
(kg/m2) 28�4 27�4 0.33
Diabetes  
n. (%) 54 (27) 105 (26) 0.63 
Non-insulin
dependent n. (%) 43 (80) 88 (84) 0.63 
 Insulin-dependent 
n. (%) 11 (20) 17 (16) 0.17 
Hypertension n. 
n. (%) 132 (67) 276 (67) 0.94 
Hypercholesterolemia 
n. (%) 161 (82) 286 (70) 0.002 
Current Smokers  
n. (%) 36 (18) 81 (20) 0.72 
Previous Smokers 
n. (%) 89 (45) 159 (39) 0.33 
Family history  
n. (%) 93 (47) 124 (30) <0.0001 
Creatinine
(�mol/L) 102�80 95�31 0.36
LV Ejection Fraction 
(%)* 59�12 61�11 0.11
MEDICAL HISTORY     
PCI
n. (%) 1 (0.01) 2 (0.004) 0.97 
Myocardial Infarction 
n. (%) 77 (39) 132 (32) 0.11 
Anterior MI 
n. (%) 11 (6) 35 (8) 0.18 
COPD
n. (%) 7 (4) 15 (4) 0.94 
Peripheral Arterial 
Disease n. (%) 15 (8) 27 (7) 0.77 
Carotid Surgery 
n. (%) 3 (1.5) 5 (1.2) 0.76 
CLINICAL PRESENTATION     
Stable Angina  
n. (%) 111 (56) 212 (52) 0.55 
CCS
n. (%) 2.23�0.7 2.27�0.7 0.64
Silent Ischemia 
n. (%) 14 (7) 49 (12) 0.13 
Unstable Angina 
n. (%) 72 (37) 149 (36) 0.97 
IB/IIB/IIIB 
n. (%) 
14(19)/28(39)/ 
17(24) 
30(20)/56(38)/ 
29(19) 0.93
IC/IIC/IIIC 
n. (%) 
0(0)/10(14)/ 
3(4)
7(5)/15(10)/ 
12(8) 0.59
MEDICATIONS AT SCREENING
�-blockers 
n. (%) 146 (74) 291 (71) 0.47 
ACE-Inhibitors 
n. (%) 80 (41) 180 (44) 0.49 
Statins
n. (%) 153 (78) 279 (68) 0.01 
ACE: angiotensin converting enzyme; PCI: percutaneous coronary 
intervention, LV: left ventricular, COPD: chronic obstructive pulmonary 
disease; MI: myocardial infarction; *: Available in 538 patients 
RESULTS
Baseline and Procedural Characteristics 
Baseline and procedural characteristics, stratified 
according to the use of GP IIb/IIIa inhibitors are shown 
in TABLE 1 and TABLE 2. One hundred ninety seven 
patients (32.4%) were treated with infusion of GP 
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IIb/IIIa inhibitor; 20 (10%) patients underwent 
abciximab (n=9); tirofiban (n=9); or eptifibatide (n=2) 
infusion in the upstream setting, 150 (76%) received 
abciximab (n=95), tirofiban (n=32) or eptifibatide 
(n=23) as downstream infusion, while 27 (14%) patients 
received abciximab (n=24) or eptifibatide (n=3) as 
bailout strategy. The two groups of patients were well 
matched for most clinical characteristics, including 
indications to revascularization, medical history and 
presence of diabetes mellitus. Age and left ventricular 
ejection fraction tended to be lower while only 
hypercholesterolemia and family history of coronary 
disease were more frequent in the group of patients 
receiving GP IIb/IIIa inhibitors. Conversely, the two 
study groups differed with respect to most procedural 
data including a greater number of treated lesions and 
implanted stents, longer total stent length, higher 
number of C and bifurcation treated lesions and more 
frequent bifurcation stenting in the group of patients 
receiving GP IIb/IIIa inhibitors (TABLE 2). In both 
groups, there was an average of 2 thrombus-containing 
lesions per 100 patients treated. Use of �-blockers, ACE-
inhibitors and Statins at screening is reported in table 1. 
In the group of patients receving GP IIb/IIIa inhibitors, 
99% of the patients received clopidogrel (90%) or 
ticlopidine (9%) pretreatment according to the protocol 
compared to 98% (91% clopidogrel; 7% ticlopidine) of 
patients who did not receive treatment with GP IIb/IIIa 
inhibitors (p=0.98). 
There was a considerable variability in the use of GP 
IIb/IIIa inhibitors in the 45 enrolling centers with 18 
(40.9%) and 4 (9%) sites showing minimal (0-20% of 
the cases) and systematic (80-100% of the cases) use of 
GP IIb/IIIa inhibitors, respectively (FIGURE 1).
30-day and 1 year Outcome 
30-day outcome both in terms of clinical events and 
bleeding rates are reported in table 3. There was no 
difference in any of the measured end-points between 
the two groups, including major and minor bleeding 
rates. Among the 27 patients receiving GP IIb/IIIa 
infusion as bailout strategy, one underwent 
reintervention within 30 days. 
The cumulative incidence of MACCE (death, 
cerebrovascular accident, myocardial infarction or target 
vessel revascularization) at one year did not differ in the 
group of patients who underwent GP IIb/IIIa inhibitor 
infusion compared to patients who did not (15.2% vs. 
11%, respectively; HR 1.4 [95% CI: 0.89-2.2]; p=0.21) 
(FIGURE 2A). The composite of death, CVA or non-fatal 
MI (7.1% vs. 4.9% in those not receiving GP IIb/IIIa 
inhibitors; HR 1.44 [95% CI: 0.73-2.87]; p=0.44) 
(FIGURE 2B) and the rate of TVR (10.6% vs. 7%; HR 
1.54 [95% CI: 0.88-2.71]; p=0.12) (FIGURE 2C) were 
both numerically higher in the GP IIb/IIIa inhibitor 
group, but none of the clinical endpoints considered, 
either combined or individually, achieved statistical 
significance (TABLE 3).
Table 2. Angiographic and Procedural Characteristics of 
the Study population
Use of GP IIb/IIIa Inhibitors
Yes No 
Variables (197 Patients 653 Lesion) 
(410 Patients 
1486 Lesions) 
P
value 
Diseased 
Segments 3.6�1.3 3.5�1.25 0.34
Diseased vessels 2.5�0.5 2.5�0.5 0.84
Vessel territory 
with stenosis    
LAD 197 (100) 408 (99) 0.82 
CFX 146 (74) 317 (77) 0.44 
RCA 157 (80) 312 (76) 0.32 
Treated Vessel     
LAD 196 (99) 404 (99) 0.74 
CFX 142 (72) 303 (74) 0.53 
RCA 152 (77) 289 (70) 0.11 
Patients receiving 
2-vi. 100 (51) 224 (55) 0.67 
Patients receiving 
3-vi. 97 (49) 186 (45) 0.64 
Patients with 
complete 
revascularization 
129 (65) 235 (57) 0.054 
Treated lesions 3.33�1.2 3.09�1.1 0.017
� 2 57 (29) 125 (30) 0.83 
3-4 102 (52) 240 (58.5) 0.44 
�5-6 36 (18) 41 (10) 0.018 
>6 2 (1) 4 (1) 0.69 
Treated vessels 2.49�0.51 2.49�0.55 0.22
Number of 
implanted stents 4.1�1.7 3.5�1.4 <0.0001 
Maximal pressure 
of stent 
deployment 
16.5�3 16.3�2.8 0.34
Total stent length 
per patient (mm) 81.4�36 68.17�29 <0.0001 
Treated lesions, n. 
(%)    
Type A 0.22�0.50 0.27�0.50 0.25
Type B1 0.83�0.90 0.89�0.90 0.46
Type B2 1.97�1.20 0.93�1.17 0.69
Type C 0.65�0.76 0.40�0.64 <0.0001 
Total occlusion < 3 
months 0.015�0.16 0.0048�0.07 0.26
Total occlusion > 3 
months 0.065�0.25 0.088�0.29 0.37
Moderate to 
severly calficied 
lesions
1.05�1.16 1.06�1.13 0.89
Thrombus 
containing lesions 0.02�0.14 0.017�0.13 0.78
Bifurcated lesions 1.26�0.99 1.09�0.99 0.03
Stented side 
branch 1.10�0.89 0.89�0.85 0.007
Balloonned side 
branch 0.046�0.2 0.07�0.28 0.31
LAD: left anterior descending; CFX: circumflex; RCA: right coronary 
artery. Vi: vessel intervention. 
Four patients in the bailout group underwent repeat 
percutaneous intervention within one year. In patients 
receiving planned (either up- or down-stream) GP 
IIb/IIIa inhibitor infusion, the unadjusted MACCE rate at 
1 year was 16.5% vs. 10.8% in those who did not, HR 
1.56 [95% CI: 0.95-2.5]; p=0.07). 
When the overall patient population was stratified 
according to the median rate of GP IIb/IIIa inhibitors 
utilization in the enrolling sites (median use 27%), the 
MACCE rate in patients treated with vs. without GP 
IIb/IIIa inhibitors was respectively 17.4% (8/46) vs. 
9%(22/244) (HR 1.95 [95% CI: 0.87-4.36]; p=0.11) in 
centers with low drug use, while it was respectively 
14.5% (22/151) vs. 13.9% (23/166) (HR 1.01 [95% CI: 
0.58-1.76]; p=0.94 in centers with high use of GP 
IIb/IIIa inhibitors. The 1-year MACCE rate was 14.8% in
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Fig. 1 Histogram for the proportion of patients treated 
with GP IIb/IIIa inhibitors per enrolling site. 
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patients treated with abciximab and 15.9% in patients 
receiving small molecules (HR 0.93[95% CI: 0.41-2.2]; 
p=0.84).
Propensity Analyses 
The median propensity value for the use of GP IIb/IIIa 
inhibitors during the index procedure (n=522) was 0.50 
(IQR: 0.3-0.73) in the group receiving GP IIb/IIIa 
inhibitors and 0.19 (IQR: 0.09-0.32) in the group who did 
not. The C-statistic for the propensity score model was 
0.72 indicating good but not excellent discrimination. 
(Hosmer–Lemeshow test p=0. 53). The adjusted hazard 
ratio for MACCE was 1.08 [95% CI: 0.71-1.8]; p=0.74. 
Matched event rates at both 30 days and one year in 
terms of the composite of death and non-fatal MI in the 
group of patient receiving treatment with GP IIb/IIIa 
inhibitor, as compared to those who did not, are shown 
in figure 3. None of the comparisons reached statistical 
significance.
Notably, in the fourth quartiles, where the overall 
incidence of death and non-fatal MI and the 
discrimination capacity of the propensity model were 
numerically higher, the event rate was reduced by more 
than 50% in the group of patients treated with GP 
IIb/IIIa inhibitors compared with those who did not. 
DISCUSSION
Despite the remarkable body of evidence supporting the 
benefit of GP IIb/IIIa inhibitors in different 
patients/lesions subsets (2-4, 16), information regarding 
their efficacy profile in patients undergoing drug eluting 
stent intervention is scant. There are several theoretical 
reasons why the impact of GP IIb/IIIa inhibitors may 
differ in patients undergoing BMS as compared to DES 
placement, including the different thrombogenic potential 
of the two stent types (17, 18) and the fact that 
complete revascularization strategy is usually more 
aggressively sought in the DES era with a higher number 
of stents deployed and more complex lesions approached 
(19). At the same time however, elective patients are 
increasingly more likely to undergo intervention once a 
steady state of ADP receptor blocker has been achieved, 
either through a longer period of pretreatment or 
administration of higher loading doses (20-22). This may
Fig. 2 One-year adverse events in patients treated 
with or without GP IIb/IIIa inhibitors.
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in turn reduce the need for more potent antiplatelet 
agents, such as GP IIb/IIIa inhibitors, in patients with 
low-risk clinical profiles (7). 
Thus, there is renewed interest in evaluating the short 
and long-term benefit of GP IIb/IIIa inhibition when 
employed as part of the contemporary interventions with 
DES (8).  
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Table 3. 30-Day and 1-year Outcome
Use of GP IIb/IIIa 
Inhibitors
Variables Yes(N=197) 
No
(N=410) P-value
30-DAY OUTCOME
MACCE 12 (6.1) § 21 (5.1) 0.76* 
Death/CVA/non-
fatal MI 8 (4.1) 17 (4.2) 0.87* 
Death/non-fatal 
MI 7 (3.6) 17 (4.2) 0.90* 
Death 0 (0) 0 (0) … 
CVA 1 (0.5) ‡ 0 (0) 0.71* 
Non-fatal MI 7 (3.6) 17 (4.2) 0.72* 
Q-wave MI 3 (1.5) 2 (0.5) 0.20* 
Non-Q Wave MI  4 (2.0) 15 (3.7) 0.26* 
Target Vessel 
Revascularization 7 (3.5)§ 9 (2.2) 0.50* 
Re-PCI 3 (1.5)§ 5 (1.2) 0.93* 
CABG 4 (2) 4 (1) 0.49* 
Sub-acute 
Occlusion† 2 (1) 3 (0.7) 0.91* 
Bleedings n. (%)    
   Major 2 (1) 2 (0.5) 0.83* 
   Minor 9 (4.5) 13 (3.2) 0.53* 
1-YEAR OUTCOME    
MACCE 30(15.2)** 45(11) 0.15 
Death/CVA/non-
fatal MI 14(7.1) 20 (4.9) 0.29 
Death/non-fatal 
MI 12 (6.1) 20 (4.9) 0.55 
Death 4 (2) 2 (0.5) 0.10 
CVA 2 (1)  2 (0.5) 0.83 
Non-fatal MI 9 (4.6) 18 (4.4) 0.93 
Q-wave MI 3 (1.5) 2 (0.5) 0.40 
Non-Q Wave MI  6 (3.0) 16 (3.9) 0.60 
Target Vessel 
Revascularization 21 (10.6)** 29 (7) 0.19 
Re-PCI 14 (7.1)** 24 (5.1) 0.61 
CABG 6 (3) 7 (1.7) 0.37 
Late Occlusion† 1(0.5) 1 (0.2) 0.82 
*: By Fischer’s exact test; 1-year outcome p-values were obtained by Log 
Rank test †: Angiographically documented, ‡: ischemic stroke occurred 3 
days after intervention. §: in one patient receiving bailout treatment with 
GP IIb/IIIa inhibitor, a repeat percutaneous intervention (PCI) occurred 
within 30 days. **: in 4 patients receiving bailout GP IIb/IIIa inhibitors 
infusion a repeat PCI occurred within 365 days. 
In a recent analysis of TAXUS IV, use of Gp IIb/IIIa 
inhibitors in association with the TAXUS � paclitaxel-
eluting  stent was independently and paradoxically 
associated with the occurrence of periprocedural 
myocardial necrosis(9). Although this may have been due 
to preferential use of GP IIb/IIIa inhibitors in more 
complex patients or lesions, no such risk factors were 
identified among the variables examined (9). Moreover, 
these unexpected findings could not be explained by an 
increased use of GP IIb/IIIa inhibitors for bailout or by 
differences in GP IIb/IIIa inhibitors use among patients.  
In the present ARTS II sub analysis, focusing on patients 
undergoing multiple vessel stenting with the sirolimus-
eluting stent, no detrimental interaction was observed 
between the stent and use of GP IIb/IIIa inhibitors by 
both univariate and propensity-adjusted analysis. 
Nevetheless, patients treated with GP IIb/IIIa inhibitors 
had a numerically higher MACCE rate than those not 
undergoing GP IIb/IIIa inhibition.
The excess of events in the GP IIb/IIIa inhibitor arm in 
ARTS II was largely driven by TVR, while the unadjusted 
composite of death and non-fatal MI were similar at both 
30 days and 1-year in the treated and untreated arms. 
Moreover, patients treated with GP IIb/IIIa inhibitors in 
the present trial had a more severe angiographic profile 
than patients who did not receive such treatment. This  
Fig. 3 Rate of death or non-fatal myocardial infarction at 
30-days (A) and one year (B) stratified into quartiles of 
propensity score (n=522 patients). 
A
0.0
2.5
5.0
7.5
10.0
No Use of GP IIb/IIIa Use of GP IIb/IIIa
I II III IV
3/112
0/18
4/102
1/28
3/80
3/49
6/64
2/69
Quartiles of Propensity Score
D
ea
th
/n
o
n
-f
at
al
 M
I
3
0
-d
ay
s 
(%
)
B
0.0
2.5
5.0
7.5
10.0
12.5
No Use of GP IIb/IIIa Use of GP IIb/IIIa
I II III IV
5/112
1/18
4/102
2/28
3/80
4/49
7/64
3/69
Quartiles of Propensity Score
D
ea
th
/ 
n
o
n
-f
at
al
 M
I
at
 3
6
5
 d
ay
s  
(%
)
suggests a selection bias among patients undergoing 
treatment with GP IIb/IIIa inhibitors. This hypothesis has 
been confirmed by i) the stratified analysis according to 
enrolling sites, where the excess of events at one year 
was almost totally confined to centers with low use of Gp 
IIb/IIIa inhibitors and ii) the propensity-adjusted 
analysis.
Our results may question the value of GP IIb/IIIa 
inhibition in the DES era in elective patients adequately 
pretreated with thienopyridines. It is tempting to 
speculate that the paradoxical (9), or neutral results in 
the present study, of the effect of GP IIb/IIIa inhibition 
so far reported in the DES era, may reflect the complex 
interplay of multiple variables.  
1) Most of the studies supporting the benefit of GP 
IIb/IIIa inhibitors in patients undergoing intervention 
date back to the pre-clopidogrel era, when ticlopidine 
was seldom administered much before PCI procedure 
(23-26) or the duration of pretreatment was not always 
accurately tracked (27). Thus, despite some preliminary 
evidence supporting the additional benefit of GP IIb/IIIa 
inhibition when given on top of pretreatment with ADP 
receptor blockers(28, 29), this may not necessarily be 
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Fig. 4 30 days MACE in patients allocated to receive GP IIb/IIIa inhibitors (white column) or placebo (black column) in 
all major randomized controlled trials evaluating abciximab in patients undergoing coronary intervention and in ARTS 
II study 
In studies where the overall event rate in the placebo-untreated group was around 6% or less, no or negligible risk reduction of MACE was observed by the 
use of GP IIb/IIIa inhibit 
the case in stable (7) or cooled-off patients like those 
enrolled in the ARTS II study. 
2) There is not a single large-scale, randomized trial 
evaluating the benefits of GP IIb/IIIa inhibitors when 
administered based upon coronary anatomy per se.
Although, complex anatomy has sometimes been 
considered as an inclusion criterion in trials (23, 25), 
patients presenting with clinical instability (i.e. troponin 
elevation, ongoing chest pain, acute or recent ECG 
changes) have always been the predominant (26, 30) or 
even the only patient population in whom the benefit of 
GP IIb/IIIa inhibitors has been clearly established (16, 
26, 31-33). Moreover, even at post-hoc analyses of the 
EPIC and EPILOG trials, it was shown that the reduction 
in complications of angioplasty with abciximab is largely 
independently of baseline lesion morphology (34). This 
further supports the concept that the clinical status of 
the patients rather than the coronary anatomy may 
explain most of the observed benefit of GP IIb/IIIa 
inhibitors administration in patients undergoing PCI. This 
paradigm has been recently supported by a sub-analysis 
of the ESPRIT trial (35) and by the ISAR-REACT-2 
study(33).
In ARTS II, investigators selected patients to receive GP 
IIb/IIIa inhibitors based on coronary anatomy rather 
based on clinical presentation. Indeed, even among the 
98 patients in whom this information was collected, 16% 
(6/37) of the group receiving GP IIb/IIIa inhibitors 
compared to 31% (19/61) (p=0.15) of those who did not 
had troponin elevation at screening. Thus, in the DES 
era, the propensity to administer GP IIb/IIIa inhibitors 
based purely on coronary anatomy may increase as a 
consequence of treating more complex lesion subsets. 
Whether such an approach is justified will need to be 
addressed by future randomized trials. 
3) In ARTS II, the overall MACCE rate at 30 days was low 
while at one year it was predominantly driven by TVR, 
especially in the GP IIb/IIIa inhibitor group. This is 
consistent with the fact that elective patients with 
complex and multiple coronary lesions have been 
selected to test the performance of the sirolimus-eluting 
stent. Intimal hyperplasia is not affected by the use of 
GP IIb/IIIa inhibitors (36) and when the present 30-days 
MACE rate is viewed in the context of all major trials 
evaluating the benefit of abciximab in the setting of PCI 
(FIGURE 4), the lack of benefit from GP IIb/IIIa inhibitors 
in the ARTS II trial is not surprising. This may explain 
why a trend favoring the use of GP IIb/IIIa inhibitors in 
the ARTS II trial was only seen in the highest quartile of 
the propensity score.  
Study Limitations 
This study has several limitations. First of all, ARTS II 
was not designed or powered to evaluate the effect of 
GP IIb/IIIa inhibitors on outcomes. This analysis should 
be viewed as exploratory and hypothesis generating. In 
an attempt at correcting for all recorded confounders 
between patients receiving or not receiving GP IIb/IIIa 
inhibitors, a non-parsimonious propensity analysis was 
employed in the study. However, we cannot rule out the 
possibility that unmeasured residual confounders might 
still have affected our overall adjusted results. 
Measurement of troponin was not mandatory in the trial, 
so that this information was not available for the majority 
of the enrolled patients. This has prevented us from 
adjusting for troponin status at entry in the present 
analysis. Considering the well-known interaction between 
troponin elevation and favorable response to GP IIb/IIIa 
inhibitors (31, 33), this information, if available for all 
patients, might have shed important light on the effect of 
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the study drugs between the treated and untreated 
patients.
Conclusions
In the ARTS II, in the context of multivessel disease 
patients undergoing elective sirolimus eluting stent 
implantation after pre-treatment with thienopyridines, 
the use of GP 2b/3a inhibitors was mainly solicited by the 
presence of complex coronary anatomy more than by 
patient clinical profile. The use of this class of antiplatelet 
agents to “bail out” situations (where efficacy has not 
been established) was not infrequent. This did not 
translate into an improved outcome in those receiving 
the treatment compared with patients who did not after 
adjustment for a broad range of potential confounders. 
Our results suggest, even if cannot prove, that even in 
the DES era, where complex and extensive CAD is more 
aggressively treated percutaneously, the use of GP 
IIb/IIIa inhibitors should be triggered by the clinical 
more than angiographic characteristics of the patients 
undergoing coronary revascularization.  
Future studies investigating the role of GP IIb/IIIa 
blockers are warranted to establish the benefit of this 
drug class when administered in patients with high risk 
clinical profile during contemporary DES-supported 
coronary intervention.
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Revascularization of Segment 6 in ARTS II 
One-year outcome in patients with multivessel disease involving the 
proximal left anterior descending artery after implantation of 
sirolimus-eluting stents compared with either bare-metal stents or 
coronary artery bypass grafting 
A Combined Analysis of the Arterial Revascularization Therapies Study (ARTS) I and II 
Marco Valgimigli, MD, Jean Fajadet, MD, Ran Kornowski, MD, Gabriel Steg, MD, Mark A de Belder, MD, FRCP, MA, 
Philippe Amedeo Betriu, MD, PhD, J. Wouter Jukema, MD, PhD, Otmar Pachinger, MD, Dick Goedhart, PhD, Jessica Kandt, 
MSc, Marco Bressers, MsC, Kristel Wittebols, Msc, Hans-Peter Stoll, MD, Patrick W. Serruys, MD, PhD 
Aims: Coronary revascularization with bare metal stents (BMS) in patients with multivessel disease (MVD) and 
involvement of the proximal left anterior descending artery (pLAD) is associated with an increased risk of in-stent 
restenosis and frequently necessitates re-intervention. In this setting, the use of sirolimus eluting stents (SES) may 
prove superior to BMS and equalize outcomes compared with coronary artery bypass grafting (CABG). We evaluated the 
incidence of major adverse cardiac and cerebrovascular events (MACCE) at 1 year after SES in MVD patients with pLAD 
disease compared with BMS or CABG. 
Methods and Results: A total of 289 MVD patients with pLAD disease recruited at 45 centres undergoing SES 
implantation in the Arterial Revascularization Therapies Study (ARTS) part II were compared with 187 and 206 patients 
with pLAD obstruction enrolled in ARTS I receiving BMS and CABG, respectively. At one year the cumulative incidence of 
MACCE in the SES was lower (10.4%) than in the BMS group (20.3%, RR 0.51 [95% CI: 0.33-0.79]; p=0.003), while it 
was almost identical to CABG patients (10.2% RR 1.02 [95% CI: 0.60-1.73]; p>0.99). After adjustment, patients 
undergoing SES implantation had a better outcome compared with those receiving BMS (adjusted HR 0.29 [95% CI: 
0.14-0.59]; p=0.0006), while they did not differ in terms of MACCE when compared with the CABG group (adjusted HR 
0.94 [95% CI: 0.43-2.08]; p=0.89). 
Conclusions: Intervention assisted by SES in MVD with pLAD involvement, by reducing the need for re-intervention 
associated with BMS, may equalize one year outcomes compared with CABG.  
Submitted
INTRODUCTION 
Coronary revascularisation in patients with multivessel 
disease (MVD) eligible for catheter-based intervention 
can be achieved either by a surgical or a percutaneous 
approach yielding similar results with respect to long-
term mortality and rates of infarction 1,2. While the use of 
bare metal stent (BMS) has led to a significant 
improvement in the early and late patency rate of treated 
arteries 3,4, the need for repeated revascularisation has 
remained substantially higher after percutaneous 
compared to surgical intervention due to high rate of in-
stent restenosis 1,2,5. Hence, the decision as to which 
revascularisation strategy to perform in the BMS era was 
mainly influenced by feasibility of the percutaneous 
treatment integrated by the predicted risk of restenosis 
based on clinical and angiographic findings.  
This process of clinical decision-making is critical 
particularly for MVD patients with involvement of the 
proximal left anterior descending artery (pLAD), who are 
at relatively high risk for developing in-stent restenosis 
when treated percutaneously 6-8 while they are known to 
derive the most benefit from surgical revascularisation 
with mammary artery conduits9-12.
The superior performance of drug-eluting stents (DES) in 
terms of restenosis prevention compared to BMS 13
renovates the interest to evaluate the clinical benefit of 
contemporary percutaneous intervention in a selected 
subset of patients traditionally referred for surgical 
intervention.
The short and mid-term outcomes of patients with MVD 
and involvement of pLAD who underwent sirolimus 
eluting stents (SES) implantation in the Arterial 
Revascularization Therapies Study (ARTS) part II was 
investigated and compared with patients with pLAD 
disease randomly allocated to receive either BMS or 
CABG as part of ARTS I. 
METHODS
Study design 
The ARTS II study design has been previously reported2,14.
Briefly, patients were consecutively enrolled via a central 
telephone service, after stratification by clinical site to ensure 
the inclusion of at least one third of patients undergoing three-
vessel intervention.  
Selection of patients 
Patients were eligible for coronary revascularization if they had 
either stable angina (Canadian Cardiovascular Society class I, II, 
III, or IV), unstable angina (Braunwald class IB, IC, IIB, IIC, 
IIIB, or IIIC), or if they had silent ischemia and at least two new 
lesions located in different major epicardial vessels and/or their 
side branches (not including the left main coronary artery) that 
were potentially amenable to stent implantation. Patients were 
required to have multivessel disease with the need for treatment 
of the left anterior descending (LAD) artery and at least one 
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other significant lesion (>50% diameter stenosis) in another 
major epicardial coronary artery. One totally occluded major 
epicardial vessel could also be included. The stenosis had to be 
amenable to stenting using a stent with a diameter of 2.5 to 
3.5mm and length of 13 to 33mm, without any restriction on the 
total stent length implanted.  
Patients with any previous coronary intervention, left main 
coronary disease, overt congestive heart failure or a left 
ventricular ejection fraction of less than 30 percent were 
excluded. Additional exclusion criteria included a history of a 
cerebrovascular accident and STEMI in the preceding week or 
with persistent elevation of CK. Measurement of troponin was 
not mandatory at screening. Patients with chest pain lasting 
longer than 30 minutes within the preceding 12 hours were also 
excluded if CK was equal or more than 2 times upper normal 
limit. 
Written, informed consent was obtained from each patient prior 
to enrolment.  The study was approved by the ethics committee 
of each participating site. 
Procedures and Post-Intervention Medications 
All interventions were performed according to current standard 
guidelines and the final interventional strategy, including the use 
of glycoprotein IIb/IIIa inhibitors, was left entirely to the 
discretion of the operator, except for the stent utilization. All 
patients were advised to maintain aspirin lifelong. Clopidogrel 
300 mg as a loading dose, or Ticlopidine, administered at a dose 
of 500 mg, was to be started at least 24 hours before the 
procedure. Clopidogrel 75 mg per day or Ticlopdine 250 mg 
twice a day was prescribed for at least two months after 
revascularization.  
Study Objectives and Endpoints 
The primary objective of this ARTS II sub-analysis was to 
compare the safety and effectiveness of coronary stent 
implantation using sirolimus-eluting stents with the use of 
metallic stent implantation or CABG in patients with multivessel 
disease involving the pLAD. The primary outcome measure was 
the incidence of major adverse cardiac and cerebrovascular 
events (MACCE) at one year comprising all-cause death, any 
cerebrovascular event, non-fatal myocardial infarction, or any 
repeat revascularization.  
End point definitions 
All deaths were considered cardiac unless a non cardiac origin 
was established clinically or at autopsy. Death from all causes 
was reported. 
Cerebrovascular events were divided into three main categories: 
stroke, transient ischemic attack (TIA), and reversible ischemic 
neurologic deficit (RIND). In the first seven days after the 
intervention, a definite diagnosis of myocardial infarction was 
made if there was documentation of new abnormal Q waves 
(according to the Minnesota code) and either a ratio of serum 
creatine kinase MB (CK-MB) iso-enzyme to total cardiac enzyme 
that was greater than 0.1 or a CK-MB value that was 5 times the 
upper limit of normal (ULN)1, 11, 12 Serum creatine kinase and CK-
MB iso-enzyme concentrations were measured 6, 12, and 18 
hours after the intervention. Beginning eight days after the 
intervention (the length of the hospital stay after surgery), 
either abnormal Q waves or enzymatic changes were sufficient 
for a diagnosis of myocardial infarction. This dual method of 
defining myocardial infarction was developed for ARTS I to 
address the difficulty of diagnosing a myocardial infarction after 
surgery. A myocardial infarction was confirmed only after the 
relevant electrocardiograms had been analyzed by the 
electrocardiographic core laboratory and adjudicated by a 
clinical-events committee. All repeat revascularization 
procedures were recorded. Events were counted from the time 
of the initial procedure. Thrombotic occlusions were defined 
either by angiographic documentation of a complete occlusion 
(TIMI flow 0 or 1) or angiographic documentation of a flow 
limiting thrombus (TIMI flow 1 or 2). All events were reviewed 
and adjudicated by an independent clinical-events committee. 
Angiographic data, including the characteristics of each lesion 
and target coronary segment, were adjudicated by an 
independent core laboratory (Cardialysis BV, Rotterdam, The 
Netherlands). The proximal LAD was defined as the segment 
between the branching point of the left main stem and the first 
major septal branch (segment 6 in the American Heart 
Association classification)15. To avoid any bias related to 
investigator-driven adjudication, involvement of the pLAD was 
centrally defined as a lumen obstruction equal or more than 
50% at visual estimation according to the analysis performed by 
the independent angiographic core-lab. 
Statistical analysis 
Continuous variables are shown as mean � SD if not otherwise 
stated and were compared using Student’s two-sample t-test. 
Categorical variables are presented as percentages and 
compared with the �2test. Survival curves were generated by 
the Kaplan-Meier method and survival amongst groups was 
compared using the log-rank test. Cox’s regression proportional 
hazards models were used to assess risk reduction of adverse 
events. Multivariable analysis, considering all potential 
confounders of primary outcome measures, defined as those 
with a univariate p-value of 0.1 or less at Cox’s regression, was 
performed for both SES vs. BMS and SES vs. CABG comparisons. 
Factors causing co-linearity in the model (investigated using a 
correlation matrix and by inspection of the estimate parameters) 
were removed. Moreover a simultaneous interaction test of the 
predicting variables with revascularisation strategy was 
performed. The interaction was calculated by comparing the 
cumulative model fit statistics of the above analysis with the fit 
statistics of an analysis stratified by treatment. The fit statistic 
used is the -2 log(Likelihood), which has a �2 distribution with �
degrees of freedom. Probability was significant at a level of 
<0.05. All statistical tests were 2-tailed. Statistical analysis was 
performed with SAS V8.02, (SAS institute, Cary, NC, USA). 
RESULTS
Patients
From April 1997 to June 1998, 1,205 patients were 
randomly assigned to undergo CABG (605 patients) or 
angioplasty with stent implantation (600 patients) at 67 
participating centers in the ARTS I. A total of 393 
patients presented with pLAD disease, of whom 187 
were randomly assigned to stenting and 206 to CABG. 
Between February 2003 and November 2003, 607 
patients at 45 participating centers, of whom 289 were 
affected by pLAD disease, were treated with SES as part 
of the ARTS II. Table 1 presents their baseline 
demographic characteristics. 
Patients treated with SES were older than those allocated 
to BMS and had a higher prevalence of diabetes mellitus, 
hypertension and hypercholesterolemia compared with 
both BMS and CABG groups; in ARTS II there were fewer 
smokers compared with ARTS I and patients suffered 
less frequently from a previous MI than those in the BMS 
group but had three vessel disease in more than 50% of 
cases compared with approximately 30% in those 
recruited in the ARTS I. The cumulative r number of 
diseased and treated lesions was also higher in ARTS II. 
Overall, A and B1 type lesions were more frequently 
observed in ARTS I patients, while B2 or C type lesions 
were more common in ARTS II patients (Table 2). 
Glycoprotein 2b/3a inhibitors were used in 33.6% in the 
SES group but in only a few patients during ARTS I. The 
left internal mammary artery (LIMA) was employed in 
93% of the cases in the CABG group while 16.5% of 
patients had bilateral left and right internal mammary 
artery (BIMA) grafting.
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Table 1 Baseline Patient Demographics  
Patient Parameters Measured SES Group        (N=289 patients) 
BMS Group         
(N=187 patients) 
CABG Group        
(N=206 patients) 
P-
value 1
P-
value 2
Age (years)      
mean ± SD 63.1±10.1 60.1±9.5 62.0±9.0 0.001 0.21 
(min - max) (35 - 80) (30 - 77) (31 - 80)   
Ejection Fraction (%)    
N 247 175 190   
mean ± SD 59.2±11.5 60.8±12.2 60.5±13.3 0.18 0.28 
(min - max) (30 - 97) (30 - 92) (30 - 91)   
Body Mass Index (kg/m2)    
mean ± SD 27.5±4.1 26.9±3.6 27.4±3.4 0.10 0.68 
(min - max) (19.9 - 42.0) (19.1 - 39.7) (18.5 - 37.0)   
Number of Men 80.6% (233/289) 78.1% (146/187) 81.1% (167/206) 0.56 1.00 
Diabetes Mellitus 24.9% (72/289) 11.2% (21/187) 14.6% (30/206) <0.001 0.005 
Hypertension 65.7% (190/289) 41.2% (77/187) 44.2% (91/206) <0.001 <0.001 
Hypercholesterolemia 73.6% (212/288) 63.1% (118/187) 58.5% (120/205) 0.019 <0.001 
History of CVA 0.7% (2/289) 1.1% (2/187) 0.5% (1/206) 0.65 1.00 
Family history of MI/sudden death <55 yr 36.5% (105/288) 39.7% (73/184) 43.9% (90/205) 0.50 0.11 
Peripheral Vascular Disease 8.0% (23/289) 5.3% (10/187) 5.3% (11/206) 0.36 0.28 
Previous MI 32.5% (94/289) 44.4% (83/187) 37.9% (78/206) 0.011 0.25 
Previous CABG 0.0% (0/289) 0.0% (0/187) 0.0% (0/206)   
Previous PTCA 0.7% (2/289) 1.1% (2/187) 2.4% (5/206) 0.65 0.13 
Carotid Surgery 1.7% (5/289) 1.1% (2/187) 1.5% (3/206) 0.71 1.00 
Chronic Obstructive Pulmonary Disease 4.8% (14/289) 6.4% (12/187) 4.4% (9/206) 0.54 1.00 
Smoking History      
Previous 39.1% (113/289) 43.5% (81/186) 51.9% (107/206) 0.34 0.006 
Current 17.6% (51/289) 27.4% (51/186) 20.4% (42/206) 0.016 0.48 
Unstable Angina 32.9% (95/289) 41.7% (78/187) 34.5% (71/206) 0.052 0.77 
Braunwald I 9.3% (27/289) 7.5% (14/187) 5.3% (11/206) 0.51 0.12 
Braunwald Ib 8.3% (24/289) 4.8% (9/187) 5.3% (11/206) 0.20 0.22 
Braunwald Ic 1.0% (3/289) 2.7% (5/187) 0.0% (0/206) 0.27 0.27 
Braunwald II 15.6% (45/289) 20.9% (39/187) 15.5% (32/206) 0.14 1.00 
Braunwald IIb 12.8% (37/289) 13.4% (25/187) 13.1% (27/206) 0.89 1.00 
Braunwald IIc 2.8% (8/289) 7.5% (14/187) 2.4% (5/206) 0.024 1.00 
Braunwald III 8.0% (23/289) 13.4% (25/187) 13.6% (28/206) 0.06 0.051 
Braunwald IIIb 6.9% (20/289) 11.8% (22/187) 12.1% (25/206) 0.10 0.057 
Braunwald IIIc 1.0% (3/289) 1.6% (3/187) 1.5% (3/206) 0.68 0.70 
Stable Angina 57.4% (166/289) 53.5% (100/187) 59.7% (123/206) 0.40 0.64 
CCS I 9.0% (26/289) 4.8% (9/187) 3.9% (8/206) 0.11 0.030 
CCS II 28.0% (81/289) 26.7% (50/187) 26.2% (54/206) 0.83 0.68 
CCS III 19.4% (56/289) 17.6% (33/187) 28.2% (58/206) 0.72 0.023 
CCS IV 1.0% (3/289) 4.3% (8/187) 1.5% (3/206) 0.029 0.70 
Silent Ischaemia 9.7% (28/289) 4.8% (9/187) 5.8% (12/206) 0.055 0.13 
SES: Sirolimus eluting stent, BMS: bare metal stent, CABG: coronary artery bypas grafting; CVA= CerebroVascular Accident; MI = Myocardial Infarction; 
CABG =Coronary Artery Bypass Graft; PTCA = Percutaneous Transluminal Coronary Angioplasty; Braunwald = Braunwald Classification; CCS = Canadian 
Cardiovascular Society Classification; p-value 1: SES vs. BMS, p-value 2: SES vs. CABG
30-day Outcomes 
The MACCE rate was 2.8% in patients receiving SES 
compared with 8.6% in the BMS group (RR 0.32 [95% 
CI: 0.14-0.74]; p=0.009) and 5.8% (RR 0.48 [95% CI: 
0.20-1.14]; p=0.11) in the CABG group (Table 3). A 
reduced incidence of death and MI was noted in the SES 
(0% and 0.7%) compared with the CABG group (2.4%, 
p=0.012 and 4.4%, RR 0.16 [95% CI: 0.03-0.73]; 
p=0.010, respectively). This was counterbalanced by the 
higher need for re-intervention observed in the group of 
patients undergoing sirolimus-eluting stenting (2.1% vs. 
0%, p=0.044), which was almost entirely due to surgical 
revascularization in patients in whom percutaneous 
intervention was not successful. In a single patient in the 
SES group, sub-acute occlusion occurred, which required 
percutaneous re-intervention.  
One-year Outcomes 
At one year the cumulative incidence of MACCE in the 
SES group was lower (10.4%) than in the BMS group  
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Table 2: Procedural Characteristics and Medications
Parameters Measured 
SES Group        
(N=289 patients 
N=1048 lesions)
BMS Group      
(N=187 patients 
N=560 lesions)
CABG Group     
(N=206 patients 
N=611 lesions)
P-
value 1
P-
value
2
   
Per Patient Analysis    
Number of Diseased Arteries    
   Single 0.7% (2/289) 3.2% (6/187) 2.9% (6/206) 0.06 0.07 
   Double 45.3% (131/289) 67.4% (126/187) 60.2% (124/206) <0.001 0.001 
   Triple 54.0% (156/289) 29.4% (55/187) 36.9% (76/206) <0.001 <0.001
Number of lesions > 50% DS 3.7±1.3 3.0±1.0 3.0±1.1 <0.001 <0.001
Number of vessels with a lesion > 50% DS 2.5±0.5 2.3±0.5 2.3±0.5 <0.001 <0.001
Number treated lesions: anastomoses/stented lesions 3.3±1.2 2.7±1.0 3.0±1.0 <0.001 <0.001
Number of Stents Implanted 3.8±1.6 2.9±1.2 ... <0.001 ...
Average stent length (mm) 19.4±3.5 16.7±3.3 ... <0.001 ...
Total stent length (mm) 73.9±33.4 48.3±21.5 ... <0.001 ...
Maximum Dilatation pressure (Atm) 16.5±28 15.0±2.7 ... <0.001 ...
    
Pharmacological Treatment     
Lipid-lowering agents 88.9% (257/289) 41.8% (77/184) 35.6% (72/202) <0.001 <0.001
Thienopyridines 97.9% (283/289) 94.6% (174/184) … 0.07 ...
Aspirin 95.8% (277/289) 96.7% (178/184) 84.2 (170/202) 0.81 <0.001
ACE-inhibitors 49.1% (142/289) 21.2% (39/184) 15.8% (32/202) <0.001 <0.001
�-blockers 76.5% (221/289) 62.0% (114/184) 59.9% (121/202) <0.001 <0.001
   
Per Lesion Analysis (%)    
Length    
-  Discrete (< 10 mm.) 60.7% (617/1016) 65.4% (351/537) 68.9% (398/578) 0.08 0.001 
-  Tubular (10-20 mm.) 26.3% (267/1016) 26.6% (143/537) 25.8% (149/578) 0.90 0.86 
-  Diffuse (> 20 mm.) 13.0% (132/1016) 8.0% (43/537) 5.4% (31/578) 0.003 <0.001
Concentric Lesion 13.8% (140/1016) 13.4% (72/536) 16.1% (93/578) 0.88 0.21 
Readily Accessible Segment 95.7% (969/1013) 96.3% (515/535) 96.4% (557/578) 0.69 0.51 
Lesion Angulation      
-  None 87.8% (891/1015) 83.4% (446/535) 86.3% (499/578) 0.020 0.43 
-  Moderate 12.1% (123/1015) 16.3% (87/535) 13.3% (77/578) 0.029 0.48 
-  Severe Bend Point 0.1% (1/1015) 0.4% (2/535) 0.3% (2/578) 0.28 0.30 
Irregular Contour 9.3% (94/1011) 11.8% (63/534) 9.0% (52/578) 0.13 0.93 
Ostial Lesion 7.0% (71/1015) 12.2% (65/534) 9.5% (55/578) <0.001 0.08 
Calcification: Moderate to Heavy 34.9% (354/1014) 21.3% (115/539) 16.3% (94/578) <0.001 <0.001
Thrombus Present 0.5% (5/1036) 1.5% (8/534) 1.0% (6/578) 0.043 0.22 
Occlusion      
-  Less than Total 98.2% (1029/1048) 96.2% (533/554) 94.6% (578/611) 0.019 <0.001
-  Total < 3 Months Old 0.1% (1/1048) 3.6% (20/554) 4.4% (27/611) <0.001 <0.001
-  Total >=3 Months Old 1.7% (18/1048) 0.2% (1/554) 1.0% (6/611) 0.006 0.29 
Bifurcation or Side Branch Lesion      
- No Major Branch Involvement 64.8% (658/1016) 65.5% (349/533) 67.5% (390/578) 0.82 0.30 
- Bifurcation Requiring Double Guide Wire 35.2% (358/1016) 34.1% (182/533) 32.5% (188/578) 0.69 0.30 
- Inability to Protect Major Side Branches 0.0% (0/1016) 0.4% (2/533) 0.0% (0/578) 0.12  
Lesion classification *      
-  Type A 7.1% (74/1048) 5.2% (29/560) 6.1% (37/611) 0.16 0.48 
-  Type B1 21.9% (230/1048) 28.0% (157/560) 30.6% (187/611) 0.007 <0.001
-  Type B2 56.6% (593/1048) 58.2% (326/560) 57.0% (348/611) 0.56 0.92 
-  Type C 14.4% (151/1048) 8.6% (48/560) 6.4% (39/611) <0.001 <0.001
-  Type A/B1 29.0% (304/1048) 33.2% (186/560) 36.7% (224/611) 0.09 0.002 
-  Type B2/C 71.0% (744/1048) 66.8% (374/560) 63.3% (387/611) 0.09 0.002 
    
p-value1: SES vs. BMS, p-value2: SES vs. CABG
(20.3%, RR 0.51 [95% CI: 0.33-0.79]; p=0.003), 
while it was almost identical compared with patients 
who underwent CABG (10.2% RR 1.02 [95% CI: 0.60-
1.73]; p>0.99), reflecting a lower rate of the 
composite of death/CVA/MI in the SES group (RR 0.31 
[95% CI: 0.13-0.74]; p=0.008) and a higher need for 
cumulative re-intervention (RR 2.85 [95% CI: 1.19-
6.85]; p=0.013). 
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Table 3: Non hierarchical clinical outcome in ARTS II 
compared to ARTS I 
SES
Group      
(N=289 
patients) 
BMS
Group      
(N=187 
patients) 
CABG
Group      
(N=206 
patients) 
P-
VALUE1
P-
VALUE2
30-DAY OUTCOME (%)
MACCE 2.8(8/289) 
8.6
(16/187) 
5.8
(12/206) 0.009 0.11 
Death/CVA/ 
MI 
1.0
(3/289) 
5.9
(11/187) 
5.8
(12/206) 0.004 0.003 
Death 0.0(0/289) 
3.2
(6/187) 
2.4
(5/206) 0.003 0.012 
CVA 0.3(1/289) 
0.5
(1/187) 
0.5
(1/206) >0.99 >0.99 
MI 0.7(2/289) 
3.2
(6/187) 
4.4
 (9/206) 0.06 0.01 
Q-Wave MI 0.7(2/289) 
2.7
(5/187) 
3.9
 (8/206) 0.12 0.02 
Non Q-Wave 
 MI 
0.0
(0/221) 
0.5
(1/187) 
0.5
 (1/206) 0.39 0.42 
Revasc. 2.1(6/289) 
4.8
(9/187) 
0.0
 (0/206) 0.11 0.044 
CABG 1.7(5/289) 
0.5
(1/187) 
0.0
 (0/206) 0.41 0.08 
Re-PTCA 0.3(1/289) 
4.3
(8/187) 
0.0
 (0/206) 0.003 >0.99 
Sub-acute 
occlusion
0.3%
(1/289) 
2.7%
(5/187) 
0.0
 (0/206) 0.037 >0.99 
365-DAY OUTCOME
MACCE 10.4(30/289) 
20.3
(38/187) 
10.2
(21/206) 0.003 >0.99 
Death/CVA/ 
MI 
2.4
(7/289) 
9.1
(17/187) 
7.8
(16/206) 0.002 0.008 
Death 1.0(3/289) 
3.7
(7/187) 
3.4
 (7/206) 0.054 0.1 
CVA 0.7(2/289) 
1.1
(2/187) 
1.0
(30/289) 0.65 >0.99 
MI 0.7(2/289) 
5.3
(10/187) 
4.9
(10/206) 0.002 0.005 
Q-Wave MI 0.7(2/289) 
4.8
(9/187) 
4.4
(9/206) 0.009 0.01 
Non Q-Wave 
 MI 
0.0
(0/221) 
0.5
(1/187) 
0.5
(1/206) 0.39 0.42 
Revasc. 8.3(24/289) 
15.5
(29/187) 
2.9
(6/206) 0.017 0.013 
CABG 2.8(8/289) 
4.3
(8/187) 
0.5
(1/206) 0.44 0.09 
Re-PTCA 5.9(17/289) 
12.3
(23/187) 
2.4
(5/206) 0.017 0.08 
Occlusion 0.7(2/289) 
2.7
(5/187) 
0.0
(0/206) 0.12 >0.99 
Late
occlusion
0.3%
(1/289) 
0.0%
(0/187) 
0.0
(0/206) >0.99 >0.99 
p-value1: SES vs. BMS, p-value2: SES vs. CABG
MI: myocardial infarction 
Kaplan-Meier estimates of MACCE, death/CVA/MI and 
repeat revascularization are shown in Figures 1A, 1B
and 1C, respectively.  
Multivariable Analysis 
After adjustment for a range of potential confounders, 
patients undergoing SES implantation had a better 
outcome compared with patients receiving BMS 
(adjusted HR 0.29 [95% CI: 0.14-0.59]; p=0.0006), 
while they did not differ in terms of MACCE in 
comparison with the CABG group (adjusted HR 0.94 
[95% CI: 0.43-2.08]; p=0.89). 
As shown in Figure 2, no statistical interaction was 
noted among all identified risk factors and type of 
treatment when the SES was compared with the BMS 
group (p=0.34 for overall interaction) or when SES 
was compared to the CABG group (p=0.14 for overall 
interaction). Of interest, the presence of hypertension 
tended to favour outcome in the SES as compared to 
the CABG group while the presence of diabetes 
tended to favourably affect outcome in the CABG 
when contrasted to the SES group (Figure 2B).
DISCUSSION
The 1-year outcomes in the total cohort of 
ARTSII in comparison to ARTSI was recently reported 
14. The results suggested that the use of SES in 
patients undergoing multivessel intervention is 
superior to BMS while it emerged as an equivalent 
strategy to CABG in terms of major adverse events. 
Whether these overall findings apply to patients with 
involvement of the pLAD, who are at increased risk for 
in-stent restenosis and benefit particularly from 
surgical revascularisation, remains uncertain. This 
information is important and may have a relevant 
impact on the clinical decision making before the 
results of the ongoing randomized trials comparing 
multi-vessel DES implantation versus surgery become 
available.
Our current findings suggest that if SES are 
used today in patients with multivessel disease and 
pLAD involvement, the need for re-intervention can be 
safely and markedly reduced compared with the use 
of BMS and that the overall outcome at one year can 
be similar to that obtained with surgical 
revascularisation. Of interest, this overall equivalence 
between SES implantation and CABG reflects a 
different impact of these two treatment strategies on 
the single components of the composite MACCE 
endpoint: the cumulative rate of death, myocardial 
infarction and cerebrovascular accidents was lower in 
the SES group, while the need for further 
revascularisation was lower in the CABG group. If 
confirmed by the on-going randomized controlled 
trials, these results may have a tremendous clinical 
and economical impact on the way multivessel disease 
patients are treated. 
Our findings however, also raise an 
additional key question. Are these historical cohorts of 
patients who underwent BMS implantation or CABG in 
ARTS I fully representative of the contemporary 
results obtainable today when BMS implantation or 
CABG are undertaken in MVD patients?
The discussion as to whether the difference in 
outcome between the SES and the BMS groups is 
entirely driven by the superior performance of SES 
may have limited interest at a time when DES are 
progressively replacing BMS in all western countries. 
Thus, the major issue which remains to be addressed 
is whether we can accept the results that in MVD 
patients with pLAD involvement SES implantation can 
lead to comparable 1-year outcome with respect to 
CABG. To ensure the highest comparability with ARTS 
I, special care has been paid in designing ARTS II, 
including stratification by clinical site for patients 
undergoing three-vessel intervention, adoption of 
identical inclusion and exclusion criteria, end-points 
definitions, primary end-point and even sites selection. 
This has finally resulted in enrolling in ARTS II a 
patient population with a higher risk profile and more 
extensive and diffuse CAD compared with ARTS I, 
reflecting the increased confidence of the 
interventional cardiologists to treat more complex 
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Figure 1 
A
B
C
Kaplan-Meier curves reporting (A) MACCE free Survival; (B) 
Death/CVA/MI free survival and (C) freedom from repeat 
revascularization in patients receiving sirolimus-eluting stent (black 
line), bare metal stent (blue line) and surgical revascularisation (red 
lines)
disease. Conversely, the pharmacological environment 
in which the patients were revascularized remained 
clearly and inevitably different in ARTS I vs. ARTS II 
with a higher use of lipid lowering agents, ACE-
inhibitors and �-blockers in the contemporary treated 
patients. This may contribute to explain the observed 
higher prevalence of hypertension and 
hypercholesterolemia –since treatment for these 
conditions is inevitably part of the definition for the 
presence of these risk factors- in the contemporary 
cohort of patients. The impact of the different 
pharmacological approaches on the observed outcome 
remains elusive and despite our multivariable model 
adjusted for these potential confounders, we cannot 
rule out the possibility that they might have 
contributed to improved outcomes in the 
contemporary compared with the historical cohorts of 
patients.
Large observational studies have established 
the internal mammary artery as the “gold standard” 
graft in CABG9-11. These studies have shown that the 
use of an internal mammary artery graft to the LAD 
coronary artery improves survival and reduces the 
incidence of late myocardial infarction, recurrent 
angina, and the need for further cardiac interventions. 
In keeping with this notion, in the CABG group 
enrolled in ARTS I, 93% of the patients received an 
internal mammary artery graft. It has been more 
recently shown that the BIMA grafting is able to 
further improve mid and long-term outcomes 
compared with the use of a single mammary artery16-
20. In ARTS I, 16.5% of the patients undergoing CABG 
received both arterial conduits. Although still not 
widely practised, BIMA is known to be feasible and 
safe in the great majority of patients who require 
multivessel bypass, including those with insulin-
dependent diabetes21-23. Thus, the relative low use of 
BIMA in ARTS I is likely to reflect the fact that this 
approach was not scientifically established at the time 
the study was conducted. As a consequence, our 
findings should not be extrapolated to the scenario 
where BIMA is the strategy of choice for MVD patients 
undergoing surgical revascularisation. Other technical 
refinements of surgical coronary revascularization 
have been recently proposed and clinically tested such 
as off-pump surgery, minimally invasive approaches, 
and robot facilitation. None of them, however, was 
conclusively shown to provide a similar benefit over 
the above-mentioned surgical standard approach in 
terms of the endpoints of ARTS I and ARTS II.  
Longer clinical follow-up are necessary in 
order to establish whether the mid-term benefit of 
SES in patients with complex and diffuse coronary 
disease is maintained beyond one year, especially in 
light of the controversial results recently reported24,25.
Finally, the adjusted impact of clinical or angiographic 
variables on outcome based on the actual 
revascularisation strategy received should be regarded 
as exploratory and hypothesis-generating. 
Conclusions
Our results suggest that if PCI using SES is 
performed on patients with MVD involving the pLAD, 
together with appropriate secondary preventive 
medication 1) the rate of major adverse events can be 
safely and markedly reduced compared with historical 
results based on the use of BMS; and 2) a similar 
overall outcome at one year may be obtained 
compared with an historical cohort of patients in 
whom a single arterial conduit and multiple vein grafts 
was the strategy of choice for revascularisation.  
In spite of all the above mentioned 
limitations, in particular the lack of randomization of 
the ARTS II cohort, our results represent the best  
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Figure 2 
A
B
Hazard ratios for 1-year MACCE and 95% confidence intervals (corrected for multivariate model) by treatment (sirolimus eluting stent (Cypher) vs. bare 
metal stent (BMS) (A) and SES versus coronary artery bypass grafting (CABG) (B). 
available evidence supporting the safety and efficacy 
of SES in MVD patients with involvement of the pLAD 
and suggest for the first time that the unrestricted use 
of SES in this context may lead to a comparable 
outcome with respect to the surgical approach. 
Prospective randomized studies, such as CARDIA, 
FREEDOM, SYNTAX and COMBAT trials are ongoing to 
confirm and extend these preliminary findings. Their 
results are expected to be available in the two year 
period 2009-2011.
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Cyphering the Complexity of Coronary Artery Disease to Predict 
Clinical Outcome in Patients with 3-Vessel Lumen Obstruction 
undergoing Contemporary Coronary Intervention 
APPLICATION OF THE SYNTAX SCORE
Marco Valgimigli, MD, Patrick W Serruys, MD, PhD, Keiichi Tsuchida, MD, PhD, Sophia Vaina, MD, Marie-Angèle Morel, 
BSc, Marcel J. van den Brand, MD, Antonio Colombo, MD, Marie Claude Morice, MD, Keith Dawkins, MD FRCP, Bernard 
de Bruyne, MD, Ran Kornowski, MD, Stefano de Servi, MD, Giulio Guagliumi, MD, J. Wouter Jukema, MD, Kristel 
Wittebols, Msc, Hans-Peter Stoll, MD, Eric Boersma, PhD, Giovanni Parrinello, PhD on behalf of the ARTS II Investigators 
Objective: We sought to assess the predictive value of the recently described Syntax score (SYSCO) in patients 
undergoing percutaneous intervention (PCI) for three-vessel disease and compare it with the modified AHA/ACC lesion 
classification system.
Background: The SYSCO was recently developed as a comprehensive angiographic scoring system aiming to assist in 
patient selection and risk-stratification for individuals with extensive coronary artery disease (CAD) undergoing 
contemporary revascularisation. A validation of this angiographic classification scheme is lacking.
Methods and Results: SYSCO, applied to 1292 lesions in 306 patients undergoing PCI for three-vessel disease in the 
Arterial Revascularization Therapies Study part II, ranged from 4 to 54.5 and after a median of 370 days (range: 274-
400) predicted the rate of major adverse cardiac and cerebrovascular events (MACCE) (HR 1.08/unit increase [95% CI: 
1.05, 1.11]; p<0.0001), with patients in the highest SYSCO tertile having a significantly higher event rate (27.9%) than 
patients in the lowest (8.7%) (HR 3.5 [95% CI: 1.7, 7.4]; p=0.001). By multivariable analyses, SYSCO independently 
predicted outcome with an almost 4 fold adjusted increase in the risk of MACCE in patients with high as compared to low 
values, based on the discrimination level provided by classification and regression tree analysis. When compared to the 
modified AHA/ACC lesion classification scheme, SYSCO showed a higher discrimination ability (c-index 0.58±0.08 vs. 
0.67±0.08, p<0.001, respectively) and a better goodness of fit at the Hosmer-Lemeshow statistic. 
Conclusions: SYSCO is a promising tool to risk stratify outcome in patients with extensive CAD undergoing 
contemporary PCI.
Submitted
Since the earliest reports of coronary angiography, the 
extent of coronary artery narrowing has been considered 
a primary determinant of survival in patients with 
coronary artery disease(1-4). The simple division into 
one, two and three vessel disease has provided a 
convenient scheme for classifying patients and it has 
been extensively employed across literature(5-7). This 
straightforward scoring system, however, is known to 
underestimate the prognostic importance of anatomy, 
especially in patients with complex and diffuse coronary 
artery disease (CAD)(8,9). To overcome this limitation, 
two approaches have been successfully applied: the 
cumulative appraisal of each lesion’s morphology(9,10) 
and the overall quantification of the myocardium in 
“jeopardy”, i.e. distal to every individual lesion in the 
coronary tree(8,11).
Dramatic changes have occurred in the approach to 
percutaneous intervention since that time, which include 
liberal use of drug eluting stents(12) and upfront 
administration of ADP receptor blockers(13,14), allowing 
treatment of more complex and extensive lesions(15) 
and lower overall risk(16). 
The syntax score (SYSCO) was recently developed as a 
comprehensive angiographic tool, which, merging and 
tailoring several previously validated CAD scoring 
systems to current era of intervention, aims to assist in 
patient selection and risk-stratification for individuals with 
extensive CAD undergoing contemporary 
revascularisation(17). A validation of this angiographic 
classification scheme is lacking.  
We applied SYSCO to 1292 lesions in 306 patients 
undergoing treatment for three vessel disease in the 
Arterial Revascularization Therapies Study part II (ARTS 
II) to examine its role in predicting short- and long-term 
incidence of major adverse events. The predictive value 
of SYSCO and the modified AHA lesion classification 
system were compared and the additive role of 
combining SYSCO to other independent outcome 
predictors in our dataset was explored.  
METHODS
Study Design and Patient Population 
ARTS II was a multicenter, non-randomized, open label, 
stratified, non-inferiority trial designed to evaluate sirolimus 
eluting stent (SES, Cypher®, Cordis, Warren, NJ) implantation 
in patients with multivessel disease using the surgical group of 
ARTS I as an historical control(18,19). The inclusion and 
exclusion criteria for ARTS II have been previously reported 
(18,19). Clopidogrel 300 mg as loading dose, or Ticlopidine, 
administered at a dose of 500 mg, was to be started at least 24 
hours before the procedure. Clopidogrel 75 mg per day or 
Ticlopidine 250 mg twice a day was prescribed for at least 2 
months after revascularization. Written, informed consent was 
obtained from each patient prior to enrolment. The ethics 
committee of each participating site approved the study. 
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Patients underwent stratification by clinical site in order to 
ensure the inclusion of at least 1/3 of patients with three-vessel 
disease. Out of a total number of 607 patients included in the 
ARTS II, 325 patients suffered from 3-vessel disease according 
to site investigators. For 19 (5.8%) of them, the diagnostic 
angiogram was not available or of poor imaging quality. Thus, a 
total of 306 patients were finally included in the current 
analysis.
Syntax Score and Angiographic Analysis 
Each coronary lesion producing 50% or more obstruction of the 
lumen in vessels �1.5 mm was separately scored and added to 
provide overall SYSCO the. The SYSCO was calculated using a 
dedicated software which integrates i) the number of lesions 
with their specific weighting factors based on the amount of 
myocardium distal to the lesion according to the Leaman 
score(11) and ii) the morphologic features of each single lesion, 
as previously reported(17) (available at 
http://www.europcronline.com/eurointervention/2nd_issue/36/). 
An example of SYSCO calculation in one of the included patients 
is shown in Figure 1A. All angiographic variables pertinent to 
the SYSCO calculation were computed by two of three 
experienced cardiologists (MV, KT, SV), blinded to procedural 
data and clinical outcome at the angiograms obtained before the 
procedure. In case of disagreement, the opinion of the third 
observer was obtained and the final decision was taken by 
consensus. All other angiographic characteristics, including the 
modified ACC/AHA lesions classification computed before the 
procedure and the completeness of revascularization by intent, 
defined as successful dilatation (i.e. residual diameter stenosis 
less than 20%) of all intended lesions, were derived from the 
angiographic core laboratory database (Cardialysis BV, 
Rotterdam, The Netherlands). For the purpose of statistical 
analysis, type A stenoses were coded 1 point, type B1 stenoses 
2 points, type B2 stenoses 3 points, and type C stenoses 4 
points as previously described(9). 
Study Objectives and Endpoints 
The primary objective of this study was to analyze the value of 
the SYSCO in predicting short- and long-term outcome in 
patients with 3-vessel disease undergoing percutaneous 
revascularization with unrestricted use of SES. The primary 
endpoint was the incidence of major adverse cardiac and 
cerebrovascular events (MACCE), which is a composite of all-
cause death, cerebrovascular event, myocardial infarction and 
repeat revascularization. We report the incidence of the primary 
endpoint at 30 and 400 days. 
End point definitions 
Death from all causes was reported. Cerebrovascular events, 
including stroke, transient ischemic attacks, and reversible 
ischemic neurologic deficits were considered. In the first 7 days 
after the intervention, a diagnosis of myocardial infarction was 
made if there was documentation of new abnormal Q waves 
(according to the Minnesota code) with an increase in creatine 
kinase (CK) or CK-MB fraction or in the absence of pathologic Q 
waves, an increase in CK or CK-MB levels to � 3 times the upper 
limit of normal (ULN) in keeping with current ACC/AHA and ESC 
guidelines for percutaneous coronary intervention (PCI) (PCI 
definition)(20,21). For an analysis of sensitivity, peri-procedural 
MI was also defined according to ARTS I and ARTS II protocol-
mandated definition if there was documentation of new 
abnormal Q waves and either a ratio of serum creatine kinase 
MB (CK-MB) iso-enzyme to total cardiac enzyme that was 
greater than 0.1 or a CK /CK-MB value that was 5 times the 
(ULN) (surgical definition)(18,19,22).
Serum CK and CK-MB iso-enzyme concentrations were 
measured 6, 12, and 18 hours after the intervention. Beginning 
8 days after the intervention, either abnormal Q waves or 
enzymatic changes were sufficient for a diagnosis of myocardial 
infarction. All repeat revascularization procedures were 
recorded. Events were counted from the time of the initial 
procedure. Thrombotic occlusions were defined based either on  
angiographic documentation of a complete occlusion (TIMI flow 
0 or 1) or angiographic documentation of a flow limiting 
thrombus (TIMI flow 1 or 2).  
Figure 1A 
Calculation of the overall Syntax score, based on each coronary lesion 
angiographic characteristics in a representative patient. TO: total 
occlusion; Les: lesion; Calc: calcification; Bifurc: bifurcation; Seg: 
segment
Statistical Analysis
Continuous variables are shown as a mean value � one standard 
deviation (SD) or as a median value and corresponding inter-
quartile range [IQR]. Differences in continuous variables 
between subgroups of patients were evaluated using Student’s 
unpaired t-tests or Mann-Whitney non-parametric tests, as 
appropriate. The distribution of the SYSCO in relation to the 
number of score lesions was analyzed through the analysis of 
variance. The normality assumption for continuous variables was 
evaluated by the Kolmogorov-Smirnov test. Categorical variables 
are presented as counts and percentages, and differences in 
categorical variables between patient subgroups were evaluated 
with the �2 test. Survival curves were generated by the Kaplan-
Meier method, and differences in survival between subgroups of 
patients was evaluated using the log-rank test. 
We applied univariable and multivariable Cox’ proportional 
hazard regression models to evaluate the relation between the 
SYSCO and the incidence of the primary endpoint, based on 
either the PCI or the surgical peri-procedural MI definition. In 
our multivariable model, we adjusted for a broad range of 
potential confounders, including the clinical and angiographical 
characteristics that are presented in tables 1 and 2. In order to 
avoid data-overfitting, we followed a stepwise modeling 
approach applying 1) a variable selection by means of the 
Akaike information criterion (AIC) (that is, a backward 
elimination with a threshold of significance depending on the 
degrees of freedom (DF) associated with the variable at hand; if 
DF = 1, then P�0.157)(23) and 2) a bootstrapped variance 
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estimation of the final model(24). We report crude and adjusted 
hazard ratios (HR) and corresponding 95% confidence intervals 
(CI).
The performance of the SYSCO and the AHA/ACC-classification 
scheme were studied with respect to discrimination and 
calibration. Discrimination refers to the ability to distinguish 
patients with MACCE from those without; it was quantified at 
30-days by the receiver operating characteristics (ROC) with 
their area under the curve (AUCs) and by the c-index for 
contrasting the long-term outcomes. The c-indices for AHA and 
SYSCO were compared by means of U-statistics(25). Calibration 
refers to whether the predicted probability of MACCE is in 
agreement with the observed probability; it was measured with 
the Hosmer-Lemeshow goodness-of-fit test. 
All variables associated to outcome at a p-value of 0.10 at Cox 
proportional regression analysis, including the AHA and SYSCO 
were subjected to classification and regression tree (CART) 
analysis to identify the best outcome predictors, in terms of 
MACCE at follow-up, and develop the risk stratification 
model(26). This method is based on recursive partitioning 
analysis and involves the segregation of different values of 
classification variables through a decision tree composed of 
progressive binary splits. This approach has the advantage to 
uncover possible interaction among predictors. All statistical 
tests were 2-tailed and probability was significant at a level of 
<0.05. Statistical analysis was performed on Statistica 6.1 
(Statsoft Inc. Tulsa, Oklahoma) and R-language (R Foundation). 
RESULTS
Syntax score and baseline or procedural 
characteristics
Three hundred and six patients and 1292 lesions in total, 
with an average of 4.22±1.2 lesions per patient, were 
analyzed. The overall SYSCO in the studied population 
had an approximately normal distribution (p=0.37) with 
a slight left-skewness (Figure 1B); it ranged from 4 to 
54.5 with a mean (95% CI) ±SD of 22.7 (21.8-23.7) 
±8.6 and a median [IQR] of 22 [16-28]. As shown in 
Figure 1C, there was a clear progression in the central 
values of the SYSCO according to the number of scored 
lesions (p<0.001); however a substantial overlap in the 
interquartile ranges of the SYSCO from 2/3 up to 6 
scored lesions and in the overall ranges from 2/3 up to 7 
scored lesions was observed. In 4 patients, 2 lesions only 
were scored since the third treated lesion in each of 
these cases was judged to result in less than 50% lumen 
obstruction at visual estimation. Baseline characteristics 
of the study population stratified across SYSCO tertiles 
are shown in table 1. Age progressively increased while 
history of coronary artery disease progressively 
decreased from the first to the third SYSCO tertile. Left 
ventricular ejection fraction, history of previous anterior 
MI and unstable angina at presentation and diagnosis of 
stable angina were also not uniformly distributed among 
the three groups. As might be expected, there was 
generally a progressive increase in complexity in most 
angiographic and procedural characteristics from first to 
third tertile (Table 2).
30-day Outcome 
Short-term outcome after intervention according to 
SYSCO tertiles is reported in table 3. No death occurred 
within the first 30 days. Patients in the first SYSCO tertile 
showed the lowest and those in the third tertile the 
highest rate of major adverse cardiac and 
cerebrovascular events. This difference was driven by 
both re-intervention and occurrence of myocardial 
infarction, particularly when the PCI definition of peri- 
Figure 1B 
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procedural MI was applied. One cerebrovascular accident 
and two angiographically confirmed subacute vessel 
occlusions occurred in the third SYSCO tertile, while none 
of these events were observed in the first or second 
SYSCO tertiles. 
Long-term Outcome 
After a median follow-up of 370 days (range: 274-400), 
SYSCO significantly predicted the rate of MACCE [death, 
CVA, MI or TVR] (HR 1.08/unit increase [95% CI: 1.05, 
1.11]; p<0.0001). The distribution of MACCE rate 
according to SYSCO tertiles is shown Figure 2A. Patients 
in the highest SYSCO tertile had a significantly higher 
event rate (27.9%) compared both with patients in the 
lowest (8.7%, HR 3.5 [95% CI: 1.7, 7.4]; p=0.001) or 
the 2 lowest SYSCO tertiles combined (9.9%, 
respectively, HR 3.09 [95% CI: 1.7, 5.5]; p=0.0001). 
Mortality was low in all the three groups (0% in the first, 
1% in the second and third SYSCO tertile (p=0.44), while 
the rate of death or MI (2.9% in the first, 3.6% in the 
second, 12.9% in the third SYSCO tertile; p=0.006), the 
composite death/CVA/MI (2.9% in the first, 3.6% in the 
second, 15% in the third SYSCO tertile; p=0.001) 
(Figure 2B) and the need for TVR (5.8% in the first, 
6.4% in the second, 15% in the third SYSCO tertile;  
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Table 1. Baseline Characteristics of the Study Population 
Syntax Score
I Tertile 
(�18)
II Tertile 
(>18-26) 
III
Tertile
(>26) 
Variables
(N=103) (N=110) (N=93) 
P
value 
Age (ys) 61�10 64�8 66�10 0.00025
Males n.(%) 81 (79) 82 (75) 71 (76) 0.78 
BMI (kg/m2) 28�4 27�4 27�4 0.42
Diabetes n.(%) 19 (18) 28 (38) 26 (36) 0.26 
Insulin-dep. (%) 5 (5) 5 (5) 6 (6) 0.81 
Hypertension n.(%) 67 (65) 78 (71) 68 (73) 0.44 
Hyperchol.terolemia 
n.(%) 83 (80) 80 (72) 68(73) 0.34 
Current Smokers 
n.(%) 21 (20) 23 (21) 14 (15) 0.51 
Family history 
n.(%) 49 (48) 39 (35) 25 (27) 0.01 
Creatinine elevation 
n.(%) 0 (0) 1 (1) 2 (2) 0.30 
LV E F (%) 63�11 59�12 60�11 0.044
MEDICAL HISTORY N.(%)
   PCI 0 (0) 0 (0) 0 (0) … 
   Myocardial 
Infarction 29 (28) 47 (43) 33 (35) 0.08 
   Anterior MI 6 (6) 16 (15) 5 (5) 0.03 
   COPD 1 (1) 5 (5) 5 (5) 0.20 
   Peripheral Arterial 
Disease 10 (10) 4 (4) 10 (10) 0.11 
   Carotid Surgery 2 (2) 1 (1) 2 (2) 0.73 
CLINICAL PRESENTATION N.(%)
   Stable Angina 64 (62) 44 (40) 57 (61) 0.001 
   CCS 2.3�0.64 2.20�0.70 2.24�0.73 0.90
   Silent Ischemia 6 (6) 15 (14) 7 (8) 0.11 
   Unstable Angina 33 (32) 51 (46) 29 (31) 0.03 
      IIIB/IIIC 7 (21)/ 1(3)
8 (16)/ 5
(10)
5 (17)/ 2
(7) 0.71
MEDICATIONS AT SCREENING N.(%)
   Aspirin 93 (90) 99 (90) 79 (85) 0.42 
�-blockers 72 (70) 89 (81) 65 (70) 0.10 
   ACE-Inhibitors 45 (44) 50 (45) 42 (45) 0.96 
   Statins 79 (77) 75 (68) 64 (69) 0.32 
MEDICATIONS AT DISCHARGE N.(%)
   Aspirin 102 (99) 107 (97) 89 (96) 0.34 
�-blockers 77 (75) 91 (83) 71 (76) 0.33 
   ACE-Inhibitors 49 (48) 59 (54) 46 (49) 0.66 
   Statins 90 (87) 96 (87) 79 (85) 0.85 
ACE: angiotensin converting enzyme; PCI: percutaneous coronary 
intervention, LV: left ventricular, COPD: chronic obstructive pulmonary 
disease; MI: myocardial infarction;  
(p=0.01) (Figure 2C) varied significantly different 
across SYSCO tertiles. When the surgical definition of 
peri-procedural MI was employed, the cumulative 
incidence of MACCE, remained significantly different in 
relation to SYSCO tertiles (p=0.001), with a higher 
overall event rate in the highest (21.5%) compared to 
the lowest (5.8%; HR 4.0 [95% CI: 1.6, 9.9]; p=0.003) 
or the 2 lowest (7.0%; HR 3.3 [95% CI: 1.7, 6.3]; 
p=0.0005) SYSCO tertiles (Figure 2D). The impact of 
SYSCO on mid and long term outcome remained 
consistent after censoring those events occurring early –
within 30 days– after the index procedure (Figure 2E).
Multivariable Analysis 
After adjustment for a range of potential confounders 
(Table 4), a higher SYSCO remained significantly 
associated with MACCE (adjusted HR 1.07 [95% CI: 
1.03, 1.11]; p=0.0003), with an adjusted HR of 3.1 
[95% CI: 1.38, 6.9, p=0.006] or 2.8 [95% CI: 1.39, 5.5, 
p=0.003] going from the lowest or the middle to the 
highest SYSCO tertile, respectively, or of 2.94 [95% CI: 
1.6, 5.3, p=0.0004] from the two lowest to the highest 
SYSCO tertile. Others predictors of outcome at 
multivariable analysis, independent of the applied 
definition of peri-procedural MI, were diabetes and 
complete revascularization (Table 4).
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One-year adverse events stratified according to the Syntax score tertiles, 
based on the PCI (A, B, E) or the surgical (D) definition of peri-procedural 
myocardial infarction. Cumulative risk of major cardio- and cerebro-
vascular adverse events (MACCE) (A, D, E); death, cerebrovascular 
accident (CVA) or myocardial infarction (B) and target vessel 
revascularization (TVR) (C). In E, those events occurring within 30 days 
after the index procedure have been censored.
Kaplan-Meier curves were constructed according to the 
four combinations generated by having high or low 
(according to the third tertile) SYSCO while undergoing 
complete or incomplete revascularization or presenting 
with or without diabetes. As shown in Figure 3A,
incomplete revascularization tended to worsen prognosis 
independently from baseline SYSCO, while the presence 
of diabetes negatively influenced outcome only in 
patients with low SYSCO at baseline (Figure 3B).
Comparing AHA lesion classification scheme to the 
Syntax score
When coded as previously described(9), the modified 
AHA/ACC lesion classification scheme ranged from 3 to 
26 with a mean±SD of 11.6 ±8.6, showing with SYSCO a 
significant but not tight correlation (r=0.48, p<0.0001). 
By univariable Cox proportional hazard analysis, the 
AHA/ACC score significantly predicted outcome in terms 
of MACCE at 400 days (1.09/unit increase [95% CI: 1.01, 
1.17, p=0.02], with patients in the highest AHA/ACC 
lesion classification tertile having a significantly higher 
event rate (30.6%) compared with both patients in the 
lowest (12.9%, HR 2.2 [95% CI: 1.06, 4.9]; p=0.03) or  
the 2 lowest AHA/ACC score tertiles combined (13.7%, 
respectively, HR 2.01 [95% CI: 1.11, 3.6]; p=0.019). 
When forced into the multivariable model reported in 
Table 4, however, the AHA/ACC score failed to emerge 
as an independent predictor of outcome (1.001 [95% CI: 
0.83, 1.06, p=0.24]) while the estimate and 95%CI for 
SYSCO remained unchanged. Similarly, including the 
AHA/ACC score among the univariable MACCE predictors 
reported in table 4 while excluding B2 or C type lesions 
in order to avoid co-linearity in the model, the AHA/ACC 
score failed to emerge as an independent predictor of 
MACCE (irrespective from the definition of MI applied) 
based on AIC selection process. 
By ROC analysis, the AUC for MACCE rate at 30-days was 
higher for SYSCO than for the AHA/ACC score (0.73, 
95%CI: 0.61-0.86 vs. 0.56, 95%CI: 0.42-0.69, p=0.02). 
At 400 days, the c-index for SYSCO resulted to be higher 
than that for the AHA/ACC score based on both the PCI 
(0.58±0.08 and 0.67±0.08, p<0.001) or the surgical 
definition (0.58±0.1 and 0.66±0.09, p=0.001) of peri-
procedural MI. The c-index for the full model, including 
both SYSCO and the AHA/ACC score was 0.73, which 
became 0.67 and 0.73 after removal of SYSCO and 
AHA/ACC score, respectively. The Hosmer-Lemeshow 
statistic was �2= 4.5, p=0.81for SYSCO and �2= 12.1, 
p=0.15 for the AHA/ACC scoring system. 
Classification tree analysis 
By evaluating all variables related to 400-day MACCE at a 
p value of 0.10 or less at univariable Cox regression 
analysis (Table 4), including the AHA score, the CART 
method confirmed SYSCO as the best single discriminator 
between patients with and without MACCE, with a 
discrimination level of 31 or 35 according to the PCI or 
surgical definition of peri-procedural MI (Figure 4).
When stratified into the discrimination level suggested by 
CART analysis, the adjusted hazard ratio for MACCE was 
3.9 [95%CI: 2, 7.3; p<0.0001] or 4.5 [95%CI: 2.1, 9.6; 
p=0.0001] for patients with high compared to those with 
low SYSCO based on PCI or surgical MI definition, 
respectively.
Based on the threshold provided by CART analysis, 
completeness of revascularization successfully stratified 
outcome in patients with high SYSCO (Figure 3C), while 
the presence of diabetes failed to impact on outcome in 
patients with both high and low SYSCO levels (Figure 
3D).
DISCUSSION
The identification of a variety of distinct features 
associated with poor prognosis in patients with CAD has 
been a major breakthrough in the modern medicine, 
both as an aid to allocate resources and as a tool to 
tailor intervention based on individual risk. Despite the 
continuous effort to detect new and progressively more 
sophisticated markers of prognosis in patients with CAD, 
the implementation of unconventional and expensive 
risk-stratification algorithms in the clinical setting remains 
problematic. Since the earliest reports of coronary 
angiography, the extent of coronary artery narrowing has 
been considered a primary and readily available 
determinant of survival in patients with coronary artery 
disease(1-4). Moreover, despite continuous refinement in 
peri-procedural anti-thrombotic therapy and intra-
coronary devices, the extent and the complexity of CAD 
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Table 2. Angiographic and Procedural Characteristics of the Study population 
Syntax Score 
I Tertile 
(�18) 
II Tertile 
(>18-26) 
III
Tertile 
(>26) 
P-
value
Variables (N=103) (N=110) (N=93)  
Diseased Lesions 3.6�0.9 4.2�1 4.9�1.3 <0.0001 
Treated lesions 3.33�0.84 3.80�1.08 3.9�1.40 0.00041
Treated Vessel     
   LAD 101 (99) 109 (100) 90 (98) 0.30 
   CFX 99 (97) 103 (95) 86 (94) 0.49 
   RCA 97 (95) 102 (94) 80 (87) 0.09 
Patients receiving 2-vessel 
intervention 11 (10) 14 (13) 19 (19) 0.88 
Patients receiving 3-vessel 
intervention 93 (90) 96 (87) 73 (79) 0.98 
Number of implanted stents 3.80�1.08 4.30�1.4 4.71�1.9 <0.0001 
Total stent length per patient (mm) 73.8�22 82.8�28 95�40 <0.0001 
Maximal pressure of stent deployment 16.8�2.8 16.4�2.8 16.6�3.1 0.55 
Treated lesions, no. (%)     
Type A 0.33�0.61 0.30�0.54 0.20�0.43 0.23 
Type B1 0.9�0.9 1.05�0.97 1.08�1 0.35 
Type B2 2.20�1.1 2.22�1.1 2.58�1.4 0.02 
Type C 0.25�0.48 0.60�0.6 0.87�0.99 <0.0001 
Total occlusion < 3 months 0�0 0.02�0.2 0.01�0.1 0.03 
Total occlusion > 3 months 0.02�0.1 0.15�0.36 0.22�0.4 0.0002 
Moderate to severely calcified lesions 0.96�1.1 1.18�1.2 1.67�1.4 0.0003 
Thrombus containing lesions 0.05�0.2 0.03�0.2 0.0�0 0.10 
Eccentric lesions 91 (90) 93 (87) 81 (90) 0.71 
Bifurcated lesions 1.06�0.95 1.17�0.93 1.62�1.2 0.0003 
Stented side branches 0.91�0.8 1.0�0.8 1.3�1.1 0.02 
Balloonned side branches 0.03�0.2 0.11�0.3 0.06�0.3 0.11 
Use of GP IIb/IIIa inhibitors 36 (35) 37 (34) 24 (26) 0.32 
Patients with complete 
revascularization 75 (73) 60 (55) 28 (30) <0.0001 
LAD: left anterior descending; CFX: circumflex; RCA: right coronary artery 
remains a well-recognized major determinant of short 
and long-term prognosis in patients undergoing 
percutaneous coronary revascularisation(27). The 
AHA/ACC lesion classification scheme was proposed in 
1986(28) and modified in 1990(9). It remains by far the 
most commonly employed lesion classification system 
worldwide. 
The SYSCO was recently developed in an attempt at 
assisting in patient selection and risk-stratification of 
individuals with extensive CAD undergoing 
revascularisation(17) of the left main coronary artery 
and/or of the three main coronary arteries; i.e. a subset 
of patients which were not or only poorly represented 
when the AHA scoring system was created and validated. 
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Table 3. 30-Day Outcome 
Syntax Score 
I Tertile 
(�18)
II Tertile 
(>18-26) 
III Tertile 
(>26) P-value*
Variables (N=103) (N=110) (N=93)  
PCI MI DEFINITION     
MACCE 0 (0) 2 (2) 7 (8) 0.005 
     Death/CVA/non-fatal MI 0 (0) 1 (1) 4 (4) 0.05 
     Death/non-fatal MI 0 (0) 1 (1) 3 (3) 0.12 
     Non-fatal MI 0 (0) 1 (1) 3 (3) 0.12 
     Non-Q Wave MI   0 (0) 0 (0) 0 (0) …
SURGICAL MI DEFINITION    
MACCE 3 (3) 5 (5) 11 (12) 0.03
Death/CVA/non-fatal MI 3 (3) 3 (3) 10 (11) 0.02 
Death/non-fatal MI 3 (3) 3 (3) 9 (10) 0.04 
Non-fatal MI 3 (3) 3 (3) 9 (10) 0.04 
Non-Q Wave MI 3 (3) 2 (2) 6 (6) 0.23 
Death 0 (0) 0 (0) 0 (0) …
CVA 0 (0) 0 (0) 1 (1) 0.32 
Q-wave MI 0 (0) 1 (0) 3 (3) 0.12 
Target Vessel Revascularization 
0 (0) 
1 (1) 5 (5) 0.02 
    Re-PCI 0 (0) 0 (0) 2 (2) 0.10 
    CABG 
0 (0) 
1 (1) 3 (3) 0.12 
Sub-acute Occlusion† 0 (0) 0 (0) 2 (2) 0.10 
*: By Fischer’s exact test; †: Angiographically documented. 
CK: creatine kinase; PCI: percutaneous coronary intervention, CABG: coronary artery bypass grafting, MI: myocardial infarction, CVA: cerebrovascular 
accidents; ULN: upper limit of normal 
To obtain some insights into the performance of the 
SYSCO in this context, patients undergoing intervention 
for three vessel disease as part of the ARTS II were 
studied, including a total of 306 patients and 1292 
lesions. Our findings suggest that SYSCO may be a 
suitable tool to risk-stratify early and late outcome in this 
subset of patients. Moreover, in the context of 3-vessel 
disease patients who have been selected according to 
the inclusion and exclusion criteria imposed by the ARTS 
II investigation(19), the SYSCO performed significantly 
better than the modified AHA/ACC lesion classification 
system in terms of prognostic accuracy. These 
statements are mainly based on the following 
observations: 
1) SYSCO predicted the rate of MACCE, with patients in 
the highest SYSCO tertile showing a significant higher 
event rate at both 30 days and 1-year compared to 
patients in the lowest or the 2 lowest SYSCO tertiles 
combined. This was true for both applied peri-procedural 
MI definitions. The impact of SYSCO on outcome 
remained consistent even after censoring those events 
occurring within the first 30 days after the index 
procedure. They might be more frequently related to the 
procedural success or the interplay between procedural 
success and coronary lesion complexity than on coronary 
lesion extension/complexity alone. 
2) After adjustment for all potential confounders, 
including clinical presentation and lesion characteristics, 
SYSCO remained an independent predictor of MACCE at 
one year follow-up, with an almost three fold increase in 
the risk of events in patients in the highest compared to 
two lowest SYSCO tertiles. 
3) Using a time-independent analysis, a better goodness 
of fit was obtained when modelling the risk provided by 
SYCO than that by the modified AHA lesion classification. 
This implies a closer relationship between observed and 
predicted event rates when SYSCO is employed.
In keeping with previous analysis, the AUC for SYSCO 
was greater than the AHA/ACC score for MACCE at 30-
days. Similarly, using a time-dependent analysis, based 
on the c-index computation, the prognostic accuracy 
provided by SYSCO was confirmed to be significantly 
higher. This was further corroborated after calculating 
the c-index for the whole model, which decreased from 
0.73 to 0.67, after forcing SYSCO out, while it remained 
unaffected after exclusion of the AHA lesion 
classification.
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Table 4. 
Variables P-Values Hazard Ratios (95%) CI �2
UNIVARIABLE ANALYSIS    
Syntax score  >0.0001 1.08 (1.05, 1.11) 26 
Complete revascularisation 0.004 0.42 (0.23, 0.76) 8.7 
No. C type lesions 0.002 1.46 (1.06, 2.6) 7.9 
No. diseased lesions 0.01 1.33 (1.08, 1.66) 6.0 
Diabetes 0.01 2.17 (1.17, 3.8) 5.8 
No. calcified lesions 0.02 1.32 (1.02, 1.60) 4.8 
No. treated lesions 0.04 0.75 (0.57, 0.98) 4.4 
Stable angina 0.08 0.78 (0.58, 1.04) 3.1 
No. bifurcated lesions 0.08 1.25 (0.96, 1.61) 2.9 
Age 0.10 1.02 (1.00, 1.04) 2.7 
Use of �-blockers at screening 0.09 0.60 (0.33, 1.08) 2.7 
Use of GP IIb/IIIa inhibitors 0.10 1.61 (0.92, 2.8) 2.6 
Total stent length 0.11 1.00 (0.99, 1.01) 2.3 
Total occlusion > 3 months 0.12 1.75 (0.85, 3.6) 2.1 
Unstable angina 0.20 1.45 (0.82, 2.5) 1.6 
History of COPD 0.30 1.84 (0.57, 6.0) 0.9 
Previous MI 0.38 0.75 (0.40, 2.4) 0.8 
Previous anterior MI 0.54 0.70 (0.22, 2.21) 0.4 
No. implanted stents 0.54 0.94 (0.77, 1.14) 0.4 
No. of ballooned side branches 0.62 1.27 (0.48, 3.3) 0.2 
Number of B2 type lesions 0.69 1.05 (0.83, 1.33) 0.2 
RCA treated 0.76 0.86 (0.31, 2.3) 0.08 
LVEF (%) 0.83 1.0 (0.98, 1.02) 0.05 
Family history 0.87 1.05 (0.58, 1.89) 0.03 
No. stented side branches 0.85 1.00 (0.73, 1.4) 0.03 
History of PAD 0.90 1.06 (0.38, 2.9) 0.01 
No. eccentric lesions 0.97 0.99 (0.39, 2.49) 0.00 
MULTIVARIABLE MODEL   47 
Syntax score 0.0003 1.07 (1.03-1.11) (95%CI at BS: 1.02-1.12)* 
Diabetes 0.002 2.07 (1.12-3.08) (95%CI at BS: 1.13-4.1)* 
Use of �-blockers 0.09 0.57(0.30, 1.09) (95%CI at BS: 0.30-1.08)*
Stable angina 0.029 0.72 (0.54-0.97) (95%CI at BS: 0.48-0.98)*
Complete revascularisation 0.006 0.51 (0.25-0.89) (95%CI at BS: 0.26-0.93)* 
*: variance matrix estimated by bootstrap (BS) analysis. GP: glycoprotein, PAD: peripheral arterial disease, LVEF: left ventricular ejection fraction, COPD: 
chronic obstructive pulmonary disease. RCA: right coronary artery. To test for co-linearity among C-type and number of calcified or bifurcated lesions, 
separate models were constructed including the number of C-type lesions only or the number of bifurcated or calcified lesions while excluding the number 
of C-type lesions, which confirmed the validity of the multivariable model reported above. Based on the surgical definition of peri-procedural myocardial 
infarction, the Syntax score remained an independent outcome predictor (HR: 1.08 [95% CI: 1.03-1.1]), together with diabetes and complete 
revascularisation. 
4) CART is a recently developed nonparametric technique 
that can select from among a large number of variables 
and their interactions those that are most important in 
determining the outcome variable to be explained. Based 
on this statistical tool, SYSCO was identified as the best 
single predictor between patients with and without 
MACCE at follow-up, with a discrimination level of 31 and 
35 according to the threshold set to define the 
occurrence of significant peri-procedural necrosis. This 
was in keeping with the c-index analysis, which showed a 
value of 0.68 for SYSCO, individually considered, while 
the full model, in the absence of SYSCO computed 0.67. 
Based on these discrimination levels, the adjusted hazard 
ratio for MACCE at follow-up increased to 3.9 or 4.5 for 
patients with high compared to those with low SYSCO 
according the PCI or surgical MI definition. Of note, this 
CART-based stratification analysis minimized the 
prognostic impact of diabetes while intensified the role of 
completeness of revascularization in the group of 
patients with high SYSCO. However, all attempts to 
combine SYSCO with other independent outcome 
predictors in our dataset, i.e. completeness of 
revascularization and diabetes, should be regarded as 
exploratory due to limited statistical power.  
Our current findings, while supporting the potential value 
of the recently described SYSCO, should be critically 
considered in the light of the following considerations: 
1) The majority of the prognostic models so far 
proposed has been derived from an original dataset, 
either from large scale registry or a randomized 
controlled trial(29). In this context, a vital aspect of 
prediction is to consider whether such a model is 
transportable to similar patients in another location(30). 
The concept is sometimes referred to as generalizability 
or validity, and a model which is found to pass such a 
test is said to be have been validated(30).  
2) SYSCO has not been derived from an analysis of an 
original dataset. Rather, it was created by an 
international group of expert interventional cardiologists 
and cardiac surgeons by merging together and tailoring, 
based on personal expertise, several previously proposed 
CAD scoring systems(17).
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Figure 3. Cumulative risk of major cardio- and cerebro-vascular adverse events (MACCE) 
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MACCE, based on the PCI definition of peri-procedural MI) according to the four combinations generated by having low (first or second tertile) or high 
(third tertile) Syntax score and undergoing complete (CR) or incomplete revascularization (ICR) (A) or presenting with or without diabetes (B). In C and D, 
the threshold defining high or low Syntax score was based on results of CART analysis 
The present report is the first attempt to evaluate the 
predictive value of this recently developed angiographic 
scoring system. Thus, we currently face the uncommon 
situation where a new scoring system is tested on a 
dataset which is different from the original one, yet the 
new score cannot be considered fully validated because 
this the only dataset in which the model has been tested. 
As such, it remains unclear whether and to what extent 
our current findings can be reproduced in a different 
group of patients with extensive CAD.
The prognostic implications of SYSCO for patients with 
three-vessel and/or left main disease undergoing either 
percutaneous or surgical coronary revascularization will 
be further evaluated in the ongoing SYNergy between 
Percutaneous Coronary Intervention with TAXus™ and 
Cardiac Surgery (SYNTAX) study(31). As soon as this 
dataset will be available, each single item of SYSCO will 
be “weighed” according to discrepancy between 
observed and predicted event rate in order to further 
optimize calibration and the interaction between global 
score and its single components with type of 
revascularisation (i.e. percutaneous versus surgical) 
investigated.
Conclusions
Our current findings are encouraging and support the 
concept that SYSCO, a recently developed angiographic 
scoring system, is potentially able to reliably and easily 
risk-stratify patients with three-vessel disease 
undergoing contemporary percutaneous intervention. 
Further confirmation from different and larger datasets is 
required before SYSCO can be considered to be 
reasonably validated and implemented into routine 
clinical practice.  
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Figure 4. 
A
B
Binary splits based on classification and regression tree (CART) analysis. Among all tested univariable predictors of outcome, the Syntax score emerged as 
the best single discriminator between patients with and without MACCE during the period of observation, with a discrimination level of 31 (A) or 35 (B) 
depending on the applied PCI or surgical peri-procedural myocardial infarction definition, respectively. 
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Case Reports
Left Ventricular Unloading and Concomitant Total
Cardiac Output Increase by the Use of Percutaneous
Impella Recover LP 2.5 Assist Device During High-Risk
Coronary Intervention
Marco Valgimigli,1 Paul Steendijk,2 George Sianos,1 Emile Onderwater,1
and Patrick W. Serruys1*
A number of techniques have been proposed for circulatory support during high-risk per-
cutaneous coronary interventions (PCI), but no single approach has achieved wide
acceptance so far. We report on a patient with severe left ventricular (LV) impairment who
underwent a PCI with the use of a new left ventricular assist device, the Impella Recover
LP 2.5 system. The effects on global cardiac output were determined by thermodilution
(TD) and LV pressure-volume loops obtained by conductance catheter. The activation of
the pump resulted in a rapid and sustained unloading effect of the LV. At the same time,
the continuous expulsion of blood into ascending aorta throughout the cardiac cycle pro-
duced by the pump resulted in an increase of systemic overall CO, measured by the TD
technique, of 1.43 L/min. The procedure was uncomplicated and the patient remained
uneventful at follow-up. Our single experience gives new input for future trials to assess
the effect of the Impella Recover LP 2.5 assist device on outcome in this subset of
patients. ' 2005 Wiley-Liss, Inc.
Key words: left ventricular assist device; high-risk percutaneous coronary intervention;
pressure-volume loop
INTRODUCTION
The growing heart failure population, combined with
technical advances in interventional procedures and
imaging, has led to an increased number of percutaneous
coronary interventions (PCIs) that are performed in
patients with severely depressed left ventricular (LV)
function. The low rate of restenosis with drug-eluting
stents is likely to stimulate this trend further [1].
However, the beneﬁt of revascularization in patients with
LV dysfunction is offset by an absolute increase of short-
and long-term mortality after contemporary PCI [2,3].
Therefore, a number of techniques have been pro-
posed for circulatory support during these high-risk
PCI, but no single approach has achieved wide accept-
ance so far [4–9]. Limited effectiveness of actual sup-
port and device-related complications have hampered
the widespread use of these devices [10].
The recently published ACC/AHA PCI guidelines
report that cardiopulmonary support for high-risk PCI
should be reserved only for patients at the extreme end of
the spectrum of hemodynamic compromise, such as those
patients with extremely depressed left ventricular function
and patients in cardiogenic shock. However, it should be
noted that support for high-risk catheterization and angio-
plasty was nearly as frequent as support for cardiogenic
shock (27.2% vs. 27.3%, respectively) in the recently pub-
lished benchmark registry [11], further reinforcing the
notion that circulatory assistance in high-risk patients is
often felt to be required even during contemporary PCI.
1Department of Interventional Cardiology, Thoraxcenter,
Erasmus MC, Rotterdam, The Netherlands
2Department of Cardiology, Leiden University Medical Center,
Leiden, The Netherlands
*Correspondence to: Dr. Patrick W. Serruys, Department of
Interventional Cardiology, Erasmus MC Rotterdam, Thoraxcenter
Bd 404, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands.
E-mail: p.w.j.c.serruys@erasmusmc.nl
Received 22 June 2004; Revision accepted 7 February 2005
DOI 10.1002/ccd.20380
Published online 13 May 2005 in Wiley InterScience (www.interscience.
wiley.com).
' 2005 Wiley-Liss, Inc.
Catheterization and Cardiovascular Interventions 65:263–267 (2005)
Chapter  18
188
We report on a patient with severe LV impairment
who underwent a PCI with the use of a new LV assist
device (LVAD), the Impella Recover LP 2.5 system. The
effects on global cardiac output were determined by ther-
modilution (TD) Swan-Ganz catheter, whereas changes
in LV function and LV (un)loading were monitored by
LV pressure-volume loops obtained by conductance
catheter [12]. The procedure was also monitored with
intracardiac echocardiography (ICE; AcuNav, Siemens).
Device Description
The Impella LVAD Recover LP 2.5 (Impella Cardio-
technik, Aachen, Germany) is a miniaturized rotary
blood pump (4 mm, 12 Fr, in outer diameter), which is
placed through the aortic valve, aspirates blood from LV
cavity, and expels it in the ascending aorta (Fig. 1). In
clinical conditions, the pump provides up to 2.5 L/min
at its maximal rotation speed of 50,000 rpm. The device,
which has the great advantage to be inserted percutane-
ously through a 13 Fr femoral sheath, is mounted on 9
Fr pigtail catheter, so that it can be easily and quickly
delivered in the LV and safely left in place up to 5 days.
The Impella Recover LP 2.5 catheter is distally con-
nected to a portable mobile console, in which invasive
pressure, recorded from the catheter, is displayed with
the actual rpm of the pump, thus guiding the correct
positioning and functioning of the device.
CASE REPORT
A 56-year-old man with a history of four myocardial
infarctions and symptomatic severe LV dysfunction
(LVEF ¼ 27%; NYHA class III) was admitted to hospital
for Braunwald class IB unstable angina. The patient had
been submitted to balloon angioplasty of the circumﬂex
artery (CFx) in 1992. However, the procedure, supported
by intra-aortic balloon counterpulsation (IABP), was then
complicated by periprocedural myocardial infarction.
His coronary angiogram revealed total occlusions of
a small nondominant right coronary artery and of an
intermediate branch at mid and ostial segments, respec-
tively. The left anterior descending artery was free
Fig. 1. Impella recover LP 2.5 catheter. In the insert, the pigtail tip is shown at bigger magni-
ﬁcation, revealing the site where blood is aspirated from the left ventricle (Inﬂow), together
with the rotor (Impeller) whose rotation generates the force needed for the continuous expul-
sion of blood into ascending aorta (Outﬂow). [Color ﬁgure can be viewed in the online issue,
which is available at www.interscience.wiley.com]
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from signiﬁcant stenoses. The dominant CFx, with sig-
niﬁcant narrowings in the mid segment and in the ﬁrst
posterolateral branch (Fig. 2a), was considered the cul-
prit vessel based on the ﬁnding of a reversible perfu-
sion defect in the LV inferior and posterlateral walls at
a stress-single photon emission computed tomography.
After inserting a 13 Fr sheath in the right femoral artery,
an angiographic Judkins right catheter was used to deliver
a dedicated exchange 0.14@ guidewire in the LV; the diag-
nostic catheter was then removed and the Impella pump
was positioned over the wire across the aortic valve under
angiographic guidance. The intracardiac AcuNav echocar-
diographic catheter was also inserted in the right ventricle
in order to conﬁrm a stable position of the pump during
intervention and to investigate any change in aortic regur-
gitation after pump insertion. The actual rpm of the pump
and aortic pressure were monitored on the Impella console.
After positioning of the Impella, a 7 Fr combined pres-
sure-conductance catheter was introduced via the left
femoral artery and placed along the long axis of the LV.
The catheter was connected to a Cardiac Function Lab
(CD Leycom, Zoetermeer, The Netherlands) for online
display and acquisition of LV pressure-volume loops.
The conductance catheter was calibrated using thermodi-
lution and hypertonic saline dilution as previously
described [13].
The hemodynamic effects of the Impella are illustrated
in Figure 3, which shows the acute changes in LV vol-
ume and pressure while changing the pump from its min-
imal (20,000 rpm) to its maximal speed (50,000 rpm). A
continuous minimal speed is required to prevent back-
ward leakage from the aorta to the LV through the pump
cannula.
The average pressure-volume loops from the pump low
(20,000 rpm) period and the pump high (50,000 rpm)
period indicate an acute unloading of the LV documented
by a reduced end-diastolic pressure (18 to 11 mm Hg),
end-diastolic volume (345 to 321 mL), and stroke volume
(94 to 76 mL). Consequently, the output generated by the
LV dropped from 5.99 to 5.01 L/min. End-systolic pres-
sure increased slightly, whereas ejection fraction was
reduced. Remaining indexes did not show important
changes.
Despite the unloading of the LV, thermodilution meas-
urements obtained during low- and high-speed pumping
showed that cardiac output increased from 5.95 to
7.38 L/min. This 1.43 L/min increase in global ﬂow,
despite the 0.98 L/min drop in output provided by the
Fig. 2. Angiographic image in right anterior oblique and caudal projection of the left coro-
nary artery before (a) and after (b) coronary intervention. Arrow indicates lesion in the left
posterolateral branch. Arrowhead indicates lesion in the mid circumﬂex artery. Double arrow-
head indicates tip of the AcuNav catheter positioned in the right ventricle. Asterisk indicates
Impella Recover LP 2.5 catheter positioned in the left ventricle.
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LV, indicates that the Impella output was 2.41 L/min.
This is close to the 2.5 L/min predicted by in vitro tests
at maximal speed.
At this stage, the conductance catheter was
removed and replaced with guiding catheter to position
a balance middle-weight 0.14@ wire (Guidant) in the
CFx. The lesion of the posterolateral branch was predi-
lated with a 1.5 � 15 mm Maverick balloon (Boston
Scientiﬁc) and the distal and proximal lesions subse-
quently stented with Taxus (Boston Scientiﬁc) 2.25 �
24 mm at 14 atm and 3.0 � 24 mm at 20 atm, respec-
tively, with good ﬁnal angiographic result (Fig. 2b).
The intervention was uneventful and the hemodynamic
status of the patient remained stable during procedure
Fig. 3. Top: Continuous left ventricular volumes and pressures recording from the conduc-
tance catheter with Impella pump at its minimum (left) and maximum (right) degree of activa-
tion. Middle: By combining instantaneous pressures and volumes during cardiac cycle, the
beat-to-beat pressure-volume (PV) loop is created before (left) and after (right) pump maxi-
mum activation. Bottom: Average PV loops at pump low and high (left), together with mean
hemodynamic measurement at thermodilution (TD) and at conductance catheter (right).
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as well. The Impella LVAD system and the 13 Fr arte-
rial femoral sheath were removed immediately after
the procedure and the patient follow-up remained
uneventful thereafter.
DISCUSSION
We reported the use of a percutaneous Impella
Recover LP 2.5 as a support strategy during high-risk
coronary intervention. Our single experience shows a
rapid and sustained unloading effect of the LV. At the
same time, the continuous expulsion of blood into
ascending aorta throughout the cardiac cycle produced
by the pump resulted in an increase of systemic overall
CO, measured by the TD technique, of 1.43 L/min.
In our case, the cardiac and systemic hemodynamic
status recorded during Impella working at minimum
speed (20,000 rpm) was taken as baseline because at this
degree of activation, the pump just compensates the
amount of blood that would ﬂow back into LV through
the lumen of the pump during diastole as a consequence
of pressure gradient between aorta and LV. In addition,
the simultaneous positioning of a 12 (Impella LVAD)
and a 7 Fr (pressure-conductance) catheter through the
aortic valve might theoretically also induce aortic regur-
gitation by disturbing valve closure. However, no signiﬁ-
cant increase of aortic regurgitation was recorded at ICE
Doppler investigation after both catheters were in place.
Finally, it should be noted that the unloading effect
of Impella on LV function was immediate, consistent
with a Frank-Starling law-related response. This would
possibly translate into a reduced cardiac metabolic
need due to the extracardiac work accomplished by the
Impella pump activation.
To evaluate this hypothesis in the future, the Impella
device could be tested both as a means to reduce LV oxy-
gen consumption (i.e., in patients with stable hemody-
namic status but severely decreased oxygen supply; in
other words, patients with acute myocardial infarction)
and as a real LV supportive technique (i.e., in patients
with low-output syndrome). Since patients undergoing
high-risk PCI can fall into both categories, future trials
assessing the hemodynamic and outcome effect of the
Impella Recover LP 2.5 assist device in this subset of
patients seem highly warranted.
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Use of Impella RECOVER LP 2.5 Left Ventricular Assist Device during 
High-risk Percutaneous Coronary Interventions
Clinical, Haemodynamic and Biochemical Findings 
Marco Valgimigli, MD, Paul Steendijk, PhD, George Sianos, MD, PhD, Pascal Vranckx, MD, Frans Boomsma, PhD, Emile 
Onderwater, BSc Sophia Vaina, MD, Jurgen M. Ligthart, BSc, Eugene McFadden, MD, FRCPI, Martin van der Ent, MD, PhD, 
Peter de Jaegere, MD, PhD, Patrick W. Serruys, MD, PhD 
Aim: To investigate in terms of clinical, haemodynamic and biochemical profile the safety and efficacy of the Impella 
RECOVER LP 2.5 left ventricular assist device during elective high risk percutaneous coronary interventions (PCI). 
Methods and Results: Ten out of twelve patients were initially enrolled to receive PCI supported by the Impella catheter; 
eight underwent pressure-volume (PV) loop analysis while 1 patient was monitored by intra-cardiac echocardiographic. Free 
haemoglobin (fHb), B-type natriuretic pepetide, catecholamines, aldosterone, angiotensin II, and endothelin were assessed 
before, every 40 minutes as average during the procedure and at 3, 12, 24 and 48 hours after intervention. The Impella 
catheter was used for 144±88 min (median [IQR] 108 [85-198]), and was removed immediately after the procedure in all 
but one patients. In 6, 3 and 2 patients, fHb levels increased above 1, 5 and 10 times the upper limit of normal (ULN), 
respectively. No significant effect was found on the tested biomarkers in Impella-supported procedures. The PV analysis 
showed the occurrence of an acute volume increase in the majority of patients immediately after Impella insertion that 
tended to persist even at maximal pump speed. This was confirmed by the intracardiac echocardiography that was 
performed in one patient.
Conclusions: The Impella RECOVER LP 2.5 remains an investigational device. Additional studies are required to elucidate 
the mechanisms responsible for the acute LV volume loading and also to quantify the degree of haemolysis induced by the 
pump in a broader set of patients. 
Submitted 
INTRODUCTION 
The need for hemodynamic support in high risk 
percutaneous interventions (HR-PCI) remains widely 
debated and controversial. It is well recognized that 
elective HR-PCI can be safely performed without 
percutaneous cardiopulmonary support or on intra-aortic 
balloon pump (IABP) in most circumstances. However, in 
patients with a borderline haemodynamic status, ongoing 
ischemia or cardiogenic shock, insertion of an IABP just 
before coronary instrumentation has been associated with 
improved outcomes(1,2). 
In view of the lack of prospective randomized data, the 
recently published ACC/AHA/SCAI PCI guidelines 
recommend the use of cardiopulmonary support for 
patients only at the extreme end of the spectrum of 
haemodynamic compromise, such as those patients with 
extremely depressed left ventricular function or patients 
with cardiogenic shock(3). Therefore the decision to 
proceed with IABP or other devices before percutaneous 
coronary intervention (PCI) remains a clinical judgment 
made by the physician based on the high-risk 
characteristics of coronary anatomy and the overall status 
of the patient(3,4). The limited effectiveness of actual 
support and device-related complications have so far 
hampered a more widespread use of these devices in our 
daily practice. 
The Impella RECOVER LP 2.5 left ventricular assist device 
(LVAD) (Impella CardioSystems GmbH, Aachen, Germany) 
is a catheter-based miniaturized rotary blood pump (4 mm 
-12Fr- in outer diameter), that is placed retrogradely 
through the aortic valve and aspirates blood from LV cavity 
and expels it in the ascending aorta. Under clinical 
conditions the pump provides up to 2.5 L/min at its 
maximal rotational speed. The device is mounted on a 9 Fr 
pigtail catheter, giving the advantage of percutaneous 
insertion via a 13 Fr femoral sheath (www.impella.com). 
We recently reported the case of a single patient with 
severe LV impairment receiving an Impella-supported 
coronary intervention(5). Twelve patients have been 
considered subsequently for Impella-supported elective 
HR-PCI as part of a single-centre, investigator-driven 
protocol. Our complete results, in terms of clinical, 
haemodynamic and biochemical findings, are presented 
here.  
Methods
Patients 
Appropriate candidates for this clinical investigation were adult 
patients of either gender with stable or unstable angina pectoris 
and a clinical indication for percutaneous coronary 
revascularisation. In addition, the patients had to have at least one 
coronary artery stenosis that was amenable to angioplasty as well 
as left ventricular ejection fraction (LVEF) < 30%, or an 
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angioplasty target vessel supplying > 50% of the viable 
myocardium, or combined left main and right coronary 
revascularization or complex lesion(s) in the last remaining patent 
artery, or refusal of surgical standby because of contraindications 
to cardiopulmonary bypass. All patients in this study provided 
written informed consent. The protocol received approval by our 
local Ethics Committee on Human Research.  
Haemodynamic Measurements 
A 7 Fr combined pressure-conductance catheter was introduced 
before positioning of the Impella via the left femoral artery and 
placed along the long axis of the LV. The catheter was connected 
to a Cardiac Function Lab (CD Leycom, Zoetermeer, the 
Netherlands) for online display and acquisition of LV pressure-
volume loops. The conductance catheter was calibrated using 
thermodilution and hypertonic saline dilution, as previously 
described(6). Cardiac output was measured by thermodiluition 
catheter (COtd) and by multiplying stroke volume as measured by 
conductance catheter by heart rate (COlv). The difference between 
COlv and COtd is mainly due to activation of the impella pump. 
The baseline (T0) haemodynamic data was acquired subsequently. 
Immediately after Impella catheter positioning the minimum level 
of pump speed (i.e. number of rotations per minutes (rpm)) 
expected to compensate the spontaneous backflow inside the 
pump cannula based on the actual pressure gradient between the 
aorta and LV during diastole was set and all haemodynamic 
measurements were repeated (T1). The same acquisition scheme 
was finally performed (T2) after setting the pump at its maximum 
level of activation (i.e. 50/52,000 rpm), unless suction was 
detected at console inspection. 
Since pump flow is linearly related to motor current, suction was 
identified as a reduction in motor current at constant level of pump 
activation. In such cases, the highest pump speed at which no 
suction occurred was selected for the T2 measurements. In all 
cases, technical assistance provided by the producing company 
(Impella Cardiotechnik, Aachen, Germany) was available to check 
for the correct positioning and functioning of the Impella device. 
After obtaining haemodynamic measurements at different levels of 
pump activation, the procedure was started with active Impella 
support. In one patient (#8) all haemodynamic measurements
were performed at the end of intervention while the baseline (T0)
was obtained immediately after Impella catheter removal.  
Intracardiac echocardiographic examination 
One patient in whom no pressure-conductance catheter was 
introduced, underwent intracardiac echocardiographic examination 
through the AcuNav catheter (Siemens Corp. Germany) inserted in 
the right ventricle. After obtaining a stable short axis view at the 
mitral valve papillary muscles level, the baseline LV area was 
quantified. After Impella catheter insertion, the same 
echocardiographic measurements were repeated at 35,000, 43,000 
and 50,000 rpm. Special care was taken to ensure a stable position 
of the AcuNav catheter during the whole acquisition process.  
Biochemical measurements 
Free haemoglobin (fHb): Whole blood was centrifuged, plasma 
and buffy coat removed and red cell layer washed several times 
with saline (pH: 7.30) until the supernatant was negative for 
protein. The resting solution was centrifuged at 1650×g. The stock 
haemoglobin solution was prepared by diluting the supernatant 
with Sørensen phosphate buffer (pH: 7.40; M/15) to a 
concentration of 30 mg per 100 ml. The exact concentration was 
measured by a photometer that had been standardized for 
haemoglobin by iron and oxygen-capacity determinants, as 
previously described(7). The upper limit of normal reference for 
fHb was 10 µmol/L. 
Biomarkers: Blood (2-3 ml) was collected in chilled heparinized 
tubes containing 3 mg of glutathione and centrifuged within 15  
min at 4°C (15 min, 3000 x g). Plasma was stored at -70°C. 
Determination of catecholamines was done by HPLC with 
fluorimetric detection(8).Blood for BNP, endothelin and aldosterone 
measurement was collected in EDTA-tubes ; the plasma was 
stored at –70°C after preparation.  BNP was measured by a 
commercially available immunoradiometric method (Shionoria, 
Osaka, Japan). Endothelin was measured using a QuantiGlo 
immunoassay kit from R&D Systems, Abingdon, UK. Aldosterone 
was measured with a commercially available radioimmunoassay kit 
(Coat-A-Count, Diagnostic Products Corporation, Los 
Angeles,CA,USA). For angiotensin II determination blood was 
collected in chilled tubes containing an inhibitor solution of EDTA, 
Remikiren and Lisinopril. Determination was performed by Seppak 
extraction and radioimmunoassay as previously described(9). 
Statistical analysis 
Values are expressed as mean�SD or median and interquartile 
range (IQR) as appropriate. The effect of Impella-supported 
intervention on the parameters of interest (i.e. haemodynamic 
variables and biochemical measurements) was investigated by the 
use of ANOVA for repeated measures and Post hoc comparisons 
were performed by Tukey honest significance difference test where 
appropriate. All statistical tests were 2-tailed. Probability was 
considered significant at a level of <0.05. Statistical analysis was 
performed using Statistica 6.1 Software (Statsoft Inc.). 
RESULTS
12 patients were enrolled in the protocol from June 2004 to 
April 2005. In Patient#4, the sheath of the Impella 
catheter could not be introduced due to an iatrogenic 
dissection of the left femoral artery which occurred during 
arterial access. Similarly, patient#7 underwent treatment 
without Impella support due to unavailability of the LVAD 
catheter at the time of the procedure. Thus, 10 patients 
undergoing intervention supported by the Impella catheter 
were finally included in the present study. Their baseline 
and procedural characteristics are summarized in Tables 1 
and 2. The overall average left ventricular ejection fraction 
(LVEF) was below 40%, while LVEF was less than 30% in 6 
patients. All patients had experienced a previous 
myocardial infarction that had involved the anterior wall in 
7 patients. Four patients (40%) had a history of 
symptomatic heart failure, eight (80%) were at high 
surgical risk according to the Euroscore and 5 (50%) 
patients had been previously refused for cardiac surgery. 
One patient (#8) with an occluded right coronary artery 
underwent treatment for a diffusely diseased venous-jump 
graft anastomosed to the left anterior descending and 
circumflex arteries, while all others received treatment of 
the native coronary system, including two patients who 
underwent treatment for an unprotected distal left main 
stenosis. On average, there were 2.2 lesions per patient, 
the majority of which were C-type according to the 
modified AHA lesions classifications; 3.6 stents per patient 
were implanted with a total stent length of more than 75 
mm. 
The positioning of the Impella was uncomplicated in all 
patients except two, in whom a second attempt to re-
position the catheter was needed due to difficulties in 
removing the guide wire after the initial positioning of the 
Impella catheter.  
The duration of LVAD support was 144±88 min (median 
(range) [IQR]: 108 (60-352) [85-198]); in one patient the  
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Table 1. Baseline characteristics 
Variables Mean�SD
Age (yrs) 62�10
Males (%) 8 (80) 
Body Mass Index (kg/m2) 28�3
Diabetes n (%) 1 (10) 
Hypertension n.(%) 7 (70) 
Hypercholesterolemia n.(%) 5 (50) 
Current Smokers n.(%) 3 (30) 
Previous Smokers n. (%) 3 (30) 
Family history n.(%) 3 (30) 
Creatinine (�mol/L) 115�56
LV Ejection Fraction (%)* 37�16
LV Ejection Fraction <40% 8 (80) 
LV Ejection Fraction <30% 6 (60) 
End diastolic volumes (ml) 188�44
End systolic volumes (ml) 125�50
MEDICAL HISTORY N.(%) 
PCI 1 (10) 
CABG 2 (20) 
Myocardial Infarction 10 (100) 
Anterior MI 7 (70) 
Renal Failure 5 (50) 
Heart failure 4 (40) 
Peripheral Arterial Disease 3(30) 
INDICATION TO REVASCULARISATION
Stable Angina n.(%) 4 (40) 
Unstable Angina n.(%) 4 (40) 
Myocardial viability n.(%) 1 (10) 
Recent cardiac arrest n.(%) 1 (10) 
Euroscore 7�3
Euroscore >5 n.(%) 8 (80) 
Patients refused by surgeon n.(%) 5 (50) 
Impella was left in place after coronary intervention, while 
in the other 9 patients it was removed at the end of the 
procedure. 
In patient #8, while receiving intervention in the only 
remaining open vessel, the arterial pressure remained 
above 90 mmHg even during a transient (approximately 25 
seconds) episode of no-reflow which followed stent 
expansion (Figure 1). In half of the patients, the 
maximum level of pump activation (i.e. around 50,000 
rpm) could not be maintained during the procedure due to 
the presence of a suction effect that disappeared in all 
cases after decreasing the rotational speed to 
approximately 40,000 rpm.  
Groin haemostasis was obtained by manual compression 
with/without Femostop® in 4 patients, with 10 french 
Prostar XL 10® in 2 patients, with a single 8 french 
Angioseal® in 2 patients, with two Angioseals in parallel 
(one 6 french and one 8 french) in one patient, and 
through a surgical percutaneous closure in one case. Three 
patients developed major groin haematoma at the site of 
Impella insertion. Four patients required red blood cells 
transfusion of two or more units due to substantial blood 
loss during and/or after the procedure.  
Impact of Impella on haemolysis 
Levels of fHb before, during and after PCI assisted by the 
Impella catheter are shown in Figure 2. Overall, 6 (60%)  
Table 2. Procedural characteristics 
Mean�SD
Variables Patients=10 
Lesions=22
Native vessel with stenosis, n.(%) 
LMCA 4 (40) 
LAD 0 (90) 
CFX 7 (70) 
RCA 7 (70) 
Treated Vessel  
LMCA 2 (20) 
LAD 6 (60) 
CFX 4 (40) 
RCA 3 (30) 
Venous Graft 1 (10) 
Patients receiving 2-vessel 
intervention 
4 (44) 
Patients receiving 3-vessel 
intervention 
2 (20) 
Treated lesions 2.2�1
> 2 3 (30) 
Type A 0.18�0.6
Type B1 0.27�0.5
Type B2 0.5�0.5
Type C 1.1�0.9
Number of implanted stents 3.6�1.8
Maximal pressure of stent deployment 19�3
Total stent length per patient (mm) 78�35
Moderate to severly calficied lesions 16 (73) 
Bifurcated lesions 6 (27) 
Bifurcation stenting 4 (18) 
patients showed fHb levels beyond the upper limit of 
normal (red line), while 5 patients had persistent fHb 
elevation in two or more consecutive samples. In the 
patient in whom the Impella was left in place after the 
procedure, the fHb peak occurred at the end of the 
procedure and not at the time of Impella removal. 
Similarly, in the patient who showed the highest levels of 
haemolysis, the peak of fHb (approximately 14 times the 
upper limit of normal) occurred 30 minutes before Impella 
removal. On the other hand, in one patient, fHb peaked 3 
hours after t removal of the Impella. In all of the other 
patients (n=7) fHb level peaked at the time of Impella 
removal. 
Haemodynamic effects of the Impella pump 
In the first consecutive nine patients enrolled a 7-Fr 
combined pressure-conductance catheter was introduced 
via the left femoral artery and placed along the long axis of 
the left ventricle directly before positioning of the Impella 
catheter (8 patients) or immediately after intervention (1 
patient, #8). Pressure recordings were judged to be of 
high quality in all patients included, while in one case 
(#11) volume-based parameters had to be discarded due 
to the presence of multiple and diffuse artefacts. There 
was no significant effect on any of the studied 
hemodynamic parameters with regards to Impella pump 
insertion and activation except for end diastolic pressure 
(p<0.01), which showed a slight increase at T1 (17±9 
mmHg vs. 15±8 mmHg at T0) followed by a decrease soon 
after the Impella was maximally activated (13±8 mmHg at 
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Figure 1. 
Aortic pressure (mmHg) signal recorded by a micromanometer positioned near the outlet of the Impella catheter), used for catheter positioning and Impella 
actual motor current (A) and speed (rpm) during intervention in patient#8. In the top right corner, a magnification of the aortic pressure at the time of a no-
reflow phenomenon while treating a graft lesion is shown. Panel A and D: Aortic pressure before and after the occurrence of no-reflow phenomenon. Panel B 
and C: Aortic pressure during no-reflow phenomenon showing almost absent (especially in figure 2) systo-diastolic excursions as expression of transient 
depression of left ventricular pumping activity
T2). The left ventricular cardiac output, stroke volume, 
end-systolic and end-diastolic volumes) tended to increase 
when the Impella catheter was inserted and activated at 
low rpm at T1 –this level of activation was expected to 
compensate backflow inside the cannula caused by the 
pressure gradient between aorta and left ventricle during 
diastole–, followed by an opposite trend as soon as the 
pump reached the highest possible rpm at T2.  
Ejection fraction and systemic cardiac output measured by 
the thermodilution catheter tended to decrease and 
increase when going from baseline (T0) to T1 and to T2, 
respectively, while end-systolic pressure and relaxation 
time constant tau remained practically unchanged over 
time.
A patient-by-patient analysis based on actual pressure-
volume loop analysis is shown in Figure 4. In the majority 
of the patients (#1, #3, #5, #6, #9 and #10) there was a 
sudden (detectable immediately after catheter insertion) 
increase in left ventricular volumes and, in some patients in 
the end-diastolic pressure as well, as soon as the Impella 
pump was inserted and activated at low rpm.  
The maximal activation of the pump (T2) produced an 
opposite effect, with variable degrees of LV volume 
unloading as compared to T1. In all these individual cases, 
however, a volume increase compared to baseline was still 
noted at T2. In patient #2 a progressive volume unloading 
going from baseline to T1 and from T1 to T2 was evident, 
while patient#8 showed an intermediate pattern of 
response, with minor volume overload at T1 that was 
overcompensated with respect to baseline at T2. 
Thus the heterogeneity of response to Impella activation 
may well explain the absence of a net significant 
haemodynamic effect produced by the pump compared to 
baseline when all data were pooled.  
Effect of Impella-supported procedure on 
circulating biomarkers 
The change over time of the tested biomarkers in patients 
undergoing intervention supported by the Impella catheter 
as compared to baseline is shown in Figure 5. None of the 
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Figure 2. 
Free haemoglobin (Hb) levels in relation to timing of intervention (PCI). The 
red line represents the upper limit of normality of the tested parameter 
according to the employed photometer test 
selected parameters showed a significant change over 
time, despite clear individual heterogeneity in response to 
the treatment as revealed by the increase in data 
dispersion (i.e. data range and interquartile range) during 
and after intervention with respect to baseline. 
Figure 3. 
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Haemodynamic variables recorded through the conductance catheter or the 
thermodilution catheter according to Fick’s technique before (baseline), or 
when the Impella catheter in place during a minimal or maximal level of 
activation (rpm). COtd: systemic cardiac output measured by thermodilution 
catheter; COlv, cardiac output according to left ventricle stroke volume as 
measured by the conductance catheter
Effect of Impella-supported procedure on left 
ventricular volumes based on the intracardiac 
AcuNav echocardiographic examination.  
In the last patient (#12), the effect of the Impella support 
on LV volumes was investigated by an intracardiac 
echocardiographic AcuNav catheter examination. The 
results are given in Table 3 while Figure 6 shows four left 
ventricle short axis views at baseline (A, B) and after 
activating the Impella support at 43000 rpm during 
diastolic and systolic phases, respectively (C, D).  
DISCUSSION 
The Impella LVAD RECOVER LP 2.5 is a miniaturized 
catheter-mounted rotary blood pump that is placed 
through the aortic valve, aspirates blood from LV cavity, 
and expels it in the ascending aorta. In clinical conditions 
the pump provides up to 2.5 L/min at its maximal 
rotational speed of 50/52,000 rpm. If placed without 
activation, the catheter would per se induce some backflow 
inside the cannula due to the pressure gradient during the 
diastolic phase between aorta and left ventricle. The actual 
amount of flow shunting back to the LV chamber during 
each diastole and the level of pump activation that is 
necessary to antagonize this intra-cannula insufficiency is 
dependent on the actual pressure gradient. Based on in 
vitro tests, a level of activation around 30,000 rpm is 
expected to neutralize the effective backflow (with some 
minor leak during diastole followed by some minor positive 
output during the systole) at a typical diastolic gradient 
between the aorta and the LV of 60/70 mmHg.  
According to this principle and guided by an engineer who 
had a major role in developing the Impella device, we set 
the level of pump activation at T1 in order to have no net 
flow within the pump cannula during each cardiac cycle. 
We thus expected to have a comparable haemodynamic 
profile at T1 as compared to baseline. 
However our findings indicate that after Impella positioning 
and with minimal activation at T1, a substantial volume 
overload occurred with respect to baseline in 7 out of 8 
patients studied, with only one individual able to 
(over)compensate for the initial volume increase during 
maximal activation of the pump at T2. In the remaining 
case, a clear LV volume and pressure unloading at each 
step of Impella catheter activation was noted. Thus, in only 
2out of the 8 patients who underwent pressure-volume 
analysis in the present protocol, a final LV unloading was 
detected at T2.  
These observations, coupled with the rather limited sample 
size of the study may explain the observed overall neutral 
effect of the Impella pump on almost all studied 
haemodynamic variables and biomarkers, including B-Type 
natriuretic peptide, whose production and secretion being 
linked to LV wall stretch, is known to closely reflect the 
haemodynamic status of the heart.  
It could be argued that the simultaneous positioning of 12 
Fr (Impella LVAD) and 7 Fr (pressure-conductance) 
catheters through the aortic valve might theoretically cause 
significant aortic regurgitation by disturbing adequate valve 
closure. However a pattern of volume overload was 
confirmed also by intracardiac echocardiographic 
examination, during which only the Impella catheter was 
positioned through aortic valve. Potentially, trans-septal 
positioning of the conductance catheter might be desirable 
in future investigations Thus although we cannot fully rule 
out the possibility that the two catheters in parallel might 
have increased the magnitude of volume overload due to 
increased aortic regurgitation, we believe this does not 
explain our current findings.  
Our study focused on elective patients undergoing HR-PCI, 
who had had their medical treatment optimized. As a 
consequence, all patients had a normal or near-normal LV 
end-diastolic pressure before intervention and this may 
have contributed to the increase of the magnitude of 
volume regurgitation and LV overload during the diastolic 
phases of the cardiac cycle at T1. This may also explain the 
high incidence of suction effect observed in our study. In 
patients with acute haemodynamic compromise or during 
the acute phase of ischemia (such as the transient no flow 
phenomenon observed in patient#8) the LV diastolic 
pressures may be, or become, particularly elevated thus 
limiting the degree of volume regurgitation towards the LV, 
while favouring a forward output towards the aortic arch. 
As an example, in patient#8 a clear effect of the Impella 
pump was observed at the stage in which a dramatic no-
flow phenomenon occurred during intervention in the last 
remaining patent artery. As shown in Figure 1, arterial 
pressure remained constantly above 90 mmHg while LV 
function was extremely, although transiently, depressed as 
shown by the minor systo-diastolic excursion. Indeed the 
patient remained completely asymptomatic during this 
phase and no inotropic support was needed. At this point, 
the reasons behind the immediate volume overloading 
which followed Impella pump positioning in most cases 
may only be speculative since our protocol was not 
designed to investigate this issue. A possible explanation is 
that while blood is continuously expelled into the aorta 
from the outlet of the Impella catheter, blood is
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Figure 4. 
Individual pressure-volume loops at baseline (black line), immediately after positioning the Impella catheter at miniminal level of activation (blue line), and with 
Impella at maximal speed (red line).  
at the same time regurgitating back into LV due to aortic 
valve insufficiency (peri-cannula leak). This may be the 
consequence of the interplay between two factors: 1) The 
presence of the Impella catheter (4 mm in outer diameter) 
may interfere with aortic valve closure, particularly when 
the pump is far from being perpendicular with respect to 
the aortic valve plane in patients with severely calcified 
leaflets; 2) in cases where the Impella pump is placed too 
deeply inside the LV although positioning may appear 
satisfactory, based on pressure tracing inspection at the 
device console, the outlet orifices may remain too closely in 
contact with the aortic valve plane. When the blood is 
expelled with great velocity out into the ascending aorta, 
turbulent vortices may be created that may force the aortic 
valves to open. In this situation, the higher the degree of 
pump activation, the higher might be the induced aortic 
regurgitation. This may explain why despite maximal 
activation of the pump in 6 patients out of 8 studied, the 
device could not compensate the acute LV volume overload 
observed at T1.  
If our speculations are correct the haemodynamic effects 
provided by the Impella catheter dependent a great deal 
on the haemodynamic status of the patient but may also 
be affected by the actual position of the Impella catheter. 
Future studies, potentially including trans-septal placement 
of the conductance catheter and slow pull-back of the 
Impella device after initial positioning, may be needed to 
substantiate our speculations. Concomitant, trans-
esophageal echocardiographic examination may provide 
additional insight. 
Finally, two issues deserve attention: a) the occurrence of 
haemolysis as a consequence of pump activation and b) 
bleeding at the site of pump insertion.  
a) We observed substantial haemolysis in 6 out of 10 
patients. In five, this was detected in two or more samples 
collected around 40 minutes apart. In three cases, levels of 
fHb increased more than 5 times the upper limit of normal 
(ULN) while in two individuals 10 times the ULN was found. 
At the same time, we clearly could observe that the degree 
of observed haemolysis was not strictly related to the 
duration of pump activation. This may be explained by the 
fact that the relatively older erythrocytes in the circulating 
pool may be subject to injury first. Thus after this early 
peak of haemolysis, the degree of fHb elevation may 
remain controlled even if the pump remains activated for 
several hours. Our study could not confirm this hypothesis, 
which needs to be tested in future investigations. The 
presence of suction during pump activation would be 
theoretically able to increase the occurrence of haemolysis 
due to increase shear stress. However, fHb levels at peak 
was not different in those with as compared to patients 
without suction during intervention, which makes the 
possibility that suction was the explanation for the high 
rate of haemolysis observed in our series quite unlikely.  
b) The need to insert an arterial 13 Fr sheath before 
Impella pump insertion exposes the patient to a risk of 
bleeding at the site of puncture, as witnessed by our 
experience. We believe that echo-guided puncture of the 
common femoral artery followed by 10 Fr Prostar XL 10® 
insertion is the best approach in order to ensure effective 
and safe vascular access when the Impella pump needs to 
be inserted 
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Figure 5. 
Levels of tested biomarkers in relation to the timing of intervention. None of the studied parameters were significantly affected by the Impella-supported 
intervention at the analysis of variance. BNP: B-type natriuretic peptide
Table 3. 
Systole Diastole 
Area (cm3) Dist_1 (cm) Dist_2 (cm) Area (cm3) Dist_1 (cm) Dist_2 (cm) 
      
Baseline 4.6 2.1 2.9 25.8 5.3 6.8 
3,500 rpm 6.5 2.5 4.1 34.5 5.8 8.8 
4,300 rpm 5.9 2.3 3.7 31.6 5.6 8.2 
50,000 rpm 5.3 2.2 3.3 28.7 5.4 7.4 
P
re
-P
C
I
40
 m
in
80
 m
in
En
d-
P
C
I
3 
h
rs
12
 h
rs 1 
g
2 
g
0
100
200
300
B
N
P
 (
p
m
ol
/l
)
P
re
-P
C
I
40
 m
in
80
 m
in
En
d-
P
C
I
3 
h
rs
12
 h
rs 1 
g
2 
g
0
1000
2000
N
or
ad
re
n
al
in
 p
g
/m
l
P
re
-P
C
I
40
 m
in
80
 m
in
En
d-
P
C
I
3 
h
rs
12
 h
rs 1 
g
2 
g
0
500
1000
A
d
re
n
al
in
 p
g
/m
l
P
re
-P
C
I
40
 m
in
80
 m
in
En
d-
P
C
I
3 
h
rs
12
 h
rs 1 
g
2 
g
50
150
250
350
450
A
ld
os
te
ro
n
 p
g
/m
l
P
re
-P
C
I
40
 m
in
80
 m
in
En
d-
P
C
I
3 
h
rs
12
 h
rs 1 
g
2 
g
0
1
2
3
4
5
6
7
En
d
ot
h
el
in
 I
 p
g
/m
l
P
re
-P
C
I
40
 m
in
80
 m
in
En
d-
P
C
I
3 
h
rs
12
 h
rs 1 
g
2 
g
50
150
250
A
n
g
ot
en
si
n
 I
I 
p
m
ol
/l
203
Impella Assist Device in High-Risk PCI 
Figure 6. 
Effect of Impella support on LV volumes in patient#12, investigated by intracardiac echocardiographic AcuNav catheter. Left ventricle short axis views during 
diastolic and systolic phases at baseline (A, B) and after activating the Impella support at 43000 rpm,(C, D) 
Study Limitations
Our study involved a limited number of patients and no 
control group was used. According to our protocol, the 
patient at baseline was supposed to be the internal 
reference of the study. However this may carry important 
limitations especially in interpreting our results in terms of 
biomarkers, which are known to be affected by the 
coronary intervention itself.  
Conclusions 
Our findings, although based on a limited sample size, 
support the idea that Impella RECOVER LP 2.5 may 
potentially become an effective and easy to use 
percutaneous LVAD. However in our view important 
technical refinements have to be considered before its use 
may be recommended outside investigational protocols. 
Additional studies are required to investigate the 
mechanisms behind the acute LV volume overload 
observed in the majority of the cases enrolled in the 
present study. Our study suggests that this may well occur 
despite positioning the Impella catheter according to 
manufacture’s instructions. Whether and how much the 
acute LV volume overload affects the haemodynamic  
support provided by the Impella pump remains unclear 
based on our data. Similarly a better quantification of the 
degree of pump-induced haemolysis in a broader set of 
patients is warranted.  
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Summary and Conclusions 
High-risk Intervention in the Drug-eluting stent era 
The use of drug-eluting stents in high-risk interventions, 
including those undertaken to treat the left main 
coronary artery (Chapter 2), multivessel disease (Chapter 
14) or on-going ST-segment elevation myocardial 
infarction (Chapters 11 and 12) appeared overall 
beneficial in comparison with traditional metallic stents. 
In particular, the use of drug eluting stents was 
associated to a remarkable decrease in late loss (Chapter 
3) which ultimately resulted in lower need for re-
intervention (Chapter 2), while no clear effect on death 
and myocardial infarction was observed. 
The safety profile of these new coronary devices 
appeared overall consistent with what has been reported 
in the pivotal trials focusing on selected patient/lesion 
subsets (Chapters 2, 3, 7, 8, 12, 14, 15, 16). The 
incidence of possible or confirmed acute, sub-acute or 
late thrombosis was low in this high-risk subset of 
patients patients undergoing treatment for left main 
coronary artery disease (Chapters 2, 3, 7, 8, 12, 14, 15, 
16) and importantly we could not confirm previous 
concerns regarding the potential association between 
intimal hyperplasia and sudden death in patients 
undergoing treatment for left main coronary artery 
disease (Chapters 7 and 8).
Our findings may question the class III indication for the 
percutaneous treatment of left main coronary artery in 
patients without contra-indication to surgery. This may 
be particularly true in patients where the lesion at the 
left main coronary artery does not require the treatment 
of its bifurcation in whom the percutaneous treatment 
with drug eluting stent was associated to a remarkably 
low incidence of major adverse events at long-term 
follow-up (Chapter8). At the same time however, our 
data may suggest that drug eluting stents may expose to 
a time-dependent increase in late loss and as such to the 
occurrence delayed in-stent restenosis in a probably 
small but still undefined proportion of patients (Chapter 
6). Similarly, it remains unclear whether this finding may 
be more frequent in selected high-risk lesion/patient 
subsets or may potentially apply to all drug eluting stent 
treated lesions.
In the setting of acute ST-segment elevation myocardial 
infarction, sirolimus eluting stent implantation did not 
result in an increased risk of acute, subacute or late 
thrombotic complications compared to bare metal stent 
(Chapter 12). However, larger studies with longer follow-
up are needed to further elucidate this issue. Drug 
eluting stents are almost three times more costly than 
traditional metallic stents and their costs are limiting their 
up-take in those countries where no specific 
reimbursement is provided. Tirofiban-supported sirolimus 
eluting stent infarct artery implantation is a promising 
strategy to improve outcome while limiting healthcare 
expenditure in patients with myocardial infarction 
undergoing primary intervention. Our study provides 
proof of concept for a new treatment strategy, which 
incorporates unrestricted use of sirolimus eluting stent, 
but results in no increase in medical expenditure 
(Chapter 12).
In the setting of acute myocardial infarction, platelet 
reactivity at entry was related to both angiographic and 
elettrocardiographic response to treatment as well as to 
the severity of cardiac injury. At 1 year, platelet reactivity 
predicted the occurrence of major cardiac adverse events 
(Chapter 13). Whether modulating platelet aggregation 
through tailored or systematic anti-platelet treatment 
overcomes the prognostic implications of spontaneous 
platelet function remains elusive and warrants further 
investigations.
The availability of drug eluting stents with their single 
digit restenosis rate even in complex coronary lesions is 
giving renewed interest to the concept of locally applied 
preventive treatment in order to prevent plaque rupture 
and its consequences. Despite the recognition that all 
major well recognized effectors involved in the 
pathogenesis of plaque vulnerability are widespread 
throughout the circulatory bed, the distribution of 
ruptured or prone to rupture plaques is known to be non-
uniform throughout the coronary tree, with the existence 
of high-risk coronary spots. We found that plaques 
located in these “hot spots” are characterized by 
increased necrotic-lipid core content (Chapters 9 and 10). 
The knowledge of relative plaque composition may be 
pivotal in the future for the process of clinical decision-
making both in the primary and secondary prevention 
setting.
In the context of multivessel disease patients, 
undergoing elective intervention the use of sirolimus 
eluting stent was safe with low rate of thrombotic 
complications (Chapters 14, 15, 16). Unstable coronary 
artery disease failed to emerge a predictor of worse 
outcome in this setting (Chapter 14), whereas the 
propensity to administer GP IIb/IIIa inhibitors, based 
purely on coronary anatomy, may increase as a 
consequence of treating more complex lesion subsets. 
Our analysis of the ARTS II trial, where the use of GP 
IIb/IIIa inhibitors was entirely left to the discretion of the 
operator, suggested than when these potent anti-platelet 
agents are mainly solicited by the presence of complex 
coronary anatomy more than by patient clinical profile 
they may fail to impact on short and long-term outcome 
(Chapter 15). Focusing on multivessel disease patients 
with involvement of proximal left anterior descending 
artery, use of multiple sirolimus eluting stent was 
associated to a reduced rate of major adverse events 
compared to historical results based on the use of bare 
metal stents and to a similar overall outcome at one year 
compared to an historical cohort of patients in whom a 
single arterial conduit and multiple vein grafts was the 
strategy of choice for revascularisation (Chapter 16).
Of interest, even in the context of unrestricted use of 
sirolimus eluting stent, coronary disease 
extension/complexity remained a strong and independent 
predictor of outcome in elective patients undergoing 
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intervention for three vessel coronary disease. The 
Syntax score is a promising tool to quantify coronary 
artery disease extension and complexity (Chapter 17).  
By drastically reducing the rate of in-stent restenosis, 
drug eluting stents opens the way to the treatment of 
patients with extensive coronary disease. In this 
population, the presence of concomitant left ventricular 
dysfunction may constitute a limitation factor for 
obtaining safe catheter-based coronary revascularisation. 
The availability of a safe and effective percutaneous 
circulatory supportive system would greatly impact on 
contemporary intervention. The Impella RECOVER LP 2.5 
is a percutaneous catheter-based miniaturized rotary 
blood pump that is placed retrogradely through the aortic 
valve and aspirates blood from left ventricular cavity and 
expels it in the ascending aorta. Despite preliminary 
findings supporting its value in terms of haemodynamic 
support (Chapter 18), we concluded that this device 
should remain in the investigational phase due to 
concerns both related to its efficacy and safety profile 
(Chapter 19) 
In conclusion, the introduction of coronary devices, such 
as drug-eluting stents, able to drastically reduce intimal 
hyperplasia after arterial injury, is extensively affecting 
the field of interventional cardiology. Some of the 
traditional subsets of coronary lesions, for which the 
results of percutaneous intervention remained sub-
optimal compared to traditional surgery in the bare metal 
stent era, such as left main coronary artery or diffuse 
multivessel disease, may be effectively treated 
percutaneously in the near future. The possibility to 
combine in-vivo tools for plaque composition evaluation 
and coronary devices leading to low rate of recurrences 
after intervention will unravel new venues for the 
prevention of plaque rupture through locally applied 
treatment.
In the drug-eluting stent era, the need to risk-stratify 
patients before intervention will increase as the natural 
consequence of undertaking revascularisation in 
progressively more complex patients. The complexity of 
coronary artery disease remains a promising and ready 
available tool to risk stratify outcome in patients with 
extensive coronary disease undergoing contemporary 
elective percutaneous intervention, while in the setting of 
acute ST-segment elevation myocardial infarction 
markers of platelet activation are promising to tailor 
aggressiveness of pharmacological intervention to 
individual needs. There is great need for a miniaturized 
percutaneous device able to support circulation and 
unload left and right cardiac chambers. Ideally, this 
should be tweaked in high-risk elective interventions with 
the aim to extend its use in emergent cases where safety, 
efficacy and easiness of use should be granted. This step 
has still to come, perhaps being the fourth revolution in 
the field of percutaneous coronary intervention.  
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Hoog-risico percutane coronaire interventies (PCI) in het tijdperk van drug-eluting stents 
Het gebruik van drug-eluting stents (DES) voor hoog-
risico procedures, inclusief hoofdstamlesies 
(hoofdstuk 2), meervats coronair lijden (hoofdstuk 
14), of ST-segment elevatie myocardinfarct 
(hoofdstukken 11 en 12), is geassocieerd met een 
betere outcome in vergelijking met bare metal stents. 
Meer specifiek reduceren DES in belangrijke mate de        
“late loss” (hoofdstuk 3), hetgeen gepaard gaat met 
een reductie in het aantal herinterventies (hoofdstuk 
2). Wat betreft de eindpunten mortaliteit en 
myocardinfarct is er geen duidelijk effect van DES. 
Deze nieuwe generatie van stents heeft een goed 
veiligheidsprofiel zoals reeds werd aangetoond in 
eerdere studies in een geselecteerde populatie van 
patienten en coronaire lesies (hoofdstukken 2, 3, 7, 
8, 12, 14, 15, 16). De incidentie van acute, subacute 
of laattijdige vormen van stent thrombose, al dan niet 
angiografisch bevestigd, was gering binnen de hoog-
risico groep patienten die een PCI ondergingen 
wegens hoofdstamlesies (hoofdstukken 2, 3, 7, 8, 12, 
14, 15, 16). De hypothese dat er een associatie 
bestaat tussen neointimahyperplasie en plotse dood 
bij patienten die percutaan werden behandeld voor 
een vernauwing van de hoofdstam, kon door ons niet 
worden bevestigd (hoofdstukken 7 en 8). 
Het uitvoeren van een PCI voor hoofdstamlesies bij 
patienten die geen contraindicatie hebben voor 
cardiale chirurgie vormt tot op heden een klasse III 
indicatie, en wordt met andere woorden niet 
onderbouwd door wetenschappelijke evidentie. Deze 
richtlijn kan door onze bevindingen in vraag worden 
gesteld, meer in het bijzonder bij patienten waarbij 
de stentimplantatie zich niet uitbreidt tot de 
hoofdstambifurcatie. In deze patientengroep is de 
incidentie van majeure cardiale events zeer laag op 
langere termijn (hoofdstuk 8). Langs de andere kant 
is het zo dat DES aanleiding kunnen geven tot een 
verdere toename van “late loss” over een langere 
termijn en bijgevolg tot het optreden van laattijdige 
in-stent restenose (ISR), weliswaar bij een 
vermoedelijk klein percentage van de patienten 
(hoofdstuk 6). Het is onduidelijk of dit fenomeen zich 
frekwenter voordoet in een geselecteerde hoog-risico 
groep van coronaire lesies/ patienten dan wel of het 
zich voordoet bij het gebruik van DES in het 
algemeen.
Bij de behandeling van het ST-segment elevatie 
myocardinfarct, gaat het gebruik van sirolimus-
eluting stents (SES) niet gepaard met een hoger 
risico op acute, subacute of laatijdige vormen van 
stent-thrombose (hoofdstuk 12). Grotere studies met 
een langere follow-up duur zijn noodzakelijk om 
hierover meer duidelijkheid te verschaffen. DES zijn 
bijna 3 maal zo duur als traditionele bare metal stents 
(BMS): deze hoge kostprijs is een belangrijke 
limiterende factor voor het gebruik van DES in landen 
waar geen specifieke terugbetaling is voorzien. Het 
gebruik van tirofiban in combinatie met SES is een 
veelbelovende strategie bij de behandeling van 
patienten met myocardinfarct die een primaire PCI 
ondergaan aangezien ze op een kosten-effectieve 
manier de outcome verbetert (hoofdstuk 12). 
De mate van bloedplaatjes activatie in de initiele fase 
van het myocardinfarct, blijkt gecorreleerd te zijn met 
de graad van angiografisch en electrocardiografisch 
herstel na behandeling, evenals de mate van cardiale 
beschadiging. De graad van bloedplaatjes activatie is 
een voorspellende factor voor het optreden van 
majeure cardiale events na 1 jaar (hoofdstuk 13). 
Nieuwe studies moeten aantonen of inhibitie van de 
bloedplaatjes aggregatie via specifieke of systemische 
therapie de prognostische implicaties van deze 
inherente bloedplaatjes activatie in gunstige zin kan 
beinvloeden.
De lage mate van restenose middels gebruik van DES 
ook bij de behandeling van complexe coronaire lesies, 
heeft het concept van lokale plaque sealing gebruik 
makende van DES ter preventie van plaque ruptuur 
en de geassocieerde klinische manifestaties ervan 
nieuw leven ingeblazen. Alhoewel  de factoren die 
een rol spelen bij het ontstaan van de vulnerabele 
plaque inwerken op de ganse coronaire circulatie, is 
de distributie van vulnerabele plaques en 
geruptureerde plaques niet uniform verdeeld over de 
coronaire arteries en blijkt dit zich voor te doen op 
specifieke plaatsen. Uit onze studies blijkt dat 
coronaire plaques op deze specifieke plaatsen voor 
een relatief groot percentage bestaan uit necrotisch 
en/of vetrijk materiaal (hoofdstukken 9 en 10). 
Inzicht in de relatieve plaque samenstelling zal in de 
toekomst vermoedelijk een belangrijke rol spelen bij 
het bepalen van de behandelingsstrategie zowel wat 
betreft primaire als secundaire preventie. 
Het gebruik van SES bij electieve PCI’s voor meervats 
coronair lijden is veilig en heeft een lage incidentie 
van stent thrombose (hoofdstukken 14, 15, 16). 
Instabiel coronair lijden is niet geassocieerd met een 
slechtere outcome in deze patientengroep (hoofdstuk 
14). Verder is er een tendens om gemakkelijker 
glycoproteine IIb/ IIIa receptor antagonisten toe te 
dienen in functie van de uitgebreidheid van het 
coronair lijden bij de behandeling van complexe 
lesies. Onze subanalyse van de ARTS II studie, waar 
het gebruik van glycoproteine IIb/ IIIa receptor 
antagonisten op individuele basis werd 
voorgeschreven door de arts die de procedure deed,  
toont aan dat deze krachtige bloedplaatjesaggregatie 
remmers de prognose op korte en lange termijn niet 
gunstig beinvloeden wanneer ze worden gebruikt in 
aanwezigheid van complexe coronaire lesies in plaats 
van in functie van het klinisch karakteristieken van de 
patient (hoofdstuk 15). In hoofdstuk 16 tonen we aan 
dat het gebruik van SES voor de behandeling van 
proximale LAD lesies bij patienten met meervats 
Samenvatting en conclusies
208
coronair lijden het aantal majeure cardiale events in 
belangrijke mate reduceert in vergelijking met een 
historische controle groep waarbij BMS werden 
gebruikt. Bovendien bleek de outcome na 1 jaar 
vergelijkbaar te zijn met een historische controle 
groep van chirurgische patienten die 
gerevasculariseerd werden met 1 enkele arteriele 
graft en verschillende veneuse grafts (hoofdstuk 16). 
Ook in de situatie waarbij onbeperkt van SES gebruik 
gemaakt wordt, blijkt de uitgebreidheid/ complexiteit 
van het coronair lijden een duidelijke en 
onafhankelijke voorspeller van de outcome bij 
patienten die een electieve PCI ondergaan voor 3-
vats coronair lijden. De Syntax score is een 
veelbelovend hulpmiddel bij de berekening van de 
uitgebreidheid en de complexiteit van het coronair 
lijden (hoofdstuk 17). 
Als gevolg van een belangrijke afname in de 
incidentie van restenose, laat het gebruik van DES 
toe ook patienten met uitgebreide coronaire ziekte te 
behandelen. In deze patientenpopulatie vormt de 
aanwezigheid van linker ventrikel dysfunctie evenwel 
een belangrijke beperking om op een veilige manier 
een percutane revascularisatie uit te voeren. De 
beschikbaarheid van een veilig en effectief percutaan 
circulatoir ondersteuningssyteem zou een belangrijke 
vooruitgang zijn bij op het gebied van hedendaagse 
PCI’s. Het Impella RECOVER LP 2.5 systeem is een 
miniatuur bloedpomp model dat percutaan via 
retrograde weg over de aortaklep wordt 
gepositioneerd. De pomp aspireert bloed uit het linker 
ventrikel en drijft het uit in de aorta ascendens. 
Preliminaire bevindingen tonen de waarde aan van de 
pomp voor wat betreft hemodynamische 
ondersteuning (hoofdstuk 18). Aangezien er in een 
daaropvolgende studie  problemen waren op het 
gebied van efficaciteit en veiligheid, blijft het gebruik 
ervan vooralsnog gelimiteerd tot het 
onderzoeksdomein (hoofdstuk 19). 
In conclusie kunnen we stellen dat de introductie van 
DES het ontstaan van neointimahyperplasie, dat 
ontstaat als gevolg van schade aan de vaatwand, in 
belangrijke mate afremt en zodoende een belangrijke 
plaats heeft verworven binnen de wereld van 
interventionele cardiologie. In een vroegere fase 
bleek het gebruik van BMS voor de behandeling van 
hoofdstamlesies of uitgebreid meervatslijden obsoleet 
aangezien de resultaten in vergelijking met cardiale 
heelkunde suboptimaal waren. DES bieden het 
perspectief in de nabije toekomst deze specifieke 
groep van coronaire lesies op een effectieve manier 
te kunnen behandelen.  
Het gebruik van beeldvormingstechnieken  in-vivo 
voor de evaluatie van plaque compositie in 
combinatie met DES, die de noodzaak tot 
herinterventie in belangrijke mate reduceren, biedt 
nieuwe perspectieven om na te gaan of een lokale 
behandeling ter preventie van plaque ruptuur 
effectief is. 
Aangezien DES toelaten meer complexere vormen 
van coronair ziekte te behandelen, is er een 
toenemende nood aan risico stratificatie vóór de 
behandeling. De uitgebreidheid van coronair lijden 
kan berekend worden volgens een bepaalde score 
(Syntax score model) en deze score laat een risico-
stratificatie toe van patienten met uitgebreide 
coronaire ziekte vooraleer een PCI te ondergaan. Bij 
de behandeling van het ST-segment elevatie 
myocardinfarct zijn bepaalde merkers van 
bloedplaatjes activatie veelbelovend aangezien zij de 
mogelijkheid bieden de intensiteit en het type van 
bloedplaatjes remmende farmacologische therapie te 
sturen in functie van de individuele patient.  
Er bestaat een grote behoefte om via percutane weg 
op een effectieve manier de circulatie te kunnen 
ondersteunen en het linker en rechter hart te kunnen 
ontlasten. Initieel moet de veiligheid, effectiviteit en 
gebruiksgemak worden aangetoond bij electieve 
hoog-risico interventies om het vervolgens te kunnen 
gebruiken in acute situaties. Deze 3 voorwaarden 
konden tot op heden nog niet worden bewerkstelligd, 
doch eenmaal hieraan voldaan zou dit percutaan 
ondersteuningssysteem de vierde revolutie kunnen 
betekenen op het gebied van percutane coronaire 
interventies.
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Art is "I"; science is "we" 
(Claude Bernard) 
Being a fellow at the Thoraxcenter per se is not easy
nor nice…this goes by definition. Nevertheless, it is 
definitively a great and worthwhile experience, which 
becomes memorable in cases like mine, where so many 
people help and support you during this endeavour. They 
make the PhD experience so valuable. They make this 
section of the book the most important one. 
The first time I came across the word Thoraxcenter was 
during the second year of residency. I had just started 
my training in the cath-lab in Brescia when my mentor 
Salvatore Curello asked me: do you know the 
Thoraxcenter? I candidly replied “not really”…that was a 
big mistake because I had to try hard before I could 
regain his esteem afterwards. 
April 2002, back to Ferrara’s cath-lab, where a salesman 
from a statin company offers me the possibility to attend 
a full immersion course on IVUS imaging at the Cleveland 
clinic: FANTASTIC! But three weeks before the scheduled 
departure, the plan of the trip changes slightly: the 
course will focus on non-invasive cardiology and it will be 
held at the Thoraxcenter. Rotterdam, which had been 
described to me like a grey, rainy industrial city, 
appeared incredibly sunny in the three days I spent there 
(typical example of the sampling error due to a low 
number of observations…) and the Erasmus MC 
appeared to me like a piece of US in Europe. The typical 
personal-based medicine approach, characterised by “I 
think….; in my practice….” disappeared all of a sudden in 
favour of the NEJM-, JAMA-, Circulation-, JACC-based 
approach. Marcel van der Brand was in charge of the 
interventional cardiology section of the course (finally 
some invasiveness was luckily kept in). He is among the 
wisest, most balanced, friendly (i.e. PimdeFeyter-like) 
and tanned interventional cardiology I have ever met. He 
guided some of us inside the sliding doors of the 
“Interventie Cardiologie”. That day started with a 
seminar on stem cells at 08:00. We obviously arrived late, 
and we broke into the room when Dr. Pieter Smits was 
just about to show some in vitro data supporting the 
concept that the skeletal myoblasts do not up-regulate 
connexin 43, and as such it remained unclear how they 
could participate to the heart contraction once injected 
(dear Pieter, thank you for showing me afterwards that 
they simply do not contract…that’s it, the mystery is 
over). The seminar finished and I thought “nice to see 
that interventional cardiologists are dedicating so much 
attention to basic science stuff”…well, you cannot 
imagine my reaction when Marcel informed me that this 
seminar was held for nurses and technicians…not 
doctors!!!
We then moved to the viewing room, where we went 
through some PCI cases…the two square metre plasma 
screen impressed me a lot…but no as much as the 
lesions that were routinely treated there. I could not 
resist the temptation to pose hundreds of questions to 
Marcel, who finished giving me David Foley’s PhD book 
where most of the answers I was looking for were 
indeed available. However, to address my request 
on…how to become a fellow of the Thoraxcenter, he 
asked “Pedro” to provide me with some insights. 
Pedro…yes, I really mean Pedro Lemos! He was running 
from one room to the other with pen and paper in his 
hand…I was witnessing the early days of the great 
RESEARCH registry. He is the rare kind of great 
researcher who is well aware that a smile can often serve 
you more than an impact factor of 20. I was firstly 
impressed by his kindness: “it would be really nice if you 
could join us as fellows…we have a lot of work to be 
done here” and afterwards, in the few months I spent 
with him at the Thorax, by his knowledge in statistics, 
clinical trials and philanthropy. I regret to have spent 
only a few months close to you but I bet our paths will 
cross again, Pedro.
Standing in the Interventie Cardiologie corridor, with 
David Foley’s PhD book in my hands, Prof Serruys 
appeared. He was in a very good mood, he looked at me 
for two seconds and said: “I see you are interested in 
good literature” and disappeared well before I could 
formulate an answer that was worthy of being said to the 
living legend of the interventional cardiology. At that 
stage, I did not predict that around 18 months after I 
would be sitting in his room in front of him for the 
traditional screening-fellows interview. All the “senior” 
interventional cardiologists are supposed to do the same. 
That was a very important moment since it was the only 
occasion I had to speak to Wim van der Giessen for more 
than 5 seconds. Wim is the kind of very rare person who 
is really able to summarise things: in three, maybe four 
words he explained to me that in the Netherlands it is 
common habit to formally share decisions and this 
process of interviewing fellows was fitting this basic 
principle…it is a pity I cannot recall the 3 or 4 words he 
put together to clearly express this concept! Thank you 
Wim for showing me some tips and tricks on how to 
survive at the Thoraxcenter and best of luck with your 
ongoing research on stem cells. 
Fifteen days after the interview, Prof Serruys called me 
on my mobile and informed me that my request to 
become fellow of the Thoraxcenter had been accepted, 
and that I was supposed to start on 1st of January. The 
first thought was…Professor Serruys is calling me on my 
mobile, incredible!! The second, wow, I will become a 
fellow of the Thorax…the third…but he said 1st of 
January…this means I have to travel the last day of the 
year, i.e. Yes Thoraxcenter, then really NO party! 
The second interview with Prof Serruys occurred around 
the end of January, while the meaning of being a fellow 
was becoming progressively clear to me. The objective of 
the meeting was to find an answer to the question: what 
do you want to do here? After 60 minutes of discussion I 
had a complex flow-chart tree in my hands (which I 
jealously keep among my most important files) where 
any topic possibly related to the field of interventional 
cardiology was listed, including drug eluting stent, 
vulnerable plaque, stem cells and in light of my past 
work in the basic science…also some experimental 
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lab!...I was indeed forgetting the biomarkers and the PV 
loop technology, they were also listed. I spent hours on 
that flow-chart trying to find an invisible connection 
between all of these topics. Later on I understood two 
concepts: these topics are not given to you straight 
away…you have to try hard to conquer them day by 
day…, secondly, I was supposed to choose ONE of those 
and to be focused on that…not try to deal with ALL of 
them at the same time!!! 
The first months of Rotterdam were quite tough, I was 
still sleeping in a Hotel, trying to find a decent but cheap 
apartment where to live, attending a full immersion 
course on Dutch while attempting to start some research 
activity at the Thorax.
Josè Ruiz Cantador, who had just arrived from Spain, 
shared with me hopes and fears along with evenings and 
week-ends during this period (he unfortunately left after 
three months). I am profoundly indebted to Josè for his 
sense of humour, sensibility and great cleverness (and 
Spanish ham as well). Patrizia and I should come to 
Barcelona more often to visit you, Eva and your friends! 
During the first year of fellowship, my office was located 
at 1200, which means third floor in the Thoraxcenter 
language (I never understood the sense of it) with Carlos 
van Mieghem and Jurgen Ligthart as room mates. 
Carlos was listening to my ItalEnglish for hours, trying to 
figure out where to go and what to do there, sharing 
advice, impressions and opinions. In other words we 
established that kind of sincere friendship between peers 
which revealed to be stronger than all the negative 
influences which are naturally around the corner in a 
place where people go to prove themselves (…the 
Thoraxcenter is often playing new episodes of Star Wars).
Carlos, I cannot avoid thanking you for the day that 
while I was warning you that Prof. Serruys was 
investigating who, among the fellows, was supposed to 
be writing about the left main, you told me: “Marco, 
would like to be in charge of that?” That moment was a 
cornerstone to find “my way at the thoraxcenter”. You 
stayed close to me in difficult moments and you have 
been enormously supportive. I really miss our 
conversations, especially when you were disappointed 
over something and I was always surprising you asking 
what was wrong with you just based on the expression 
of your face. The Multislice CT coronary angiography has 
a great future in your interventional cardiologist hands. 
Jurgen, the “Guru” of the IVUS; who can see clearly 
beyond the greys that everybody see in IVUS cross 
sections, incredibly kind attitude and always available 
(which sometimes can be quite dangerous in such a 
place). It was a real pleasure to share the room and so 
many hours with you, thank you for lending me your 
eyes to understand the black and white of things. 
Hei Jurg, I still have something to tell you (you are 
probably expecting this)… Dooooeeeei.  
The first month finished. While getting desperate for the 
fact that the Home hotel (more the latter than the former 
actually) was draining my budget, Giorgios George
Sianos conquered my gratitude suggesting to get in 
touch with Marcoen Scholten, who was seeking a tenant 
after Akis left. Marcoen is a Dutch –even if his sense of 
hospitality makes him appear a typically south European–
- gentleman. Thanks a lot Marcoen for everything, my 
bike is always ready for you in Italy and do not forget 
that Italian wines are definitively much better than those 
sold as such in Albert Heijn. Dear George, I wish I could 
reach one day part of your attitude towards the catheter 
and wires, which is an incredible cocktail of rare technical 
skills, (self)-determination and …some unconsciousness. 
Eugene McFadden had arrived as senior cardiologist 13 
months before me. The first time I saw him I thought he 
was a grown up fellow due to his humble way of 
speaking and interacting with people.  
It took me some time to know him a little bit better: I am 
always too shy especially with shy people. When he left 
the Thorax at the end of March 2005, I thanked God for 
the privilege of knowing him. Eugene taught me the ins 
and outs of the cath-lab, including the way to reach the 
major medical journals and how to think in big whilst 
remaining humble. Eugene, I owe you a lot (apart from 
probably 100 or more cigarettes!!), and I will always 
thank you for this. A bien tôt! 
Working late every evening, including Saturday and 
Sunday, was my way to get to know a unique person the 
of the Thoraxcenter: Doctor Aki Balk. Her office was just 
behind my working station. Aki, also very hard worker, 
was frequently trying to push me to spend at least some 
hours of my life outdoors. Aki, thank you for all of your 
kindness, help and support, I have always regarded you 
as a real friend inside the Thoraxcenter.  
The ACC congress 2005 was approaching. Prof. Serruys 
was invited to give (among the other 100 lectures of 
course!!) a 360 degrees lecture on interventional 
cardiology, the title was something like “interventional 
cardiology where are we heading?” This was my first 
occasion to get closer to The Professor (while you work 
with him on his presentations, he is able to weigh you 
from head to toe…) and to Jiro Aoki. Jiro was “The 
Japanese Fellow”. The force from Japan is very strong at 
the Thoraxcenter and the list of successful interventional 
cardiologists who flew high after their prolonged visit at 
the Throaxcenter is very long. Jiro will definitively be 
among them: clever, humble, hard worker, is sometimes 
hiding some more western attitudes behind a typical 
Japanese appearance which altogether make Jiro an 
intriguing atypical Japanese. Jiro, thank you for 
everything that you taught to me, for letting us sample 
your wonderful Asato, and for your fantastic stories 
about fish…people who say Japanese lack imagination 
must be very confused. 
After 4 months of pure research activity, my name finally 
appeared in the on-call roster. This pushed me inside the 
clinical side of cath-lab, which is an entity full of nurses 
and technicians who are only apparently separated from 
research, yet they actually constitute its real scaffolding 
by carrying it out, understanding it and often enjoying it. 
I am indebted to all of them for their help and patience, 
in particular to Anna-Marie, who taught me all the 
secrets of QCA with her Dutch-Canadian kindness, the 
smart and sensible Dick, Gio, Elco, Max, Maaike and John, 
who recorded kilometres of pressure tracings during the 
impella cases, and Emilie…well Emilie’s story definitively 
deserves a separate paragraph.  
The first time I met Emilie was immediately after my first 
interview with Prof Serruys. He approached me in the 
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viewing room and said “Prof Serruys told me to contact 
you for setting up a research protocol to evaluate 
whether machrophage activation in vitro produces an 
increase in temperature which is detectable by this 
catheter”…I started wondering whether the guy in front 
of me was a real technician or rather Kenneth Chien from 
la Jolla….. Emile, thank you for all your help with the 
terrible PV loop machine, I wish you all the best with 
your new activity in the industry, lucky them who can 
rely on your value now.  
The word “PV loop” naturally leads me to Paul Steendijk, 
who brought me into the magic world of pressures and 
volumes. Well, actually if we imagine the PV loop entity 
as a room, I’d rather better say that while Paul was 
gently inviting me inside, I experienced a lot of attrition 
to completely cross the entrance…the disappointing 
“evaluation version only” software of the PV loop 
machine definitively played a role in this. Thank you Paul 
for all of your efforts in trying to give a sense to all the 
PV recordings I was bringing to you. Your corrections to 
my draft papers have always been of outstanding quality. 
Paul, I really admired your scientific rigor…but please 
convince yourself that respecting your own deadlines 
from time to time does not necessarily mean you do not 
have it!! 
Thanks also to Folkert ten Cate for his patience (I hope 
we will see our common efforts soon finalised), Evelyn 
Regar, who was always very supportive and friendly, to 
Sjoerd Hofma, now working in Groningen, and to Martin 
van der Ent, who indirectly helped me to revise my 
priorities at the Thorax at the right moment, to Johannes 
Schaar, the pulpo chap, to Eric Duckers, the chosen one, 
to Koen Nieman, the future and to all secretarial staff, in 
particular to Anja who is probably still crying desperately 
after my departure. Among the arts assistenten, a special 
thanks to Martijn Akkerhuis and Jawed Polad. Peter de 
Jaegere, the clinical-head. Your help and comprehension 
were so nice, speaking or making jokes with you was 
always very pleasant; you were friendly and open to any 
request from my side (including your kind sponsorship to 
the TCT young investigator award). I enjoyed a lot 
working close to you (I actually performed more than 
50% of my PCI cases under your supervision!) and I 
wish you and Sofie all the best. I am one of your fans.  
“One of the most valuable experiences of being at the 
Thoraxcenter is being part of the team of Fellows from 
around the world” (From Angela Hoye, PhD book page 
244).
I totally agree with Angela (thanks Angela for this) 
regarding this statement. While you are at the 
Thoraxcenter you see the world as a surprisingly small 
entity, and Andrew from Australia contributed a lot to 
this feeling considering that he was able to teach me a 
lot about Europe, including Italy (I am serious)!! 
The dangerous Vijay, from India will remain memorable 
to me for his capability to enjoy Rotterdam  day and 
night with the same level of enthusiasm and dedication; 
it is a pity you could not stay longer to teach us how you 
managed it! 
Gaston and his wife Ines were a real breakthrough for 
me: eating, chating, drinking, working with them was 
always fun. Ines, who could not hide her typical Italian 
temperament in the way she expressed herself…Marco, 
que mieeeerda decis?...was at the same time bringing to 
all of the conversations a spin of Argentinean laughs and 
good humour. Gato, in spite of his young age, which was 
almost offending us old fellows (thank you Andrew for 
being the eldest), is an amazing mature person, who has 
already clear in mind his real goals in life. Gato, I owe 
you a great deal, your “mountains” and your trust 
literally saved my…rear; knowing you has been a real 
cornerstone…even if my liver does not always agree with 
this statement! “meditate on what you taught to me…I 
will”  . I hope to remain close to you and sorry for being 
a boring old Italian who needs to sleep after 12 hours of 
work and 2 litres of Argentinean wine! 
When Jiro finally became a Jedi and left, Keiichi Tsuchida 
first and Shuzou Tanimoto afterwards took over to 
warrant continuity in the Japanese tradition of the 
Thoraxcenter. I will never forget the image of Keiichi 
reviewing angiograms till late in the viewing room every 
evening, searching for all possible bifurcations treated in 
the previous years at the Throaxcenter (…can you 
imagine how many they must be?). While reviewing 
ARTS II angiograms with him for the Syntax score, I 
realised he is the biggest expert of bifurcation in the 
world, and I am sure that Anthony would accept his sub-
analysis of ARTS II on bifurcations if he knew his true 
value!
The force of Shuzou, proud disciple of Kenko Tanabe, 
also impressed me a lot when he could quietly (at least 
outside…) keep working as if nothing had happened 
while his sweet Yui came much prematurely to light to 
visit the foreign Dutch country.  
Strange to say but the Thorax gave me the opportunity 
to get in contact with Elena Biagini, who lives and works 
just at few miles from me in Italy. She is really 
impressive; always laughing and down-regulating herself, 
she could have a tremendous amount of work done 
exploiting all possible infrastructures of the Erasmus MC 
and beyond. Elena, I am planning the PIADA trial and I 
hope that you cannot avoid being involved in such a 
pleasant piece of work. I am looking forward to it. 
While wearing my orange plaster, in August 2005, Hector 
Garcia Garcia joined the group of the Thoraxcenter 
fellows. He soon revealed himself not only as smart and 
a valuable researcher, but also as an incredibly funny 
guy. Fond of statistics as well as world food (Hector, I 
cannot find one among the 100 pictures I have of you in 
which you are not eating!), Hector is the fellow 
everybody would like to work with (by the way, I look 
forward to seeing how you will manage to put all your 
topics together in your PhD book). Hector, thank you for 
all of your help and kindness, my house (when I own one 
of course, so take this as a metaphor for the time being!) 
will always be open to you, Lulu, Andres and all the 
south American Mafia! 
I will miss Sophia Vaina a lot. After my upgrade to 1600 
(fourth floor), she was my neighbour in the office. Sophia 
came to the Thoraxcenter with an impressive clear mind: 
to become an outstanding interventional cardiologist, no 
matter the price to get there! However, in between 
procedures, she loved to chat a little… Sophia, I think 
you and I were the two most stressed fellows (well, after 
Keiichi), while the big Hector was perfectly 
counterbalancing all of us. Sophia, Thank you very much 
for being so sweet and supportive, I am sure you will 
become the best Greek interventionalist very soon: I 
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know you still have problems in performing the double 
inverted super-crush technique in extensively calcified 
vessel without pre-dilation with a single hand during 
night call or the direct stenting a CTO with bridging 
collaterals...but it will come…do not worry! 
It is a shame that I did not get the opportunity to work 
much with Joost Daemen…incredible but true…the only 
local guy among us. Generous, hard worker, he is in the 
lucky, but now also quite challenging, position of 
handling the magic Throaxcenter database: success! 
Thanks a lot to Paul Cummins, now the great managing 
editor of Eurointervention and Arno Ruiter, the marathon 
racer, always very helpful and kind. Paul, the Irish-Dutch 
chap who always knew when to cover someone with 
insults along the corridors (this is the way he introduced 
himself to me….) or to offer you a cigarette and say: yes,
I know, you are right, I know... any news from Eugene?
Thanks a lot, Paul.  
Part of the success of the Thoraxcenter is certainly due 
to Cardialysis. Cardialysis is the place of dreams for a 
researcher, where dozens and dozens of professionals do 
research not just for fun or for “just a period”, rather for 
living.
Cardialysis played a major role during my fellowship in 
Rotterdam and I am indebted to the whole structure for 
their help: Marie-Angèle Morel, for her natural 
enthusiasm and kindness, always ready to help, Gerrit-
Anne van Es, the smartest political statistician I have 
ever met, Jeroen Kleijne, with whom, going from skeletal 
myoblasts to Taxus stents was always a pleasure to work 
with, to the whole statistical department (Marco, Dick, 
Tessa, Jessica) for their patience, advice and never 
ending support, Janette Symons, for her wonderful and 
relaxing smile, to Yvonne for being so supportive and to 
Pascal.
I met Pascal Vranckx for the first time during a meeting 
in Cardialysis. The second time was in the office of The 
Professor. I do not remember the third time, but I do 
remember Pascal that I owe you a great deal (you have 
even helped me to get this book funded!!!). Pascal is a 
recombinant figure, being motivated and a hard worker 
as a fellow, but also wise and politically correct as a 
senior, he surely will be among the emerging European 
interventional cardiologists in the near future. But most 
importantly working with you Pascal was real fun and I 
look forward to seeing what the two of us can do 
together in the future. 
I have no words to express my gratitude to my 
paranymphs, Patrizia and Pierfrancesco. 
Pierfrancesco Agostoni joined the Thoraxcenter for just a 
few months in the summer 2004. He came to increase 
his knowledge in palpography. This was what he actually 
did for the first month, buried on the 23th floor. Then I 
met him and I could not resist the temptation to involve 
him in what I was working on. Surprisingly smart, born 
as “letter to the journal” writer and then as successful 
meta-analysis thanks to the influence of Beppe Biondi-
Zoccai, he is now becoming a brilliant interventional 
cardiologist. He did a fantastic job in an extraordinary 
short time in our “IVUS paper” while he was busy 
retrieving the data from the surgical database…the 
missing paper(s) in this thesis. I am really sorry I could 
not defend his work as I wished! But this experience 
taught me a lot, and I promise you Ago this will not 
happen a second time: we have a lot to do in the future 
together, and I look forward to your enthusiasm, ideas 
and balance.  
Patrizia, Patty, Malagutti, Malaguttona. My life. My 
favourite co-worker. My love. She joined me at the 
Thoraxcenter during the second year of my fellowship, 
and she changed everything (if you do not believe this, 
please ask Gato, he will mimic me before and after, very 
funny!).  
She is an incredibly hard worker, precise and meticulous.  
With her spectacular QCA, we reached JAMA, JACC 
several times and AHJ. I sincerely hope nobody will 
discover how truly good you are at research otherwise, I 
may loose my secret. It is impossible to thank you 
properly for your outstanding contribution to this thesis, 
which belongs to you in the same proportion as it does 
to me.
Si dice sempre in questi casi..senza di te questo lavoro 
non sarebbe mai stato scritto, beh, questa frase è tutto 
meno che retorica in questa circostanza! Si contruisce 
sempre a piccoli passi. Non vedo l’ora di correre al tuo 
fianco.
Patty also introduced me in the multislice CT world. Pim, 
I will never stop thanking you for your understanding 
and support. You are a myth of the Thoraxcenter and the 
lucky ones who know you can fully understand why. 
Thank you Pim for accepting to be one of my promoters. 
Your dedication to research is perfectly balanced by your 
clinical sensibility. Thanks also to the whole Multi-slice CT 
group, including Manuel, the Master of PCs and the king 
of kindness, Giuseppe, The Sicilian, Alessandro and 
Ludovico who studied all of the available literature on the 
vulnerable plaque (!) and kept discussing its unravelled 
features for months during lunch time, to Francesca, The 
American who was born in Italy, Nico, the Dutch co-boss,
Filippo, the Italian co-boss and the great Bob, whose hair 
style inspired Patty and I on how to name our favourite 
plant in Rotterdam.
A lot of people at the Thoraxcenter made my life much 
easier. Among them, I would like to mention Prof. 
Simoons for his understanding in the most critical 
moment of my PhD experience, Prof. de Jong, for his 
friendship, Ron van Domburg, with whom I regret not 
having spent more time, to Linda Smit and the magic 
Annet Louw, who made all PhD bureaucracy a smooth 
and enjoyable step, Jan Tuin and Paula Delfos for their 
professionalism and kindness. 
I am deeply indebted to all of the committee members 
whose prestige and international credibility bring light 
and honour to this thesis.  
The first time I saw William Wijns was during the annual 
congress of the Italian invasive cardiology society some 
years ago in Como. He was asked to speak about the 
role of PCI in stable coronary artery disease when he 
clearly stated the truth…medical treatment may be even 
better from a prognostic standpoint…the message was 
not well received by the audience…since then I kept 
appreciating his scientific rigor, his balance and smart 
attitude and…hey guys…what a style! 
I should write a separate chapter about my Professor 
Ferrari. I betrayed your basic science to become an 
inverventional cardiologist…something you will never 
213
Acknowledgment
forgive me for…Thank you for believing in me since the 
early days, thank you for supporting me when nobody 
was even in the mood to, a new challenge close to you is 
just about to start, I hope I will be able to show you how 
big is my gratitude towards you is in the following years.
Eric Boersma has always been a hero for me with his 
“reappraisal of the golden hour” much before I came to 
the Thorax. The truth is that knowing Eric a little bit 
more has led me to simply increase my appreciation 
towards him. Very busy but always surprisingly well 
organized he significantly contributed to the biggest 
successes of this thesis! I know it will be almost 
impossible to keep working with you in the future 
Eric…but I will give it a try anyhow! 
Gabriel, I have never understood why, but I have felt as 
a friend of yours since the early days I met you in Capri, 
between stem cells and some mozzarella cheese. 
Subsequently, I had the privilege of knowing you better 
as part of the steering committee of the nameless “ex 
superiority trial” (by the way your High-Tech proposal 
was not bad at all!) and now I am even working with a 
true fan of yours…Prof Martial Hamon. It seems that  
destiny is pushing me towards you and your excellent 
work, I hope it will be highly successful, then! 
A special thanks to Prof. Alfredo Rodriguez, who kindly 
accepted to be a member of my PhD committee and for 
his great and highly appreciated support in the MULTI-
STRATEGY project and to Prof D. Poldermans, for his 
remarkable capability to go directly to the point.  
Dulcis in fundo, it is time to focus on HIM, Prof PW 
Serruys, who in some way made the majority of the 
above mentioned interconnections possible, and 
acknowledging them is an indirect way to thank HIM as 
well. For an interventional cardiologist Patrick Serruys is 
the Thoraxcenter and the Thoraxcenter is Patrick 
Serruys…this is one of the first basic laws the fellow 
discovers. He wonderfully played the role of Obi-Wan 
Kenobi for several years and trained, with the help of his 
outstanding teams, dozens of Jedis around the world. I 
learned hundreds of things from HIM, the living legend 
of interventional cardiology, (starting from witnessing 
that this title is absolutely very well deserved!!): the way 
he tries hard every second of his life to push himself 
beyond any boundaries, to understand more and to do 
more than anybody else, how he fights everyday to 
reach and maintain his astonishing level of knowledge 
and international recognition in the field, the way he 
attracts and plays with industries in the full respect of  
science and the truth (which is something not too 
fashionable nowadays unfortunately!!). I will never stop 
thanking you PROFESSOR for all this and for the privilege 
to work close to and on behalf of you. Knowing you was 
my first priority coming to the Thorax. Getting a PhD 
with you is the second one. The third will be to stay in 
close contact with you and keep learning from you and 
your team beyond my fellowship. I will endeavour to 
achieve my third priority with the same of level of 
intensity and enthusiasm you have seen me doing for the 
first two.
Last, but not least, I would like to go back to my roots in 
cardiology. I was born as an internal medicine doctor in 
Bologna and becoming a cardiologist has not been so 
easy, thanks to the very flexible Italian University system. 
Prof Bruno Magnani was a key figure in this transition; he 
first stirred me with his scientific rigor wonderfully 
applied to patient care, and then he paved my way with 
his good-natured and paternal attitude. Dear Prof 
Magnani, your advice and two disciples  (i.e. Prof Marco 
Bonvicini and Angelo Placci) took me to Ferrara, where I 
had the privilege of finding my professor Ferrari 
(…another disciple of yours actually, in a certain way). I 
wish I could grow up in line with his and your teachings 
even if…at a distance. 
Elda, Bruno, Barbara, Stefano, Luca…adoro riconoscermi 
in tutti voi. Grazie. 
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